ABSTRACT

This material provides documentation for users of the 2014 National Ambulatory Medical Care Survey (NAMCS) micro-data file. NAMCS is a national probability sample survey of visits to office-based physicians conducted by the National Center for Health Statistics. It is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. A summary of changes for 2014 is presented first which highlights all of the most important information for data users. Section I, "Description of the National Ambulatory Medical Care Survey," includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, population estimates, and sampling errors. Section II provides technical information about variables on the file, as well as a list of all physician specialties eligible for sampling. Section III contains marginal data and estimates for selected items on the data record. The appendixes contain sampling errors, instructions and definitions for completing the electronic Patient Record forms, and lists of codes used in the survey. THIS PAGE WAS LEFT BLANK INTENTIONALLY.

SUMMARY OF CHANGES FOR 2014

The 2014 NAMCS micro-data file is, for the most part, similar to the 2013 file, but there are some important changes. These are described in more detail below and primarily reflect changes to the survey instruments -- the automated Patient Record form and Physician Induction Interview form. Data users are also encouraged to refer to the 2012 NAMCS Public Use Data File Documentation, which contains important information about major changes implemented for the 2012 survey year that also apply to 2013 and 2014 NAMCS.

A. State-Based Estimates and Weighting Variables

As mentioned above, the NAMCS sampling design changed in 2012, in order to allow state-based estimates for the 34 most populous states. For 2014, a state-based sample was used once again, but this time it included the 17 most populous states and Wisconsin. The remaining states, which were located within 7 of the 9 Census divisions, were grouped by their Census division into what are called 'division remainders.'

As in 2013, there are two visit weighting variables on the 2014 file. The first is the traditional PATWT variable which is used to weight sample data to obtain national, regional (Northeast, Midwest, South, and West) and division-level (New England, Middle Atlantic, East North Central, West North Central, South Atlantic, East South Central, West South Central, Mountain, and Pacific) estimates.

The second weighting variable is called the PATWTST variable, which is used to make state visit estimates. The traditional weighting variable (PATWT) and the state weighting variable (PATWTST) should not be used interchangeably, especially when combining years of data. That is, the state weighting variables have been designed to be used for individual state estimates. A third weighting variable, PHYSWT, is used to make estimates of office-based physicians who are in-scope for NAMCS, but this weight is only based on physicians who saw patients during their reporting period. Physicians who participated in the survey but did not see any patients during their reporting period are not included, and those who refused to participate are not included. Because of these limitations, physician-level estimates derived from NAMCS visit data are not necessarily generalizable to all office-based physicians. In order to include these other groups (for example, those who did not provide any sampled visit data), provider-level files, based on the physician induction interview only, are available in the NCHS Research Data Center.

B. Specialty Strata

For 2014, physicians were grouped into just two strata for sampling purposes (primary care and other), which was the same as in 2012 and 2013. Physician lists for systematic sampling by state were sorted according to physician specialty groups, in order to obtain a reasonable distribution of physicians across the traditional specialty groups used prior to 2012. Unlike 2012, however, the 2013 and 2014 NAMCS did not include the three 'hard strata' supplemental samples of physicians in the specialty groups of allergy and immunology, oncology, and pulmonology. These specialties were not specifically targeted in 2013 or 2014, but instead were grouped within the broader specialty groups to which they were assigned in previous years. For example, the specialty of allergy and immunology was typically grouped in the "All Other" specialty category prior to 2012, and was included in this category for 2013 and 2014.

C. Data Collection and Comparability of 2014 NAMCS Estimates with Previous Years of Data

For 2014, the mode of data collection continued to be the automated laptop-assisted instrument used since 2012, and additional research was conducted to assess any data anomalies between 2013 and 2014 data.

To accomplish this, more than 30 tables of 2014 estimates were compared with the same tables of 2013 estimates. The variables that were compared included most of those published in the annual survey web

PAGE 4

tables. Significant changes between the two years were noted and investigated. While many estimates were not statistically different in each year, some unexpected results were found. These may reflect actual differences, or they may be related to the changes in item format, the new automated data collection system and/or the increase in Census abstraction. Data users are advised to take these factors into account when using these items or comparing them with previous years. Specific findings include the following, with results being weighted to national estimates:

---First-listed reason for visit was missing for 7.2% of visits in 2014 compared with 0.4% in 2013. The problem was concentrated in the first three months of the year (missing rate for that quarter was 22.8% compared with 1.5% during the rest of the year) and resulted from a problem with the automated survey instrument. The high rate of missingness would be important for anyone trying to make seasonal or quarterly estimates with this variable.

---The percentage of visits with missing medication data dropped to 1.3% in 2014 compared with 3.2% in 2013.

---The percentage of visits with 'other disposition' decreased to 10.7% from 25.3% in 2013. This is most likely related to the expansion of disposition categories in 2014.

---Visits with a primary diagnosis of general medical examination increased to 3.7% compared with 2.9% in 2013.

---Injury-related visits increased to 8.5% from 6.6% in 2013. This may be related to a change in the survey instrument which allowed for the reporting of causes of injury for the first time in 10 years.

--Visits with missing or unknown major reason for visit which is a categorical variable reflecting the physician's assessment and is not to be confused with patient's expressed reason for visit) increased to 3.5% from 1.9% in 2014.

NCHS staff will continue to monitor these and other changes with regard to 2014 data and beyond in an effort to better assess how much may be attributed to data collection and processing vs. real-world treatment patterns.

D. Nonresponse Bias

Physician-level response (successful collection of data in the Physician Induction Interview) for the core (non-CHC) NAMCS sample was 54.8% (weighted) in 2014, but only 36.8% (weighted) of physicians provided data for at least one sampled visit and, thus, are the only ones to have data in the public use file. This was slightly lower than the response rates noted for 2013.

A detailed analysis of nonresponse bias at both levels of physician response was conducted by NCHS using 2012 data (1) (<u>http://www.cdc.gov/nchs/data/series/sr_02/sr02_171.pdf</u>). Nonresponse bias for 2012 NAMCS estimates was evaluated at the physician-level and at the visit-level. Both levels of response were examined by: 1) comparing percent distributions of respondents and non-respondents by physician characteristics available for all in scope sample physicians; 2) comparing response rates by physician characteristics with the national response rate; 3) analyzing nonresponse bias after adjustments for post-survey nonresponse adjustments were applied; and 4) estimating bias in the physician-level estimates from both levels of response by comparing them with those from an external survey. In addition nonresponse bias at the visit level was examined by comparing numbers of visits estimated from the total sample with numbers of visits estimated using nonresponse adjusted weights.

After adjustment for nonresponse in groups defined by targeted states, Census division, metropolitan status, and physician specialty categories, no or negligible biases were observed between full sample

physician estimates and physician estimates for both NAMCS respondent types. However, bias toward overestimating solo practitioners and underestimating physicians in larger practices (group or HMO, practices with 11 or more physicians) persisted after adjustments for nonresponse in comparison with estimates based on the total sample and external estimates.

Nonresponse bias should be taken into consideration when analyzing and interpreting 2014 data. In addition to survey nonresponse, rates of missingness increased for some survey items starting in 2012, especially race and ethnicity. However, race and ethnicity item nonresponse showed some decrease in 2014 as described below. Item nonresponse is discussed in more detail in Section I.

E. Injury Coding

The 2014 survey instrument included several new injury items. For injury and poisoning related visits, the follow-up question was asked, "Did the injury or poisoning occur within 72 hours prior to the date and time of the visit?" For all visits related to injury, poisoning, or adverse effect of medical treatment, a text entry could be made describing the cause. This text entry was later coded by medical coders using the International Classification of Diseases, 9th Revision, Clinical Modification's Supplementary Classification of External Causes of Injury and Poisoning.

Items pertaining to injury have changed several times since 2010. In addition to current injury item formats, we also include, for trending and consistency check purposes, recoded injury items using a format that is comparable with the injury variables used in 2010, 2011, 2012, and 2013. These variables are described in more detail in the Codebook section.

For 2014, injury data were edited using a program which reviewed reason for visit, cause of injury, and diagnosis codes, and assigned injury and intentionality status accordingly. In this way, records which did not specifically state an injury but for which injury codes for reason, cause, or diagnosis were present were recoded appropriately. Records which stated an injury but for which no corroborating data could be found were assigned to a 'questionable' injury status, allowing data users to make their own determination as desired.

F. Race and Ethnicity

Item nonresponse rates for race and ethnicity experienced some improvement in 2014. The missing rate for race was 26.9 percent (unweighted) and 29.7 percent (weighted). For ethnicity, it was 27.6 percent (unweighted) and 25.2 percent (weighted). The ethnicity rate improved significantly compared with 2013's rate of 30.9 percent (weighted).

Starting with 2009 data, NAMCS adopted the technique of model-based single imputation for missing race and ethnicity data, as described in more detail in Section I. This model was used to impute 2014 data, with modifications which reflect the state-based sampling design.

Users should be aware that high percentages of item nonresponse may lead to biased estimates, particularly if the imputation algorithm omitted a variable of importance, and that the single imputation algorithm may underestimate some standard errors. We anticipate this underestimate to be fairly small for most estimates, particularly those with design effects of 5 or greater. However, standard errors may be underestimated more substantially for those domains with design effects under 5. For more information about the decision to adopt a model-based single imputation methodology, see the 2009 NAMCS Public Use Data File Documentation:

(ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/doc09.pdf).

G. Laboratory Results

For 2014, the decision was made to include laboratory test results on the public use file as they were reported in the automated survey instrument by Census abstractors. Data users should keep in mind that in prior years, outlier lab values were edited or capped during the data processing process, as described in the annual public use file documentation for each year. For 2014, outlier values are included so that researchers can assess the data and make their own determinations about how to use them. More information is included in the Codebook descriptions for specific laboratory tests.

H. Survey Items

Below is a description of all new, modified, and deleted items from the automated instruments pertaining directly to the 2014 public use file.

1. New or Modified Items

NOTE: The headings and corresponding section locations reflected in the 2014 NAMCS Patient Record Sample Card may not be identical to those in the automated electronic Patient Record Form. The Sample Card (available at the Ambulatory Health Care Data website) is a general representation of the automated instrument, using a more easily read format that is similar to the original paper forms used in earlier years.

Patient Information

- a. "Specify gestation week" A definition was added as follows: "Gestation week refers to the number of weeks plus 2 that the offspring has spent developing in the uterus".
- b. "Expected source(s) of payment for this visit" The response category of "Medicaid or CHIP" was modified to "Medicaid or CHIP or other state-based program."
- c. Tobacco use Response categories changed from "Not current", "Current", and "Unknown" in 2013 to "Never smoker," "Former smoker," "Current smoker," and "Unknown" in 2014.

Biometrics/Vital signs

- d. The section heading changed from "Vital signs" in 2013 to "Biometrics/Vital signs" in 2014.
- e. Blood Pressure A new instruction was added: "If multiple measurements are taken, record the last measurement."

Reason for Visit:

- f. "Major reason for this visit" was moved into this section (in 2013, it was part of the "Continuity of Care" section). The item has an additional response category in 2014 due to the "Pre/Post-Surgery category from past years being split into separate categories for "Pre-surgery" and "Post-surgery".
- g. In past years, up to 3 reasons for visit could be entered for each visit. In 2014, two additional fields were added to make a total of five. The item instruction was revised as follows: "List the first 5 reasons for visit (i.e., symptoms, problems, issues, concerns of the patient) in the order in which they appear, start with the chief complaint and then move to the patient history for additional reasons."

Injury:

h. For this item, "Is this visit related to an injury, poisoning, or adverse effect of medical treatment", wording changes were made to two response categories. In 2013, the first category was "Yes, injury/trauma"; this was changed to "Yes, injury". The third category, "Yes, adverse effect of medical treatment" was changed to "Yes, adverse effect of

medical/surgical care or adverse effect of medicinal drug.

- i. New item: "Did the injury or poisoning occur within 72 hours prior to the date and time of this visit?" This only displayed in the automated instrument if an injury or poisoning had been indicated.
- j. The question "Is this injury or poisoning intentional or unintentional" was given a slight format change from the 2013 version ("Is this injury/poisoning unintentional or intentional?") The order of the "Unintentional" and "Intentional" response categories was switched in 2014, with "Intentional" appearing first this year. Also, the 2013 category of "Unintentional" was changed in 2014 to "Unintentional (e.g., accidental)", and the "Unknown" category in 2013 was changed to "Intent Unclear" in 2014.
- k. New item: "Cause of injury, poisoning, or adverse effect" This write-in item was added with the following instructions: "Describe the place and circumstances that preceded the injury, poisoning, or adverse effect. Examples: 1 Injury (e.g., patient fell while walking down stairs at home and sprained her ankle; patient was bitten by a spider); 2 Poisoning (e.g., 4 year old child was given adult cold/cough medication and became lethargic; child swallowed large amount of liquid cleanser and began vomiting); 3 adverse effect (e.g., patient developed a rash on his arm 2 days after taking penicillin for an ear infection)." Up to three causes could be coded by NCHS medical coders using the ICD-9-CM's Supplementary Classification of External Causes of Injury and Poisoning.

Continuity of care:

- I. "Has the patient been seen in your practice before?" was changed to "Has the patient been seen in this practice before?"
- m. "How many past visits in the last 12 months?" was changed to "How many past visits to this practice in the last 12 months?"

Provider's diagnosis for this visit:

- n. In past years, up to three diagnoses could be recorded. For 2014, two additional "other" diagnosis fields were added to make a total of five.
- In the section, "Regardless of the diagnoses previously entered, does the patient now have –", new checkboxes were added for Alcohol misuse, abuse or dependence; Alzheimer's disease/dementia; Chronic kidney disease (CKD); Coronary artery disease (CAD), ischemic heart disease (IHD) or history of myocardial infarction (MI); End stage renal disease (ESRD); History of pulmonary embolism (PE) or deep vein thrombosis (DVT); HIV infection/AIDS; Obstructive sleep apnea (OSA); and Substance abuse or dependence.
- p. In the section, "Regardless of the diagnoses previously entered, does the patient now have", "Cerebrovascular disease/History of stroke or transient ischemic attack (TIA)" was changed to "Cerebrovascular disease/stroke (CVA) or transient ischemic attack (TIA)".
- q. In the section, "Regardless of the diagnoses previously entered, does the patient now have", the Diabetes checkbox was separated into 1) Diabetes mellitus (DM); Type 1, 2) Diabetes mellitus (DM); Type 2, 3) Diabetes mellitus (DM); and Type unspecified.
- r. In the section, "Regardless of the diagnoses previously entered, does the patient now have", for the Obesity category, the accompanying label "Provider-diagnosed and documented in record" added in 2013 was removed.

Services:

s. The instruction for this item was modified to display: "Enter all examinations/screenings, laboratory tests, imaging, procedures, treatments, and health education/counseling ordered or provided."

- t. In 2013, the Services section included 7 sections (Examinations, Blood Tests, Imaging, Other Tests and Procedures, Non-Medication Treatment, Health Education/Counseling, and Other Services not listed); in 2014, the section headings were modified to Examinations/Screenings, Laboratory Tests, Imaging, Procedures, Treatments, Health Education/Counseling, and Other Services not listed.
- In the Services section, these checkboxes were added: Alcohol misuse screening (includes AUDIT, MAST, CAGE, T-ACE); Domestic violence screening; Substance abuse screening (includes NIDA/NM ASSIST, CAGE-AID, DAST-10); Basic metabolic panel; Comprehensive metabolic panel; Creatinine/Renal function panel; Culture, blood; Culture, throat; Culture, urine; Culture, other; Gonorrhea test; Hepatitis testing/Hepatitis panel; Liver enzymes/Hepatic function panel; Rapid strep test; TSH/Thyroid panel; Vitamin D test; Cryosurgery (cryotherapy)/Destruction of tissue; Tuberculosis skin testing/PPD; Upper gastrointestinal endoscopy/EGD; Occupational therapy; Alcohol abuse counseling; Diabetes education; Genetic counseling; Substance abuse counseling.
- v. In the Services section, these checkboxes were modified slightly: "Glucose" was modified to "Glucose/serum"; "Other ultrasound" was modified to "Ultrasound"; and four categories (biopsy, colonoscopy, excision of tissue and sigmoidoscopy) which had also asked if the service was provided (using single "Provided" checkboxes) now have separate "yes" and "no" checkboxes for each question.

Medications & Immunizations

- w. The instruction for the item was modified to read "Were any prescription or nonprescription drugs ORDERED or PROVIDED (by any route of administration) at this visit? Include Rx and OTC drugs, immunizations, allergy shots, oxygen, anesthetics, chemotherapy, and dietary supplements that were ordered, supplied, administered, or continued during this visit. Include drugs prescribed at a previous visit if the patient was instructed at THIS VISIT to continue with the medication." In addition, overall "Yes" and "No" answer options were added, replacing the former "None" box.
- x. The number of medications that could be reported was increased from 10 to 30.

Providers and Disposition:

- y. Under the Time Spent with Provider item, the instruction was changed from "Enter zero if no provider seen" to "Enter estimated time spent with sampled provider – Enter 0 if no provider seen."
- z. The categories under the Visit Disposition item expanded from 4 to 9. The current categories are: 1) Return to referring physician; 2) Refer to other physician; 3) Return in less than 1 week; 4) Return in 1 week to less than 2 months; 5) Return in 2 months or greater; 6) Return at unspecified time; 7) Return as needed (p.r.n); 8) Refer to ER/Admit to hospital; and 9) Other.

Tests:

aa. Fasting blood glucose (FBG) was changed to Blood glucose (BG). bb.Date of test (mm/dd/yyyy) was modified to "Date of test."

From the Physician Induction Interview, modifications were made to several items related to Electronic Medical Records (EMR)/Electronic Health Records (EHR) and several new items were added, as detailed below.

Many of the computerized capabilities asked about in 2014 were the same as in 2013. These include: recording patient history and demographic information, patient problem list, vital signs, clinical notes, patient smoking status, ordering prescriptions, lists of patients' medications and allergies, providing reminders for guideline-based interventions or screening tests, ordering lab tests, viewing lab results, viewing imaging results, generating lists of patients with particular health conditions, electronic reporting to immunization registries, providing patients with clinical summaries for each visit, exchanging secure

messages with patients, and sharing any patient health information electronically with other providers. But a number of features were asked about for the first time, or the questions about them were modified. They include the following questions:

- cc. [Item 30] Has your practice made an assessment of the potential risks and vulnerability of your electronic health information within the last 12 months?
- dd. [Item 31] Does your EHR have the capability to electronically send health information to another provider whose EHR system is different from your system?
- ee. [Item 33a] The question: "Medicare and Medicaid offer incentives to practices that demonstrate, meaningful use of health IT. Are there plans to apply for these incentive payments?" from 2013 was modified to: "Are there plans to apply for Stage 1 of these incentive payments?" in 2014.
- ff. [Item 33b] Are there plans to apply for Stage 2 incentive payments?
- gg. [Item 34i(3)] If practice has the computerized capability for ordering prescriptions, are drug formulary checks performed?
- hh. [Item 34I] Does practice have the computerized capability for ordering radiology tests?
- ii. [Item 34p] Identifying patients due for preventive or follow-up care in order to send patients reminders

The referral and care coordination questions (items 35a, 36a, 37a, and 38a) which were asked in the 2013 NAMCS) have different sub-questions in 2014:

- jj. [Item 35a] Do you refer any of your patients to providers outside of your office or group? (If yes, answer 35b and 35c)
 - i. [Item 35b] Do you send the patient's clinical information to the other providers? ii.[Item 35c] Do you send it electronically (not fax)?
- kk. [Item 36a] Do you see any patients referred to you by providers outside of your office or group? (If yes, answer 36b and 36c)
 - i. [Item 36b] Do you send a consultation report with clinical information to the other providers?
 - ii.[Item 36c] Do you send it electronically (not fax)?
- II. [Item 37a] Do you take care of patients after they are discharged from an inpatient setting? (If yes, answer 37b, 37c, and 37d)
 - i. [Item 37b] Do you receive a discharge summary with clinical information from the hospital?
 - ii.[Item 37c] Do you receive the information electronically (not fax)?
 - iii.[Item 37d] Can you automatically incorporate the received information into your EHR system without manually entering the data?
- mm. [Item 38a] Do you share any patient health information electronically (not fax) with other providers, including hospitals, ambulatory providers, or labs? (If yes, answer 38b, 38c, and 38d) (Note: 38b not shown as it is same as in 2013.)
 - i. [Item 37c] If yes, is the patient health information that you share electronically sent directly from your EHR system to another EHR system?
 - ii. [Item 37d] With what types of providers do you electronically share patient health information (e.g., lab results, imaging reports, problem lists, medication lists)? 1) Ambulatory providers inside your office/group; 2) ambulatory providers outside your office/group; 3) Hospitals with which you are affiliated; 4) Hospitals with which you are not affiliated; 5) Behavioral health providers; 6) Long-term care providers; and 7) Home health providers.

2. Deleted Items

- a. From the electronic Patient Record, under Diagnosis, in the section: "Regardless of the diagnoses previously entered, does the patient now have", the Chronic Renal Failure checkbox was removed.
- b. Under Services, the General Physical Exam checkbox item was removed.

From the Physician Induction Interview, the following items were removed:

- c. When did you first intend to apply for meaningful use incentives?
- d. Does your practice have this computerized capability: providing patients with an electronic copy of their health information?
- e. If you refer any of your patients to providers outside of your office or group, do you receive a report back from the other provider with results of the consultation?
- f. If you refer any of your patients to providers outside of your office or group and you receive a report back, do you receive it electronically (not fax)?
- g. If you see any patients referred to you by providers outside of your office or group, do you receive notification of both the patient's history and reason for consultation?
- h. If you see any patients referred to you by providers outside of your office or group and receive notification of both the patient's history and reason for consultation, do you receive it electronically (not fax)?
- i. Do you share the following electronically (not fax) with 1) hospitals with which you are affiliated? 2) ambulatory providers inside your office/group? 3) hospitals with which you are not affiliated? 4) ambulatory providers outside your office/group?
 - a. Lab results
 - b. Imaging reports
 - c. Patient problem lists
 - d. Medication lists
 - e. Medication allergy lists
- j. Do you share any lab results, imaging reports, patient problem lists, medication lists, or medication allergy lists using a Summary Care Record?
- k. If you refer any of your patients to providers outside of your office or group, do you receive a report back from the other provider with results of the consultation?
- I. If you refer any of your patients to providers outside of your office or group and receive a report back from the other provider with results of the consultation, do you receive it electronically (not fax)?
- m. If you see any patients referred to you by providers outside of your office or group, do you receive notification of both the patient's history and reason for consultation?
- n. If you see any patients referred to you by providers outside of your office or group and receive notification of both the patient's history and reason for consultation, do you receive it electronically (not fax)?
- o. If you take care of patients after they are discharged from an inpatient setting, do you receive all of the information you need to continue managing the patient?
- p. If you take care of patients after they are discharged from an inpatient setting and receive all of the information you need to continue managing the patient, is the information available when needed?
- q. If you take care of patients after they are discharged from an inpatient setting and receive all of the information you need to continue managing the patient, do you receive the information electronically (not fax)?

ble of Conte	ents
--------------	------

Page

Abstract	
Summary of Changes for 2014	
I. Description of the National Ambulatory Medical Care Survey	
A. Introduction	
B. Scope of the survey	
C. Sampling frame and size of sample	
D. Sample design	
E. Population figures	
F. Field activities	
G. Data collection	
H. Confidentiality	27
I. Data processing	28
J. Medical coding	33
K. Estimation procedures	38
L. Sampling errors	40
M. Patient visit weight	40
N. Physician code and patient code	41
O. Use of the physician-level weight	
References	42
	40.404
II. Codebook and Physician Specialty List	
A. Codebook	
B. Physician specialty list	
C. AMA specialties regrouped into primary, medical and surgical	
III. Marginal Data	135-142
A. Patient visits	
B. Drug mentions	
C. Physicians	
D. States	
Appendixes	
Appendix I	143-167
A. Standard errors and variance estimation	
B. 2014 NAMCS Patient Record Form - Instructions and definitions	
C. Definitions of certain terms used in NAMCS	164
Appendix II	168-205
A. Reason for Visit Classification.	
Appendix III	
A. Generic codes and names in numeric order	
B. Drug entry codes and names in numeric order	
C. Multum Lexicon end-user license agreement	257
D. Multum classification of therapeutic classes (drug categories)	

Table of Contents (cont.)

List of Tables and Figures

Table 1. Number of physicians in the universe, total sample, sample response categories, response rates, number of participants, and participation rate by sampled physician specialty group: National Ambulatory Medical Care Survey, 2014	
Table 2. Number of physicians in total sample, sample response categories, response rates, number of participants, and participation rate by division and selected states: National Ambulatory Medical Care Survey, 2014 17	
Table 3. U.S. population estimates used in computing annual visit rates for theNational Ambulatory Medical Care Survey, by age, race, and sex: July 1, 2014	
Table 4. U.S. population estimates used in computing annual visit rates for theNational Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2014	
Table 5. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey for the 18 most populous states (targeted by the sample design for separate estimation): July 1, 2014	

I. DESCRIPTION OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY

A. INTRODUCTION

This micro-data file contains data collected in the 2014 National Ambulatory Medical Care Survey (NAMCS). NAMCS is a national probability sample survey conducted by the Division of Health Care Statistics, National Center for Health Statistics (NCHS). For 2014, the sampling design allowed for the estimation of ambulatory medical care visits to office-based physicians and community health centers in 18 states and in 7 additional groups formed by aggregating the remaining states within their Census divisions. These data can also be weighted to produce national estimates that describe the utilization of ambulatory medical care services in the United States. Only visits to office-based physicians are included in this data file. Visits to community health centers (CHCs) are not included. A separate file containing CHC visits to both physicians and non-physician practitioners (also sometimes called mid-level providers) is planned for a future release.

The mode of data collection for 2014 NAMCS is the same as that adopted in 2012 and 2013, a computerassisted electronic tool. In most cases, Census Field Representatives abstracted records from medical charts using a laptop computer and an automated survey instrument. In a small number of cases, physicians or their staff entered the requested information on a Census laptop or through a web portal using a modified version of the automated instrument. Data were obtained for a total of 45,710 sampled visits. For a description of the survey design and data collection procedures, see below.

Please note the following important points concerning analysis of NAMCS data on this micro-data file:

PATIENT VISIT WEIGHTS

Micro-data file users should be fully aware of the importance and proper use of the two "patient visit weights" – one for producing national, regional, and divisional estimates, and one for producing state-based estimates. These should not be used interchangeably, and state-based estimates will not sum to national estimates because only the 17 most populous states plus Wisconsin were sampled in 2014. Information about the patient visit weights is presented on pages 2 and 40. If more information is needed, the staff of the Ambulatory and Hospital Care Statistics Branch can be consulted by calling (301) 458-4600 during regular working hours.

RELIABILITY OF ESTIMATES

Users should also be aware of the reliability or unreliability of survey estimates, particularly smaller estimates. The National Center for Health Statistics considers an estimate to be reliable if it meets TWO conditions: it is based on at least 30 sample records and it has a relative standard error of 30 percent or less (i.e., the standard error is no more than 30 percent of the estimate). For more information, see Appendix I or contact the staff of the Ambulatory and Hospital Care Statistics Branch.

B. SCOPE OF THE SURVEY

The basic sampling unit for NAMCS is the physician-patient encounter or visit. Traditionally, only visits to the offices of nonfederally employed physicians classified by the American Medical Association (AMA) or the American Osteopathic Association (AOA) as "office-based, patient care" were included in NAMCS. Physicians in the specialties of anesthesiology, pathology, and radiology are excluded from the physician universe. However, starting in 2006, in addition to the traditional sample, NAMCS included a sample of

community health centers, using information from the Health Resources and Services Administration and the Indian Health Service to construct a sampling frame. From each sampled community health center, an additional sample of health care providers was selected, which could include physicians as well as non-physician practitioners -- physician assistants, nurse practitioners, and nurse midwives.

From 2006, when NAMCS added the CHC stratum, through 2011, visits to CHC-sampled physicians were included with visits to traditionally sampled office-based physicians on the data files. Starting with 2012, however, only visits to office-based physicians are included on the NAMCS publidata products and the information provided in this documentation pertains only to the traditional (core) office-based component of NAMCS. CHC visits to physicians as well as non-physician practitioners sampled as part of the CHC panel are expected to be released as separate data products for 2012 forward.

Types of contacts not included in the 2014 NAMCS were those made by telephone, those made outside the physician's office (for example, house calls), visits made in hospital settings (unless the physician has a private office in a hospital and that office meets the NAMCS definition of "office"), visits made in institutional settings by patients for whom the institution has primary responsibility over time (for example, nursing homes), and visits to doctors' offices that are made for administrative purposes only (for example, to leave a specimen, pay a bill, or pick up insurance forms).

C. SAMPLING FRAME AND SIZE OF SAMPLE

The sampling frame for the 2014 NAMCS (core sample, not including CHC delivery sites) was composed of all physicians listed in the master files maintained by the AMA and AOA, at a point roughly 6 months prior to the start of the survey year, who met the following criteria:

- -- Office-based or hospital-employed, as defined by the AMA and AOA;
- -- Principally engaged in patient care activities;
- -- Nonfederally employed;
- -- Not in specialties of anesthesiology, pathology, and radiology
- -- Younger than 85 years of age at the time of the survey.

IMPORTANT: New to the NAMCS in 2014 is the expansion of the sampling frame to include physicians whom the AMA classifies as "hospital-employed." This expansion of the NAMCS physician sampling frame is due to concerns that NAMCS was not covering visits made to office-based practices which are owned by hospitals, and to increases in reported hospital purchases of physician practices in recent years.

The 2014 NAMCS traditional or core sample included 9,989 physicians: 9,501 Medical Doctors and 488 Doctors of Osteopathy. Sample physicians were screened at the time of the survey to assure that they met the above-mentioned criteria. A total of 3,973 physicians did not meet all of the criteria and were ruled out of scope (ineligible) for the study. The most frequent reasons for being out of scope were that the physician did not see ambulatory patients, was retired, or was not office-based.

Of the 6,016 in-scope (eligible) physicians, 2,179 participated in the study by submitting data for sample patient visits. These data were collected for 45,710 visits, either by Census Field Representative abstraction (45,614 records) or by physicians or their staffs (96 records). In either case, an automated tool was used, which replaced the traditional paper Patient Record Form (PRF) used prior to 2012. For the sake of simplicity, the abstracted records will continue to be described as PRFs in the survey documentation.

A total of 503 physicians saw no patients during their assigned reporting period because of vacations, illness, or other reasons for being temporarily not in practice and hence did not provide any PRFs. Of the 2,179 physicians for whom PRFs were abstracted, 1,822 participated fully or adequately (i.e. at least half of the PRFs expected, based on the total number of visits during the reporting week, were submitted), and 357 participated minimally (i.e. fewer than half of the expected number of PRFs were submitted). The unweighted response rate for visit data was 38.7 percent (39.0 percent weighted), based on the number of full responders and those who saw no patients during their sample week. The weighted participation rate was 45.0 percent based on the total of full and minimal responders including those who saw no patients during their reporting week (Table 1). Response and participation rates by Census Division and selected states are shown in Table 2.

D. SAMPLE DESIGN

As in 2013, the 2014 NAMCS sampling design utilized a stratified two-stage sample, with physicians selected in the first stage and visits in the second stage. List samples of physicians were used in order to produce separate estimates for individual states with the largest populations.

The 17 most populous states were targeted for individual visit estimation. These include California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Michigan, New Jersey, Georgia, North Carolina, Virginia, Washington, Massachusetts, Indiana, Arizona, and Tennessee. Estimates were also produced for the state of Wisconsin because it was the only state remaining in its Division after targeting the 17 most populous states. The remaining 32 states and the District of Columbia were grouped according to their U.S. Census Bureau divisions into seven larger areas called 'division remainders'. These are composed of Connecticut, Maine, New Hampshire, Rhode Island, and Vermont from the New England Division; Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota from the West North Central Division; Delaware, the District of Columbia, Maryland, South Carolina, and West Virginia from the South Atlantic Division; Alabama, Kentucky, and Mississippi from the East South Central Division; Louisiana, Oklahoma, and Arkansas from the West South Central Division; Colorado, Idaho, New Mexico, Montana, Nevada, Utah, and Wyoming from the Mountain Division; and Alaska, Hawaii, and Oregon from the Pacific Division. There are nine Census Bureau Divisions in all. All states were included separately from the remaining two Divisions (Middle Atlantic and East North Central). Therefore, there are a total of 25 distinct geographical areas composed of states and division remainders which make up the United States for the 2014 NAMCS sample.

Table 1. Number of physicians in the universe, total sample, sample response categories, response rates, number of participants, and participation rate by sampled physician specialty group: National Ambulatory Medical Care Survey, 2014

Physician specialty group at sampling Total	Universe(1) 565,182	Total 9,989	Out of Scope 3,973	In Scope 6,016	Respon- dents 2,325	Response rates: unweighted (weighted) (2) 38.7 (39.0)	Partici- pants(3) 2,682	Participation rate: weighted (3) 45.0
General and	000,102	0,000	0,010	0,010	2,020		2,002	1010
family practice	95,478	1,295	443	852	353	41.4 (39.9)	406	46.7
Internal						/		
medicine	86,542	1,124	531	593	231	39.0 (40.1)	279	48.8
Pediatrics	62,127	941	454	487	239	49.1 (50.7)	271	56.6
General surgery	19,090	446	167	279	118	42.3 (43.6)	134	47.9
Obstetrics and gynecology	35,920	506	165	341	133	39.0 (36.6)	154	42.7
Orthopedic surgery	21,146	482	97	385	134	34.8 (34.2)	152	38.9
Cardiovascular diseases	17,998	396	108	288	102	35.4 (36.4)	120	42.7
Dermatology	10,216	213	31	182	71	39.0 (36.2)	85	42.6
Urology	8,667	198	42	156	59	37.8 (36.5)	66	41.0
Psychiatry	34,615	712	320	392	129	32.9 (33.8)	152	39.1
Neurology	12,471	272	110	162	61	37.7 (39.0)	68	42.6
Ophthalmology	16,594	361	64	297	102	34.3 (32.4)	121	39.3
Otolaryngology	8,286	190	52	138	43	31.2 (29.7)	50	33.5
All other specialties	136,032	2,853	1,389	1,464	550	37.6 (37.9)	624	42.4

(1) Data are derived from the American Medical Association and the American Osteopathic Association and represent the total number of physicians who were eligible for the 2014 NAMCS sample.

(2) Respondents are physicians for whom at least one-half of their expected number of Patient Record forms were completed (full responders) and also include physicians who saw no patients during their sampled week. Response rate is the number of respondents divided by the number of in-scope physicians.

(3) Participants are physicians for whom at least one Patient Record form was completed (full and minimal responders) and also include physicians who saw no patients during their sampled week. Participation rate is the number of participants divided by the number of in-scope physicians.

Table 2. Number of physicians in total sample, sample response categories, response rates, number of participants, and participation rate by division and selected states: National Ambulatory Medical Care Survey, 2014

Division/State	Total (1)	Out of Scope	In Scope	Respon- dents	Response rates: unweighted (weighted) (2)	Partici- pants	Weighted Participant rate(3)
Total	9,989	3,973	6,016	2,325	38.6 (39.0)	2,682	45.0
New England							
MA	396	217	179	58	32.4 (33.4)	77	44.2
CT,ME,NH,RI,VT	409	172	237	71	30.0 (30.4)	80	34.4
Middle Atlantic							
NY	396	151	245	69	28.2 (28.6)	89	37.1
PA	396	160	236	78	33.1 (32.9)	88	37.3
NJ	396	144	252	74	29.4 (28.9)	97	38.7
East North Central							
IL	396	142	254	117	46.1 (46.9)	139	55.8
ОН	396	185	211	69	32.7 (34.0)	78	37.9
MI	395	156	239	119	49.8 (49.8)	124	51.9
IN	396	128	268	123	45.9 (46.5)	133	50.1
WI	396	121	275	135	49.1 (51.9)	143	55.0
West North Central							
IA,KS,NE,SD,ND,MN,MO	341	130	211	93	44.1 (44.7)	100	47.5
South Atlantic							
FL	396	141	255	88	34.5 (34.3)	124	49.1
GA	396	155	241	75	31.1 (31.1)	86	35.4
NC	396	217	179	37	20.7 (22.3)	67	38.2
VA	395	141	254	92	36.2 (36.0)	115	45.4
SC,WV,DE,DC,MD	477	204	273	103	37.7 (42.9)	113	44.8
East South Central							
TN	396	136	260	105	40.4 (41.0)	152	59.4
AL,KY,MS	409	155	254	113	44.5 (45.1)	125	49.5
West South Central							
ТХ	396	157	239	91	38.1 (39.6)	96	42.2
LA,OK,AR	409	158	251	103	41.0 (42.0)	111	45.4

Mountain AZ	396	161	235	98	41.7 (43.0)	104	45.7
CO,UT,NV,NM,ID,MT,WY	409	178	231	88	38.1 (35.5)	96	38.8
Pacific							
CA	396	141	255	113	44.3 (44.3)	123	48.8
WA	396	174	222	107	48.2 (50.7)	108	51.0
OR,HI,AK	409	149	260	106	40.8 (44.9)	114	48.3

NOTE: Division and State represent location of sampling location. A total of 18 states were targeted for separate estimation. States not targeted for separate estimation were grouped into division remainders and sampled accordingly.

(1) Data are derived from the American Medical Association and the American Osteopathic Association and represent the total number of physicians who were eligible for the 2014 NAMCS sample.

(2) Respondents are physicians for whom at least one-half of their expected number of Patient Record forms were completed (full responders) and also include physicians who saw no patients during their sampled week. Response rate is the number of respondents divided by the number of in-scope physicians.

(3) Participants are physicians for whom at least one Patient Record form was completed (full and minimal responders) and also include physicians who saw no patients during their sampled week. Participation rate is the number of participants divided by the number of in-scope physicians.

The sampling (hard) strata were defined by Census division, the 18 targeted states, and primary care specialty status. Primary care status was defined as practicing in any of the following specialties:

Adolescent Medicine (Family Practice) Adolescent Medicine (Internal Medicine) Adolescent Medicine (Pediatrics) **Emergency Medicine/Family Medicine** Family Medicine/Preventive Medicine **Family Practice** General Practice Geriatric Medicine (Family Practice) Geriatric Medicine (Internal Medicine) Gvnecology Hospice & Palliative Medicine (Family Medicine) Internal Medicine Internal Medicine/Family Practice Internal Medicine/Pediatrics Internal Medicine/Preventive Medicine **Obstetrics Obstetrics & Gynecology Pediatric Sports Medicine** Pediatrics

Physicians were given a random number and assigned to their respective sampling stratum. Within each sampling stratum, they were sorted by their SPECRDET value. SPECRDET is a two part code which combines an integer value for the physician's broad specialty group (General and Family Practice, Internal Medicine, Pediatrics, Obstetrics and Gynecology, General Surgery, Orthopedic Surgery, Cardiovascular Diseases, Dermatology, Urology, Psychiatry, Neurology, Ophthalmology, Otolaryngology, and a residual category for All Other Specialties) with a decimal value indicating primary care, surgical or medical specialty.

Sorting was done first by the decimal portion of SPECRDET and next by the integer portion. Within SPECRDET, physicians were next sorted by MSA status (location in a metropolitan statistical area or not, based on Office of Management and Budget designations from Census 2010 data. Within MSA status, physicians were then sorted by their SPEC value, the 3-digit alphanumeric code indicating their specific specialty. Within each of the implicit strata defined by SPECRDET/MSA status/SPEC within the hard strata, physicians were ordered by the previously assigned random number. Within each of the 25 hard strata, a systematic random sample was selected from the list of sorted physicians. On average, 399 physicians were selected from within each state or division remainder, with actual numbers ranging from 341 to 477.

Because primary care specialty physicians dominate the traditional (office-based, no CHCs) NAMCS population, the NAMCS physician sample was stratified by primary care versus other specialties to prevent primary care physicians from dominating the sample at the expense of the remaining specialties. The portion of the physician sample selected from the primary care strata was limited to 36 percent, which is the portion allocated to the primary care strata in samples for prior years of the core NAMCS.

The final stage was the selection of patient visits within the annual practices of sample physicians. This involved two steps. First, the total physician sample was divided into 52 subsamples using systematic sampling from a list in which the physicians were sorted in the order of their selection to the total sample and those subsamples were then randomly assigned to the 52 weeks in the survey year. Second, a systematic random sample was selected from a chronologic list of visits seen during the assigned week. As done since 2012, this sampling was mainly conducted by Census Field Representatives, although physicians could select their own sample if desired. The sampling rate varied for this final step from a 100-percent sample for very small practices to a 10-percent sample for very large practices as determined in the physician interview. The method by which the sampling rate was determined is available (2).

E. POPULATION FIGURES

The base population used in computing annual visit rates is presented in tables 3-5. The denominators used in calculating 2014 visit rates for age, sex, race, ethnicity, and geographic region are Census 2010based postcensal estimates of the civilian noninstitutionalized population of the United States. The population estimates are special tabulations developed by the Population Division, U.S. Census Bureau, from the July 1, 2014 set of state population estimates by age, sex, race, and ethnicity.

Population estimates by metropolitan statistical area (MSA) status are based on estimates of the civilian noninstitutionalized population from the 2014 National Health Interview Survey (NHIS), National Center for Health Statistics, compiled according to the February 2013 Office of Management and Budget definition of core-based statistical areas. See http://www.census.gov/population/metro/data/pastmetro.html for more information about MSA definitions.

Estimates of visit rates for metropolitan and non-metropolitan statistical areas from 2003-2014 may differ somewhat from those reported in 2002 and previous years because of methodological differences in how the denominators were calculated. In survey years 1995-2005, the NHIS used metropolitan areas as defined by the Office of Management and Budget, June 30, 1993. In survey years 1994-2002, the NHIS used 1990-based Census estimates as controls. Because NAMCS used Census 2000-based population estimates beginning in 2001, adjustments needed to be made to the MSA figures obtained from the NHIS in 2001 and 2002. For 2010-2014, special tabulations were obtained from the Office of Analysis and Epidemiology, NCHS, where each year of data was compiled according to the December 2009 OMB

 Table 3. U.S. population estimates used in computing annual visit rates for the National Ambulatory

 Medical Care Survey, by age, race, and sex: July 1, 2014

Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	313,672,860	3,946,554	15,924,807	41,151,725	43,010,105	42,263,007
Male	153,217,332	2,016,979	8,135,994	21,003,624	21,695,646	20,873,938
Female	160,455,528	1,929,575	7,788,813	20,148,101	21,314,459	21,389,069
White Only	243,106,418	2,824,567	11,433,014	30,106,255	31,814,990	31,820,096
Male	119,804,751	1,444,646	5,851,055	15,408,939	16,148,750	15,979,899
Female	123,301,667	1,379,921	5,581,959	14,697,316	15,666,240	15,840,197
Black Only	40,780,688	602,520	2,422,331	6,169,122	6,623,649	5,779,908
Male	19,033,518	306,764	1,229,510	3,126,132	3,251,645	2,653,265
Female	21,747,170	295,756	1,192,821	3,042,990	3,372,004	3,126,643
AIAN* Only	3,887,259	64,517	257,048	652,673	646,336	590,447
Male	1,939,567	32,915	130,619	331,527	327,199	301,086
Female	1,947,692	31,602	126,429	321,146	319,137	289,361
	17 0 10 0 10	004 000	040 500	0.070.040	0.007.040	0.000.450
Asian Only	17,249,610	201,860	819,590	2,076,946	2,297,612	2,920,453
Male	8,189,145	103,368	418,069	1,048,350	1,157,816	1,389,346
Female	9,060,465	98,492	401,521	1,028,596	1,139,796	1,531,107
NHOPI* Only	720,831	12,435	48,636	117,070	116,194	127,601
Male	361,042	6,364	24,911	59,486	58,406	65,200
Female	359,789	6,071	23,725	57,584	57,788	62,401
Multiple						
Races	7,928,054	240,655	944,188	2,029,659	1,511,324	1,024,502
Male	3,889,309	122,922	481,830	1,029,190	751,830	485,142
Female	4,038,745	117,733	462,358	1,000,469	759,494	539,360

*NHOPI is Native Hawaiian/Other Pacific Islander. AIAN is American Indian/Alaska Native.

Geographic	Geographic Region totals		Metropolitan Statistical Area totals		
Northeast	55,403,548	MSA	272,914,209		
Midwest	66,752,759	Non-MSA	40,758,651		
South	117,451,370				
West	74,065,183				

Race and sex	35-44	45-54	55-64	65-74	75+
All races	39,679,478	42,931,040	39,819,836	26,171,532	18,774,776
Male	19,426,863	20,973,687	19,134,318	12,234,461	7,721,822
Female	20,252,615	21,957,353	20,685,518	13,937,071	11,052,954
White Only	30,300,416	33,995,070	32,469,770	22,099,590	16,242,650
Male	15,116,213	16,844,510	15,796,922	10,454,925	6,758,892
Female	15,184,203	17,150,560	16,672,848	11,644,665	9,483,758
Black Only	5,194,565	5,401,570	4,579,522	2,472,723	1,534,778
Male	2,333,194	2,461,298	2,064,116	1,055,614	551,980
Female	2,861,371	2,940,272	2,515,406	1,417,109	982,798
AIAN* Only	515,750	487,965	374,343	194,451	103,729
Male	260,150	241,409	179,797	91,949	42,916
Female	255,600	246,556	194,546	102,502	60,813
Asian Only	2,810,017	2,357,291	1,887,187	1,137,992	740,662
Male	1,308,811	1,098,034	851,551	508,427	305,373
Female	1,501,206	1,259,257	1,035,636	629,565	435,289
NHOPI*	101 747	96 440	61 004	22.084	16 711
Only	101,747	86,449	61,904	32,084	16,711
Male	51,168	42,759	30,178	15,506	7,064
Female	50,579	43,690	31,726	16,578	9,647
Multiple					
Races	756,983	602,695	447,110	234,692	136,246
Male	357,327	285,677	211,754	108,040	55,597
Female	399,656	317,018	235,356	126,652	80,649

Table 3. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey, by age, race, and sex: July 1, 2014 - con.

*NHOPI is Native Hawaiian/Other Pacific Islander. AIAN is American Indian/Alaska Native.

HISPANIC						
Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	54,729,821	1,012,818	4,117,083	10,021,482	9,253,934	8,667,496
Male	27,458,961	516,614	2,096,724	5,103,271	4,724,529	4,473,653
Female	27,270,860	496,204	2,020,359	4,918,211	4,529,405	4,193,843
White Only	48,212,636	857,750	3,506,291	8,660,744	8,090,397	7,611,265
Male	24,217,119	437,531	1,785,954	4,411,406	4,135,806	3,942,286
Female	23,995,517	420,219	1,720,337	4,249,338	3,954,591	3,668,979
Black Only	2,587,902	59,051	230,772	517,592	461,681	425,573
Male	1,253,784	30,125	117,353	263,391	232,715	203,816
Female	1,334,118	28,926	113,419	254,201	228,966	221,757
AIAN* Only	1,595,417	30,992	122,380	299,333	277,472	271,679
Male	827,794	15,824	62,192	152,249	143,103	147,519
Female	767,623	15,168	60,188	147,084	134,369	124,160
Asian Only	546,570	12,404	48,115	106,938	95,374	89,851
Male	270,581	6,293	24,550	54,878	47,595	44,834
Female	275,989	6,111	23,565	52,060	47,779	45,017
NHOPI* Only	193,504	4,222	16,483	36,945	33,380	36,572
Male	99,691	2,144	8,359	18,710	17,162	20,167
Female	93,813	2,078	8,124	18,235	16,218	16,405
Multiple Races	1,593,792	48,399	193,042	399,930	295,630	232,556
Male	789,992	24,697	98,316	202,637	148,148	115,031
Female	803,800	23,702	94,726	197,293	147,482	117,525
i ontaio	222,200	20,7 02	3.,,20	107,200	1.7,102	11,020

Table 4. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2014

*NHOPI is Native Hawaiian/Other Pacific Islander. AIAN is American Indian/Alaska Native.

HISPANIC					
Race and sex	35-44	45-54	55-64	65-74	75+
All races	7,862,297	6,266,272	4,030,066	2,115,445	1,382,928
Male	3,963,793	3,136,446	1,935,336	954,924	553,671
Female	3,898,504	3,129,826	2,094,730	1,160,521	829,257
White Only	7,007,043	5,628,758	3,636,547	1,933,296	1,280,545
Male	3,543,784	2,825,613	1,748,102	872,889	513,748
Female	3,463,259	2,803,145	1,888,445	1,060,407	766,797
Black Only	220 601	250 202	166 112	01 500	48 608
Black Only	338,681	258,293	166,113	81,538	48,608
Male	156,045	119,816	76,646	35,483	18,394
Female	182,636	138,477	89,467	46,055	30,214
AIAN* Only	235,772	180,261	107,653	45,974	23,901
Male	125,392	94,638	54,747	22,208	9,922
	110,380	94,038 85,623	52,906	22,208	13,979
Female	110,560	03,023	52,900	25,700	13,979
Asian Only	76,410	56,695	35,054	16,465	9,264
Male	37,749	27,472	16,340	7,307	3,563
Female	38,661	29,223	18,714	9,158	5,701
NHOPI* Only	28,063	19,737	10,837	4,738	2,527
Male	14,718	9,962	5,277	2,172	1,020
Female	13,345	9,775	5,560	2,566	1,507
Multiple Races	176,328	122,528	73,862	33,434	18,083
Male	86,105	58,945	34,224	14,865	7,024
Female	90,223	63,583	39,638	18,569	11,059

Table 4. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2014 - con.

*NHOPI is Native Hawaiian/Other Pacific Islander. AIAN is American Indian/Alaska Native.

Table 4. U.S. population estimates used in computing annual visit rates for the National Ambulatory
Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2014 – con.

All races Male Female258,943,039 125,758,371 133,184,6682,933,736 1,500,365 1,500,365 1,433,37111,807,724 6,039,270 15,900,353 5,768,45433,756,171 16,971,117 16,400,285 16,785,05433,595,511 16,400,285 17,195,226White Only Male Female194,893,782 95,587,632 99,306,1501,966,817 1,007,1157,926,723 4,065,101 10,997,53321,445,511 12,012,94423,724,593 12,012,944 12,037,613 12,171,218
Female133,184,6681,433,3715,768,45415,229,89016,785,05417,195,226White Only194,893,7821,966,8177,926,72321,445,51123,724,59324,208,831Male95,587,6321,007,1154,065,10110,997,53312,012,94412,037,613
White Only 194,893,782 1,966,817 7,926,723 21,445,511 23,724,593 24,208,831 Male 95,587,632 1,007,115 4,065,101 10,997,533 12,012,944 12,037,613
Male 95,587,632 1,007,115 4,065,101 10,997,533 12,012,944 12,037,613
Male 95,587,632 1,007,115 4,065,101 10,997,533 12,012,944 12,037,613
Female 99,306,150 959,702 3,861,622 10,447,978 11,711,649 12,171,218
Black Only 38,192,786 543,469 2,191,559 5,651,530 6,161,968 5,354,335
Male 17,779,734 276,639 1,112,157 2,862,741 3,018,930 2,449,449
Female 20,413,052 266,830 1,079,402 2,788,789 3,143,038 2,904,886
AIAN* Only 2,291,842 33,525 134,668 353,340 368,864 318,768
Male 1,111,773 17,091 68,427 179,278 184,096 153,567
Female 1,180,069 16,434 66,241 174,062 184,768 165,201
Asian Only 16,703,040 189,456 771,475 1,970,008 2,202,238 2,830,602
Male 7,918,564 97,075 393,519 993,472 1,110,221 1,344,512
Female 8,784,476 92,381 377,956 976,536 1,092,017 1,486,090
NHOPI*
NHOPP Only 527,327 8,213 32,153 80,125 82,814 91,029
Male 261,351 4,220 16,552 40,776 41,244 45,033
Female 265,976 3,993 15,601 39,349 41,570 45,996
Multiple
Races 6,334,262 192,256 751,146 1,629,729 1,215,694 791,946
Male 3,099,317 98,225 383,514 826,553 603,682 370,111
Female 3,234,945 94,031 367,632 803,176 612,012 421,835

*NHOPI is Native Hawaiian/Other Pacific Islander. AIAN is American Indian/Alaska Native.

NON-HISPANIC

Table 4. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2014 - con.

Race and sex	35-44	45-54	55-64	65-74	75+
All races	31,817,181	36,664,768	35,789,770	24,056,087	17,391,848
Male	15,463,070	17,837,241	17,198,982	11,279,537	7,168,151
Female	16,354,111	18,827,527	18,590,788	12,776,550	10,223,697
White Only	23,293,373	28,366,312	28,833,223	20,166,294	14,962,105
Male	11,572,429	14,018,897	14,048,820	9,582,036	6,245,144
Female	11,720,944	14,347,415	14,784,403	10,584,258	8,716,961
Black Only	4,855,884	5,143,277	4,413,409	2,391,185	1,486,170
Male	2,177,149	2,341,482	1,987,470	1,020,131	533,586
Female	2,678,735	2,801,795	2,425,939	1,371,054	952,584
AIAN* Only	279,978	307,704	266,690	148,477	79,828
Male	134,758	146,771	125,050	69,741	32,994
Female	145,220	160,933	141,640	78,736	46,834
Asian Only	2,733,607	2,300,596	1,852,133	1,121,527	731,398
Male	1,271,062	1,070,562	835,211	501,120	301,810
Female	1,462,545	1,230,034	1,016,922	620,407	429,588
NHOPI* Only	73,684	66,712	51,067	27,346	14,184
Male	36,450	32,797	24,901	13,334	6,044
Female	37,234	33,915	26,166	14,012	8,140
Multiple Races	580,655	480,167	373,248	201,258	118,163
Male	271,222	226,732	177,530	93,175	48,573
Female	309,433	253,435	195,718	108,083	69,590

*NHOPI is Native Hawaiian/Other Pacific Islander. AIAN is American Indian/Alaska Native.

Table 5. U.S. population estimates used in computing annual visit rates for the 2014 National Ambulatory Medical Care Survey for the 18 targeted states (targeted by the sample design for separate estimation)

United States Arizona	313,672,860 6,620,453
California	38,275,734
Florida	19,567,675
Georgia	9,889,655
Illinois	12,693,004
Indiana	6,496,756
Massachusetts	6,667,118
Michigan	9,797,804
New Jersey	8,829,886
New York	19,496,482
North Carolina	9,726,076
Ohio	11,419,227
Pennsylvania	12,579,706
Tennessee	6,443,129
Texas	26,453,416
Virginia	8,112,786
Washington	6,950,784
Wisconsin	5,683,727

SOURCE: These are U.S. Bureau of the Census postcensal estimates of the civilian noninstitutionalized population for the 18 targeted states. They were developed by the Population Division, U.S. Census Bureau using the July 1, 2014 set of state population estimates, and reflect Census 2010 data. More information may be obtained from the Census website at <u>www.census.gov.</u>

definition of core-based statistical areas. The 2010 NHIS estimates were further adjusted based on the 2010 population estimates obtained from the Census Bureau (which were based on Census 2000). For 2014, the NHIS estimates were adjusted based on the 2014 population estimates obtained from the Census Bureau (which were based on Census 2010).

Population estimates for race groups in the 2014 NAMCS are based on the 2010 U.S. Census in which respondents were able to indicate more than one race category. Since 2001, the denominators used for calculating race-specific visit rates in NAMCS reports reflect multiple-race reporting. Specific race denominators reflect persons with a single race identification, and a separate denominator is available for persons with more than one race designation.

Data indicate that multiple races are recorded for a patient less frequently in medical records compared to their numbers in the general population. The 2014 population estimates indicate that 2.5 percent of the total population identify themselves as being of multiple races. In contrast, multiple race patients account for just 0.4 percent of weighted NAMCS visits (based on known race data only). (REMINDER: Beginning with the 2009 NAMCS, NAMCS data only include imputed values for the race categories White, Black, and Other; see 2009 or 2010 NAMCS Public Use File Documentation Summary of Changes for more information.) This is roughly the same percentage reported in the 2013 NAMCS and earlier years. The difference may exist because abstractors are less likely to know and record the multiple race preference of the patient. It suggests that the race population rates calculated for 2014 may be slight overestimates for the single race categories and slight underestimates for the multiple race category, but it should be kept in mind that race data are missing for approximately 27 percent (unweighted) and 30 percent (weighted) of 2014 NAMCS records overall.

F. FIELD ACTIVITIES

The first contact with the sample physician is through a letter from the Director, NCHS. After the physician receives the introductory letter (along with letters from professional medical societies which endorse NAMCS), the Field Representative (FR) telephones the physician to establish basic eligibility and to schedule an appointment. At the appointment, the FR explains the survey to the physician and to any staff who may be involved in abstracting the data. The decision is also made regarding who will perform the visit sampling and data abstraction. Also at the initial visit, the FR obtains the practice characteristics of up to five office locations (expanded from four in 2011) where the physician sees patients during the reporting week. If the physician or his/her staff are performing data abstraction, the FR contacts the physician's office just before, during and after the reporting week to remind him or her about the survey and to answer any questions that may arise. After abstraction has been completed, the physician is given a certificate of appreciation for her or his participation.

G. DATA COLLECTION

In 2014, the mode of data collection for NAMCS was through the use of an automated survey tool. This is described in more detail in the 2012 NAMCS Public Use Data File Documentation, since 2012 was the first year that NAMCS switched to an electronic mode of data collection.

The automated survey tool was accessible either by Census laptop or by web portal. Prior to the introduction of the automated survey tool in 2012, data collection for NAMCS was expected to be carried out by the physician or the physician's staff. However, over time, abstraction from medical charts by Census field representatives became more common. Since 2012, Census FR abstraction using laptop computers and the automated instrument is the preferred mode for data collection. For physicians who requested to do their own data collection, a web portal containing a modified version of the automated tool was available, or a Census laptop could be left behind for physician use. In 2014, 99.8 percent of records were obtained through Census FR abstraction, and the rest were obtained by physician/medical staff reporting.

Physicians were instructed to keep a daily listing of all patient visits during the assigned reporting week using an arrival log, optional worksheet, or similar method. This list was the sampling frame to indicate the visits for which data were to be recorded. It was to include both scheduled and unscheduled patients, but not cancellations or no-shows. Visits were selected from the list either by Census FRs or medical staff using a random start and a predetermined sampling interval based on the physician's estimated visits for the week and the number of days the physician was expected to see patients that week. In this way, a systematic random sample of visits was obtained. The sampling procedures were designed so that about 30 electronic Patient Records would be completed during the assigned reporting week. This was intended to minimize the data collection workload and maintain equal reporting levels among sample physicians regardless of practice size.

Data for sampled visits were recorded on laptops using the automated survey tool which emulated the traditional paper survey instrument, the Patient Record form. The 2014 Patient Record "Sample Card" showing the data items included in the survey is available at the Ambulatory Health Care Data website: <u>http://www.cdc.gov/nchs/ahcd/ahcd_survey_instruments.htm#namcs</u>. Terms and definitions relating to the automated Patient Record are included in Appendix I.

H. CONFIDENTIALITY

In April 2003, the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) was implemented to establish minimum Federal standards for safeguarding the privacy of individually identifiable health information. No personally identifying information, such as patient's name or address or Social Security number, is collected in NAMCS. Data collection is authorized by Section 306 of the Public Health Service Act (Title 42, U.S. Code, 242k). All information collected is held in the strictest confidence

PAGE 28

according to law [Section 308(d) of the Public Health Service Act (42, U.S. Code, 242m(d))] and the Confidential Information Protection and Statistical Efficiency Act (Title 5 of PL 107-347). The NAMCS protocol has been approved by the NCHS Research Ethics Review Board annually starting in February 2003. Waivers of the requirements to obtain informed consent of patients and patient authorization for release of patient medical record data by health care providers were granted.

In the spring of 2003, NAMCS implemented additional data collection procedures to help providers assure patient confidentiality. Census Bureau Field Representatives were trained on how the Privacy Rule allows physicians to make disclosures of protected health information without patient authorization for public health purposes and for research that has been approved by a Research Ethics Review Board. Physicians were encouraged to accept a data use agreement between themselves and NCHS, since the Privacy Rule allows physicians to disclose limited data sets (i.e., data sets with no direct patient identifiers) for research and public health purposes if such an agreement exists.

Assurance of confidentiality was provided to all physicians according to Section 308 (d) of the Public Health Service Act (42 USC 242m). Strict procedures were utilized to prevent disclosure of NAMCS data. All information which could identify the physician was confidential and was seen only by persons engaged in NAMCS, and was not disclosed or released to others for any other purpose. Names or other identifying information for individual patients were not removed from the physician's office.

Prior to release of the public use data file, NCHS conducts extensive disclosure risk analysis to minimize the chance of any inadvertent disclosure. Based on research conducted by NCHS for 2014 NAMCS, certain variables were subject to masking in some cases (patient race, whether visit occurred in a metropolitan statistical area, is physician a medical doctor or doctor of osteopathy, is physician in solo or group practice, physician's diagnosis, and medication). Furthermore, outlier values for certain variables (age, age of pregnant patient, height, weight, number of past visits in last 12 months, and time spent with physician) were top coded in accordance with NCHS confidentiality requirements. Masking was performed in such a way to cause minimal impact on the data; data users who wish to use unmasked data can apply to the NCHS Research Data Center.

I. DATA PROCESSING

1. Edits

Once electronic data were collected by the Census Bureau, a number of steps were required for data processing. Specifications for checking, configuring, and transmitting the data files were developed by NCHS and applied by the Census Bureau. Data files were transmitted either to NCHS for further processing, or to SRA International, Durham, North Carolina. At NCHS, the data underwent multiple consistency checks and review of verbatim entries. SRA edited and coded verbatim entries which required medical coding (patient's reason for visit, physician's diagnosis, cause of injury, and procedures). Medication editing and coding were performed entirely at NCHS by the NAMCS Drug Database Coordinator.

2. Quality Control

All SRA medical coding and keying operations were subject to quality control procedures. The contractor randomly selected a 10 percent sample of records which were independently recoded and compared. Differences were adjudicated by a quality control supervisor with error rates reported to NCHS. Coding error rates for the 10 percent sample ranged between 0.4 and 1.2 percent.

3. Adjustments for Item Nonresponse

Unweighted item nonresponse rates exceeded 5.0 percent for the following data items:

Variable	Variable Description	Denominator	Nonresponse %
PREGNANT	Is patient pregnant?	Visit by females of childbearing age	9.8
GESTWK	Week of gestation	All visits by pregnant females	18.5
ETHUN	Patient ethnicity – unimputed	All visits	27.6
RACEUN	Patient race – unimputed	All visits	26.9
USETOBAC	Tobacco Use	All visits	21.4
PAYTYPER	Type of payment (recoded from multiple sources using hierarchy)	All visits	6.8
TEMPF	Temperature (in Fahrenheit)	All visits	63.3
BMI	Body mass index - calculated from height and weight	All visits	34.3
BPSYS	Systolic blood pressure	All visits	33.1
BPDIAS	Diastolic blood pressure	All visits	33.1
HTIN	Height in inches	All visits	32.8
WTLB	Weight in pounds	All visits	23.2
INJURY72	Did the injury or poisoning occur within 72 hours prior to the date and time of this visit?	Injury- and poisoning-related visits	50.5
INTENT	Is this injury/poisoning unintentional or intentional?	Injury- and poisoning-related visits	30.6
CAUSE1	Cause of injury #1	Injury- and poisoning-related visits	30.0
REFER	Was patient referred for visit?	All visits not made to patient's primary care provider	17.5
PASTVIS	How many past visits in the last 12 months?	All visits by established patients	17.0
RFV1	Patient's reason for visit #1	All visits	7.2
ASTH_CON	Asthma control	All visits with asthma checked as a chronic condition	8.9
ASTH_SEV	Asthma severity	All visits with asthma checked as a chronic condition	8.9

PAGE 30		2014 NAMCS MICRO-DATA FILE DOCUMEN	NTATION
EXCIPROV	Excision of tissue provided	All visits where excision was reported	65.5
BIOPROV	Biopsy provided	All visits where biopsy was reported	18.5
SIGPROV	Sigmoidoscopy provided	All visits where sigmoidoscopy was reported	9.7
NCMED1	Is Medication #1 new or continued?	All visits w/Med1	17.7
NCMED2	Is Medication #2 new or continued?	All visits w/Med2	16.9
NCMED3	Is Medication #3 new or continued?	All visits w/Med3	17.5
NCMED4	Is Medication #4 new or continued?	All visits w/Med4	17.3
NCMED5	Is Medication #5 new or continued?	All visits w/Med5	17.9
NCMED6	Is Medication #6 new or continued?	All visits w/Med6	18.6
NCMED7	Is Medication #7 new or continued?	All visits w/Med7	19.1
NCMED8	Is Medication #8 new or continued?	All visits w/Med8	19.9
NCMED9	Is Medication #9 new or continued?	All visits w/Med9	21.1
NCMED10	Is Medication #10 new or continued	All visits w/Med10	21.5
NCMED11	Is Medication #11 new or continued	All visits w/Med11	23.0
NCMED12	Is Medication #12 new or continued	All visits w/Med12	22.7
NCMED13	Is Medication #13 new or continued	All visits w/Med13	23.2
NCMED14	Is Medication #14 new or continued	All visits w/Med14	24.7
NCMED15	Is Medication #15 new or continued	All visits w/Med15	24.8
NCMED16	Is Medication #16 new or continued	All visits w/Med16	26.1
NCMED17	Is Medication #17 new or continued	All visits w/Med17	28.5
NCMED18	Is Medication #18 new or continued	All visits w/Med18	29.4
NCMED19	Is Medication #19 new or continued	All visits w/Med19	30.0
NCMED20	Is Medication #20 new or continued	All visits w/Med20	30.0
NCMED21	Is Medication #21 new or continued	All visits w/Med21	34.1
NCMED22	Is Medication #22 new or continued	All visits w/Med22	39.1
NCMED23	Is Medication #23 new or continued	All visits w/Med23	41.2
NCMED24	Is Medication #24 new or continued	All visits w/Med24	38.8
NCMED25	Is Medication #25 new or continued	All visits w/Med25	40.0
NCMED26	Is Medication #26 new or continued	All visits w/Med26	38.9
NCMED27	Is Medication #27 new or continued	All visits w/Med27	35.6
NCMED28	Is Medication #28 new or continued	All visits w/Med28	30.6
NCMED29	Is Medication #29 new or continued	All visits w/Med29	31.7
NCMED30	Is Medication #30 new or continued	All visits w/Med30	20.0
TIMEMD	Time spent with provider	All visits where a provider was seen	35.8

A1C	Was blood for HbA1c test drawn at visit or within past 12 months?	All visits for selected specialties	8.0
TGS	Was blood for triglycerides (TGS) test drawn at visit or within past 12 months?	All visits for selected specialties	7.8
LDL	Was blood for LDL test drawn at visit or within past 12 months?	All visits for selected specialties	7.7
HDL	Was blood for HDL test drawn at visit or within past 12 months?	All visits for selected specialties	7.7
CHOL	Was blood for total cholesterol test drawn at visit or within past 12 months?	All visits for selected specialties	7.7
SERUM	Was blood for serum creatinine drawn at visit or within past 12 months?	All visits for selected specialties	7.7
FBG	Was blood for fasting blood glucose (FBG) drawn at visit or within past 12 months?	All visits for selected specialties	7.6
REVOTHR	Percent of patient care revenue from other	All visits	25.6
REVCASER	Percent of patient care revenue from case rates	All visits	25.6
REVCAPR	Percent of patient care revenue from capitation	All visits	25.5
REVFFSR	Percent of patient care revenue from fee-for- service	All visits	25.4
PRMANR	Percent of patient care revenue from managed care contracts	All visits	20.1
HHSMU	Does your current system meet meaningful use criteria as defined by the Department of Health and Human Services?	All visits	18.2
PRPATR	Percent of patient revenue from patient payments	All visits	15.3
PROTHR	Percent of patient revenue from other	All visits	15.3
PRPRVTR	Percent of patient care revenue from private insurance	All visits	15.2
PRMAIDR	Percent of patient care revenue from Medicaid	All visits	15.2
PRMCARER	Percent of patient care revenue from Medicare	All visits	15.2

PAGE 32	2014 NAMCS N	/ICRO-DATA FILE DOCUM	IENTATION
DIFFEHR	Does your EHR have the capability to electronically send health information to another provider whose EHR system is different from your system?	All visits where DIFFEHR is applicable	13.6
EGRAPH	If viewing lab results included, can EHR/EMR automatically graph a specific patient's lab results over time?	All visits where EGRAPH is applicable	11.1
SECURCHCK	Has your practice made an assessment of the potential risks and vulnerability of your electronic health information within the last 12 months?	All visits where SECURCHCK is applicable	10.5
EPTREC	Does practice have computerized capability: providing patients the ability to view online, download, or transmit information from their medical record	All visits where EPTREC is applicable	9.9
ECQM	Does practice have computerized capability: reporting clinical quality measures to federal or state agencies	All visits where ECQM is applicable	8.4
MUSTAGE2	Plans to apply for stage 2 meaningful use incentive payments?	All visits where MUSTAGE2 is applicable	7.5
EFORMULA	If orders for prescriptions submitted electronically, drug formulary checks performed?	All visits where EFORMULA is applicable	7.4
EPTEDU	Does practice have computerized capability: identifying educational resources for patients' specific conditions	All visits where EPTEDU is applicable	6.9
EHRTOEHR	Is the patient health information that you share electronically sent directly from your EHR system to another EHR system?	All visits where EHRTOEHR is applicable	6.5
EIMMREG	Does practice have computerized capability: electronic reporting to immunization registries	All visits where EIMMREG is applicable	6.4
NNOCHRGE	Type of payments accepted from new patients: no charge/charity	All visits from providers that currently accept "new" patients	8.2
CAPITATE	Type of payments accepted from new patients: capitated private insurance	All visits from providers that currently accept "new" patients	6.8

As shown in the chart above, denominators for the above rates were adjusted to account for skip patterns in the data collection instrument. For example, only visits to physicians who accepted new patients were

included in the calculation of whether the physician accepted new patients with Medicaid, etc. Physician nonresponse to the initial item may also be taken into account, which would make nonresponse rates for the secondary item somewhat higher.

IMPORTANT: For items such as vital signs (patient height and weight, etc.), nonresponse rates are calculated for all visits, but it should be considered that such measurements are not routinely taken or reported at visits to certain specialties, such as psychiatry or dermatology among others. It is advisable for researchers to calculate their own nonresponse rates for their topic of interest; these rates are only provided as a general indicator.

Some missing data items were imputed by randomly assigning a value from a Patient Record form with similar characteristics, where similar visits were generally those with the same physician specialty, geographic region, and 3-digit ICD-9-CM codes for primary diagnosis. Race and ethnicity were imputed using a model-based, single, sequential regression imputation method. The model for imputing race and ethnicity used the following variables: Census race and ethnicity population estimates for ZIP code levels, duration of visit, patient age, patient sex, whether the visit occurred in an MSA, physician specialty recode, whether the visit included hypertension as a current diagnosis/chronic condition, diagnosis group, major reason for visit, and an indicator for patient ZIP code or provider ZIP (the latter was used for the Census variables if patient ZIP was not available). Also in 2014, time spent with physician was imputed using a similar model-based, single, sequential regression imputation method.

The following variables were imputed: birth year (0.1 percent), sex (0.6 percent), ethnicity (27.6 percent), race (26.9 percent), have you or anyone in your practice seen patient before? (2.0 percent), if yes, how many past visits in last 12 months? (13.9 percent of visits by established patients), and time spent with physician (36.2 percent of visits where a physician was seen). Blank or otherwise missing responses are so noted in the data.

J. MEDICAL CODING

The Patient Record form contains several medical items which use three separate coding systems. As stated previously, the following items -- patient's reason for visit, physician's diagnosis, cause of injury, and procedures --were transmitted to SRA International, Inc., Durham, North Carolina for processing. The medication item was coded by the NAMCS Drug Database Coordinator. These items and their coding systems are described briefly below.

1. <u>Patient's Complaint(s), Symptoms(s) or Other Reason(s) for this Visit</u>: Information on patient's reason for visit was collected in the automated Patient Record and coded according to <u>A Reason for Visit Classification for Ambulatory Care</u> (RVC) (3). The updated classification is available (4), and the list of codes is shown in Appendix II. The classification was updated to incorporate several new codes as well as changes to existing codes. The system continues to utilize a modular structure. The digits 1 through 8 precede the 3-digit RVC codes to identify the various modules as follows:

Prefix Module

- "1" = Symptom module
- "2" = Disease module
- "3" = Diagnostic, screening, and preventive module
- "4" = Treatment module
- "5" = Injuries and adverse effects module
- "6" = Test results module
- "7" = Administrative module
- "8" = Uncodable entries
- "-9" = Special code = blank

Up to five reasons for visit (up from the typical three in previous years) were coded from the reason for visit item in sequence; coding instructions for this item are contained in the Reason for Visit Classification and Coding Manual (4).

2. Cause of Injury, Poisoning, or Adverse Effect: Up to three causes of injury, poisoning, or adverse effect were coded from responses to the "Cause of injury, poisoning, or adverse effect" section in the Injury/Poisoning item on the NAMCS PRFs. Causes were coded using the Supplementary Classification of External Causes of Injury and Poisoning (E-codes), <u>International Classification of Diseases</u>, 9th Revision, Clinical Modification</sup> (ICD-9-CM) (5). In the classification, E-codes range from E000-E999, and many, but not all, codes have an additional fourth digit to provide greater specificity. For the NAMCS public use file, the 'E' has been dropped.

There is an implied decimal between the third and fourth digits; inapplicable fourth digits have a dash inserted.

Examples: 895- = E895 = Accident caused by controlled fire in private dwelling 9056 = E905.6 = Venomous marine animals and plants as the cause of poisoning and toxic reactions

In addition to these character codes, we have also provided numeric recodes for the cause of injury fields at the end of the record format. Please see page 52 in the Codebook section for more information on using the numeric recodes.

3. <u>Provider's Diagnosis for this Visit</u>: Diagnostic information on the automated Patient Record was coded according to the <u>International Classification of Diseases</u>, 9th Revision, <u>Clinical Modification</u> (ICD-9-CM) (5). The ICD-9-CM codes are provided in two formats, character and numeric. Please see page 52 in the Codebook section for information on the background, purpose, and appearance of the numeric recodes. The rest of this paragraph describes the format of the character version.

The character version ICD-9-CM codes are not prefixed or zerofilled on the data file. For example, 38100 = 381.00 = Acute nonsuppurative otitis media, unspecified.

There is an implied decimal between the third and fourth digits. For inapplicable fourth or fifth digits, a dash has been inserted.

For example, 4011- = 401.1 = Essential hypertension, benign.

Supplementary classification codes are not prefixed or zerofilled.

For example, V700- = V70.0 = Routine general medical examination at a health care facility.

In addition to the diagnostic codes from the ICD-9-CM the following unique codes in the diagnostic fields were developed by AHCSB staff:

- V990- = noncodable diagnosis, insufficient information for coding, illegible diagnosis
- V991- = left before being seen, patient walked out, not seen by doctor, left against medical advice
- V992- = transferred to another facility, sent to see specialist
- V993- = HMO will not authorize treatment
- V997- = entry of "none," "no diagnosis," "no disease," "healthy"
- -9 = blank

A maximum of five diagnoses (up from the typical three used in previous years) were coded in sequence. Coding instructions concerning diagnoses are contained in the NAMCS Coding Requirements Manual, volume 1 (6).

NOTE: The "Services" item in the automated Patient Record uses a checkbox format under the subheadings of Examinations/Screenings, Laboratory tests, Imaging, Procedures, Treatments, and Health Education/Counseling. It also allows for the coding of up to 9 open-ended fields in the last section, Other Services Not Listed. The combined format for all of these items was already being used in the data files beginning with 2009 data, achieved through data processing methods as explained in the 2009 public use file documentation. The 2014 instrument reflects the combined format, which should eliminate much of the ambiguity found during data processing in past years where the same procedure was sometimes reported by survey participants under different items.

Character format codes have an implied decimal between the second and third position and do not use prefixes or zerofills. Codes without an applicable 4th digit have a dash inserted. Please note that, as with the diagnosis codes described above, the file also contains numeric recodes for procedures. These are described in the Codebook section.

For 2014, checkboxes were added to the computerized tool, based on commonly reported write-in procedures from previous years of data. This measure was intended to facilitate reporting and reduce costs associated with medical coding of text entries. The result of this change is a decrease in the number of visits with write-in procedures, with a resulting loss of detail.

5. <u>Medications & Immunizations</u>: The NAMCS drug data collected under "Medications and Immunizations" have been classified and coded using the entry name (the entry made on the Patient Record) according to a unique classification scheme developed at NCHS (7). The medical classification system of drugs by entry name uses a five-digit coding scheme which is updated regularly to include new products. It includes the following special codes:

-9 = blank 99980 = unknown entry, other 99999 = illegible entry

For 2014, up to 30 medications could be recorded for each visit. A list of drug codes by entry name is included in Appendix III.

In addition to drugs coded by entry name, this file contains the following drug information:

a. Generic drug code: Beginning with the 2006 data release, drugs are coded in terms of their generic components and therapeutic classifications using Lexicon Plus[®], a proprietary database of Cerner Multum, Inc., also used by the National Health and Nutrition Examination Survey, NCHS. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market.

In accordance with the license agreement, NCHS publications, tabulations, and software applications should cite the Multum Lexicon as the source and basis for the coding and classification of NAMCS drug data. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: <u>http://www.cerner.com/multum_solutions/</u>.

Beginning with the 2006 data release, all drug codes based on entry name (using NCHS' classification system as cited above) were also assigned a unique generic drug code from Multum's Lexicon Drug Database, whenever possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's

ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NAMCS drug data.

For example, prior to 2006, if Tylenol No. 3 was reported in NAMCS, it was assigned a drug entry code of 32920 to reflect the entry of Tylenol No. 3. Using the NCHS generic classification, it was also given a code of 51380 in the generic code field to represent a combination product, and then received separate ingredient codes for acetaminophen and codeine. Under Multum, there is a single generic code that reflects the combination of acetaminophen with codeine.

The format of the generic drug code (now called DRUGID rather than GEN) also changed starting in 2006. Rather than the 5 digit numeric code used prior to 2006, the generic drug code is 6 digits, beginning with the letters "a", "c" or "d". Codes beginning with the letter "n" were also used, starting with 2009 data. All Multum codes begin with the letter "d", but there were some drug names reported by NAMCS participants that were not found in the Lexicon Drug Database. These were assigned unique drug codes beginning with an "a" where a drug's ingredients could be determined, or a "c" in the case where a drug's ingredients could not be determined for 2006-2007. Beginning with 2008 data, "n" codes have been used to code all drugs newly appearing in the NAMCS data for which a code could not be found in Multum. The variables DRUGID1 through DRUGID30 reflect the generic codes for each drug reported.

b. Prescription status code: A code designed to identify the legal status (prescription or nonprescription) of the drug entry.

c. Controlled substance status code: A code used to denote the degree of potential abuse and federal control of a drug entry.

d. Composition status code: A code used to distinguish between single-ingredient and combination drugs.

e. Therapeutic category code: In data years prior to 2006, a 4-digit code was used to identify up to three therapeutic classes to which the drug entry might belong. These were based on the standard drug classifications used in the National Drug Code Directory, 1995 edition (8).

However, as mentioned above, Multum's therapeutic classification system is now being used. The Multum Lexicon provides a 3-level nested category system that assigns a therapeutic classification to each drug and each ingredient of the drug (e.g., for naproxen: the broadest category is central nervous system agents [level 1]; the more detailed category is analgesics [level 2]; and the most detailed category is nonsteroidal anti-inflammatory agents [level 3]). Not all drugs have three classification levels; some may only have two [e.g. for digoxin: cardiovascular agents [level 1]; inotropic agents [level 2]), others only have one. See Appendix III for the complete Multum category scheme.

Each drug may have up to four therapeutic categories on the data file. The variables RX1CAT1 through RX10CAT4 reflect the unique Multum drug categories for a particular drug; these are character values with codes from '001' through '341'. **This variable will always show the most detailed therapeutic level available of a particular drug.** For example, psychotherapeutic agents in Multum are further classified into a second more detailed level as antidepressants or antipsychotics. Antidepressants are further classified into seven subcategories (miscellaneous antidepressants, SSRI antidepressants, tricyclic antidepressants, monoamine oxidase inhibitors, phenylpiperazine antidepressants, tetracyclic antidepressants, and SSNRI antidepressants); antipsychotics are further classified into five subcategories. For a drug categorized as a tricyclic antidepressant, it would have a drug category code of '209', reflecting the Level 3 code. Other drugs may have only two levels available, such as immunologic agents. There are seven level 2 categories of immunologic agents, and no further breakdowns into a third level in the Multum

system. Therefore, RX1CAT1 would reflect only a second level code in that case. So, using RX1CAT1-RX10CAT4 will allow one to identify the most specific level of a drug, but **will not, by itself, identify whether that code reflects the first, second, or third level.**

In order to understand each level in terms of the Multum hierarchy, we have also placed on the file additional variables that show the full first, second, and third levels, if applicable, for each drug category for each drug. For example, in the case of the tricyclic antidepressant mentioned earlier, RX1CAT1='307'. But there are three additional variables corresponding to that drug's first therapeutic category. RX1V1C1 (meaning Drug 1, Level 1 of Therapeutic Category 1) would be '242' (psychotherapeutic agents), RX1V2C1 (Drug 1, Level 2 of Therapeutic Category 1) would be '249' (antidepressants), and RX1V3C1 (Drug 1, Level 3 of Therapeutic Category 1) would be '307' (tricyclic antidepressants). If there were no second or third level for a particular category, the entry would be blank (' '). This is repeated for each of the drug's maximum of four therapeutic categories. The three levels can easily be concatenated by data users if they wish to obtain a complete code showing the full level structure applicable to each drug's therapeutic categories. An advantage of having separate levels is that it allows data users to aggregate drugs at any level desired. SAS code is provided at the website for micro-data users who wish to group therapeutic categories in various ways.

All drugs were coded using Multum drug categories, even those drugs not found in Multum's drug database. "Unspecified" drugs were assigned to their respective therapeutic category (e.g., hormones – unspecified: category id=97, category name=hormones). Drugs that could not be assigned to any drug entry name (MED1-10 = 99980, 99999) were not assigned a therapeutic drug category.

In some cases, NCHS was able to categorize a drug's therapeutic class at the first or second Multum level, but not at the more detailed level. When this occurred, the undetermined levels are designated as '999' in the data.

As mentioned above, Multum uses a "combination" category for some multiple ingredient drugs. These include antihypertensive combinations, antiasthmatic combinations, upper respiratory combinations, psychotherapeutic combinations, bronchodilator combinations, sex hormone combinations, skeletal muscle relaxant combinations, and narcotic analgesic combinations. This categorization may be sufficient for certain analyses but not for others because it lacks information about the therapeutic effect of the individual ingredients that make up the combination. For example, the drug HYDROCHLOROTHIAZIDE; LOSARTAN is identified as an antihypertensive combination.

Therefore, we know that this drug has an antihypertensive drug effect. However, based on this combination category we do not know that the drug's single ingredients have the therapeutic effects of a diuretic and angiotensin II inhibitor, which is relevant for some analyses.

As a result, NCHS decided that, in addition to assigning therapeutic categories to each drug, a separate file would be provided listing the ingredients for each drug along with the therapeutic classes for each ingredient. In the case of single ingredient drugs, the ingredient therapeutic categories would be the same as the drug therapeutic categories. This separate downloadable file (the current version is DRUG_INGREDIENTS_2014 and can be found under the "DRUGS" folder in the Downloadable Documentation section of the website: <u>ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/drugs/</u>) can be matched to the main file using the DRUGID code. For each DRUGID on the main file the

can be matched to the main file using the DRUGID code. For each DRUGID on the main file, the supplemental file contains up to 5 ingredients and up to 3 therapeutic category codes for each ingredient. In past years, codes used to identify the active generic ingredients of combination drugs were included on the data file.

IMPORTANT: In 2014, we have continued to update and revise the drug characteristics in our ambulatory care drug database, which underwent substantial revision in 2002. From 2002-2005, each drug entry had

up to three therapeutic classes associated with it, compared with a single therapeutic class in prior years. These factors made trend analysis more problematic, and the solution was to provide researchers with a Drug Characteristics file, which was updated annually, at our website. The characteristics from this file (prior to Multum adoption) could be applied by matching on drug codes to previous years of data in order to get the most accurate results when doing analysis of drug trends. A SAS program for applying drug characteristics from the then-current drug database to previous years of NAMCS data was also made available for downloading. These files are all still available on the NAMCS website, but are mainly of use only if the researcher is limiting analysis to years of data prior to 2006 and wishes to retain the old National Drug Code Directory therapeutic categories.

Starting with the 2006 survey, however, with the adoption of the Multum Lexicon for coding drugs according to generic ingredients and therapeutic categories, a new solution for trend analysis was necessary. Therefore, along with the 2006 data file release, we provided a separate downloadable mapping file (MEDCODE_DRUGID_MAP_2006), which allows data users to match all of the drug codes used in previous years (for example, MED1-MED8 in 2005) with the corresponding Multum DRUGID code for generic composition of the drug and its corresponding therapeutic categories. Once that has been accomplished, users can also, if they wish, match to the drug ingredient file as described above. The mapping file is updated for each new year, and can be downloaded at: http://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/drugs/. Researchers should keep in mind, however, that in cases where drug characteristics have legitimately changed over the years (e.g., moving from prescription to non-prescription status), using the current updated version of the drug characteristics will overwrite all of the previous characteristics with current ones.

For users who are interested in analyzing drug data, one method involves the isolation of those records with drugs, or drug mentions, and the creation of a separate data file of drug mentions. Each automated Patient Record for 2014 can have up to 30 drug mentions recorded, so whatever file is created would need to include all of them. This method can be used for obtaining estimates of drug mentions, but is not recommended for variance estimation. Rather, the structure of the visit file should be kept intact when estimating variance. In order to do this, estimates of drug mentions can be obtained by creating a new weight variable (called DRUGWT in this example). This variable is created by multiplying PATWT (the patient visit weight) by NUMMED (the number of medications recorded at the sampled visit) or DRUGWT=PATWT*NUMMED. DRUGWT can then be used in place of PATWT to weight one's data; it produces the estimated number of drug mentions rather than visits. (See Codebook section for more on PATWT and NUMMED.)

This documentation contains some marginal data for drug mentions. Also provided are drug coding lists in Appendix III. To facilitate searching for drugs in Appendix III, it is recommended that researchers utilize the online search function in Adobe Acrobat with the pdf document, or visit the survey website and use the online drug database under Research Tools (<u>http://www.cdc.gov/nchs/ahcd/ahcd_database.htm</u>). Should the data user need additional assistance in analyzing data on drug mentions, the staff of the Ambulatory and Hospital Care Statistics Branch is available by calling (301) 458-4600. Our website can be accessed at: <u>http://www.cdc.gov/nchs/namcs.htm</u>

K. ESTIMATION PROCEDURES

Statistics produced from the 2014 NAMCS were derived by a multistage estimation procedure. The procedure produces essentially unbiased national estimates and has four components: 1) inflation by reciprocals of the selection probabilities, 2) adjustment for nonresponse, 3) a ratio adjustment to fixed totals, and 4) weight smoothing. Each of these components is described below.

1. Inflation by Reciprocals of Sampling Probabilities

Since the survey utilized a two-stage sample design starting in 2012, there were two probabilities:

- a) the probability of selecting a physician within a stratum
- b) the probability of selecting a patient visit within the physician's practice

The strata used for the first probability were defined by practice type (primary care or nonprimary care) and geographical areas defined by the nine Census divisions and the 17 most populous states. The last probability was defined to be the exact number of office visits during the physician's specified reporting week divided by the number of Patient Record forms completed. All weekly estimates were inflated by the number of weeks annually in which the physician typically sees patients in his/her practice to derive annual estimates.

2. Adjustment for Nonresponse

NAMCS visit estimates were adjusted to account for in-scope physicians who did not provide PRFs (non-PRF physicians) either because they saw no patients during their sample week or failed to provide PRFs for visits by patients they did see during their sample week. For 2014, these adjustments account for nonresponse within physician specialty group, the 25 geographical areas defined by selected states and division remainders for the 2014 NAMCS, and metropolitan statistical area status.

Beginning with 2004 data, changes were made to the nonresponse adjustment factor to account for the seasonality of the reporting period. Weights for nonresponding physicians were shifted to responding physicians in reporting periods within the same quarter of the year. The shift in nonresponse adjustment did not significantly affect any of the overall annual estimates.

Beginning with 2003 data, the adjustment for non-PRF physicians differs from the adjustment used in prior years. The revised nonresponse adjustment uses information on physicians' practice sizes, as measured by number of weekly visits, and for variability in number of weeks that participating physicians saw patients during the year. Previously, these characteristics were assumed to be the same for physicians providing patient encounter information and those not providing such information. However, research showed that these two assumptions are not always true. In general, the weekly visit volume for non-PRF physicians was larger than for PRF physicians. Also, physicians who saw no patients during their sample week tended to see patients fewer weeks annually than did physicians who saw patients during their week. To minimize understatement (and in some cases, overstatement) of visits, the nonresponse adjustment factor was revised to include information on the number of weeks physicians actually practiced during a typical year and the number of visits physicians reported seeing during a normal practice week. Both data items were collected for responding and nonresponding physicians during the induction interview starting with the 2001 survey.

The 2003 weight with the revised nonresponse adjustment increased the overall visit estimate by 12 percent over the same estimate obtained using the original weight. For this reason, 2003 and subsequent year visit estimates are not entirely comparable to visit estimates computed using the previous weighting strategy. If researchers are presenting data with estimates or rates across these years, we recommend including a footnote such as the following: "The weights for 2003 and later years include adjustments for variation in the typical number of weeks worked annually and for variation in visit volume in a work week, whereas the weights for earlier years do not. The revised weighting algorithm increased visit estimates."

3. Ratio Adjustment

A post-ratio adjustment was made within each of the physician specialty groups and area sampling strata. The ratio adjustment is a multiplication factor which had as its numerator the number of physicians in the universe in each physician specialty group and area and as its denominator the estimated number of physicians in that particular specialty group and area. The numerator was based on figures obtained from the AMA and AOA master files for the survey year, and the denominator was the estimated number based on the sample.

4. Weight Smoothing

Each year there may be a few sample physicians whose final visit weights are large relative to those for the rest of the sample. There is a concern that those few may adversely affect the ability of the resulting statistics to reflect the universe, especially if the sampled patient visits to some of those few physicians should be unusual relative to the universe. Extremes in final weights also increase the resulting variances. Extreme weights can be truncated, but this leads to an understatement of the total visit count. The technique of weight smoothing is used instead, because it preserves the total estimated visit count within each specialty by shifting the "excess" from visits with the largest weights to visits with smaller weights.

Excessively large visit weights were trimmed, and a ratio adjustment was performed to yield the same estimated total visit count as the unsmoothed weights. The ratio adjustment is a multiplication factor that uses as its numerator the total visit count in each physician group before the largest weights are trimmed, and, as its denominator, the total visit count in the same group after the largest weights are trimmed. This smoothing was done within each physician group defined by specialty, the 25 geographic survey areas used for the 2014 survey, and MSA status.

L. SAMPLING ERRORS

Procedures for calculating sampling errors as well as estimates of standard errors of statistics derived from NAMCS are described elsewhere (2) as well as in Appendix I of this document.

M. PATIENT VISIT WEIGHTS

The 2014 NAMCS data file contains two "patient visit weights" – one (PATWT) for producing national, regional and divisional estimates from sample data, and the other (PATWTST) for producing state estimates from sample data. These are vital components of the survey data and micro-data file users should understand how to use them correctly.

The statistics contained on the micro-data file reflect data concerning only a sample of patient visits, not a complete count of all the visits that occurred in the United States. Each record on the data file represents one visit in the sample of 45,710 visits. In order to obtain visit estimates from survey data, each record is assigned an inflation factor called the "patient visit weight." By aggregating the patient visit weights contained in the PATWT variable on the 45,710 sample records for 2014, the user can obtain the estimated total of 884,707,172 office visits made in the United States. By aggregating the patient visit weights contained in the PATWTST variable within each of the 18 individual states targeted for separate estimates, data users can obtain the estimated totals of office visits made in those states.

The traditional weighting variable (PATWT) and the state weighting variable (PATWTST) are not interchangeable. That is, the state weighting variable is only to be used for individual state estimates and will not sum to national estimates because only 18 states were targeted for state-level estimation. Furthermore, PATWTST should not be used to make divisional estimates, even within the additional 7 'division remainders', which contain the smallest 32 states and the District of Columbia, grouped within their Census divisions. PATWT should be used to produce those estimates.

PAGE 40

Users may notice that the PATWTST variable contains miniscule weights (0.00001) for visits that were sampled within division remainders rather than by state. These include the New England, West North Central, South Atlantic, East South Central, West South Central, Mountain and Pacific Division Remainders. This was done to ensure that such visits were not dropped from analysis due to having non-positive weights. If these visits were dropped, as occurs with SUDAAN software, variance estimation would be affected.

The marginal tables on pages 135-142 contain data on numbers of records for selected variables as well as the corresponding national estimated number of visits and drug mentions obtained by aggregating the PATWT version of "patient visit weights" on those records. Similar tables are also provided for physician-level estimates. A table containing estimated visit totals for each state using the PATWTST variable is also provided.

N. PHYSICIAN CODE and PATIENT CODE

The purpose of these codes is to allow for greater analytical depth by permitting the user to link individual Patient Record forms on the data file with individual physicians' practices. This linkage enables users to conduct more comprehensive analysis without violating the confidentiality of patients or physicians.

To uniquely identify a record, both the unique 4-digit physician code and the 3-digit patient code must be used. Patient codes are merely a sequential numbering of the visits recorded by the physician and alone will not uniquely identify visit records.

O. USE OF THE PHYSICIAN-LEVEL WEIGHT

The physician-level weight (PHYSWT) has been available on the public use since the 2005 data release, but is available for earlier years in the NCHS Research Data Center. These weights allow data users to calculate physician-level estimates. There is one weight for each physician which appears on the first visit record only for that physician. When running an analysis of physician-level characteristics using PHYSWT, it is recommended to select only those records where PHYSWT is greater than 0. This will result in correct sample counts, which are useful for assessing reliability. Weighted estimates will be correct either way, because of the one weight per physician format.

It should be kept in mind, however, that estimates at the physician level generated using PHYSWT only reflect those physicians who saw patients in their sample week. There were an additional 503 physicians who responded to the 2014 NAMCS but did not see any patients during their sampled week due to being on vacation or other reasons. The physician estimates produced using NAMCS data in public use data files do not include data for such physicians nor physicians who did see patients in their sample week but who refused to participate in the survey. Therefore, estimates made with PHYSWT may be biased due to the omission of such physicians, if such physicians have different characteristics than those who provided data on sample visits. Physician-level estimates from the NAMCS visit-level file are better for analyzing visit characteristics at the physician level, because such characteristics would not be biased by the omission of physicians who didn't see patients. For example, one could examine average time spent with physicians across physicians rather than simply across visits. This type of analysis is slightly complicated; a description along with sample SAS code is available at the Ambulatory Health Care Data website.

Data users should also keep in mind the effects of nonresponse bias when producing physician-level estimates. See page 3 for additional information or contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

REFERENCES

- Hing E, Shimizu IM, Talwalkar A. Nonresponse bias in estimates from the 2012 National Ambulatory Medical Care Survey. National Center for Health Statistics. Vital Health Stat 2(171). 2016.
- Physician Induction Interview Form. National Ambulatory Medical Care Survey. OMB No. 0920-0234.
- 3. Schneider D, Appleton L, McLemore T. A Reason for Visit Classification for Ambulatory Care. National Center for Health Statistics. Vital Health Stat 2(78). 1979.
- 4. National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey Reason for Visit Classification and Coding Manual: (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.
- 5. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services. Official version: International Classification of Diseases, Ninth Revision, Clinical Modification, Sixth Edition. DHHS Pub No. (PHS) 06-1260.
- National Ambulatory Medical Care Survey: Coding Requirements (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.
- 7. Koch H, Campbell W. The Collection and Processing of Drug Information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 2(90). 1982.
- 8. Food and Drug Administration. National Drug Code Directory, 1995 edition. Washington: Public Health Service. 1995.

II. CODEBOOK AND PHYSICIAN SPECIALTY LIST

A. CODEBOOK

Number of records = 45,710

This section consists of a detailed breakdown of each variable on the record, including a sequential item number, field length, file location, and brief description, along with valid codes. Most data are from the automated Patient Record form (PRF). The American Medical Association (AMA), the American Osteopathic Association (AOA) and the automated Physician Induction Interview (reference 3) are alternate sources of data. Some information is obtained by recoding selected data from these sources.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
			DATE OF VISIT	
1	2	1-2	[VMONTH] MONTH OF VISIT	
			01-12: January-December	
2	1	3	[VDAYR] DAY OF WEEK OF VISIT	
			1 = Sunday 2 = Monday 3 = Tuesday 4 = Wednesday 5 = Thursday 6 = Friday 7 = Saturday	
3	3	4-6	[AGE] PATIENT AGE (reported in years or derived from date of visit and date of birth) Age has been top coded in accordance with NCHS confidentiality requirements.	
			000 = Under 1 year 001-091 = 1-91 years 092 = 92 years or older	
4	1	7	[AGER] AGE RECODE	
			1 = Under 15 years 2 = $15-24$ years 3 = $25-44$ years 4 = $45-64$ years 5 = $65-74$ years 6 = 75 years and over	

PAGE 44			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
5	3	8-10	[AGEDAYS] AGE IN DAYS FOR PATIENTS LESS THAN ONE YEAR OF AGE (derived from date of visit and date of birth)
			-7 = Not applicable 0-364 (0 = Less than one day old)
6	1	11	[SEX] SEX
			1 = Female 2 = Male
7	2	12-13 [P	REGNANT] IF FEMALE. IS PATIENT PREGNANT?
			-9 = Blank -8 = Unknown -7 = Not Applicable 1 = Yes 2 = No
8	2	14-15	[GESTWK] IF PATIENT IS PREGNANT, SPECIFY GESTATION WEEK
			-9 = Blank -8 = Unknown -7 = Not Applicable 2-44
9	2	16-17	[ETHUN] UNIMPUTED ETHNICITY
			This variable is NOT imputed. Ethnicity data were missing for 27.6 percent of NAMCS visit records. -9 = Blank -8 = Unknown -6 = Refused to answer 1 = Hispanic or Latino 2 = Not Hispanic or Latino
10	2	18-19	[RACEUN] UNIMPUTED RACE
			This variable is NOT imputed. Race data were missing for 26.9 percent of NAMCS visit records.
			-9 = Blank 1 = White 2 = Black or African American 3 = Asian 4 = Native Hawaiian or Other Pacific Islander 5 = American Indian or Alaska Native 6 = More than one race reported

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
11	1	20	[ETHIM] IMPUTED ETHNICITY
			Missing data for ethnicity were imputed for this variable. Ethnicity data were missing for 27.6 percent of NAMCS visit records. 1 = Hispanic 2 = Not Hispanic
12	1	21	[RACER] IMPUTED RACE
			Missing data for race were imputed for this variable. Race data were missing for 26.9 percent of NAMCS visit records. 1 = White 2 = Black 3 = Other
13	1	22	[RACERETH] IMPUTED RACE/ETHNICITY
			Missing race and ethnicity data were imputed for this variable. Both race and ethnicity were missing for 20.9 percent of records. Race alone was missing for an additional 6.0 percent, and ethnicity alone was missing for an additional 6.7 percent of records.
			NOTE: In survey years prior to 2009, the categories were Non- Hispanic White, Non-Hispanic Black, Hispanic, Asian, Native Hawaiian/Other Pacific Islander, American Indian or Alaska Native, and Multiple Races. Starting in 2009, the decision was made to reformulate this item. Hispanic can now be of any race.
			1 = White Only, Non-Hispanic 2 = Black Only, Non-Hispanic 3 = Hispanic 4 = Other Race/Multiple Race, Non-Hispanic
14	1	23	[NOPAY] NO RESPONSE TO EXPECTED SOURCE(S) OF PAYMENT FOR THIS VISIT
			0 = At least one source of payment was reported 1 = All expected source of payment boxes are blank
15	1	24	[PAYPRIV] EXPECTED SOURCE OF PAYMENT: PRIVATE INSURANCE
			0 = No 1 = Yes
16	1	25	[PAYMCARE] EXPECTED SOURCE OF PAYMENT: MEDICARE
			0 = No 1 = Yes

PAGE 46			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
17	1	26	[PAYMCAID] EXPECTED SOURCE OF PAYMENT: MEDICAID or CHIP
			0 = No 1 = Yes
18	1	27	[PAYWKCMP] EXPECTED SOURCE OF PAYMENT: WORKER'S COMPENSATION
			0 = No 1 = Yes
19	1	28	[PAYSELF] EXPECTED SOURCE OF PAYMENT: SELF-PAY
			0 = No 1 = Yes
20	1	29	[PAYNOCHG] EXPECTED SOURCE OF PAYMENT: NO CHARGE/CHARITY
			0 = No 1 = Yes
21	1	30	[PAYOTH] EXPECTED SOURCE OF PAYMENT: OTHER
			0 = No 1 = Yes
22	1	31	[PAYDK] EXPECTED SOURCE OF PAYMENT: UNKNOWN
			0 = No 1 = Yes

ITEM	FIELD	FILE	[ITEM NAME], DESCRIPTION, AND CODES
NO.	LENGTH	LOCATION	
23	2	32-33	[PAYTYPER] RECODED PRIMARY EXPECTED SOURCE OF PAYMENT FOR THIS VISIT (Recoded from 'Expected Sources of Payment for this Visit' using this hierarchy of payment categories: Medicare, Medicaid or CHIP/SCHIP, Private Insurance, Worker's Compensation, Self-Pay, No Charge/Charity, Other, Unknown)

IMPORTANT: For more information about earlier versions of the variable PAYTYPE, and variable PAYTYPER which used a different hierarchy of payment categories, please see the 2009 NAMCS Public Use Data File Documentation.

- -9 = Blank
- -8 = Unknown
- 1 = Private insurance
- 2 = Medicare
- 3 = Medicaid or CHIP
- 4 = Worker's Compensation
- 5 =Self-pay
- 6 = No charge/charity
- 7 = Other

24 2 34-35 [USETOBAC] TOBACCO USE

- -9 = Blank
- -8 = Unknown
- 1 = Never smoked
- 2 = Former smoker
- 3 = Current smoker

INJURY VARIABLES

There are three separate injury-related variables: one which asks if the visit was related to injury/trauma, poisoning, or adverse effects of medical care, a second item (new in 2014) which asks whether the injury or poisoning occurred within 72 hours prior to the visit, and a third item which asks about intentionality. This format is different from survey years prior to 2012, when one item was used which combined whether the visit was related to injury/poisoning/adverse effect and what the intent was. Also, in years before 2012, 'poisoning' was not listed as a separate category.

For trending purposes, the variables INJURY, INJR1, and INJR2 are still available in 2014. The differences between these variables are explained in more detail in the 2010 NAMCS Public Use Data File Documentation. Briefly, INJURY reflects the broad definition of injury used traditionally in NAMCS. INJR1 has been recoded from INJURY and uses a narrower definition of injury which was recommended by subject matter experts in the NCHS Office of Analysis and Epidemiology (OAE). It is based mainly on first-listed reason for visit and first-listed diagnosis and does not include adverse effects of medical treatment. INJR2 is based on the narrower NCHS OAE definition, but includes second-, third-, fourth-, and fifth-listed reasons and diagnoses, not just first-listed.

The INJDET variable contained in survey years before 2012 is no longer collected. However, a similar item (INJDET_TRD) was created during data processing using data from the new injury items (INJPOISAD and INTENT), as well as Reason for Visit and Diagnosis. In addition, each record contained verbatim entries which are not included in the public use file but which were used to evaluate whether a visit was injury related. INJDET_TRD can be compared with INJDET from previous years. Similarly, two

PAGE 4	8		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

recoded variables INJDETR1_TRD and INJDETR2_TRD were created, which can be trended with INJDETR1 and INJDETR2 from previous years. INJDETR1_TRD uses the narrower OAE definition, comparable to INJR1, and INJDETR2_TRD uses the OAE definition used with INJR2.

As mentioned previously, INJPOISAD and INTENT replaced the previous INJDET variable on the survey instrument. INJPOISAD is provided here in three versions for consistency with the other injury items. The first version (INJPOISAD) is edited according to the broad injury definition used with NAMCS data and is comparable with INJURY and INJDET_TRD. INJPOISADR1 uses the narrower OAE definition comparable to INJR1 and INJDETR1_TRD. INJPOISADR2 uses the same definition as INJR2 and INJDETR2_TRD.

25	2	36-37	[INJURY] Is this visit related to an injury, poisoning, or adverse effect of medical treatment? – Based on Injury, Reason for Visit, Cause of Injury and Diagnosis items, using the broad definition of injury traditionally used with NAMCS data.
			 -9 = Blank -8 = Unknown 0 = No 1 = Yes 2 = Questionable injury status (indicates visits which were reported to be injury related but for which there was no indication on the record based on reason for visit, cause of injury, or diagnosis)
26	1	38	[INJR1] Is this visit related to an injury or poisoning? Recoded version #1 (recoded from Injury, Reason for Visit, Cause of Injury and Diagnosis items).
			0 = No (includes blank and unknown; can be crossed with INJURY to see where those occur) 1 = Yes

This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **first-listed reason for visit**, **first-listed cause of injury**, **and first-listed diagnosis** only. Note that adverse effects of medicinal drugs and adverse effects or complications of medical and surgical care are not included in this definition. However, that information, based on **first-listed reason for visit and first-listed diagnosis**, can be found in category 4 of the INJDETR1_TRD item.

27	1	39	[INJR2] Is this visit related to an injury or poisoning? Recoded version #2 (recoded from Injury, Reason for Visit, Cause of Injury, and Diagnosis items).
			0 = No (includes blank and unknown; can be crossed with INJURY to see where these occur) 1 = Yes

This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **any-listed reason for visit, any-listed cause of injury, and any-listed diagnosis.** Note that adverse effects of medicinal drugs and adverse effects or complications of medical and surgical care are not included in this definition. However, that information, based on **any-listed**

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

reason for visit, any-listed cause of injury, and any-listed diagnosis, can be found in category 4 of the INJDETR2_TRD item.

adverse effe		40-41	[INJPOISAD] Is this visit related to an injury/trauma, poisoning, or adverse effect of medical treatment? (2012 was the first year for this format on the automated Patient Record form.)		
			-9 = Blank -8 = Unknown 1 = Yes, injury/trauma 2 = Yes, poisoning 3 = Yes, adverse effect of medical treatment 4 = No 5 = Questionable injury status		
29	1	42	[INJPOISADR1] Is this visit related to an injury/trauma, poisoning, or adverse effect of medical treatment? (Recoded version #1, based on first-listed Reason for Visit, Cause of Injury, and Diagnosis.)		
			 1 = Yes, injury/trauma 2 = Yes, poisoning 3 = Yes, adverse effect of medical treatment 4 = No (includes blank and unknown; can be crossed with INJURY to see where those occur) 		
INJPOISADR1 uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on first-listed reason for visit, first-listed cause of injury, and first-listed diagnosis only. In addition, first-listed reason for visit, first-listed cause of injury, and first-listed diagnosis codes were used to edit checkbox 3.					

30 1 43 [INJPOISADR2] Is this visit related to an injury/trauma, poisoning, or adverse effect of medical treatment? (Recoded version #2, based on any-listed (first, second, or third) Reason for Visit, Cause of Injury, and Diagnosis.)

1	_ `	Vac	ini	ium	/tr	auma	2
L	=	res,		un	y/u	aum	1

2 =Yes, poisoning

3 = Yes, adverse effect of medical treatment

4 = No (includes blank and unknown; can be crossed with INJURY to see where those occur)

INJPOISADR2 uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on any-listed reason for visit, any-listed cause of injury, and any-listed diagnosis. In addition, any-listed reason for visit, any-listed cause of injury, and any-listed diagnosis codes were used to edit checkbox 3.

PAGE 50)		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
31	2	44.45	 [INJURY72] Did the injury or poisoning occur within 72 hours prior to the date and time of this visit? -9=Blank -8=Unknown -7=Not applicable 1=Yes 2=No
32	2	46-47	 [INTENT] Is this injury or poisoning intentional or unintentional? NOTE: The order of the categories was changed on the survey instrument for 2014. Previously, "Unintentional" was listed first. Use caution when combining data across years. -9 = Blank -8 = Unknown 1 = Intentional 2 = Unintentional 3 = Questionable injury status
33	2	48-49	[INJDET_TRD] Is this visit related to any of the following:

This variable was created during data processing using INJURY, INTENT, Reason for Visit, Cause of Injury, and Diagnosis, as well as any relevant verbatim entries on the record.

- -9 = Blank
- -8 = Unknown
- -5 = Intentionality does not apply
- 1 = Unintentional injury/poisoning
- 2 = Intentional injury/poisoning
- 3 = Injury/poisoning unknown intent
- 4 = Adverse effect of medical/surgical care or adverse effect of medicinal drug
- 5 = Visit is not related to injury/poisoning or adverse effect of medical treatment
- 6 = Questionable injury status

|--|

ITEM	FIELD	FILE	[ITEM NAME], DESCRIPTION, AND CODES
NO.	LENGTH	LOCATION	
34	1	50	[INJDETR1_TRD] (INJURY/POISONING/ADVERSE EFFECT – Recoded version #1).

Is this visit related to any of the following:

This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **first-listed reason for visit**, **first-listed cause of injury**, **and first-listed diagnosis** only. In addition, **first-listed reason for visit**, **first-listed cause of injury**, **and first-listed diagnosis** codes were used to edit checkbox 4.

			 1 = Unintentional injury/poisoning 2 = Intentional injury/poisoning 3 = Injury/poisoning – unknown intent 4 = Adverse effect of medical/surgical care or adverse effect of medicinal drug 5 = Visit Is not related to injury/poisoning or adverse effect of medical treatment 	
35	1	51	[INJDETR2_TRD] (INJURY/POISONING/ADVERSE EFFECT – Recoded version #2).	
			Is this visit related to any of the following:	
This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on any-listed reason for visit, any-listed cause of injury, and any-listed diagnosis . In addition, any-listed reason for visit, any-listed cause of injury, and any-listed diagnosis codes were used to edit checkbox 4.				
			 1 = Unintentional injury/poisoning 2 = Intentional injury/poisoning 3 = Injury/poisoning – unknown intent 4 = Adverse effect of medical/surgical care or adverse effect of medicinal drug 5 = Visit is not related to injury/poisoning or adverse effect of medical treatment 	
			PATIENT'S REASON(S) FOR VISIT (See page 33 in Section I and Coding List in Appendix II.)	
36	5	52-56	[RFV1] REASON # 1	
			-9 = Blank 10050-89990 = 1005.0-8999.0	
37	5	57-61	[RFV2] REASON # 2	
			-9 = Blank 10050-89990 = 1005.0-8999.0	

PAGE 52

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
38	5	62-66	[RFV3] REASON # 3
			-9 = Blank 10050-89990 = 1005.0-8999.0
39	5	67-71	[RFV4] REASON # 4
			-9 = Blank 10050-89990 = 1005.0-8999.0
40	5	72-76	[RFV5] REASON # 5
			-9 = Blank 10050-89990 = 1005.0-8999.0
41	4	77-80	[CAUSE1] CAUSE OF INJURY #1 (ICD-9-CM, E-Codes) There is an implied decimal between the third and fourth digits; for inapplicable fourth digits, a dash is inserted. A prefix 'E' is implied. Codes in the 700- series were developed by the Ambulatory and Hospital Care Statistics Branch.
			-9 = Not applicable/Blank 700- = Drug use/abuse 710- = Alcohol use/abuse 8000-999[-] = E800.0-E999
42	4	81-84	[CAUSE2] CAUSE OF INJURY #2 (ICD-9-CM, E-Codes) There is an implied decimal between the third and fourth digits; for inapplicable fourth digits, a dash is inserted. A prefix 'E' is implied. Codes in the 700- series were developed by the Ambulatory and Hospital Care Statistics Branch.
			NOTE: CAUSE2 and CAUSE3 include additional activity codes (E000.0-E030.0) that can be used to indicate the activity of the patient seeking health care for an injury or health condition.
			-9 = Not applicable/Blank 700- = Drug use/abuse 710- = Alcohol use/abuse 0000-999[-] = E000.0-E999
43	4	85-88	[CAUSE3] CAUSE #3 (ICD-9-CM, E-Codes) There is an implied decimal between the third and fourth digits; for inapplicable fourth digits, a dash is inserted. A prefix 'E' is implied. See CAUSE #2 for details.

NUMERIC RECODES FOR CAUSE OF INJURY

The following recodes are included on the public use file to facilitate analysis of visits using ICD-9-CM Ecodes. It had come to our attention in the past that some users of NHAMCS data find it preferable to use

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

the numeric field recodes rather than the alphanumeric fields in certain data applications. Users can make their own choice about which format best suits their needs (more information can be found on page 34).

44	4	89-92	[CAUSE1R] CAUSE OF INJURY #1 (Recode to Numeric Field) -9 = Blank 7000 = Drug use/abuse 7100 = Alcohol use/abuse 8000-9999 = E800.0 - E999.[9]
45	4	93-96	[CAUSE2R] CAUSE OF INJURY #2 (Recode to Numeric Field) -9 = Blank 7000 = Drug use/abuse 7100 = Alcohol use/abuse 0000-9999 = E000.0 - E999.[9]
46	4	97-100	[CAUSE3R] CAUSE OF INJURY #3 (Recode to Numeric Field) See CAUSE2R.
47	2	101-102	[PRIMCARE] ARE YOU THE PATIENT'S PRIMARY CARE PHYSICIAN? -9 = Blank -8 = Unknown 1 = Yes 2 = No
48	2	103-104	[REFER] WAS PATIENT REFERRED FOR THIS VISIT?
			-9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No
49	1	105	[SENBEFOR] HAS THE PATIENT BEEN SEEN IN YOUR PRACTICE BEFORE?
			1 = Yes, established patient 2 = No, new patient

PAGE 54			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
50	3	106-108	[PASTVIS] HOW MANY PAST VISITS IN THE LAST 12 MONTHS? The value has been topcoded at 35 for visits to all specialties except psychiatry and at 135 for visits to psychiatrists. Top coding of outlier values was done in accordance with NCHS confidentiality requirements.
			-7 = Not applicable 0-34 = 0-34 visits 35 = 35 visits or more (applies to all specialties except psychiatry) 36-134 (psychiatry only) 135 = 135 visits or more (psychiatry only)
51	2	109-110	[MAJOR] MAJOR REASON FOR THIS VISIT
			-9 = Blank 1 = New problem (<3 mos. onset) 2 = Chronic problem, routine 3 = Chronic problem, flare-up 4 = Pre surgery 5 = Post surgery 6 = Preventive care (e.g. routine prenatal, well-baby, screening, insurance, general exams)
			DIAGNOSES (See page 34, Section 1 for explanation of coding.)
			Note: Physician's diagnosis was modified slightly on 1.0 percent of records due to confidentiality requirements.
52	5	111-115	[DIAG1] DIAGNOSIS # 1 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted.
			-9 = Blank 0010[-] - V829[-] = 001.0[0]-V82.9[0] V990- = Noncodable, insufficient information for coding, illegible V991- = Left before being seen; patient walked out; not seen by doctor; left against medical advice V992- = Transferred to another facility; sent to see specialist V993- = HMO will not authorize treatment V997- = Entry of "none," "no diagnosis," "no disease," or "healthy"
53	2	116-117	[PRDIAG1] IS DIAGNOSIS #1 PROBABLE, QUESTIONABLE, OR RULE OUT?
			-7 = Not applicable 1 = Yes 2 = No

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
54	5	118-122	[DIAG2] DIAGNOSIS # 2 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
55	2	123-124	[PRDIAG2] IS DIAGNOSIS #2 PROBABLE, QUESTIONABLE, OR RULE OUT?
			-7 = Not applicable 1 = Yes 2 = No
56	5	125-129	[DIAG3] DIAGNOSIS # 3 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
57	2	130-131	[PRDIAG3] IS DIAGNOSIS #3 PROBABLE, QUESTIONABLE, OR RULE OUT?
			-7 = Not applicable 1 = Yes 2 = No
58	5	132-136	[DIAG4] DIAGNOSIS # 4 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
59	2	137-138	[PRDIAG4] IS DIAGNOSIS #3 PROBABLE, QUESTIONABLE, OR RULE OUT?
			-7 = Not applicable 1 = Yes 2 = No
60	5	139-143	[DIAG5] DIAGNOSIS # 5 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
61	2	144-145	[PRDIAG5] IS DIAGNOSIS #3 PROBABLE, QUESTIONABLE, OR RULE OUT?
			-7 = Not applicable 1 = Yes 2 = No
			NUMERIC RECODES FOR DIAGNOSES

The following items were included on the public use file to facilitate analysis of visits using ICD-9-CM codes. Prior to the 1995 public use file, all ICD-9-CM diagnosis codes on the NAMCS micro-data file were converted from alphanumeric to numeric fields according to the following coding conventions: A prefix of '1' was added to ICD-9-CM codes in the range of 001.0[-] through 999.9[-]. A prefix of '20' was

PAGE 56			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

substituted for the letter 'V' for codes in the range of V01.0[-] through V82.9[-]. Inapplicable fourth or fifth digits were zerofilled. This conversion was done to facilitate analysis of ICD-9-CM data using Ambulatory Care Statistics software systems. Specific coding conventions are discussed in the public use documentation for each data year.

In 1995, however, the decision was made to use actual ICD-9-CM codes on the public use data file. Codes were not prefixed, and a dash was inserted for inapplicable fourth or fifth digits. This had the advantage of preserving actual codes and avoiding possible confusion over the creation of some artificial codes due to zerofilling.

It had come to our attention in the past that some users of NAMCS data find it preferable to use the numeric field recodes rather than the alphanumeric fields in certain data applications. Therefore, since data year 1997, we have included numeric recodes for ICD-9-CM diagnosis codes on our datasets. These are in addition to the actual codes for these diagnoses which appear earlier on the public use file. Users can make their own choice about which format best suits their needs.

62	6	146-151	[DIAG1R] DIAGNOSIS # 1 (Recode to Numeric Field)
			-9 = Blank 100100-208290 = 001.0[0]-V82.9[0] 209900 = Noncodable, insufficient information for coding, Illegible 209910 = Left before being seen; patient walked out; not seen by doctor; left against medical advice 209920 = Transferred to another facility; sent to see specialist 209930 = HMO will not authorize treatment 209970 = Entry of "none," "no diagnosis," "no disease," or "healthy"
63	6	152-157	[DIAG2R] DIAGNOSIS # 2 (Recode to Numeric Field) Same as DIAG1R.
64	6	158-163	[DIAG3R] DIAGNOSIS # 3 (Recode to Numeric Field) Same as DIAG1R.
65	6	164-169	[DIAG4R] DIAGNOSIS # 4 (Recode to Numeric Field) Same as DIAG1R.
66	6	170-175	[DIAG5R] DIAGNOSIS # 5 (Recode to Numeric Field) Same as DIAG1R.
			REGARDLESS OF THE DIAGNOSES WRITTEN ABOVE, DOES THE PATIENT NOW HAVE:
			0 = No 1 = Yes
67 68 69 70	1 1 1 1	176 177 178 179	[ETOHAB] Alcohol misuse, abuse, or dependence [ALZHD] Alzheimer's Disease [ARTHRTIS] Arthritis [ASTHMA] Asthma

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
71	2	180-181	[ASTH_SEV] Asthma severity -9 = Blank -7 = Not applicable 1 = Intermittent 2 = Mild persistent 3 = Moderate persistent 4 = Severe persistent 5 = Other, specify 6 = None recorded
72	2	182-183	[ASTH_CON] Asthma control -9=Blank -7=Not applicable 1=Well-controlled 2=Not well controlled 3=Very poorly controlled 4=Other, specify 5=None recorded
73	1	184	[CANCER] Cancer
74	1	185	[CEBVD] Cerebrovascular disease/History of stroke or transient ischemic attack (TIA)
75	1	186	[CKD] Chronic kidney disease
76 77	1 1	187 188	[COPD] Chronic obstructive pulmonary disease (COPD)
78	1	189	[CHF] Congestive heart failure [CAD] Coronary artery disease, ischemic heart disease, or history of myocardial infarction
79	1	190	[DEPRN] Depression
80	1	191	[DIABTYP1] Diabetes mellitus, type I
81	1	192	[DIABTYP2] Diabetes mellitus, type II
82	1	193	[DIABTYP0] Diabetes mellitus, type unspecified
83	1	194	[ESRD] End stage renal disease
84 05	1	195	[HPE] History of pulmonary embolism or deep vein thrombosis
85 86	1 1	196 197	[HIV] HIV infection [HYPLIPID] Hyperlipidemia
80 87	1	197	[HTN] Hypertension
88	1	199	[OBESITY] Obesity
89	1	200	[OSA] Obstructive sleep apnea
90	1	201	[OSTPRSIS] Osteoporosis
91	1	202	[SUBSTAB] Substance abuse
92	1	203	[NOCHRON] None of the above
			0 = "None" not checked 1 = "None" checked 2 = Entire item blank
93	2	204-205	[TOTCHRON] TOTAL NUMBER OF CHRONIC CONDITIONS
			-9 = Entire item blank 0-11 (highest number reported)

PAGE 58	3		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			VITAL SIGNS
94	1	206	[HTTAKE] Was height measurement reported? (Created during data processing based on reported data.)
			0 = No 1= Yes
95	2	207-208	[HTIN] PATIENT'S HEIGHT (inches) Height has been top coded in accordance with NCHS confidentiality requirements.
			-9 = Blank 72 = 72 inches or more (top code for females) 77 = 77 inches or more (top code for males)
96	1	209	[WTTAKE] Was weight measurement reported? (Created during data processing based on reported data.)
			0 = No 1= Yes
97	3	210-212	[WTLB] PATIENT'S WEIGHT (pounds) Weight has been top coded in accordance with NCHS confidentiality requirements. -9 = Blank 5-349 350 = 350 lbs. or more
98	8	213-220	[BMI] Body-Mass Index This was calculated from Patient's Height and Weight during data processing. It contains a decimal point and up to 2 decimal places. BMI was not calculated for pregnant females, patients under age 2, or patients with a recorded height and/or weight that fell outside of acceptable ranges. Also, BMI was recalculated to reflect topcoded values for height and weight.
			-9 = Missing data -7 = Not calculated -5 = Height and/or weight outside of acceptable ranges 9.18-68.35 (reported range)
99	1	221	[TEMPTAKE] Was temperature reported? (Created during data processing based on reported data.)
			0 = No 1= Yes

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
100	4	222-225	[TEMPF] Temperature (Fahrenheit) There is an implied decimal between the third and fourth digits.
			-9 = Blank 900 – 1086 = 90.0-108.6 Fahrenheit (reported range)
101	1	226	[BLODPRES] Was blood pressure reported? (Created during data processing based on reported data.)
			0 = No 1= Yes
102	3	227-229	[BPSYS] Blood pressure – systolic
			-9 = Blank 67 – 268 (reported range)
103	3	230-232	[BPDIAS] Blood pressure – diastolic -9 = Blank 24-155 (reported range) 998 = P, Palp, DOP, or DOPPLER
			SERVICES
104	1	233	[SERVICES] Were any examinations, blood tests, imaging, other tests, non-medication treatment or health education ordered or provided at this visit?
			NOTE: In previous years, diagnostic and screening services were collected in one question on the Patient Record Form, non- medication services in another, and health education in a third. As described in the annual public use file documentation since 2009, the diagnostic and screening services item was combined with the non-medication services item to create a combined services item during data processing. For 2014, all services were combined into one item on the automated Patient Record Form.
			0 = No services were reported 1 = At least one service was reported
			0 = No, 1 = Yes for each category below
			Examinations:
105 106 107 108 109 110 111	1 1 1 1 1 1	234 235 236 237 238 239 240	[ETOH] Alcohol abuse screening [BREAST] Breast exam [DEPRESS] Depression screening exam [DVS] Domestic violence screening [FOOT] Foot exam [NEURO] Neurologic exam [PELVIC] Pelvic exam

PAGE 60)		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
112 113 114 115	1 1 1 1	241 242 243 244	[RECTAL] Rectal exam [RETINAL] Retinal exam [SKIN] Skin exam [SUBST] Substance abuse screening
			Laboratory tests:
116 117 118 119 120 121 122 123 124 125 126 127 128	1 1 1 1 1 1 1 1 1 1 1	245 246 247 248 249 250 251 252 253 254 255 256 257	[BMP] Basic metabolic panel [CBC] CBC (Complete blood count) [CHLAMYD] Chlamydia test [CMP] Comprehensive metabolic panel [CREAT] Creatinine or renal function panel [BLDCX] Blood culture [TRTCX] Blood culture [TRTCX] Throat culture [URNCX] Urine culture [OTHCX] Other culture [GLUCOSE] Glucose [GCT] Gonorrhea serum [HGBA] HgbA1C (Glycohemoglobin) [HEPTEST] Hepatitis testing
129 130 131 132 133 134 135 136 137 138 139	1 1 1 1 1 1 1 1 1	258 259 260 261 262 263 264 265 266 267 268	[HIVTEST] HIV test [HPVDNA] HPV DNA test [CHOLEST] Lipid profile [HEPATIC] Liver enzyme/hepatic function panel [PAP] Pap test [PREGTEST] Pregnancy test/HCG test [PSA] PSA (Prostate specific antigen) [STREP] Rapid strep test [THYROID] TSH/Thyroid panel [URINE] Urinalysis (UA) [VITD] Vitamin D test
140	1	269	Imaging: [ANYIMAGE] This item was created during data processing and
140		203	indicates whether any of the imaging boxes were checked.
141 142 143 144 145 146 147	1 1 1 1 1 1	270 271 272 273 274 275 276	[BONEDENS] Bone mineral density [CATSCAN] CT Scan [ECHOCARD] Echocardiogram [OTHULTRA] Other ultrasound [MAMMO] Mammography [MRI] MRI [XRAY] X-ray and procedures
148	1	277	[OTHIMAGE] Other imaging NOTE: This was not a checkbox category on the survey. It was created during data processing based on responses to the "other services not listed" items, in which data respondents could enter names of procedures which were later coded using ICD-9-CM procedure codes.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			Procedures:
149 150	1 1	278 279	[AUDIO] Audiometry [BIOPSY] Biopsy
151	2	280-281	[BIOPROV] Biopsy provided -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No
152 153 154 155 156 157 158	1 1 1 1 1 1	282 283 284 285 286 287 288	[CARDIAC] Cardiac stress test [COLON] Colonscopy [CRYO] Cryosurgery/Destruction of tissue [EKG] EKG/ECG [EEG] Electroencephalogram (EEG) [EMG] Electromyogram (EMG) [EXCISION] Excision of tissue
159	2	289-290	[EXCIPROV] Excision of tissue provided -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No
160 161 162	1 1 1	291 292 293	[FETAL] Fetal monitoring [PEAK] Peak flow [SIGMOID] Sigmoidoscopy
163	2	294-295	[SIGPROV] Sigmoidoscopy provided -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No
164 165 166 167	1 1 1 1	296 297 298 299	[SPIRO] Spirometry [TONO] Tonometry [TBTEST] Tuberculosis skin testing [EGD] Upper gastrointestinal endoscopy
168	1	300	[SIGCOLON] Sigmoidoscopy/Colonoscopy This item was created during data processing and indicates whether any type of sigmoidoscopy or colonoscopy was ordered or provided, as reported in the checkbox data or write-in procedures. This estimate will be slightly greater than just combining data from SIGMOID and COLON because of the addition of overlapping ICD-9- CM procedure codes that couldn't be assigned to either SIGMOID or

PAGE 6	2		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			COLON. This is a summary variable only and should not be added to results from the checkbox or write-in procedure fields.
			Treatments:
169	1	301	[CSW] Cast/Splint/Wrap
170	1	302	CAM Complementary alternative medicine
171	1	303	[DME] Durable medical equipment
172	1	304	[HOMEHLTH] Home health care
173	1	305	[MENTAL] Mental health counseling, excluding psychotherapy
174	1	306	[OCCUPY] Occupational therapy
175	1	307	[PT] Physical therapy
176	1	308	[PSYCHOTH] Psychotherapy
177	1	309	[RADTHER] Radiation therapy
178	1	310	
170	I	310	[WOUND] Wound care
			Health education/Counseling:
179	1	311	[ETOHED] Alcohol abuse counseling
180	1	312	[ASTHMAED] Asthma education
181	1	313	ASTHMAP Asthma action plan given to patient
182	1	314	[DIAEDUC] Diabetes education
183	1	315	DIETNUTR] Diet/Nutrition
184	1	316	[EXERCISE] Exercise
185	1	317	[FAMPLAN] Family planning/Contraception
186	1	318	[GENETIC] Genetic counseling
187	1	319	[GRWTHDEV] Growth/Development
188	1	320	[INJPREV] Injury prevention
189	1	321	[STDPREV] STD prevention
190	1	322	[STRESMGT] Stress management
191	1	323	[SUBSTED] Substance abuse counseling
192	1	324	[TOBACED] Tobacco use/Exposure
193	1	325	[WTREDUC] Weight reduction
155	I	525	
194	1	326	[OTHSERV] Other services not listed
			PROCEDURES
Patient	Record Form	. To get a cor	ne write-in fields under "Other Services Not Listed" on the automated inplete picture of the number and type of procedures reported at a visit, from all of the procedure fields.
195	4	327-330	[PROC1] Write-in procedure #1

			ICD-9-CM Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. -9 = Blank 0001-999 = 00.01-99.99
196	4	331-334	[PROC2] Write-in procedure #2: see PROC1 for details

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
197	4	335-338	[PROC3] Write-in procedure #3: see PROC1 for details
198	4	339-342	[PROC4] Write-in procedure #4: see PROC1 for details
199	4	343-346	[PROC5] Write-in procedure #5: see PROC1 for details
200	4	347-350	[PROC6] Write-in procedure #6: see PROC1 for details
201	4	351-354	[PROC7] Write-in procedure #7: see PROC1 for details
202	4	355-358	[PROC8] Write-in procedure #8: see PROC1 for details
203	4	359-362	[PROC9] Write-in procedure #9: see PROC1 for details

NUMERIC RECODES FOR PROCEDURES 1-9

The following recodes are included on the public use file to facilitate analysis of visits using ICD-9-CM codes. It had come to our attention in the past that some users of NAMCS data find it preferable to use the numeric field recodes rather than the alphanumeric fields in certain data applications. Users can make their own choice about which format best suits their needs.

204	4	363-366	[PROC1R] Write-in procedure #1 A left-justified numeric code with an implied decimal after the first two digits; inapplicable fourth digits are zero-filled. -9 = Blank 0001-999 = 00.01-99.99
205 206 207 208 209 210 211 212	4 4 4 4 4 4 4 4	367-370 371-374 375-378 379-382 383-386 387-390 391-394 395-398	[PROC2R] Write-in procedure #2: see PROC1R for details [PROC3R] Write-in procedure #3: see PROC1R for details [PROC4R] Write-in procedure #4: see PROC1R for details [PROC5R] Write-in procedure #5: see PROC1R for details [PROC6R] Write-in procedure #6: see PROC1R for details [PROC7R] Write-in procedure #7: see PROC1R for details [PROC8R] Write-in procedure #8: see PROC1R for details [PROC9R] Write-in procedure #9: see PROC1R for details
213	1	399	[EXAM] Examination This item was created during data processing and indicates whether any of the write-in procedures reflect an ICD-9-CM code indexed specifically to Examinations. It is a summary variable only and should not be added to results from the write- in procedure fields.
214	2	400-401	[SERVCNT] Total number of services reported as ordered or provided at the visit. Includes all services and vital sign determinations, including write-in entries for procedures (adjusted to avoid double counting between procedures that could be reported as both a checkbox and with more detail in the write-in field). 0-58 (31 was the highest number reported in 2014)
215	1	402	[ALLSERV] Were any services ordered or provided at the visit, including vital sign determinations? 0 = No services were ordered or provided at the visit 1 = At least one service was ordered or provided at the visit

		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		MEDICATIONS & IMMUNIZATIONS (See page 35 for more information. See Appendix III for Code List.)
216 1 4	403	[MED] WERE ANY PRESCRIPTION OR NON-PRESCRIPTION DRUGS ORDERED OR PROVIDED (BY ANY ROUTE OF ADMINISTRATION) AT THIS VISIT? 0 = No 1 = Yes 2 = Entire item blank, including "None" box
217 5 4	404-408	[MED1] MEDICATION #1 -9 = Blank 00000-99227 = 00000-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	409-413 414-418 419-423 424-428 429-433 434-438 439-443 444-448 449-453 454-458 459-463 464-468 469-473 474-478 479-483 484-488 489-493 494-498 499-503 504-508 509-513 514-518 519-523 524-528 529-533 534-538 539-543 544-548 549-553	<pre>[MED2] MEDICATION #2 - See MED1 [MED3] MEDICATION #3 - See MED1 [MED4] MEDICATION #4 - See MED1 [MED5] MEDICATION #5 - See MED1 [MED6] MEDICATION #6 - See MED1 [MED7] MEDICATION #7 - See MED1 [MED9] MEDICATION #0 - See MED1 [MED9] MEDICATION #10 - See MED1 [MED10] MEDICATION #10 - See MED1 [MED12] MEDICATION #11 - See MED1 [MED13] MEDICATION #12 - See MED1 [MED13] MEDICATION #13 - See MED1 [MED13] MEDICATION #14 - See MED1 [MED16] MEDICATION #15 - See MED1 [MED16] MEDICATION #15 - See MED1 [MED17] MEDICATION #17 - See MED1 [MED18] MEDICATION #18 - See MED1 [MED19] MEDICATION #19 - See MED1 [MED19] MEDICATION #19 - See MED1 [MED20] MEDICATION #20 - See MED1 [MED21] MEDICATION #21 - See MED1 [MED22] MEDICATION #22 - See MED1 [MED22] MEDICATION #23 - See MED1 [MED23] MEDICATION #24 - See MED1 [MED24] MEDICATION #25 - See MED1 [MED25] MEDICATION #25 - See MED1 [MED26] MEDICATION #26 - See MED1 [MED27] MEDICATION #27 - See MED1 [MED28] MEDICATION #28 - See MED1 [MED29] MEDICATION #29 - See MED1 [MED29] MEDICATION #29 - See MED1 [MED29] MEDICATION #20 - See MED1 [MED29] MEDICATION #30 - See MED1 [MED29] MEDICATION #30 - See MED1 [MED29] MEDICATION #30 - See MED1 [MED20] MEDICATION #30 - See MED1 [MED30] MEDICATI</pre>

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
248	2	556-557	[NCMED2] Was medication #2 new or continued? See NCMED1.
249	2	558-559	NCMED3 Was medication #3 new or continued? See NCMED1.
250	2	560-561	NCMED4 Was medication #4 new or continued? See NCMED1.
251	2	562-563	[NCMED5] Was medication #5 new or continued? See NCMED1.
252	2	564-565	NCMED6 Was medication #6 new or continued? See NCMED1.
253	2	566-567	NCMED7 Was medication #7 new or continued? See NCMED1.
254	2	568-569	NCMED8 Was medication #8 new or continued? See NCMED1.
255	2	570-571	NCMED9 Was medication #9 new or continued? See NCMED1.
256	2	572-573	[NCMED10] Was medication #10 new or continued? See NCMED1.
257	2	574-575	[NCMED11] Was medication #11 new or continued? See NCMED1.
258	2	576-577	[NCMED12] Was medication #12 new or continued? See NCMED1.
259	2	578-579	[NCMED13] Was medication #13 new or continued? See NCMED1.
260	2	580-581	[NCMED14] Was medication #14 new or continued? See NCMED1.
261	2	582-583	[NCMED15] Was medication #15 new or continued? See NCMED1.
262	2	584-585	[NCMED16] Was medication #16 new or continued? See NCMED1.
263	2	586-587	[NCMED17] Was medication #17 new or continued? See NCMED1.
264	2	588-589	[NCMED18] Was medication #18 new or continued? See NCMED1.
265	2	590-591	[NCMED19] Was medication #19 new or continued? See NCMED1.
266	2	592-593	[NCMED20] Was medication #20 new or continued? See NCMED1.
267	2	594-595	[NCMED21] Was medication #21 new or continued? See NCMED1.
268	2	596-597	[NCMED22] Was medication #22 new or continued? See NCMED1.
269	2	598-599	[NCMED23] Was medication #23 new or continued? See NCMED1.
270	2	600-601	[NCMED24] Was medication #24 new or continued? See NCMED1.
271	2	602-603	[NCMED25] Was medication #25 new or continued? See NCMED1.
272	2	604-605	[NCMED26] Was medication #26 new or continued? See NCMED1.
273	2	606-607	[NCMED27] Was medication #27 new or continued? See NCMED1.
274	2	608-609	[NCMED28] Was medication #28 new or continued? See NCMED1.
275	2	610-611	[NCMED29] Was medication #29 new or continued? See NCMED1.
276	2	612-613	[NCMED30] Was medication #30 new or continued? See NCMED1.
277	2	614-615	[NUMMED] NUMBER OF MEDICATIONS CODED 0 – 30
278	2	616-617	[NUMNEW] NUMBER OF NEW MEDICATIONS CODED 0 – 30
279	2	618-619	[NUMCONT] NUMBER OF CONTINUED MEDICATIONS CODED 0 – 30
			NOTE: For NUMNEW and NUMCONT, the value '0' can reflect the following situations: for NUMNEW, a) no drug listed; b) drug listed as continued medication only; or c) drug listed but unknown whether new or continued; for NUMCONT, a) no drug listed; b) drug listed as new medication only, or c) drug listed but unknown whether new or continued
			PROVIDERS SEEN
			0 = No, 1 = Yes
280 281	1 1	620 621	[NOPROVID] No answer to item [PHYS] Physician

PAGE 65

PAGE 66			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
282 283 284 285 286 287	1 1 1 1 1	622 623 624 625 626 627	[PHYSASST] Physician assistant [NPNMW] Nurse practitioner/Midwife [RNLPN] RN/LPN [MHP] Mental health provider [OTHPROV] Other provider [PROVNONE] None; no providers seen
288	3	628-630	 [TIMEMD] TIME SPENT WITH MD (in minutes) Time spent with MD has been top coded in accordance with NCHS confidentiality requirements. 0-89 minutes 90 = 90 minutes or more VISIT DISPOSITION 0 = No, 1 = Yes
289 290 291 292 293 294 295 296 297 298	1 1 1 1 1 1 1 1	631 632 633 634 635 636 637 638 639 640	[NODISP] No answer to item [RETREFPHY] Return to referring physician [REFOTHMD] Refer to other physician [RETAPPT1] Return in less than 1 week [RETAPPT2] Return in 1 week to less than 2 months [RETAPPT3] Return in 2 months or greater [RETUNSP] Return at unspecified time [RETNEED] Return as needed (p.r.n.) [ERADMHOS] Refer to emergency department/Admit to hospital [OTHDISP] Other visit disposition

TESTS

NOTE: These data were only collected for visits to selected specialties. Specialties not included were the following: general surgery, orthopedic surgery, dermatology, urology, neurology, psychiatry, ophthalmology, and otolaryngology.

IMPORTANT NOTE: Unlike previous years, lab results were not edited for 2014 but appear as they were reported in the automated Patient Record form. Anomalous results are possible and researchers should evaluate the data carefully before drawing conclusions. For 2014, lab results were also included on the public use file for serum creatine. While most of these results fall within expected ranges, a small percentage are unusually high and may reflect values measured in μ mol/L rather than mg/dL. Starting in 2016, abstractors are able to select the specific unit if different than mg/dL which is the default.

299	2	641-642	[CHOL] WAS BLOOD FOR TOTAL CHOLESTEROL TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12
			MONTHS PRIOR TO THE VISIT?
			-9 = Blank
			 -7 = Not applicable, provider not sampled
			1 = Yes

2 = None found within 12 months

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
300	3	643-645	[CHOLRES] MOST RECENT RESULT FOR TOTAL CHOLESTEROL -9 = Blank -8 = Unknown -7 = Not applicable, provider not sampled 0-495 mg/dL (reported range)
301	4	646-649	[DAYDCHOL] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF CHOLESTEROL LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 0 = Up to 365 days before date of visit to date of visit
302	2	650-651	 [HDL] WAS BLOOD FOR HIGH DENSITY LIPOPROTEIN (HDL) TEST DRAWN ON THE DAY OF THE SAMPLED VIIST OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months
303	3	652-654	[HDLRES] MOST RECENT RESULT FOR HIGH DENSITY LIPOPROTEIN -9 = Blank -8 = Unknown -7 = Not applicable, provider not sampled 1-160 mg/dL (reported range)
304	4	655-658	[DAYDHDL] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF HDL LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 0 = Up to 365 days before date of visit to date of visit
305	2	659-660	 [LDL] WAS BLOOD FOR LOW DENSITY LIPOPROTEIN (LDL) TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months
306	3	661-663	[LDLRES] MOST RECENT RESULT FOR LOW DENSITY LIPOPROTEIN (LDL) -9 = Blank -8 = Unknown -7 = Not applicable, provider not sampled 0-340 mg/dL (reported range)

PAGE 68			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
307	4	664-667	[DAYDLDL] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF LOW DENSITY LIPOPROTEIN (LDL) LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 0 = Up to 365 days before date of visit to date of visit
308	4	668-671	[LIPIDERR] CALCULATED LDL RESULT. NOT TO BE USED FOR ANALYSIS. This variable is to be used for comparison to the LDLRES value to point out possible errors in the lipid test reporting. -999 = Blank -28 - 340

Note: LIPIDERR was calculated for records with non-negative values for ALL lipid numbers (cholesterol, HDL, LDL, and TGS) and only when all of these tests dated from the same day. The following formula was used: LIPIDERR=(CHOLRES-HDLRES-(TGSRES/5)). The value was then rounded. Some lab values were capped during data collection, which should be considered when interpreting LIPIDERR.

309	4	672-675	[LDLDIFF] DIFFERENCE BETWEEN REPORTED LDL RESULT (LDLRES) AND CALCULATED LDL (LIPIDERR). NOT TO BE USED FOR ANALYSIS. This variable is to be used for comparison to the LDLRES value in order to point out possible errors that may exist in the lipid test reporting. -999 = Blank -129 - 178
310	2	676-677	[TGS] WAS BLOOD FOR TRIGLYCERIDES TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months
311	3	678-680	[TGSRES] MOST RECENT RESULT FOR TRIGLYCERIDES -9 = Blank -8 = Unknown -7 = Not applicable, provider not sampled 0-999 mg/dL (reported range)
312	4	681-684	[DAYDTGS] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF TRIGLYCERIDES LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 0 = Up to 365 days before date of visit to date of visit

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
313	2	685-686	 [A1C] WAS BLOOD FOR GLYCOHEMOGLOBIN (HbA1c) TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months
314	4	687-690	[A1CRES] MOST RECENT RESULT FOR GLYCOHEMOGLOBIN (HbA1c)TRIGLYCERIDES TEST -9 = Blank -8 = Unknown -7 = Not applicable, provider not sampled 0.0 - 96.0% (reported range)
315	4	691-694	[DAYDA1C] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF GLYCOHEMOGLOBIN (HbA1c) LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 0 = Up to 365 days before date of visit to date of visit
316	2	695-696	 [FBG] WAS BLOOD FOR FASTING BLOOD GUCOSE (FBG) TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months
317	3	697-699	[FBGRES] MOST RECENT RESULT FOR FASTING BLOOD GLUCOSE (FBG) TEST -9 = Blank -8 = Unknown -7 = Not applicable, provider not sampled 1-559 mg/dL (reported range)
318	4	700-703	[DAYDFBG] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF FASTING BLOOD GLUCOSE (FBG) LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 0 = Up to 365 days before date of visit to date of visit
319	2	704-705	[SERUM] WAS BLOOD FOR SERUM CREATININE DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months

PAGE 70			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
320	4	706-709	[SERUMRES] MOST RECENT RESULT FOR SERUM CREATININE See IMPORTANT NOTE under TESTS for more about serum creatinine results. -9 = Blank -8 = Unknown -7 = Not applicable, provider not sampled 0.1-95 mg/dL (reported range)
321	4	710-713	[DAYDSERUM] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF SERUM CREATININE LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 0 = Up to 365 days before date of visit to date of visit
PATIEN	T RECORD I		IOW WHETHER DATA WERE REPORTED ON THE AUTOMATED ALCULATED DURING DATA PROCESSING, OR WHETHER DATA LANKS ****
322	2	714-715	[AGEFLAG] Was patient age reported on the automated Patient Record Form or calculated during data processing based on date of visit and date of birth?
323	1	716	 -9 = Birth date imputed 0 = Calculated by NCHS 1 = Entered by respondent [GESTFL] Was gestation week calculated by NCHS during data
	·		processing based on date of visit and date of last menstrual period? 0 = Calculated by NCHS 1 = Not calculated by NCHS
			IMPUTED ITEMS
			0 = Not imputed 1 = Imputed
324 325 326 327 328 329 330	1 1 1 1 1 1	717 718 719 720 721 722 723	[BDATEFL] Patient birth year [SEXFL] Patient sex [ETHNICFL] Patient ethnicity [RACERFL] Patient race [SENBEFL] Has patient been seen in your practice before? [PASTFL] If yes, how many past visits in last 12 months? [TIMEMDFL] Time spent with physician (minutes)
331	4	724-728	[PHYCODE] PHYSICIAN CODE - A unique code assigned to all records from a particular physician. 24-10008

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, A	ND CODES
332	3	729-731	[PATCODE] PATIENT CODE - A r identify each individual record from 1-90	
333	2	732-733	[SPECR] PHYSICIAN SPECIALTY This is a 14-group specialty variab variable in previous survey years v	le that is consistent with the SPECR
			 01 = General and family practice 03 = Internal medicine 04 = Pediatrics 05 = General surgery 06 = Obstetrics and gynecology 07 = Orthopedic surgery 08 = Cardiovascular diseases 	09 = Dermatology 10 = Urology 11 = Psychiatry 12 = Neurology 13 = Ophthalmology 14 = Otolaryngology 15 = All other

(Note: For SPECR, doctors of osteopathy (formerly stratum 02) have been aggregated with doctors of medicine according to their self-designated practice specialty, and therefore are not differentiated in the variable range. To isolate doctors of osteopathy from medical doctors using the Physician Specialty Recode variable, it is necessary to crosstabulate it with Type of Doctor located in position 735.)

334	1	734	[SPECCAT] PHYSICIAN SPECIALTY GROUP (Recoded from internal data using categories on page 132.) 1 = Primary care specialty 2 = Surgical care specialty 3 = Medical care specialty
335	1	735	[MDDO] TYPE OF DOCTOR 1 = M.D Doctor of Medicine 2 = D.O Doctor of Osteopathy
336	1	736	[RETYPOFFR] TYPE OF OFFICE SETTING FOR THIS VISIT (Recoded) 1 = Private solo or group practice 2 = Other
337	2	737-738	[SOLO] DO YOU HAVE A SOLO PRACTICE, OR ARE YOU ASSOCIATED WITH OTHER PHYSICIANS IN A PARTNERSHIP, A GROUP PRACTICE, OR SOME OTHER WAY AT THIS VISIT LOCATION? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Solo 2 = Non-solo

PAGE 72			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
338	2	739-740	[EMPSTAT] ARE YOU A FULL OR PART OWNER, EMPLOYEE, OR INDEPENDENT CONTRACTOR AT THIS VISIT LOCATION?
			-9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Full owner 2 = Part owner 3 = Employee 4 = Contractor
339	2	741-742	 [OWNSR] WHO OWNS THE PRACTICE AT THIS VISIT LOCATION? (Recoded) -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Physician or physician group 2 = Medical/Academic health center; other hospital 3 = Insurance company, health plan, or HMO; other health care Corporation; other
340	2	743-744	[PATEVEN] DO YOU SEE PATIENTS IN THE OFFICE DURING THE EVENING OR ON WEEKENDS? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Yes 2 = No
			DURING LAST NORMAL WEEK OF PRACTICE, DID YOU MAKE ENCOUNTERS OF THE FOLLOWING TYPES WITH PATIENTS:
341	2	745-746	[NHVISR] NURSING HOME VISITS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes
342	2	747-748	[HOMVISR] OTHER HOME VISITS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes
343	2	749-750	[HOSVISR] HOSPITAL VISITS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
344	2	751-752	[TELCONR] TELEPHONE CONSULTS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes
345	2	753-754	[ECONR] INTERNET/EMAIL CONSULTS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes
346	2	755-756	[EBILLANY] DOES YOUR PRACTICE SUBMIT ANY CLAIMS ELECTRONICALLY (ELECTRONIC BILLING)? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Yes 2 = No
347	2	757-758	[EMEDREC] DOES YOUR PRACTICE USE AN ELECTRONIC HEALTH RECORD (EHR) OR ELECTRONIC MEDICAL RECORD (EMR) SYSTEM? Do not include billing records systems. -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, all electronic 2 = Yes, part paper and part electronic 3 = No
348	2	759-760	[HHSMU] DOES YOUR CURRENT SYSTEM MEET MEANINGFUL USE CRITERIA AS DEFINED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No
349	2	761-762	[SECURCHCK] HAS YOUR PRACTICE MADE AN ASSESSMENT OF THE POTENTIAL RISKS AND VULNERABILITY OF YOUR ELECTRONIC HEALTH INFORMATION WITHIN THE LAST 12 MONTHS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No

PAGE 74			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
350	2	763-764	[DIFFEHR] DOES YOUR EHR HAVE THE CAPABILITY TO ELECTRONICALLY SEND HEALTH INFORMATION TO ANOTHER PROVIDER WHOSE EHR SYSTEM IS DIFFERENT FROM YOUR SYSTEM? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No
351	2	765-766	[EMRINS] AT YOUR PRACTICE, ARE THERE PLANS FOR INSTALLING A NEW EMR SYSTEM OR REPLACING THE CURRENT SYSTEM WITHIN THE NEXT 18 MONTHS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 3 = Maybe
352	2	767-768	[MUSTAGE1] MEDICARE AND MEDICAID OFFER INCENTIVES TO PRACTICES THAT DEMONSTRATE, MEANINGFUL USE OF HEALTH IT. AT YOUR PRACTICE, ARE THERE PLANS TO APPLY FOR STAGE 1 OF THESE INCENTIVE PAYMENTS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, we already applied 2 = Yes, we intend to apply 3 = Uncertain if we will apply 4 = No, we will not apply
353	2	769-770	[MUSTAGE2] ARE THERE PLANS TO APPLY FOR STAGE 2 INCENTIVE PAYMENTS? [for meaningful use payments] -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No 3 = Maybe

2014 NAMCS MICRO-DATA FILE DOCUMENTATION PAGE				
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
the year be cons	rs. In the follo	owing section, e format used	features of a practice's computerized capabilities have chan items with an "R" suffix have been recoded in each year sinc in the 2009 Physician Induction Interview, to make trending e the current format. New items may appear in both formats as	e 2010 to asier.
			PLEASE INDICATE WHETHER YOUR PRACTICE HAS EA THE FOLLOWING COMPUTERIZED CAPABILITIES AND OFTEN THESE CAPABILITIES ARE USED: (APPLIES TO ITEMS 354-405)	
354	2	771-772	[EDEMOG] RECORDING PATIENT HISTORY AND DEMO INFORMATION -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No	GRAPHIC
355	2	773-774	[EDEMOGR] RECORDING PATIENT HISTORY AND DEMOGRAPHIC INFORMATION (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1= Yes 2= No 4= Turned off	
356	2	775-776	[EPROLST] IF YES TO RECORDING PATIENT HISTORY . DEMOGRAPHIC INFORMATION, DOES THIS INCLUDE A PROBLEM LIST -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No	
357	2	777-778	[EPROLSTR] IF YES TO RECORDING PATIENT HISTORY DEMOGRAPHIC INFORMATION, DOES THIS INCLUDE A PROBLEM LIST (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off	

PAGE 76			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
358	2	779-780	[EVITAL] RECORDING AND CHARTING VITAL SIGNS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
359	2	781-782	[EVITALR] RECORDING AND CHARTING VITAL SIGNS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
360	2	783-784	 [ESMOKE] RECORDING PATIENT SMOKING STATUS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
361	2	785-786	[ESMOKER] RECORDING PATIENT SMOKING STATUS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
362	2	787-788	[EPNOTES] RECORDING CLINICAL NOTES -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
363	2	789-790	[EPNOTESR] RECORDING CLINICAL NOTES (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1= Yes 2= No 4= Turned off

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
364	2	791-792	[EMEDALG] IF YES TO RECORDING CLINICAL NOTES, DO THE NOTES INCLUDE A LIST OF PATIENT'S MEDICATIONS AND ALLERGIES? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
365	2	793-794	[EMEDALGR] IF YES TO RECORDING CLINICAL NOTES, DO THE NOTES INCLUDE A LIST OF PATIENT'S MEDICATIONS AND ALLERGIES? (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
366	2	795-796	[EMEDID] RECONCILING LISTS OF PATIENTS' MEDICATIONS TO IDENTIFY THE MOST ACCURATE LIST -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but NOT used routinely 4 = No
367	2	797-798	[EMEDIDR] RECONCILING LISTS OF PATIENTS' MEDICATIONS TO IDENTIFY THE MOST ACCURATE LIST (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
368	2	799-800	[EREMIND] REMINDERS FOR GUIDELINE-BASED INTERVENTIONS AND/OR SCREENING TESTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No

PAGE 78			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
369	2	801-802	[EREMINDR] REMINDERS FOR GUIDELINE-BASED INTERVENTIONS AND/OR SCREENING TESTS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
370	2	803-804	 [ECPOE] ORDERING PRESCRIPTIONS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
371	2	805-806	[ECPOER] ORDERING PRESCRIPTIONS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
372	2	807-808	 [ESCRIP] IF YES TO ORDERING PRESCRIPTIONS, ARE PRESCRIPTIONS SENT ELECTRONICALLY TO THE PHARMACY? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
373	2	809-810	[ESCRIPR] IF YES TO ORDERING PRESCRIPTIONS, ARE PRESCRIPTIONS SENT ELECTRONICALLY TO THE PHARMACY? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
374	2	811-812	[EWARN] IF YES TO ORDERING PRESCRIPTIONS, ARE WARNINGS OF DRUG INTERACTIONS OR CONTRAINDICATIONS PROVIDED? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
375	2	813-814	[EWARNR] IF YES TO ORDERING PRESCRIPTIONS, ARE WARNINGS OF DRUG INTERACTIONS OR CONTRAINDICATIONS PROVIDED? (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
376	2	815-816	 [EFORMULA] IF YES TO ORDERING PRESCRIPTIONS, ARE DRUG FORMULARY CHECKS PERFORMED? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
377	2	817-818	[EFORMULAR] IF YES TO ORDERING PRESCRIPTIONS, ARE DRUG FORMULARY CHECKS PERFORMED? (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off

PAGE 80			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
378	2	819-820	[ECTOE] ORDERING LAB TESTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
379	2	821-822	[ECTOER] ORDERING LAB TESTS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
380	2	823-824	 [EORDER] IF YES TO ORDERING LAB TESTS, ARE ORDERS SENT ELECTRONICALLY? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
381	2	825-826	[EORDERR] IF YES TO ORDERING LAB TESTS, ARE ORDERS SENG ELECTRONICALLY? (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
382	2	827-828	[ERESULT] VIEWING LAB RESULTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
383	2	829-830	[ERESULTR] VIEWING LAB RESULTS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
84	2	831-832	 [EGRAPH] IF YES TO VIEWING LAB RESULTS, CAN THE EHR/EMR AUTOMATICALLY GRAPH A SPECIFIC PATIENT'S LAB RESULTS OVER TIME? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
385	2	833-834	[EGRAPHR] IF YES TO VIEWING LAB RESULTS, CAN THE EHR/EMR AUTOMATICALLY GRAPH A SPECIFIC PATIENT'S LAB RESULTS OVER TIME? (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
386	2	835-836	[ERADI] ORDERING RADIOLOGY TESTS? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
387	2	837-838	[ERADIR] ORDERING RADIOLOGY TESTS? (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off

PAGE 8	2		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
388	2	839-840	[EIMGRES] VIEWING IMAGING RESULTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
389	2	841-842	[EIMGRESR] VIEWING IMAGING RESULTS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
390	2	843-844	[EPTEDU] IDENTIFYING EDUCATIONAL RESOURCES FOR PATIENTS' SPECIFIC CONDITIONS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
391	2	845-846	[EPTEDUR] IDENTIFYING EDUCATIONAL RESOURCES FOR PATIENTS' SPECIFIC CONDITIONS (recoded for trending) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
392	2	847-848	 [ECQM] REPORTING CLINICAL QUALITY MEASURES TO FEDERAL OR STATE AGENCIES (SUCH AS CMS OR MEDICAID) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
393	2	849-850	[ECQMR] REPORTING CLINICAL QUALITY MEASURES TO FEDERAL OR STATE AGENCIES (SUCH AS CMS OR MEDICAID) (recoded) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
394	2	851-852	 [EIDPT] IDENTIFYING PATIENTS DUE FOR PREVENTIVE OR FOLLOW-UP CARE IN ORDER TO SEND PATIENTS REMINDERS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
395	2	853-854	[EIDPTR] IDENTIFYING PATIENTS DUE FOR PREVENTIVE OR FOLLOW-UP CARE IN ORDER TO SEND PATIENTS REMINDERS? (recoded) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
396	2	855-856	[EGENLIST] GENERATING LISTS OF PATIENTS WITH PARTICULAR HEALTH CONDITIONS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
397	2	857-858	[EGENLISTR] GENERATING LISTS OF PATIENTS WITH PARTICULAR HEALTH CONDITIONS (recoded) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off

PAGE 84			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
398	2	859-860	[EIMMREG] ELECTRONIC REPORTING TO IMMUNIZATION REGISTRIES -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
399	2	861-862	[EIMMREGR] ELECTRONIC REPORTING TO IMMUNIZATION REGISTRIES (recoded) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
400	2	863-864	 [ESUM] PROVIDING PATIENTS WITH CLINICAL SUMMARIES FOR EACH VISIT -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
401	2	865-866	 [ESUMR] PROVIDING PATIENTS WITH CLINICAL SUMMARIES FOR EACH VISIT (recoded) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
402	2	867-868	 [EMSG] EXCHANGING SECURE MESSAGES WITH PATIENTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
403	2	869-870	[EMSGR] EXCHANGING SECURE MESSAGES WITH PATIENTS (recoded) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
404	2	871-872	[EPTREC] PROVIDING PATIENTS THE ABILITY TO VIEW ONLINE, DOWNLOAD, OR TRANSMIT INFORMATION FROM THEIR MEDICAL RECORD -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No
405	2	873-874	[EPTRECR] PROVIDING PATIENTS THE ABILITY TO VIEW ONLINE, DOWNLOAD, OR TRANSMIT INFORMATION FROM THEIR MEDICAL RECORD (recoded) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off
406	2	875-876	[REFOUT] DO YOU REFER ANY OF YOUR PATIENTS TO A PROVIDER OUTSIDE OF YOUR OFFICE OR GROUP? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No
407	2	877-878	[REFOUTS] IF YES TO "DO YOU REFER ANY OF YOUR PATIENTS TO A PROVIDER OUTSIDE OF YOUR OFFICE OR GROUP?", DO YOU SEND THE PATIENT'S CLINICAL INFORMATION TO THE OTHER PROVIDERS? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No

PAGE 86	3		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
408	2	879-880	 [REFOUTSE] IF YES TO "DO YOU SEND THE PATIENT'S CLINICAL INFORMATION TO THE OTHER PROVIDERS", DO YOU SEND IT ELECTRONICALLY (NOT FAX)? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No
409	2	881-882	[REFIN] DO YOU SEE PATIENTS REFERRED TO YOU BY PROVIDERS OUTSIDE OF YOUR OFFICE OR GROUP? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No
410	2	883-884	 [REFINS] IF YES TO "DO YOU SEE PATIENTS REFERRED TO YOU BY PROVIDERS OUTSIDE OF YOUR OFFICE OR GROUP?", DO YOU SEND A CONSULTATION REPORT WITH CLINICAL INFORMATION TO THE OTHER PROVIDERS? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No
411	2	885-886	 [REFINSE] IF YES TO "DO YOU SEND A CONSULTATION REPORT WITH CLINICAL INFORMATION TO THE OTHER PROVIDERS?", DO YOU SEND THE CONSULTATION REPORT ELECTRONICALLY (NOT FAX)? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No
412	2	887-888	[INPTCARE] DO YOU TAKE CARE OF PATIENTS AFTER THEY ARE DISCHARGED FROM AN INPATIENT SETTING? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
413	2	889-890	[DISSUM] IF YES TO "DO YOU TAKE CARE OF PATIENTS AFTER THEY ARE DISCHARGED FROM AN INPATIENT SETTING?", DO YOU RECEIVE A DISCHARGE SUMMARY WITH CLINICAL INFORMATION FROM THE HOSPITAL? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No
414	2	891-892	[DISSUME] IF YES TO "DO YOU RECEIVE A DISCHARGE SUMMARY WITH CLINICAL INFORMATION FROM THE HOSPITAL?", DO YOU RECEIVE THE DISCHARGE SUMMARY WITH CLINICAL INFORMATION ELECTRONICALLY (NOT FAX)? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No
415	2	893-894	[INCORINFO] IF YES TO "DO YOU RECEIVE THE DISCHARGE SUMMARY WITH CLINICAL INFORMATION ELECTRONICALLY (NOT FAX)?", CAN YOU AUTOMATICALLY INCORPORATE THE DISCHARGE SUMMARY INFORMATION INTO YOUR EHR WITHOUT MANUALLY ENTERING THE DATA? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 3 = Not applicable, I do not have an EHR system
416	2	895-896	[ESHARE] DO YOU SHARE ANY PATIENT HEALTH INFORMATION ELECTRONICALLY (NOT FAX) WITH OTHER PROVIDERS, INCLUDING HOSPITALS, AMBULATORY PROVIDERS, OR ELECTRONICALLY (NOT FAX) LABS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No

PAGE 88			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			HOW DO YOU ELECTRONICALLY SHARE PATIENT HEALTH INFORMATION?
417 418 419 420 421	2 2 2 2 2	897-898 899-900 901-902 903-904 905-906	[ESHAREEHR] EHR/EMR [ESHAREWEB]Web portal (separate from EHR/EMR) [ESHAREOTH] Other electronic method [ESHAREUNK] Unknown [ESHAREREF] Refused to answer question
			 -9 = Entire item (38.b on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1 = Box is marked
422	2	907-908	[EHRTOEHR] IF YES TO "DO YOU SHARE ANY PATIENT HEALTH INFORMATION ELECTRONICALLY (NOT FAX) WITH OTHER PROVIDERS, INCLUDING HOSPITALS, AMBULATORY PROVIDERS, OR ELECTRONICALLY (NOT FAX) LABS?", IS IT SENT DIRECTLY FROM YOUR EHR SYSTEM TO ANOTHER EHR SYSTEM? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No
			WITH WHAT TYPES OF PROVIDERS DO YOU ELECTRONICALLY SHARE PATIENT HEALTH INFORMATION?
423 424 425 426 427 428 429 430 431	2 2 2 2 2 2 2 2 2 2	909-910 911-912 913-914 915-916 917-918 919-920 921-922 923-924 925-926	 [ESHAREPROV1] Ambulatory providers inside your office/group [ESHAREPROV2] Ambulatory providers outside your office/group [ESHAREPROV3] Hospitals with which you are affiliated [ESHAREPROV4] Hospitals with which you are not affiliated [ESHAREPROV5] Behavioral health providers [ESHAREPROV6] Long-term care providers [ESHAREPROV7] Home health providers [ESHAREPROV7] Home health providers [ESHAREPROVUNK] Unknown [ESHAREPROVREF] Refused to answer question -9 = Entire item (38.d on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked

1 = Box is marked

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
432	2	927-928	 [PRMCARER] Roughly, what percent of your patient care revenue comes from Medicare? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
433	2	929-930	 [PRMAIDR] Roughly, what percent of your patient care revenue comes from Medicaid? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
434	2	931-932	 [PRPRVTR] Roughly, what percent of your patient care revenue comes from private insurance? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
435	2	933-934	 [PRPATR] Roughly, what percent of your patient care revenue comes from patient payments? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
436	2	935-936	 [PROTHR] Roughly, what percent of your patient care revenue comes from other sources? (including charity, research, Champus, VA, etc.) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent

PAGE 90	0		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
437	2	937-938	 [PRMANR] Roughly, what percentage of the patient care revenue received by this practice comes from (these) managed care contracts? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
438	2	939-940	 [REVFFSR] Roughly, what percent of your patient care revenue comes from usual, customary, and reasonable fee-forservice? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
439	2	941-942	 [REVCAPR] Roughly, what percent of your patient care revenue comes from capitation? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
440	2	943-944	 [REVCASER] Roughly, what percent of your patient care revenue comes from case rates (e.g. package pricing/episode of care)? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent
441	2	945-946	 [REVOTHR] Roughly, what percent of your patient care revenue comes from other sources? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
442	2	947-948	[ACEPTNEW] Are you currently accepting "new" patients into your practice? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No
443	2	949-950	[CAPITATE] From those "new" patients, which of the following types of payment do you accept? - Capitated private insurance -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No
444	2	951-952	[NOCAP] From those "new" patients, which of the following types of payment do you accept? - Non-capitated private insurance -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No
445	2	953-954	 [PRIVATE] (Derived from responses to CAPITATE and NOCAP) From those "new" patients, which of the following types of payment do you accept? – Private insurance (capitated or non-capitated) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Private insurance 2 = No private insurance
446	2	955-956	[NMEDCARE] From those "new" patients, which of the following types of payment do you accept? – Medicare -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No

PAGE 92	2		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
447	2	957-958	[NMEDCAID] From those "new" patients, which of the following types of payment do you accept? – Medicaid -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No
448	2	959-960	[NWORKCMP] From those "new" patients, which of the following types of payment do you accept? – Workers compensation -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No
449	2	961-962	[NSELFPAY] From those "new" patients, which of the following types of payment do you accept? – Self-pay -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No
450	2	963-964	[NNOCHRGE] From those "new" patients, which of the following types of payment do you accept? – No charge -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No
451	2	965-966	 [PHYSCOMP] WHICH OF THE FOLLOWING METHODS BEST DESCRIBES YOUR BASIC COMPENSATION? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Fixed salary 2 = Share of practice billings or workload 3 = Mix of salary and share of billings or other measures of performance(e.g., your own billings, practice financial performance, quality measures, practice profiling) 4 = Shift, hourly or other time-based payment 5 = Other

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			CLINICAL PRACTICES MAY TAKE VARIOUS FACTORS INTO ACCOUNT WHEN DETERMINING THE COMPENSATION (SALARY, BONUS, PAY RATE, ETC.) PAID TO THE PHYSICIANS IN THE PRACTICE. PLEASE INDICATE WHETHER THE PRACTICE EXPLICITLY CONSIDERS EACH OF THE FOLLOWING FACTORS IN DETERMINING YOUR COMPENSATION:
452	2	967-968	[COMPPROD] FACTORS THAT REFLECT YOUR OWN PRODUCTIVITY -9 = Entire item 44 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked
453	2	969-970	[COMPSAT] RESULTS OF SATISFACTION SURVEYS FROM YOUR OWN PATIENTS -9 = Entire item 44 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked
454	2	971-972	[COMPQUAL] SPECIFIC MEASURES OF QUALITY, SUCH AS RATES OF PREVENTIVE SERVICES FOR YOUR PATIENTS -9 = Entire item 44 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked
455	2	973-974	[COMPDROF] RESULTS OF PRACTICE PROFILING, THAT IS, COMPARING YOUR PATTERN OF USING MEDICAL RESOURCES WITH THAT OF OTHER PHYSICIANS -9 = Entire item 44 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked
456	2	975-976	[COMPFIN] THE OVERALL FINANCIAL PERFORMANCE OF THE PRACTICE -9 = Entire item 44 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked
457	2	977-978	[COMPUNK] UNKNOWN -9 = Entire item 44 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked
458	2	979-980	[COMPREF] REFUSED TO ANSWER -9 = Entire item 44 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked

PAGE 94			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
459	3	981-983	[SDAPPT] Roughly, what percent of your daily visits are same day appointments? -9 = Blank -6 = Refused to answer question 0-100
460	2	984-985	[SASDAPPT] Does your practice set time aside for same day appointments? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Yes 2 = No
461	2	986-987	[APPTTIME] On average, about how long does it take to get an appointment for a routine medical exam? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Within 1 week 2 = 1-2 weeks 3 = 3-4 weeks 4 = 1-2 months 5 = 3 or more months 6 = Do not provide routine exams
462	1	988	[REGIONOFF] GEOGRAPHIC REGION (Based on location where majority of visit records were sampled) 1 = Northeast 2 = Midwest 3 = South 4 = West
463	1	989	 [DIVISIONOFF] CENSUS CIVIL DIVISION (Based on location where majority of visit records were sampled) 1 = New England (Northeast Region) 2 = Middle Atlantic (Northeast Region) 3 = East North Central (Midwest Region) 4 = West North Central (Midwest Region) 5 = South Atlantic (South Region) 6 = East South Central (South Region) 7 = West South Central (South Region) 8 = Mountain (West Region) 9 = Pacific (West Region)

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
464	2	990-991	[FIPSSTOFF] STATE/DIVISION REMAINDER (Based on location where majority of visit records were sampled)
			NOTE: 18 states were targeted for sampling. The remaining states were grouped within their Census division and sampled as 'division remainders.' Records in division remainders should only be weighted using the PATWT variable; records in targeted states should only be weighted using the PATWTST variable. 04 = Arizona 06 = California 12 = Florida 13 = Georgia 17 = Illinois 18 = Indiana 25 = Massachusetts 26 = Michigan 34 = New Jersey 36 = New York 37 = North Carolina 39 = Ohio 42 = Pennsylvania 47 = Tennessee 48 = Texas 51 = Virginia 53 = Washington 55 = Wisconsin 91 = New England Division Remainder 92 = West North Central Division Remainder 93 = South Atlantic Division Remainder 94 = Mountain Division Remainder 95 = Pacific Division Remainder 96 = East South Central Division Remainder 97 = West South Central Division Remainder 97 = West South Central Division Remainder
465	1	992	[MSA] METROPOLITAN/NON-METROPOLITAN STATUS (Based on physician location in conjunction with the definition of the Bureau of the Census and the U.S. Office of Management and Budget.)
			1 = MSA (Metropolitan Statistical Area)

2 = Not MSA (includes micropolitan statistical areas)

PAGE 95

PAGE 96			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM	FIELD	FILE	[ITEM NAME], DESCRIPTION, AND CODES
NO.	LENGTH	LOCATION	

DRUG-RELATED INFO FOR MEDICATION #1

NOTE: Starting with the 2006 data release, all drug codes based on entry name (using NCHS' standard classification system) were also assigned a unique generic drug code from Multum's Lexicon Drug Database, where possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NAMCS drug data. All Multum codes start with the letter "d" but there were some drugs reported in NAMCS that could not be assigned a code in Multum. For 2006 and 2007, these received a prefix of either "a" (when ingredients could be determined) or "c" (when ingredients could not be determined). Beginning with 2008, the use of "a" and "c" codes was replaced with "n" codes. For more on the structure of the drug data (including information on therapeutic class and drug ingredients), please see page 35.

466	6	993-998	[DRUGID1] DRUG ID (See page 229 for more information.)
			a07001-a92507 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d08524 = Multum code n00000-n13006 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008)
467	1	999	[PRESCR1] PRESCRIPTION STATUS CODE1 = Prescription Drug4 = Illicit [not used in NAMCS]2 = Nonprescription Drug5 = Both Prescription and Over-the-3 = UndeterminedCounter
468	1	1000	[CONTSUB1] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
469	1	1001	[COMSTAT1] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES			
470	3	1002-1004	[RX1CAT1] MULTUM DRUG CATEGORY # 1			
Level 1 coded to	Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 35. The complete Multum classification is shown in Appendix III.					
		00	" " = Blank/Not applicable01 - 899 = Drug category			
471	3	1005-1007	[RX1CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.			
472	3	1008-1010	[RX1CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.			
473	3	1011-1013	[RX1CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.			
			DRUG CATEGORY LEVELS			
			See RX1CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.			
474 475 476 477	3 3 3 3	1014-1016 1017-1019 1020-1022 1023-1025	[RX1V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX1V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX1V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX1V1C4] Level 1 of MULTUM DRUG CATEGORY # 4			
478 479 480 481	3 3 3 3	1026-1028 1029-1031 1032-1034 1035-1037	[RX1V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX1V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX1V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX1V2C4] Level 2 of MULTUM DRUG CATEGORY # 4			
482 483 484 485	3 3 3 3	1038-1040 1041-1043 1044-1046 1047-1049	[RX1V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX1V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX1V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX1V3C4] Level 3 of MULTUM DRUG CATEGORY # 4			

PAGE 98			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #2
Р	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
486	6	1050-1055	[DRUGID2] DRUG ID
487	1	1056	[PRESCR2] PRESCRIPTION STATUS CODE
488	1	1057	[CONTSUB2] CONTROLLED SUBSTANCE STATUS CODE
489	1	1058	[COMSTAT2] COMPOSITION STATUS CODE
490	3	1059-1061	[RX2CAT1] MULTUM DRUG CATEGORY # 1
491	3	1062-1064	[RX2CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
492	3	1065-1067	[RX2CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
493	3	1068-1070	[RX2CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
494 495 496 497	3 3 3 3	1071-1073 1074-1076 1077-1079 1080-1082	[RX2V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
498 499 500 501	3 3 3 3	1083-1085 1086-1088 1089-1091 1092-1094	[RX2V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX2V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX2V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX2V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
502 503 504 505	3 3 3 3	1095-1097 1098-1100 1101-1103 1104-1106	

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #3
Р	lease see "DF	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
506	6	1107-1112	[DRUGID3] DRUG ID
507	1	1113	[PRESCR3] PRESCRIPTION STATUS CODE
508	1	1114	[CONTSUB3] CONTROLLED SUBSTANCE STATUS CODE
509	1	1115	[COMSTAT3] COMPOSITION STATUS CODE
510	3	1116-1118	[RX3CAT1] MULTUM DRUG CATEGORY # 1
511	3	1119-1121	[RX3CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
512	3	1122-1124	[RX3CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
513	3	1125-1127	[RX3CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
514 515 516 517	3 3 3 3	1128-1130 1131-1133 1134-1136 1137-1139	[RX3V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX3V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX3V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX3V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
518 519 520 521	3 3 3 3	1140-1142 1143-1145 1146-1148 1149-1151	[RX3V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX3V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX3V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX3V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
522 523 524 525	3 3 3 3	1152-1154 1155-1157 1158-1160 1161-1163	[RX3V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX3V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX3V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX3V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 100			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #4
Р	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
526	6	1164-1169	[DRUGID4] DRUG ID
527	1	1170	[PRESCR4] PRESCRIPTION STATUS CODE
528	1	1171	[CONTSUB4] CONTROLLED SUBSTANCE STATUS CODE
529	1	1172	[COMSTAT4] COMPOSITION STATUS CODE
530	3	1173-1175	[RX4CAT1] MULTUM DRUG CATEGORY # 1
531	3	1176-1178	[RX4CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
532	3	1179-1181	[RX4CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
533	3	1182-1184	[RX4CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
534 535 536 537	3 3 3 3	1185-1187 1188-1190 1191-1193 1194-1196	[RX4V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
538 539 540 541	3 3 3 3	1197-1199 1200-1202 1203-1205 1206-1208	[RX4V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX4V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX4V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX4V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
542 543 544 545	3 3 3 3	1209-1211 1212-1214 1215-1217 1218-1220	[RX4V3C2] Level 3 of MULTUM DRUG CATEGORY # 2

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #5
	Please see "DF	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
546	6	1221-1226	[DRUGID5] DRUG ID
547	1	1227	[PRESCR5] PRESCRIPTION STATUS CODE
548	1	1228	[CONTSUB5] CONTROLLED SUBSTANCE STATUS CODE
549	1	1229	[COMSTAT5] COMPOSITION STATUS CODE
550	3	1230-1232	[RX5CAT1] MULTUM DRUG CATEGORY # 1
551	3	1233-1235	[RX5CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
552	3	1236-1238	[RX5CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
553	3	1239-1241	[RX5CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
554 555 556 557	3 3 3 3	1242-1244 1245-1247 1248-1250 1251-1253	[RX5V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX5V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX5V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX5V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
558 559 560 561	3 3 3 3	1254-1256 1257-1259 1260-1262 1263-1265	[RX5V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX5V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX5V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX5V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
562 563 564 565	3 3 3 3	1266-1268 1269-1271 1272-1274 1275-1277	[RX5V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX5V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX5V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX5V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 102			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #6
Р	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
566	6	1278-1283	[DRUGID6] DRUG ID
567	1	1284	[PRESCR6] PRESCRIPTION STATUS CODE
568	1	1285	[CONTSUB6] CONTROLLED SUBSTANCE STATUS CODE
569	1	1286	[COMSTAT6] COMPOSITION STATUS CODE
570	3	1287-1289	[RX6CAT1] MULTUM DRUG CATEGORY # 1
571	3	1290-1292	[RX6CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
572	3	1293-1295	[RX6CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
573	3	1296-1298	[RX6CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
574 575 576 577	3 3 3 3	1299-1301 1302-1304 1305-1307 1308-1310	[RX6V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX6V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX6V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX6V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
578 579 580 581	3 3 3 3	1311-1313 1314-1316 1317-1319 1320-1322	[RX6V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX6V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX6V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX6V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
582 583 584 585	3 3 3 3	1323-1325 1326-1328 1329-1331 1332-1334	[RX6V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX6V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX6V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX6V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #7
PI	ease see "DF	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
586	6	1335-1340	[DRUGID7] DRUG ID
587	1	1341	[PRESCR7] PRESCRIPTION STATUS CODE
588	1	1342	[CONTSUB7] CONTROLLED SUBSTANCE STATUS CODE
589	1	1343	[COMSTAT7] COMPOSITION STATUS CODE
590	3	1344-1346	[RX7CAT1] MULTUM DRUG CATEGORY # 1
591	3	1347-1349	[RX7CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
592	3	1350-1352	[RX7CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
593	3	1353-1355	[RX7CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
594 595 596 597	3 3 3 3	1356-1358 1359-1361 1362-1364 1365-1367	[RX7V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX7V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX7V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX7V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
598 599 600 601	3 3 3 3	1368-1370 1371-1373 1374-1376 1377-1379	[RX7V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX7V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX7V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX7V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
602 603 604 605	3 3 3 3	1380-1382 1383-1385 1386-1388 1389-1391	[RX7V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX7V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX7V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX7V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 104			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #8
P	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
606	6	1392-1397	[DRUGID8] DRUG ID
607	1	1398	[PRESCR8] PRESCRIPTION STATUS CODE
608	1	1399	[CONTSUB8] CONTROLLED SUBSTANCE STATUS CODE
609	1	1400	[COMSTAT8] COMPOSITION STATUS CODE
610	3	1401-1403	[RX8CAT1] MULTUM DRUG CATEGORY # 1
611	3	1404-1406	[RX8CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
612	3	1407-1409	[RX8CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
613	3	1410-1412	[RX8CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
614 615 616 617	3 3 3 3	1413-1415 1416-1418 1419-1421 1422-1424	[RX8V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX8V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX8V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX8V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
618 619 620 621	3 3 3 3	1425-1427 1428-1430 1431-1433 1434-1436	
622 623 624 625	3 3 3 3	1437-1439 1440-1442 1443-1445 1446-1448	[RX8V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX8V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX8V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX8V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG-RELATED INFO FOR MEDICATION #9
P	lease see "DF	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
626	6	1449-1454	[DRUGID9] DRUG ID
627	1	1455	[PRESCR9] PRESCRIPTION STATUS CODE
628	1	1456	[CONTSUB9] CONTROLLED SUBSTANCE STATUS CODE
629	1	1457	[COMSTAT9] COMPOSITION STATUS CODE
630	3	1458-1460	[RX9CAT1] MULTUM DRUG CATEGORY # 1
631	3	1461-1463	[RX9CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
632	3	1464-1466	[RX9CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
633	3	1467-1469	[RX9CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
634 635 636 637	3 3 3 3	1470-1472 1473-1475 1476-1478 1479-1481	[RX9V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX9V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX9V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX9V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
638 639 640 641	3 3 3 3	1482-1484 1485-1487 1488-1490 1491-1493	[RX9V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX9V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX9V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX9V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
642 643 644 645	3 3 3 3	1494-1496 1497-1499 1500-1502 1503-1505	[RX9V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX9V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX9V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX9V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 106			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		DRU	G-RELATED INFO FOR MEDICATION #10
Р	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
646	6	1506-1511	[DRUGID10] DRUG ID
647	1	1512	[PRESCR10] PRESCRIPTION STATUS CODE
648	1	1513	[CONTSUB10] CONTROLLED SUBSTANCE STATUS CODE
649	1	1514	[COMSTAT10] COMPOSITION STATUS CODE
650	3	1515-1517	[RX10CAT1] MULTUM DRUG CATEGORY # 1
651	3	1518-1520	[RX10CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
652	3	1521-1523	[RX10CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
653	3	1524-1526	[RX10CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
654 655 656 657	3 3 3 3	1527-1529 1530-1532 1533-1535 1536-1538	[RX10V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
658 659 660 661	3 3 3 3	1539-1541 1542-1544 1545-1547 1548-1550	[RX10V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX10V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX10V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX10V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
662 663 664 665	3 3 3 3	1551-1553 1554-1556 1557-1559 1560-1562	[RX10V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX10V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX10V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX10V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES			
DRUG-RELATED INFO FOR MEDICATION #11						
Please see "DRUG-RELATED INFO FOR MEDICATION #1" (page 96) for coding information.						
666	6	1563-1568	[DRUGID11] DRUG ID			
667	1	1569	[PRESCR11] PRESCRIPTION STATUS CODE			
668	1	1570	[CONTSUB11] CONTROLLED SUBSTANCE STATUS CODE			
669	1	1571	[COMSTAT11] COMPOSITION STATUS CODE			
670	3	1572-1574	[RX11CAT1] MULTUM DRUG CATEGORY # 1			
671	3	1575-1577	[RX11CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.			
672	3	1578-1580	[RX11CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.			
673	3	1581-1583	[RX11CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.			
			DRUG CATEGORY LEVELS			
674 675 676 677	3 3 3 3	1584-1586 1587-1589 1590-1592 1593-1595	[RX11V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX11V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX11V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX11V1C4] Level 1 of MULTUM DRUG CATEGORY # 4			
678 679 680 681	3 3 3 3	1596-1598 1599-1601 1602-1604 1605-1607	[RX11V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX11V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX11V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX11V2C4] Level 2 of MULTUM DRUG CATEGORY # 4			
682 683 684 685	3 3 3 3	1608-1610 1611-1613 1614-1616 1617-1619	[RX11V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX11V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX11V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX11V3C4] Level 3 of MULTUM DRUG CATEGORY # 4			

PAGE 108			2014 NAMCS MICRO-DATA FILE DOCUMENTATION		
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES		
DRUG-RELATED INFO FOR MEDICATION #12					
Please see "DRUG-RELATED INFO FOR MEDICATION #1" (page 96) for coding information.					
686	6	1620-1625	[DRUGID12] DRUG ID		
687	1	1626	[PRESCR12] PRESCRIPTION STATUS CODE		
688	1	1627	[CONTSUB12] CONTROLLED SUBSTANCE STATUS CODE		
689	1	1628	[COMSTAT12] COMPOSITION STATUS CODE		
690	3	1629-1631	[RX12CAT1] MULTUM DRUG CATEGORY # 1		
691	3	1632-1634	[RX12CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.		
692	3	1635-1637	[RX12CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.		
693	3	1638-1640	[RX12CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.		
			DRUG CATEGORY LEVELS		
694 695 696 697	3 3 3 3	1641-1643 1644-1646 1647-1649 1650-1652	[RX12V1C2] Level 1 of MULTUM DRUG CATEGORY # 2		
698 699 700 701	3 3 3 3	1653-1655 1656-1658 1659-1661 1662-1664	[RX12V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX12V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX12V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX12V2C4] Level 2 of MULTUM DRUG CATEGORY # 4		
702 703 704 705	3 3 3 3	1665-1667 1668-1670 1671-1673 1674-1676			

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

706	6	1677-1682	[DRUGID13] DRUG ID
707	1	1683	[PRESCR13] PRESCRIPTION STATUS CODE
708	1	1684	[CONTSUB13] CONTROLLED SUBSTANCE STATUS CODE
709	1	1685	[COMSTAT13] COMPOSITION STATUS CODE
710	3	1686-1688	[RX13CAT1] MULTUM DRUG CATEGORY # 1
711	3	1689-1691	[RX13CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
712	3	1692-1694	[RX13CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
713	3	1695-1697	[RX13CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
714 715 716 717	3 3 3 3	1698-1700 1701-1703 1704-1706 1707-1709	
718 719 720 721	3 3 3 3	1710-1712 1713-1715 1716-1718 1719-1721	[RX13V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX13V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX13V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX13V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
722 723 724 725	3 3 3 3	1722-1724 1725-1727 1728-1730 1731-1733	• •

PAGE 1	10		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		DRU	G-RELATED INFO FOR MEDICATION #14
Ρ	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
726	6	1734-1739	[DRUGID14] DRUG ID
727	1	1740	[PRESCR14] PRESCRIPTION STATUS CODE
728	1	1741	[CONTSUB14] CONTROLLED SUBSTANCE STATUS CODE
729	1	1742	[COMSTAT14] COMPOSITION STATUS CODE
730	3	1743-1745	[RX14CAT1] MULTUM DRUG CATEGORY # 1
731	3	1746-1748	[RX14CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
732	3	1749-1751	[RX14CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
733	3	1752-1754	[RX14CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
734 735 736 737	3 3 3 3	1755-1757 1758-1760 1761-1763 1764-1766	[RX14V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX14V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX14V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX14V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
738 739 740 741	3 3 3 3	1767-1769 1770-1772 1773-1775 1776-1778	[RX14V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX14V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX14V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX14V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
742 743 744 745	3 3 3 3	1779-1781 1782-1784 1785-1787 1788-1790	[RX14V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX14V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX14V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX14V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		DRU	G-RELATED INFO FOR MEDICATION #15
F	Please see "DI	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
746	6	1791-1796	[DRUGID15] DRUG ID
747	1	1797	[PRESCR15] PRESCRIPTION STATUS CODE
748	1	1798	[CONTSUB15] CONTROLLED SUBSTANCE STATUS CODE
749	1	1799	[COMSTAT15] COMPOSITION STATUS CODE
750	3	1800-1802	[RX15CAT1] MULTUM DRUG CATEGORY # 1
751	3	1803-1805	[RX15CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
752	3	1806-1808	[RX15CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
753	3	1809-1811	[RX15CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
754 755 756 757	3 3 3 3	1812-1814 1815-1817 1818-1820 1821-1823	[RX15V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX15V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX15V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX15V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
758 759 760 761	3 3 3 3	1824-1826 1827-1829 1830-1832 1833-1835	[RX15V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX15V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX15V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX15V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
762 763 764 765	3 3 3 3	1836-1838 1839-1841 1842-1844 1845-1847	[RX15V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX15V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX15V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX15V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 1	12		2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		DRU	G-RELATED INFO FOR MEDICATION #16
Ρ	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
766	6	1848-1853	[DRUGID16] DRUG ID
767	1	1854	[PRESCR16] PRESCRIPTION STATUS CODE
768	1	1855	[CONTSUB16] CONTROLLED SUBSTANCE STATUS CODE
769	1	1856	[COMSTAT16] COMPOSITION STATUS CODE
770	3	1857-1859	[RX16CAT1] MULTUM DRUG CATEGORY # 1
771	3	1860-1862	[RX16CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
772	3	1863-1865	[RX16CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
773	3	1866-1868	[RX16CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
774 775 776 777	3 3 3 3	1869-1871 1872-1874 1875-1877 1878-1880	[RX16V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX16V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX16V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX16V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
778 779 780 781	3 3 3 3	1881-1883 1884-1886 1887-1889 1890-1892	[RX16V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX16V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX16V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX16V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
782 783 784 785	3 3 3 3	1893-1895 1896-1898 1899-1901 1902-1904	

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

786	6	1905-1910	[DRUGID17] DRUG ID
787	1	1911	[PRESCR17] PRESCRIPTION STATUS CODE
788	1	1912	[CONTSUB17] CONTROLLED SUBSTANCE STATUS CODE
789	1	1913	[COMSTAT17] COMPOSITION STATUS CODE
790	3	1914-1916	[RX17CAT1] MULTUM DRUG CATEGORY # 1
791	3	1917-1919	[RX17CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
792	3	1920-1922	[RX17CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
793	3	1923-1925	[RX17CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
794 795 796 797	3 3 3 3	1926-1928 1929-1931 1932-1934 1935-1937	[RX17V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX17V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX17V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX17V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
798 799 800 801	3 3 3 3	1938-1940 1941-1943 1944-1946 1947-1949	[RX17V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX17V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX17V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX17V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
802 803 804 805	3 3 3 3	1950-1952 1953-1955 1956-1958 1959-1961	[RX17V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX17V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX17V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX17V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE [·]	114
-------------------	-----

PAGE 114			2014 NAMCS MICRO-DATA FILE DOCUMENTATIO	
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
		DRU	G-RELATED INFO FOR MEDICATION #18	
	Please see "Di	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.	
806	6	1962-1967	[DRUGID18] DRUG ID	
807	1	1968	[PRESCR18] PRESCRIPTION STATUS CODE	
808	1	1969	[CONTSUB18] CONTROLLED SUBSTANCE STATUS CODE	
809	1	1970	[COMSTAT18] COMPOSITION STATUS CODE	
810	3	1971-1973	[RX18CAT1] MULTUM DRUG CATEGORY # 1	
811	3	1974-1976	[RX18CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.	
812	3	1977-1979	[RX18CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.	
813	3	1980-1982	[RX18CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.	
			DRUG CATEGORY LEVELS	
814 815 816 817	3 3 3 3	1983-1985 1986-1988 1989-1991 1992-1994	[RX18V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX18V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX18V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX18V1C4] Level 1 of MULTUM DRUG CATEGORY # 4	
818 819 820 821	3 3 3 3	1995-1997 1998-2000 2001-2003 2004-2006	[RX18V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX18V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX18V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX18V2C4] Level 2 of MULTUM DRUG CATEGORY # 4	
822 823 824 825	3 3 3 3	2007-2009 2010-2012 2013-2015 2016-2018	[RX18V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX18V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX18V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX18V3C4] Level 3 of MULTUM DRUG CATEGORY # 4	

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

826	6	2019-2024	[DRUGID19] DRUG ID
827	1	2025	[PRESCR19] PRESCRIPTION STATUS CODE
828	1	2026	[CONTSUB19] CONTROLLED SUBSTANCE STATUS CODE
829	1	2027	[COMSTAT19] COMPOSITION STATUS CODE
830	3	2028-2030	[RX19CAT1] MULTUM DRUG CATEGORY # 1
831	3	2031-2033	[RX19CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
832	3	2034-2036	[RX19CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
833	3	2037-2039	[RX19CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
834 835 836 837	3 3 3 3	2040-2042 2043-2045 2046-2048 2049-2051	[RX19V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX19V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX19V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX19V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
838 839 840 841	3 3 3 3	2052-2054 2055-2057 2058-2060 2061-2063	[RX19V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX19V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX19V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX19V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
842 843 844 845	3 3 3 3	2064-2066 2067-2069 2070-2072 2073-2075	[RX19V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX19V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX19V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX19V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE	116	
PAGE	110	

			2014 NAMCS MICRO-DATA FILE DOCUMENTATI			
			FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES		
			DRU	G-RELATED INFO FOR MEDICATION #20		
		Please see "DI	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.		
	846	6	2076-2081	[DRUGID20] DRUG ID		
	847	1	2082	[PRESCR20] PRESCRIPTION STATUS CODE		
	848	1	2083	[CONTSUB20] CONTROLLED SUBSTANCE STATUS CODE		
	849	1	2084	[COMSTAT20] COMPOSITION STATUS CODE		
	850	3	2085-2087	[RX20CAT1] MULTUM DRUG CATEGORY # 1		
	851	3	2088-2090	[RX20CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.		
	852	3	2091-2093	[RX20CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.		
	853	3	2094-2096	[RX20CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.		
				DRUG CATEGORY LEVELS		
	854 855 856 857	3 3 3 3	2097-2099 2100-2102 2103-2105 2106-2108	[RX20V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX20V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX20V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX20V1C4] Level 1 of MULTUM DRUG CATEGORY # 4		
	858 859 860 861	3 3 3 3	2109-2111 2112-2114 2115-2117 2118-2120	[RX20V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX20V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX20V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX20V2C4] Level 2 of MULTUM DRUG CATEGORY # 4		
	862 863 864 865	3 3 3 3	2121-2123 2124-2126 2127-2129 2130-2132	[RX20V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX20V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX20V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX20V3C4] Level 3 of MULTUM DRUG CATEGORY # 4		

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

866	6	2133-2138	[DRUGID21] DRUG ID
867	1	2139	[PRESCR21] PRESCRIPTION STATUS CODE
868	1	2140	[CONTSUB21] CONTROLLED SUBSTANCE STATUS CODE
869	1	2141	[COMSTAT21] COMPOSITION STATUS CODE
870	3	2142-2144	[RX21CAT1] MULTUM DRUG CATEGORY # 1
871	3	2145-2147	[RX21CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
872	3	2148-2150	[RX21CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
873	3	2151-2153	[RX21CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
874 875 876 877	3 3 3 3	2154-2156 2157-2159 2160-2162 2163-2165	
878 879 880 881	3 3 3 3	2166-2168 2169-2171 2172-2174 2175-2177	[RX21V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX21V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX21V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX21V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
882 883 884 885	3 3 3 3	2178-2180 2181-2183 2184-2186 2187-2189	[RX21V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX21V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX21V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX21V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

GE 1	18	
N /		

PAGE 118			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM FIELD FILE NO. LENGTH LOCATION			[ITEM NAME], DESCRIPTION, AND CODES
		DRU	G-RELATED INFO FOR MEDICATION #22
Р	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
886	6	2190-2195	[DRUGID22] DRUG ID
887	1	2196	[PRESCR22] PRESCRIPTION STATUS CODE
888	1	2197	[CONTSUB22] CONTROLLED SUBSTANCE STATUS CODE
889	1	2198	[COMSTAT22] COMPOSITION STATUS CODE
890	3	2199-2201	[RX22CAT1] MULTUM DRUG CATEGORY # 1
891	3	2202-2204	[RX22CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
892	3	2205-2207	[RX22CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
893	3	2208-2210	[RX22CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
894 895 896 897	3 3 3 3	2211-2213 2214-2216 2217-2219 2220-2222	
898 899 900 901	3 3 3 3	2223-2225 2226-2228 2229-2231 2232-2234	[RX22V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX22V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX22V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX22V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
902 903 904 905	3 3 3 3	2235-2237 2238-2240 2241-2243 2244-2246	[RX22V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX22V3C3] Level 3 of MULTUM DRUG CATEGORY # 3

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		DRU	G-RELATED INFO FOR MEDICATION #23
	Please see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
906	6	2247-2252	[DRUGID23] DRUG ID
907	1	2253	[PRESCR23] PRESCRIPTION STATUS CODE
908	1	2254	[CONTSUB23] CONTROLLED SUBSTANCE STATUS CODE
909	1	2255	[COMSTAT23] COMPOSITION STATUS CODE
910	3	2256-2258	[RX23CAT1] MULTUM DRUG CATEGORY # 1
911	3	2259-2261	[RX23CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
912	3	2262-2264	[RX23CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
913	3	2265-2267	[RX23CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
914 915 916 917	3 3 3 3	2268-2270 2271-2273 2274-2276 2277-2279	[RX23V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX23V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX23V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX23V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
918 919 920 921	3 3 3 3	2280-2282 2283-2285 2286-2288 2289-2291	[RX23V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX23V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX23V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX23V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
922 923 924 925	3 3 3 3	2292-2294 2295-2297 2298-2300 2301-2303	[RX23V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX23V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX23V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX23V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 12	20		2014 NAMCS MICRO-DATA FILE DOCUMENTATION		
ITEM FIELD FILE NO. LENGTH LOCATION			[ITEM NAME], DESCRIPTION, AND CODES		
		DRU	G-RELATED INFO FOR MEDICATION #24		
Ρ	lease see "Dl	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.		
926	6	2304-2309	[DRUGID24] DRUG ID		
927	1	2310	[PRESCR24] PRESCRIPTION STATUS CODE		
928	1	2311	[CONTSUB24] CONTROLLED SUBSTANCE STATUS CODE		
929	1	2312	[COMSTAT24] COMPOSITION STATUS CODE		
930	3	2313-2315	[RX24CAT1] MULTUM DRUG CATEGORY # 1		
931	3	2316-2318	[RX24CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.		
932	3	2319-2321	[RX24CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.		
933	3	2322-2324	[RX24CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.		
			DRUG CATEGORY LEVELS		
934 935 936 937	3 3 3 3	2325-2327 2328-2330 2331-2333 2334-2336	[RX24V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX24V1C3] Level 1 of MULTUM DRUG CATEGORY # 3		
938 939 940 941	3 3 3 3	2337-2339 2340-2342 2343-2345 2346-2348	[RX24V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX24V2C3] Level 2 of MULTUM DRUG CATEGORY # 3		
942 943 944 945	3 3 3 3	2349-2351 2352-2354 2355-2357 2358-2360	[RX24V3C2] Level 3 of MULTUM DRUG CATEGORY # 2		

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		DRU	G-RELATED INFO FOR MEDICATION #25
Р	lease see "DF	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.
946	6	2361-2366	[DRUGID25] DRUG ID
947	1	2367	[PRESCR25] PRESCRIPTION STATUS CODE
948	1	2368	[CONTSUB25] CONTROLLED SUBSTANCE STATUS CODE
949	1	2369	[COMSTAT25] COMPOSITION STATUS CODE
950	3	2370-2372	[RX25CAT1] MULTUM DRUG CATEGORY # 1
951	3	2373-2375	[RX25CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
952	3	2376-2378	[RX25CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
953	3	2379-2381	[RX25CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
954 955 956 957	3 3 3 3	2382-2384 2385-2387 2388-2390 2391-2393	[RX25V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX25V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX25V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX25V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
958 959 960 961	3 3 3 3	2394-2396 2397-2399 2400-2402 2403-2405	[RX25V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX25V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX25V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX25V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
962 963 964 965	3 3 3 3	2406-2408 2409-2411 2412-2414 2415-2417	[RX25V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX25V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX25V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX25V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 122			2014 NAMCS MICRO-DATA FILE DOCUMENTATION		
ITEM FIELD FILE NO. LENGTH LOCATION			[ITEM NAME], DESCRIPTION, AND CODES		
		DRU	G-RELATED INFO FOR MEDICATION #26		
Р	lease see "DI	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.		
966	6	2418-2423	[DRUGID26] DRUG ID		
967	1	2424	[PRESCR26] PRESCRIPTION STATUS CODE		
968	1	2425	[CONTSUB26] CONTROLLED SUBSTANCE STATUS CODE		
969	1	2426	[COMSTAT26] COMPOSITION STATUS CODE		
970	3	2427-2429	[RX26CAT1] MULTUM DRUG CATEGORY # 1		
971	3	2430-2432	[RX26CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.		
972	3	2433-2435	[RX26CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.		
973	3	2436-2438	[RX26CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.		
			DRUG CATEGORY LEVELS		
974 975 976 977	3 3 3 3	2439-2441 2442-2444 2445-2447 2448-2450	[RX26V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX26V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX26V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX26V1C4] Level 1 of MULTUM DRUG CATEGORY # 4		
978 979 980 981	3 3 3 3	2451-2453 2454-2456 2457-2459 2460-2462	[RX26V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX26V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX26V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX26V2C4] Level 2 of MULTUM DRUG CATEGORY # 4		
982 983 984 985	3 3 3 3	2463-2465 2466-2468 2469-2471 2472-2474	[RX26V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX26V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX26V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX26V3C4] Level 3 of MULTUM DRUG CATEGORY # 4		

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

986	6	2475-2480	[DRUGID27] DRUG ID
987	1	2481	[PRESCR27] PRESCRIPTION STATUS CODE
988	1	2482	[CONTSUB27] CONTROLLED SUBSTANCE STATUS CODE
989	1	2483	[COMSTAT27] COMPOSITION STATUS CODE
990	3	2484-2486	[RX27CAT1] MULTUM DRUG CATEGORY # 1
991	3	2487-2489	[RX27CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
992	3	2490-2492	[RX27CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
993	3	2493-2495	[RX27CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
994 995 996 997	3 3 3 3	2496-2498 2499-2501 2502-2504 2505-2507	[RX27V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX27V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX27V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX27V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
998 999 1000 1001	3 3 3 3	2508-2510 2511-2513 2514-2516 2517-2519	[RX27V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX27V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX27V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX27V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
1002 1003 1004 1005	3 3 3 3	2520-2522 2523-2525 2526-2528 2529-2531	[RX27V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX27V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX27V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX27V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 124

PAGE 124			2014 NAMCS MICRO-DATA FILE DOCUMENTATIO				
ITEM FIELD NO. LENGTH		FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES				
			וופס	G-RELATED INFO FOR MEDICATION #28			
			DRU	G-RELATED INFO FOR MEDICATION #28			
	F	Please see "Di	RUG-RELATE	D INFO FOR MEDICATION #1" (page 96) for coding information.			
	1006	6	2532-2537	[DRUGID28] DRUG ID			
	1007	1	2538	[PRESCR28] PRESCRIPTION STATUS CODE			
	1008	1	2539	[CONTSUB28] CONTROLLED SUBSTANCE STATUS CODE			
	1009	1	2540	[COMSTAT28] COMPOSITION STATUS CODE			
	1010	3	2541-2543	[RX28CAT1] MULTUM DRUG CATEGORY # 1			
	1011	3	2544-2546	[RX28CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.			
	1012	3	2547-2549	[RX28CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.			
	1013	3	2550-2552	[RX28CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.			
				DRUG CATEGORY LEVELS			
	1014 1015 1016 1017	3 3 3 3	2553-2555 2556-2558 2559-2561 2562-2564	[RX28V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX28V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX28V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX28V1C4] Level 1 of MULTUM DRUG CATEGORY # 4			
	1018 1019 1020 1021	3 3 3 3	2565-2567 2568-2570 2571-2573 2574-2576	[RX28V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX28V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX28V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX28V2C4] Level 2 of MULTUM DRUG CATEGORY # 4			
	1022 1023 1024 1025	3 3 3 3	2577-2579 2580-2582 2583-2585 2586-2588	[RX28V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX28V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX28V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX28V3C4] Level 3 of MULTUM DRUG CATEGORY # 4			

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

1026	6	2589-2594	[DRUGID29] DRUG ID
1027	1	2595	[PRESCR29] PRESCRIPTION STATUS CODE
1028	1	2596	[CONTSUB29] CONTROLLED SUBSTANCE STATUS CODE
1029	1	2597	[COMSTAT29] COMPOSITION STATUS CODE
1030	3	2598-2600	[RX29CAT1] MULTUM DRUG CATEGORY # 1
1031	3	2601-2603	[RX29CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
1032	3	2604-2606	[RX29CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
1033	3	2607-2609	[RX29CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.
			DRUG CATEGORY LEVELS
1034 1035 1036 1037	3 3 3 3	2610-2612 2613-2615 2616-2618 2619-2621	[RX29V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX29V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX29V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX29V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
1038 1039 1040 1041	3 3 3 3	2622-2624 2625-2627 2628-2630 2631-2633	[RX29V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX29V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX29V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX29V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
1042 1043 1044 1045	3 3 3 3	2634-2636 2637-2639 2640-2642 2643-2645	[RX29V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX29V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX29V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX29V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 126			2014 NAMCS MICRO-DATA FILE DOCUMENTATION			
ITEM NO.	FIELD LENGTH	FILE LOCATION [ITEM NAME], DESCRIPTION, AND CODES				
	DRUG-RELATED INFO FOR MEDICATION #30					
Ple	ease see "DF	RUG-RELATEI	D INFO FOR MEDICATION #1" (page 100) for coding information.			
1046	6	2646-2651	[DRUGID30] DRUG ID			
1047	1	2652	[PRESCR30] PRESCRIPTION STATUS CODE			
1048	1	2653	[CONTSUB30] CONTROLLED SUBSTANCE STATUS CODE			
1049	1	2654	[COMSTAT30] COMPOSITION STATUS CODE			
1050	3	2655-2657	[RX30CAT1] MULTUM DRUG CATEGORY # 1			
1051	3	2658-2660	[RX30CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.			
1052	3	2661-2663	[RX30CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.			
1053	3	2664-2666	[RX30CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.			
			DRUG CATEGORY LEVELS			
1054 1055 1056 1057	3 3 3 3	2667-2669 2670-2672 2673-2675 2676-2678	[RX30V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX30V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX30V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX30V1C4] Level 1 of MULTUM DRUG CATEGORY # 4			
1058 1059 1060 1061	3 3 3 3	2679-2681 2682-2684 2685-2687 2688-2690	[RX30V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX30V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX30V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX30V2C4] Level 2 of MULTUM DRUG CATEGORY # 4			
1062 1063 1064 1065	3 3 3 3	2691-2693 2694-2696 2697-2699 2700-2702	[RX30V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX30V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX30V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX30V3C4] Level 3 of MULTUM DRUG CATEGORY # 4			

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

NAMCS SAMPLE DESIGN VARIABLES

NAMCS sampling design variables (in masked format) were first added to the 2000 public use file, and data years from 1993-1999 were re-released to include them. These variables were for use with statistical software such as SUDAAN that takes into account the complex sampling design of the survey. However, for those running versions of SAS, Stata, SPSS and other software that assumes a single stage of sampling, the multi-stage design variables provided on the public use files could not be used without modification. Therefore, in 2002, two new variables, CSTRATM and CPSUM, were developed, that could be used in such programs instead of the multi-stage variables. In 2003, the decision was made to include on the public use file just these two variables and not the multi-stage design variables that appeared in the past.

Until such time as the older public use files may be re-released to include these variables, data users wishing to combine data from 2003 and later years with data from earlier years will find it necessary to create CSTRATM and CPSUM for the earlier files. A technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files,* is available for downloading at the Ambulatory Health Care Data website: http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. This paper gives instructions on how to configure data files prior to 2002 for variance estimation based on 1-stage sampling models, such as those used in SAS proc surveymeans, Stata, SPSS, and the SUDAAN with-replacement option, and how to handle instances of single-case strata in the data on the older files. Please also see the section on Relative Standard Errors in the current document for more information on these variables and how to use them. PSU is primary sampling unit.

In 2014, NAMCS utilized a list sample, as described in more detail on page 15. For consistency with previous years, the same names used in earlier years have been used for the two new sample design variables. For additional information on combining data across years with the old and new sample designs, please see p. 2.

1066	8	2703-2710	[CSTRATM] Masked clustered stratum marker 10114101-12514102
1067	6	2711-2716	[CPSUM] Sampled provider marker 100024-110008
1068	4	2717-2720	[YEAR] SURVEY YEAR 2014
1069	1	2721	[SETTYPE] SETTING TYPE This item is intended for use when combining data from NAMCS and NHAMCS.
			1 = Physician office (NAMCS)
1070	11	2722-2732	[PATWT] PATIENT VISIT WEIGHT (NOT FOR STATE ESTIMATES) (See page 2 for more information.)
			This variable has been produced as an unrounded integer in 2014, which will make estimates slightly more precise. It is ONLY for use in producing national, regional, division, and MSA-level estimates, NOT state estimates.

721.0413 - 344892.4782

PAGE 128			2014 NAMCS MICRO-DATA FILE DOCUMENTATION
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
1071	12	2733-2744	[PATWTST] PATIENT VISIT WEIGHT FOR STATE ESTIMATES (See page 2 for more information.)
			This variable has been produced as an unrounded integer in 2014, which will make estimates slightly more precise. It is ONLY for use in producing state estimates, NOT national, regional, division, or MSA- level estimates.
aggregated within their division) were giv cannot be made for these records (a tota			on remainders' (that is, not part of the 18 targeted states, but in states ere given miniscule values for PATWTST (.00001). State estimates (a total of 13,291), but assigning some value for PATWTST was ng dropped from statistical software when calculating variances.
			0.00001 – 344892.4782
1072	9	2745-2753	[PHYSWT] PHYSICIAN WEIGHT
			Physician weight enables data users to make physician-level estimates. See also "Description of the NAMCS," Marginal Data, and Appendix I.
			21.71878 – 700.98102
1073	1	2754-2754	[HTWTFL] DID HEIGHT OR WEIGHT FALL OUTSIDE OF ACCEPTABLE RANGES? 0 = Height and weight are within acceptable ranges 1 = Height and/or weight are outside acceptable ranges

B. PHYSICIAN SPECIALTY LIST

The 2014 NAMCS sample design (see page 15) did not use physician specialty groups to form sampling strata. Physicians within each state or division remainder were stratified based on whether they were engaged in primary care or not. But within those strata, physicians were sorted based on broad specialty group and type of specialty (primary, medical, surgical), as explained earlier. Below is a list of the AMA physician specialties that were eligible for selection within each of these 'soft' sampling strata.

GENERAL AND FAMILY PRACTICE

- AMF Adolescent Medicine (Family Practice)
- AMI Adolescent Medicine (Internal Medicine)
- EFM Emergency Medicine/Family Medicine
- FMP Family Medicine/Preventive Medicine
- FP Family Practice
- FPG Geriatric Medicine (Family Practice)
- GP General Practice
- HPF Hospice & Palliative Medicine (Family Medicine)
- IFP Internal Medicine/Family Practice
- IMG Geriatric Medicine (Internal Medicine)
- IPM Internal Medicine/Preventive Medicine

INTERNAL MEDICINE

IM Internal Medicine

PEDIATRICS (Primary Care)

- ADL Adolescent Medicine (Pediatrics)
- MPD Internal Medicine/Pediatrics
- PD Pediatrics
- PSM Pediatric Sports Medicine

PEDIATRICS (Medical)

- CAP Child Abuse Pediatrics
- CCP Pediatric Critical Care Medicine
- DBP Developmental Behavioral Pediatrics
- EMP Pediatrics Emergency Medicine
- HPP Hospice & Palliative Medicine (Pediatrics)
- NDN Neurodevelopmental Disabilities
- (Psychiatry & Neurology) NDP Neurodevelopmental Disabilities (Pediatrics)
- NPM Neonatal-Perinatal Medicine
- PDA Pediatric Allergy
- PDC Pediatric Cardiology
- PDE Pediatric Endocrinology
- PDI Pediatric Infectious Diseases
- PDP Pediatric Pulmonology
- PDT Medical Toxicology (Pediatrics)
- PEM Pediatric Emergency Medicine (Pediatrics)
- PG Pediatric Gastroenterology
- PHO Pediatric Hematology/Oncology
- PMG Pediatrics Medical Genetics
- PN Pediatric Nephrology

PEDIATRICS (Medical)

- PPR Pediatric Rheumatology
- PTP Pediatric Transplant Hepatology

GENERAL SURGERY (Surgical)

GS General Surgery

OBSTETRICS AND GYNECOLOGY (Primary Care)

- GYN Gynecology
- OBG Obstetrics and Gynecology
- OBS Obstetrics

OBSTETRICS AND GYNECOLOGY (Surgical)

- FPR Female Pelvic Medicine and Reconstructive Surgery (Obstetrics & Gynecology)
- GO Gynecological Oncology
- HPO Hospice & Palliative Med (Obstetrics & Gynecology)
- MFM Maternal & Fetal Medicine
- OCC Critical Care Medicine (Obstetrics & Gynecology)

ORTHOPEDIC SURGERY (Surgical)

- HSO Hand Surgery
- OAR Adult Reconstructive Orthopedics
- OFA Foot and Ankle Orthopedics
- OMO Musculoskeletal Oncology
- OP Pediatric Orthopedics
- ORS Orthopedic Surgery
- OSM Sports Medicine (Orthopedic Surgery)
- OSS Orthopedic Surgery of the Spine
- OTR Orthopedic Trauma

CARDIOVASCULAR DISEASES (Medical)

CD Cardiovascular Diseases

DERMATOLOGY (Medical)

D Dermatology

UROLOGY (Surgical)

U Urology

UP Pediatric Urology

PSYCHIATRY (Medical)

- ADP Addiction Psychiatry
- CHP Child and Adolescent Psychiatry
- CPP Pediatrics/Psychiatry/Child &
- Adolescent Psychiatry NUP Neuropsychiatry
- P Psychiatry
- PFP Forensic Psychiatry
- PYA Psychoanalysis
- PYG Geriatric Psychiatry
- PYM Psychosomatic Medicine

NEUROLOGY (Medical)

- CHN Child Neurology
- CN Clinical Neurophysiology
- ENR Endovascular Surgical Neuroradiology (Neurology)
- EPL Epilepsy
- ESN Endovascular Surgical Neuroradiology N Neurology
- NRN Neurology/Diagnostic Radiology/Neuroradiology
- VN Vascular Neurology

OPHTHALMOLOGY (Surgical)

- OPH Ophthalmology
- OPR Ophthalmic Plastic and Reconstructive Surgery
- PO Pediatric Ophthalmology

OTOLARYNGOLOGY (Surgical)

- NO Neurotology (Otolaryngology)
- OTO Otolaryngology
- PDO Pediatric Otolaryngology
- PSO Plastic Surgery within the Head & Neck (Otolaryngology)
- SMO Sleep Medicine (Otolaryngology)

ALL OTHER (Surgical)

- AS Abdominal Surgery
- ASO Advanced Surgical Oncology
- CCS Surgical Critical Care (Surgery)
- CFS Craniofacial Surgery
- CHS Congenital Cardiac Surgery (Thoracic Surgery)
- CRS Colon & Rectal Surgery
- CS Cosmetic Surgery

ALL OTHER (Surgical)

- DS Dermatologic Surgery
- ES Endovascular Surgical Neuroradiology (Neurological Surgery)
- FPS Facial Plastic Surgery
- HNS Head & Neck Surgery
- HPS Hospice and Palliative Medicine (Surgery)
- HS Hand Surgery
- HSP Hand Surgery (Plastic Surgery)
- HSS Hand Surgery (Surgery)
- NS Neurological Surgery
- NSP Pediatric Surgery (Neurology)
- OMF Oral & Maxillofacial Surgery
- PCS Pediatric Cardiothoracic Surgery
- PDS Pediatric Surgery (Surgery)
- PRD Procedural Dermatology
- PS Plastic Surgery
- PSH Plastic Surgery within the Head & Neck
- PSP Plastic Surgery within the Head & Neck (Plastic Surgery)
- SO Surgical Oncology
- TRS Traumatic Surgery
- TS Thoracic Surgery
- TTS Transplant Surgery
- VS Vascular Surgery

ALL OTHER (Medical)

- A Allergy
- ADM Addiction Medicine
- AHF Advanced Heart Failure and Transplant Cardiology
- AI Allergy and Immunology
- ALI Clinical Laboratory Immunology (Allergy & Immunology)
- AM Aerospace Medicine
- **CBG** Clinical Biochemical Genetics
- CCG Clinical Cytogenetics
- CCM Critical Care Medicine (Internal medicine)
- CG Clinical Genetics
- CMG Clinical Molecular Genetics
- DDL Clinical and Lab Derm Immunology
- DIA Diabetes
- EM Emergency Medicine
- END Endocrinology, diabetes and metabolism
- EP Epidemiology
- ESM Sports Medicine (Emergency Medicine)
- ETX Medical Toxicology (Emergency Medicine)
- FPP Psychiatry/Family Practice
- FSM Family Practice/Sports Medicine
- GE Gastroenterology
- GPM General Preventive Medicine
- HEM Hematology (Internal medicine)
- HEP Hepatology
- HO Hematology/Oncology

ALL OTHER (Medical)

HPE	Hospice & Palliative Medicine
	(Emergency Medicine)
HPI	Hospice & Palliative Medicine (Internal
	Medicine)
	Hospice & Palliative Medicine
HPN	Hospice & Palliative Medicine (Psychiatry
	& Neurology)
HPR	Hospice & Palliative Med (Physical
IC	Medicine)
ICE	Interventional Cardiology
	Clinical Cardiac Electrophysiology Infectious Diseases
ID IEC	
IEC	Internal Medicine/Emergency Medicine/Critical Care Medicine
IG	
ILI	Immunology
ILI	Clinical and Laboratory Immunology
IMD	(Internal Medicine) Internal Medicine/Dermatology
ISM	Internal Medicine - Sports Medicine
LM	Legal Medicine
MDM	
MEM	Internal Medicine/Emergency Medicine
MG	Medical GeneticsMO – Medical Oncology
MBG	Medical Biochemical Genetics
MN	Internal Medicine/Neurology
MP	Internal Medicine/Psychiatry
MPM	
	Rehabilitation
NC	Nuclear Cardiology
NEP	Nephrology
NMN	Neuromuscular Medicine
NMP	Neuromuscular Medicine (Physical
	Medicine & Rehabilitation)
NTR	Nutrition
OM	Occupational Medicine
OMM	Osteopathic Manipulative Medicine
PA	Clinical Pharmacology
PCC	Pulmonary Critical Care Medicine
PDD	Pediatric Dermatology
PDM	Pediatrics/Dermatology
PE	Pediatric Emergency Medicine
-	(Emergency Medicine)
PHL	Phlebology
PHM	Pharmaceutical Medicine

PHM Pharmaceutical Medicine

ALL OTHER (Medical)

- PHP Public Health and General Preventive Medicine
- PLI Clinical and Laboratory Immunology (Pediatrics)
- PLM Palliative Medicine
- PM Physical Medicine and Rehabilitation
- PME Pain Management
- PMM Pain Medicine
- PMN Pain Medicine (Neurology)
- PMP Pain Management (Physical Medicine and Rehabilitation)
- PPM Pediatrics/Physical Medicine & Rehabilitation
- PPN Pain Medicine (Psychiatry)
- **PRO** Proctology
- PRS Sports Medicine (Physical Medicine and Rehabilitation)
- PTX Medical Toxicology (Preventive Medicine)
- PUD Pulmonary Diseases
- PYN Psychiatry (Neurology)
- **REN Reproductive Endocrinology**
- RHU Rheumatology
- **RPM** Pediatric Rehabilitation Medicine
- SCI Spinal Cord Injury Medicine
- SME Sleep Medicine
- SMI Sleep Medicine (Internal Medicine)
- SMN Sleep Medicine (Psychiatry & Neurology)
- SMP Sleep Medicine (Pediatrics)
- THP Transplant Hepatology (Internal Medicine)
- UCM Urgent Care Medicine
- UM Underseas Medicine (Preventive Medicine)
- UME Underseas Medicine (Emergency Medicine)
- VM Vascular Medicine
- OS Other Specialty
- US Unspecified

PAGE 132

C. AMA SPECIALTIES REGROUPED INTO PRIMARY CARE, SURGICAL, AND MEDICAL SPECIALTIES

Below is a list of the AMA physician specialties comprising the NAMCS 'soft' sample strata, as described above, regrouped into primary care, surgical, and medical specialties for analytic purposes (see SPECCAT variable on file layout).

PRIMARY CARE SPECIALTIES

- ADL Adolescent Medicine (Pediatrics)
- AMF Adolescent Medicine (Family Practice)
- AMI Adolescent Medicine (Internal Medicine)
- EFM Emergency Medicine/Family Medicine
- FMP Family Medicine/Preventive Medicine
- FP Family Practice
- FPG Geriatric medicine (Family Practice)
- GP General Practice
- **GYN** Gynecology
- HPF Hospice & Palliative Medicine (Family Medicine)
- IFP Internal Medicine/Family Practice
- IM Internal Medicine
- IMG Geriatric Medicine (Internal Medicine)
- IPM Internal Medicine/Preventive Medicine
- MPD Internal Medicine/Pediatrics
- OBG Obstetrics & Gynecology
- OBS Obstetrics
- PD Pediatrics
- PSM Pediatric Sports Medicine

SURGICAL SPECIALTIES

- AS Abdominal Surgery
- ASO Advanced Surgical Oncology
- CCS Surgical Critical Care (Surgery)
- CFS Craniofacial Surgery
- CHS Congenital Cardiac Surgery (Thoracic Surgery)
- CRS Colon & Rectal Surgery
- CS Cosmetic Surgery
- DS Dermatologic Surgery
- ES Endovascular Surgical Neuroradiology (Neurological Surgery)
- FPR Female Pelvic Medicine and Reconstructive Surgery
- FPS Facial Plastic Surgery
- GO Gynecological Oncology
- GS General Surgery
- HNS Head & Neck Surgery
- HPO Hospice & Palliative Medicine (Obstetrics & Gynecology
- HPS Hospice and Palliative Medicine (Surgery)
- HS Hand Surgery
- HSO Hand Surgery (Orthopedics)
- HSP Hand Surgery (Plastic Surgery)

SURGICAL SPECIALTIES

- HSS Hand Surgery (Surgery)
- MFM Maternal & Fetal Medicine
- NO Neurotology (Otolaryngology)
- NS Neurological Surgery
- NSP Pediatric Surgery (Neurology)
- OAR Adult Reconstructive Orthopedics
- OCC Critical Care Medicine (Obstetrics & Gynecology)
- OFA Foot And Ankle, Orthopedics
- OMF Oral and Maxillofacial Surgery
- OMO Musculoskeletal Oncology
- OP Pediatric Orthopedics
- OPH Ophthalmology
- OPR Ophthalmic Plastic and Reconstructive Surgery
- ORS Orthopedic Surgery
- OSM Sports Medicine (Orthopedic Surgery)
- OSS Orthopedic Surgery Of The Spine
- OTO Otolaryngology
- OTR Orthopedic Trauma
- PCS Pediatric Cardiothoracic Surgery
- PDO Pediatric Otolaryngology
- PDS Pediatric Surgery (Surgery)
- PO Pediatric Ophthalmology
- PRD Procedural Dermatology
- PS Plastic Surgery
- PSH Plastic Surgery Within the Head & Neck
- PSO Plastic Surgery Within the Head & Neck (Otolaryngology)
- PSP Plastic Surgery Withi the Nead & Neck (Plastic Surgery)
- SMO Sleep Medicine (Otolaryngology)
- SO Surgical Oncology
- TRS Trauma Surgery
- TS Thoracic Surgery
- TTS Transplant Surgery
- U Urology
- UP Pediatric Urology
- VS Vascular Surgery

MEDICAL SPECIALTIES

- A Allergy
- ADM Addiction Medicine
- ADP Addiction Psychiatry

MEDICAL SPECIALTIES

- AHF Advanced Heart Failure and Transplant Cardiology
- AI Allergy & Immunology
- ALI Clinical Laboratory Immunology (Allergy & Immunology)
- AM Aerospace Medicine
- CAP Child Abuse Pediatrics
- **CBG** Clinical Biochemical Genetics
- CCG Clinical Cytogenetics
- CCM Critical Care Medicine (Internal Medicine)
- CCP Pediatric Critical Care Medicine
- CD Cardiovascular Disease
- CG Clinical Genetics
- CHN Child Neurology
- CHP Child and Adolescent Psychiatry
- CMG Clinical Molecular Genetics
- CN Clinical Neurophysiology
- CPP Pediatrics/Psychiatry/Child & Adolescent Psychiatry
- D Dermatology
- DBP Developmental Behavioral Pediatrics
- DDL Clinical And Lab Derm Immunology
- DIA Diabetes
- EM Emergency Medicine
- EMP Pediatrics/Emergency Medicine
- ENDEndocrinology, Diabetes and MetabolismENREndovascular Surgical Neuroradiology
- (Neurology)
- EP Epidemiology
- EPL Epilepsy
- ESM Sports Medicine (Emergency Medicine)
- ESN Endovascular Surgical Neuroradiology
- ETX Medical Toxicology (Emergency Medicine)
- FPP Psychiatry/Family Practice
- FSM Family Practice/Sports Medicine
- GE Gastroenterology
- GPM General Preventive Medicine
- HEM Hematology (Internal Medicine)
- HEP Hepatology
- HO Hematology/Oncology
- HPE Hospice & Palliative Medicine (Emergency Medicine)
- HPI Hospice & Palliative Medicine (Internal Medicine)
- HPM Hospice & Palliative Medicine
- HPN Hospice & Palliative Medicine (Psychiatry & Neurology)
- HPP Hospice & Palliative Medicine (Pediatrics)
- HPR Hospice & Palliative Medicine (Physical Medicine)
- IC Interventional Cardiology

MEDICAL SPECIALTIES

- ICE Clinical Cardiac Electrophysiology
- ID Infectious Disease
- IEC Internal Medicine/Emergency Medicine/ Critical Care Medicine
- IG Immunology
- ILI Clinical and Laboratory Immunology (Internal Medicine)
- IMD Internal Medicine/Dermatology
- ISM Internal Medicine Sports Medicine
- LM Legal Medicine
- MBG Medical Biochemical Genetics
- MDG Internal Medicine/Medical Genetics
- MDM Medical Management
- MEM Internal Medicine/Emergency Medicine
- MG Medical Genetics
- MN Internal Medicine/Neurology
- MP Internal Medicine/Psychiatry
- MPM Internal Medicine/Physical Medicine And Rehabilitation
- N Neurology
- NC Nuclear Cardiology
- NDN Neurodevelopmental Disabilities (Psychiatry & Neurology)
- NDP Neurodevelopmental Disabilities (Pediatrics)
- NEP Nephrology
- NMN Neuromuscular Medicine
- NMP Neuromuscular Medicine (Physician Medicine and Rehabilitation)
- NPM Neonatal Perinatal Medicine
- NRN Neurology/Diagnostic
 - Radiology/Neuroradiology
- NTR Nutrition
- NUP Neuropsychiatry
- OM Occupational Medicine
- OMM Osteopathic Manipulative Medicine
- ON Medical Oncology
- P Psychiatry
- PA Clinical Pharmacology
- PCC Pulmonary Critical Care Medicine
- PDA Pediatric Allergy
- PDC Pediatric Cardiology
- PDD Pediatric Ddermatology
- PDE Pediatric Endocrinology
- PDI Pediatric Infectious Diseases
- PDM Pediatrics/Dermatology
- PDP Pediatric Pulmonology
- PDT Medical Toxicology (Pediatrics)
- PE Pediatric Emergency Medicine (Emergency Medicine)

MEDICAL SPECIALTIES

- PEM Pediatric Emergency Medicine (Pediatrics)
- PFP Forensic Psychiatry
- PG Pediatric Gastroenterology
- PHL Phlebology
- PHM Pharmaceutical Medicine
- PHO Pediatric Hematology/Oncology
- PHP Public Health and General Preventive Medicine
- PLI Clinical and Laboratory Immunology (Pediatrics)
- PLM Palliative Medicine
- PM Physical Medicine & Rehabilitation
- PME Pain Management
- PMG Pediatrics Medical Genetics
- PMM Pain Medicine
- PMN Pain Medicine (Neurology)
- PMP Pain Management (Physical Medicine & Rehabilitation)
- PN Pediatric Nephrology
- PPM Pediatrics/Physical Medicine & Rehabilitation
- PPN Pain Medicine (Psychiatry)
- PPR Pediatric Rheumatology
- PRO Proctology

MEDICAL SPECIALTIES

- PRS Sports Medicine (Physical Medicine & Rehabilitation)
- PTP Pediatric Transplant Hepatology
- PTX Medical Toxicology (Preventive Medicine)
- PUD Pulmonary Disease
- PYA Psychoanalysis
- PYG Geriatric Psychiatry
- PYM Psychosomatic Medicine
- PYN Psychiatry/Neurology
- REN Reproductive Endocrinology
- RHU Rheumatology
- **RPM** Pediatric Rehabilitation Medicine
- SCI Spinal Cord Injury Medicine
- SME Sleep Medicine
- SMI Sleep Medicine (Internal Medicine)
- SMN Sleep Medicine (Psychiatry & Neurology)
- SMP Sleep Medicine (Pediatrics)
- THP Transplant Hepatology (Internal Medicine)
- UCM Urgent Care Medicine
- UM Underseas Medicine (Preventive Medicine)
- UME Underseas Medicine (Emergency Medicine)
- VM Vascular Medicine
- VN Vascular Neurology
- OS Other Specialty
- US Unspecified Specialty

III. MARGINAL DATA

A. PATIENT VISITS

PATIENT AGE

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	45,710	884,707,170	100.000
1 - Under 15 years	6,680	118,264,335	13.368
2 - 15-24 years	3,281	60,414,265	6.829
3 - 25-44 years	8,484	168,087,083	18.999
4 - 45-64 years	13,787	273,423,302	30.906
5 - 65-74 years	7,178	143,354,656	16.204
6 - 75 years and over	6,300	121,163,530	13.695

PATIENT SEX

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	45,710	884,707,170	100.000
1 - Female	26,137	508,760,241	57.506
2 - Male	19,573	375,946,929	42.494

PATIENT RACE RECODE (WITH MISSING DATA IMPUTED)

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	45,710	884,707,170	100.000
1 - White	39,371	753,215,010	85.137
2 - Black	4,138	81,037,510	9.160
3 - Other	2,201	50,454,650	5.703

EXPECTED PRIMARY SOURCE OF PAYMENT [based on PAYTYPER, a recoded variable, see more about this variable on page 47] CATEGORY RECORDS WEIGHTED VISITS PERCENT Total 45,710 884,707,170 100.000 -9 - All sources of payment are blank 1,078 15,880,628 1.795 -8 - Unknown 2,026 27,469,815 3.105 22,422 442,688,505 1 - Private insurance 50.038 2 - Medicare 12,076 236,832,098 26.770 3 - Medicaid, CHIP or other state-based program 5,042 96,626,894 10.922 4 - Worker's compensation 390 7,651,775 0.865 43,000,082 5 - Self-pay 1,935 4.860 6 - No charge/Charity 75 1,642,096 0.186 7 - Other 666 12,915,278 1.460 MAJOR REASON FOR VISIT CATEGORY RECORDS WEIGHTED VISITS PERCENT Total 45,710 884,707,170 100.000 -9 - Blank 31,267,216 1,388 3.534 1 - New problem 13,306 (less than 3 mos. onset) 262,609,252 29.683 2 - Chronic problem, routine 296,657,326 15,312 33.532 65,499,063 3 - Chronic problem, flare-up 3,545 7.403 4 - Pre-surgery 854 13,692,455 1.548 5 - Post-surgery 2,775 45,487,202 5.141 8,530 169,494,656 6 - Preventive care 19.158 _____ HAS THE PATIENT BEEN SEEN IN YOUR PRACTICE BEFORE? CATEGORY WEIGHTED VISITS RECORDS PERCENT Total 45,710 884,707,170 100.000 1 - Yes, established patient 37,920 743,187,682 84.004 2 - No, new patient 7,790 141,519,488 15.996

NUMBER OF MEDICATION CODES THIS VISIT

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT	
Total	45,710	884,707,170	100.000	
0	10,757	219,246,339	24.782	
1	7,996	156,863,502	17.731	
2	5,613	110,569,425	12.498	
3	4,066	81,316,769	9.191	
4	3,183	61,322,278	6.931	
5	2,529	50,217,332	5.676	
6	2,017	38,957,366	4.403	
7	1,626	31,976,796	3.614	
8	1,415	26,153,683	2.956	
9	1,234	21,251,208	2.402	
10	1,039	18,636,828	2.107	
11	809	13,442,141	1.519	
12	708	12,295,038	1.390	
13	573	9,710,877	1.098	
14	462	6,733,303	0.761	
15	368	5,949,732	0.673	
16	289	4,400,792	0.497	
17	213	3,892,434	0.440	
18	179	2,529,666	0.286	
19	154	2,480,315	0.280	
20	113	1,568,027	0.177	
21	91	1,712,045	0.194	
22	60	818,735	0.093	
23	46	760,797	0.086	
24	35	457,685	0.052	
25	22	298,827	0.034	
26	23	257,731	0.029	
27	28	242,236	0.027	
28	21	249,229	0.028	
29	11	89,741	0.010	
30	30	306,292	0.035	

- -

PHYSICIAN SPECIALTY

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	45,710	884,707,170	100.000
1 - General/family practice	8,965	193,275,867	21.846
3 - Internal medicine	4,908	126,759,774	14.328
4 - Pediatrics	5,628	97,733,750	11.047
5 - General surgery	1,477	18,918,388	2.138
6 - Obstetrics and gynecology	2,801	47,044,406	5.318
7 - Orthopedic surgery	2,818	50,406,134	5.697
8 - Cardiovascular diseases	1,777	39,027,429	4.411
9 - Dermatology	1,625	27,522,401	3.111
10 - Urology	1,308	18,162,606	2.053
11 - Psychiatry	1,724	41,498,479	4.691
12 - Neurology	964	12,008,175	1.357
13 - Ophthalmology	2,211	41,676,048	4.711
14 - Otolaryngology	896	12,778,146	1.444
15 - Other specialties	8,608	157,895,567	17.847

B. DRUG MENTIONS

PATIENT AGE

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT	
Total	175,422	3,150,460,641	100.000	
1 - Under 15 years	11,274	192,353,215	6.106	
2 - 15-24 years	6,091		3.394	
3 - 25-44 years	21,801		12.767	
4 - 45-64 years	57,903		32.984	
5 - 65-74 years	39,368	723,848,910	22.976	
6 - 75 years and over	38,985	685,954,749	21.773	
PATIENT SEX				
CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT	
Total	175,422	3,150,460,641	110.000	
1 - Female		1,833,089,073		
2 - Male	72,941	1,317,371,568	45.997	
PHYSICIAN SPECIALTY				
CATEGORY		RECORDS WE	IGHTED MENTIONS	PERCENT
Total		175,422	3,150,460,641	100.000
1 - General/family practice		40,656	819,916,990	26.025
3 - Internal medicine		26,384	623,469,704	19.790
4 - Pediatrics		1 0,314	167,785,573	5.326
5 - General surgery		3,890	35,863,944	1.138
6 - Obstetrics and gynecology			77,227,597	2.451
7 - Orthopedic surgery		7,730		3.727
8 - Cardiovascular diseases		12,379	248,772,481	7.896
9 - Dermatology		•	63,547,314	2.017
10 - Urology		6,285	64,043,555	2.033
11 - Psychiatry		3,978	99,062,556	3.144
12 - Neurology		3,455	35,216,894	1.118
13 - Ophthalmology		5,908	100,645,883	3.195
14 - Otolaryngology		3,071	37,743,573	1.198
15 - Other specialties		41,304	659,756,503	20.942

DRUG THERAPEUTIC CATEGORIES (USING LEVEL 1 CODES)

CATEGORY

RECORDS WEIGHTED MENTIONS PERCENT

Total	189550	3,396,881,835	100.000
'OO1'=Anti-infectives	8167	160,278,312	4.718
'020'=Antineoplastics	1265	19,790,362	0.583
'O28'=Biologicals	67	1,130,212	0.033
'040'=Cardiovascular agents	26781	484,385,880	14.260
'057'=Central nervous system agents	36873	672,569,925	19.800
'081'=Coagulation modifiers	8224	145,512,739	4.284
'087'=Gastrointestinal agents	11263	195,175,620	5.746
'097'=Hormones	10311	180,710,370	5.320
'105'=Miscellaneous agents	4489	78,437,942	2.309
'113'=Genitourinary tract agents	1641	29,059,249	0.855
<pre>'115'=Nutritional products</pre>	17609	289,967,206	8.536
'122'=Respiratory agents	13623	243,333,292	7.163
'133'=Topical agents	12592	215,925,065	6.357
ʻ153'=Plasma expanders	3	30,950	0.001
'218'=Alternative medicines	4678	77,468,181	2.281
'242'=Psychotherapeutic agents	9074	173,136,602	5.097
'254'=Immunological agents	5993	112,664,511	3.317
'331'=Radiologic agents	79	1,426,942	0.042
'358'=Metabolic agents	16473	310,405,552	9.138
'365'=Medical gases	174	3,367,262	0.099
'899'=Pharmaceutical aids	171	2,105,662	0.062

Therapeutic categories are based on Lexicon Plus®, a proprietary database of Cerner Multum, Inc. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: https://www.cerner.com/cerner_multum/. For more information on coding therapeutic categories in NAMCS, see page 35.

C. PHYSICIAN ESTIMATES

.....

PHYSICIAN SPECIALTY

CATEGORY	RECORDS	WEIGHTED PHYSICIANS	S PERCENT
Total 1 - General/family practice 3 - Internal medicine 4 - Pediatrics 5 - General surgery 6 - Obstetrics and gynecology 7 - Orthopedic surgery 8 - Cardiovascular diseases 9 - Dermatology 10 - Urology	2,179 379 232 224 93 130 136 92 65 60	337,139 68,104 47,499 34,603 9,778 23,297 17,302 13,868 8,065 6,637	5.132 4.113 2.392
11 - Psychiatry	110	15,164	
12 - Neurology 13 - Ophthalmology 14 - Otolaryngology 15 - Other specialties	48 100 39 471	7,156 14,122 5,300 66,244	4.189 1.572
IS THIS A SOLO PRACTICE?			
CATEGORY	RECORDS	WEIGHTED PHYSICIANS	S PERCENT
Total -8 - Unknown 1 - Solo 2 - Non-solo	2,179 1 679 1,499	116,618 220,175	0.103 34.591
SPECIALTY TYPE			
CATEGORY	RECORDS	WEIGHTED PHYSICIANS	S PERCENT
Total 1 - Primary care specialty 2 - Surgical care specialty 3 - Medical care specialty	2,179 946 549 684	171,644	50.912 20.293

D. STATE ESTIMATES

STATE WHERE MAJORITY OF PHYSICIAN'S VISITS WERE SAMPLED

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total (18 targeted states)	45,710	661,712,232	100.000
Arizona	2,002	17,319,171	2.617
California	2,440	107,297,338	16.215
Florida	1,691	66,769,019	10.090
Georgia	1,500	26,734,734	4.040
Illinois	2,341	37,126,009	5.611
Indiana	2,567	18,968,248	2.867
Massachusetts	1,015	15,573,743	2.354
Michigan	2,120	28,295,218	4.276
New Jersey	1,330	31,111,935	4.702
New York	1,443	72,021,991	10.884
North Carolina	954	22,500,175	3.400
Ohio	1,248	29,406,558	4.444
Pennsylvania	1,381	37,972,000	5.738
Tennessee	2,208	22,859,059	3.455
Texas	1,699	69,535,283	10.508
Virginia	1,660	24,276,747	3.669
Washington	2,143	18,021,826	2.724
Wisconsin	2,677	15,923,177	2.406

NOTE: Figures in this table reflect the 18 states targeted for estimation. An additional 13,291 records were sampled in state aggregates within their Census division. To produce estimates by division, one must use the patient visit weight PATWT, not the state-based patient visit weight PATWTST.

APPENDIX I

A. STANDARD ERRORS AND VARIANCE ESTIMATION

The standard error is primarily a measure of the sampling variability that occurs by chance because only a sample is surveyed, rather than the entire universe. The relative standard error (RSE) of an estimate is obtained by dividing the standard error of the estimate by the estimate itself and is expressed as a percentage of the estimate.

In the past, NAMCS micro-data file documentation contained formulas for approximating relative standard errors based on generalized variance curves as well as tables showing lowest reliable estimates based on curve coefficients. This was provided as an alternative for data users who lacked analytic software to produce standard errors and other measures of sampling variability. However, it has long been recognized that such approximations are less accurate than those produced using a statistical software package that takes into account the complex sample designs of surveys. As more data users have obtained access to sophisticated computer software over time, and as recent efforts by NCHS research staff to refine the generalized variance curves did not yield significant improvements, the decision was made starting with 2011 NAMCS data to discontinue the provision of these approximate methods of variance estimation.

Using computer software like SUDAAN to produce standard errors will, in general, yield results that are more accurate than those produced using generalized variance curves. This is especially true for clustered variables like race, provider seen, or expected source of payment. However, standard errors produced with such software using masked design variables, while improving substantially over generalized variance curve results, will not always be as accurate as those produced using unmasked data. Data files containing unmasked variables are confidential and are only available through the NCHS Research Data Center.

Starting with the 2012 NAMCS, a new sampling methodology was employed that used a list sample rather than a clustered sample. The design variables reflect the new sampling methodology. Examples of SUDAAN, SAS, Stata, and SPSS statements which incorporate these new design variables for variance estimation purposes are presented below.

The following example is for use with the 2014 NAMCS public use file. It can also be used to approximate variances for visit estimates when 2014 NAMCS data are combined with data from the National Hospital Ambulatory Medical Care Survey, which still uses the pre-2012 NAMCS clustered PSU sample design, or with previous years of NAMCS data.

SUDAAN 1-stage WR (With-Replacement) Option

This code provides a with-replacement ultimate cluster (1-stage) estimate of standard errors for a cross-tabulation with a dataset called TEST.

PROC CROSSTAB DATA = TEST DESIGN=WR; NEST CSTRATM CPSUM /MISSUNIT;

It is important to keep the following in mind when trying to combine or analyze data across years:

NAMCS public use files from 2003-2014 only include first-stage design variables in their masked form, CSTRATM and CPSUM, for use in WR design options. From 1993-2002, a full set of masked design variables was provided. The decision to switch to ultimate cluster variables was initially made because many popular software products could not make use of the full set of design variables. Instructions are provided for public use file data users on the survey website regarding how to create CSTRATM and CPSUM for data years prior to 2002, in order to have a consistent set of design variables for analysis. See the technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files*, for more information: http://www.cdc.gov/nchs/namcs.htm.

PAGE 144

If software other than SUDAAN is used to approximate estimate variances, other statements will be required by that software. The variance variables required by that software are the same as those defined above for SUDAAN software.

SAS - PROC SURVEYMEANS

PROC SURVEYMEANS DATA=TEST; CLUSTER CPSUM; STRATA CSTRATM;

Stata - For use with ultimate cluster design option:

The pweight (PATWT), strata (CSTRATM), and PSU (CPSUM) are set with the svyset command as follows:

<u>Stata 8:</u> svyset [pweight=patwt], psu(cpsum) strata(cstratm)

<u>Stata 9 and later:</u> svyset cpsum [pweight=patwt], strata(cstratm)

<u>SPSS</u>

To obtain variance estimates which take the sample design into account, IBM SPSS Inc.'s Complex Samples module can be used. This description applies to version 24.0. From the main menu, first click on 'Analyze', then 'Complex Samples', then 'Prepare for Analysis'. The 'Analysis Preparation Wizard' can be used to set CSTRATM as the stratum variable, CPSUM as the cluster variable, and PATWT as the weighting variable. The WR design option may be chosen. This will create the PLAN FILE syntax, which should resemble the code below, where PLAN FILE reflects the location you have selected to store the file on your computer:

CSPLAN ANALYSIS /PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN' /PLAN VARS ANALYSISWEIGHT=PATWT /PRINT PLAN /DESIGN STAGELABEL= 'ANY LABEL' STRATA=CSTRATM CLUSTER=CPSUM /ESTIMATOR TYPE=WR.

After creating the plan file, various analyses can be selected from the 'Complex Samples' menu. This is an example of a crosstabulation with options selected for counts, percents, and standard errors, with missing data (if any) included:

CSTABULATE /PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN' /TABLES VARIABLES = AGER BY SEX /CELLS POPSIZE ROWPCT COLPCT /STATISTICS SE COUNT /MISSING SCOPE = TABLE CLASSMISSING = INCLUDE.

Results using IBM SPSS with the WR option were found to be the same as those obtained using SUDAAN Release 11.0.1 with the WR option.

IMPORTANT NOTE REGARDING PHYSICIAN-LEVEL ESTIMATES:

The examples above can be used when producing visit or drug estimates. For physician-level estimates, the statements are the same, but replace PATWT with PHYSWT.

The PHYSWT variable itself should only be used to make estimates at the physician level. For this reason, it is only placed on the first record for each physician on the public use file. When running purely physicianlevel analysis, it is recommended that only records with PHYSWT > 0 be selected; this will give the correct sample counts and will not affect estimation of variance. Weighted estimates will be correct either way. For RDC researchers, please be sure to specify if PHYSWT is required and how it will be used, so that files can be constructed properly.

In addition to generating estimates for physician characteristics at the physician level, the addition of PHYSWT also means that one can link visit data with physician data. For example, one could examine average time spent with physicians across physicians rather than simply across visits. This type of analysis is slightly complicated; a description along with sample SAS code is available at the Ambulatory Health Care Data website. For more information, contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

B. 2014 NAMCS ELECTRONIC PATIENT RECORD FORM - INSTRUCTIONS AND DEFINITIONS

NOTE: In years prior to 2012, NAMCS data collection agents were provided with a manual containing the Patient Record Form Instructions. This was used to train physicians and/or medical staff in completing the questionnaires and in familiarizing the data collection agents with the survey instructions in cases where they abstracted the data directly from medical records. Starting in 2012 when a computer-assisted mode of data collection was used for the first time, data collection agents abstracted data from medical records for nearly all sampled visits and recorded them using an automated tool. This tool contained online help screens which could be accessed during data collection for most data items, replacing the old paper manuals. What is shown below is a compilation of the various help screen texts and taken from the automated instrument.

PATIENT INFORMATION

Ethnicity

Ethnicity refers to a person's national or cultural group. There are two categories for ethnicity, "Hispanic or Latino" and "Not Hispanic or Latino".

Enter the appropriate category according to the information in the medical record. If the patient's ethnicity is not known and is not obvious, enter the category which in your judgment is most appropriate. The definitions of the categories are listed below.

Do not determine the patient's ethnicity from his/her last name.

Ethnicity	Definition
1 - Hispanic or Latino	A person of Cuban, Mexican, Puerto Rican, South or Central American or other Spanish culture or origin regardless of race.
2- Not Hispanic or Latino	All other persons.

Race

Enter all appropriate categories based on the information in medical record. If the patient's race is not known or not obvious, enter the categories which in your judgment is (are) most appropriate. Do not determine the patient's race from their last name.

Race	Definition
1-White	A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.
2-Black or African American	A person having origins in any of the black racial groups of Africa.
3-Asian	A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.
4-Native Hawaiian or Other Pacific Islander	A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.

5-American Indian or	A person having origins in any of the original peoples of North America, and who
Alaska Native	maintains cultural identification through tribal affiliation or community
	recognition.

Expected source(s) of	Definition
payment	
1-Private Insurance	Charges paid in-part or in-full by a private insurer (e.g., Blue Cross/Blue Shield) either directly to the physician/CHC provider or reimbursed to the patient. Include charges covered under a private insurance sponsored prepaid plan.
2-Medicare	Charges paid in-part or in-full by a Medicare plan. Includes payments directly to the physician/CHC provider as well as payments reimbursed to the patient. Include charges covered under a Medicare sponsored prepaid plan.
3-Medicaid or CHIP or other state-based program	Charges paid in-part or in-full by a Medicaid plan. Includes payments made directly to the the physician/CHC provider as well as payments reimbursed to the patient. Include charges covered under a Medicaid sponsored prepaid plan or the Children's Health Insurance Program(CHIP).
	PROGRAM NAMES FOR MEDICAID, CHIP, STATE-/LOCAL- SPONSORED, AND OTHER HEALTH INSURANCE PROGRAMS
	Please find your state.
	Note: Medicaid programs are often called "Medicaid", "Medical Assistance Program", or "Title 19". Children's Health Insurance Programs are often called "CHIP", "SCHIP", or "Title XXI Program". Many states have unique names for their health insurance programs. Those programs are listed below, by state. [NOTE: A comprehensive list of Medicaid, CHIP and other state-based programs was provided to Census abstractors, but is not included in the public use file documentation.]
4-Worker's compensation	Includes programs designed to enable employees injured on the job to receive financial compensation regardless of fault.
5-Self-pay	Charges, to be paid by the patient or patient's family which will not be reimbursed by a third party. "Self- pay" includes visits for which the patient is expected to be ultimately responsible for most of the bill, even though the patient never actually pays it. DO NOT check this box for a copayment or deductible.
6-No charge/Charity	Visits for which no fee is charged (e.g., charity, special research, or teaching). Do not include visits paid for as part of a total package (e.g., prepaid plan visits, post- operative visits included in a surgical fee, and pregnancy visits included in a flat fee charged for the entire pregnancy). Mark the box or boxes that indicate how the services were originally paid.
7- Other	Any other sources of payment not covered by the above categories, such as CHAMPUS, state and local governments, private charitable organizations, and other liability insurance (e.g., automobile collision policy coverage).
8-Unknown	The primary source of payment is not known.

Expected Source(s) of Payment For This Visit

Tobacco Use

Tobacco use is defined as smoking cigarettes/cigars, using snuff, or chewing tobacco.

Enter "Not current" if the patient does not currently use tobacco. Enter "Current" if the patient uses tobacco.

[NOTE: This item changed for 2014 with new categories of "never smoker", "current smoker" and "former smoker"; however, it was noted in the production of the public use file documentation that the Help Screen text had not been updated.]

VITAL SIGNS

Enter the patient's height if measured at this visit in the appropriate field, i.e.,-(ft and/or/in or cm). If it was not measured at this visit and the patient is 21 years of age or over, then review the chart (up to 1 year) for the last time that height was recorded and enter that value.

Enter the patient's weight if measured at this visit in the appropriate field (lb oz or kg or gm [grams]). Only collect weight at current visit and not during pregnancy.

Enter the patient's initial temperature if measured at this visit. Enter the appropriate type of measurement (degrees C or F).

Blood Pressure – SYSTOLIC

Refers to the top number of the blood pressure measurement. If multiple measurements are taken, record the last measurement.

Blood Pressure – DIASTOLIC

Refers to the bottom number of the blood pressure measurement. If multiple measurements are taken, record the last measurement. Enter 998 for P, PALP, DOPP, or DOPPLER.

INJURY/POISONING/ADVERSE EFFECT

If ANY PART of this visit was related to an injury or poisoning or adverse effect of medical or surgical care or an adverse effect of a medicinal drug, then enter the appropriate answer category.

The injury/poisoning/adverse effect does not need to be recent.

It can include those visits for follow-up or previously treated injuries and visits for flare-ups of problems due to old injuries.

Injury/Poisoning/Adverse effect	Definition
1-Yes, injury	Definition: An injury involves damage to the body resulting from such events as motor vehicle crashes, transportation, falls, striking against or being struck by a person or object, burns, drowning, suffocation, cuts and stabbings, overexertion, foreign bodies, being crushed by machinery, beaten with fists or objects, gunshot/pellet gun wounds, etc.
	Inclusion/Exclusion Criteria for Yes, Injury
	Includes Visits involving:

	NL 222.2.
	New injuries
	Follow-up for previously treated injuries
	Flare-ups of problems due to old injuries
	Excludes
	Visits involving:
	 Injuries caused by medical/surgical care or ingestion of a
	harmful substance
	Bodily harm from other external causes, such as infectious
	diseases, and internal causes, such as chronic diseases
2-Yes, poisoning	Definition: A poisoning involves the ingestion, inhalation, absorption through the skin, or injection of a substance resulting in a harmful effect.
	Inclusion/Exclusion Criteria for Yes, poisoning
	Includes
	Visits involving ingestion/exposure to:
	Household cleaners
	Pesticides
	Carbon monoxide
	Alcohol containing products (ethanol, ethyl alcohol, methanol)
	except situations described in the "excludes" category.
	Nonpharmaceutical inhalants
	Overdose or misuse of prescription drugs, over-the-counter
	medications, vitamins, and illicit/street drugs
	Alcohol-based topical agent used for medicinal purposes
	Excludes
	Visits involving:
	 Harmful effects from bacterial illnesses (such as "food poisoning")
	Drunkenness
	Alcohol withdrawal
	 Combination of alcohol and drugs (if drugs are involved, choose
	poisoning, drug-induced
	 Alcohol used for medicinal purposes (choose poisoning, drug-
	induced)
	Drug withdrawal
3-Yes, adverse effect of medical/surgical care or adverse effect of medicinal drug	An adverse effect of medical treatment involves a reaction to the patient's own prescription or over-the-counter medication or dietary supplement taken according to directions, the label, or as prescribed. Unintended and undesired effects include: adverse drug reactions, allergic drug reactions, side effects, drug-drug interactions, drug-alcohol interactions.
	An adverse effect of surgical treatment includes bodily harm directly caused by surgical care or the placement of a medical product/device in a patient. Examples include pneumothorax from central venous catheter placement, postoperative wound infection, a foreign object left in the body after a procedure, etc. Inclusion/Exclusion Criteria for Yes, adverse effect of medical/surgical care or adverse effect of medicinal drug

	 Includes An adverse effect that occurred after use of one's own prescribed or over-the-counter medication/ supplement taken as prescribed or directed. Surgical care provided in error or according to standards of practice, but resulting in bodily harm to the patient. Presenting complaints/diagnoses may include keywords such as: "adverse," "allergic," "side effects," "caused by or induced by," "reaction to" or "secondary to."
	 Excludes Visits involving: Illegal drugs. Patients EXCEEDING the prescribed or recommended dose of prescription drugs, OTC medications, or dietary supplements. Patients who took LESS than the prescribed or recommended dose. Patients who took prescribed medication belonging to someone else. Patients with an allergic reaction to a food or insect bite.
4-No	Select No when: Visit is not related to an injury or poisoning or adverse effect of medical/surgical treatment.
5-Unknown	Definition: It is unknown whether this visit is related to an injury or poisoning or adverse effect of medical or surgical treatment

REASON FOR VISIT

Enter the patient's complaint(s), symptoms(s) or other reason(s) for this visit in the patient's own words. Space has been allotted for the "most important" and four "other" complaints, symptoms, and reasons as indicated below.

- 1. Most important
- 2. Other
- 3. Other
- 4. Other
- 5. Other

The most important reason should be entered in (1). Space is available for four reasons in (2), (3), (4) and (5). By "most important" we mean the problem or symptom which in the physician's judgment was most responsible for the patient making this visit. Since we are interested only in the patient's most important complaints/ symptoms/reasons, it is not necessary to record more than five.

This is one of the most important items on the Patient Record form. No similar data on visits are available in any other survey and there is tremendous interest in the findings. Please take the time to be sure you understand what is wanted—especially the following three points:

- We want the patient's principal complaint(s), symptom(s) or any other reason(s) in the patient's own words. The physician may recognize right away, or may find out after the examination, that the real problem is something entirely different. In this item we are interested in how the patient defines the reason for the visit (e.g., "cramps after eating," or "fell and twisted my ankle").
- The item refers to the patient's complaint, symptom, or other reason for this visit. Conceivably, the patient may be undergoing a course of treatment for a serious illness, but if

his/her principal reason for this visit is a cut finger or a twisted ankle, then that is the information we want.

• There will be visits by patients for reasons other than some complaint or symptom. Examples might be well baby check-up or routine prenatal care. In such cases, simply record the reason for the visit.

Reminder: If the reason for a patient's visit is to pay a bill, ask the physician to complete an insurance form, or drop off a specimen, then the patient is not eligible for sample. A Patient Record form should not be completed for this patient.

CONTINUITY OF CARE

Are you the patient's primary care physician? / Was patient referred for this visit?

The primary care physician/provider plans and provides the comprehensive primary health care of the patient.

Enter "Yes" if the health care provided to the patient during this visit was from his/her primary care physician/provider. If the provider seen at this visit was substituting for the primary care physician/provider, also enter "Yes."

Enter "No" if care was not from the primary care physician/provider or "Unknown" if it is not known.

If "No" or "Unknown" is entered, also indicate whether the patient was referred for this visit by another health care provider. This item provides an idea of the "flow" of ambulatory patients from one provider to another. Enter the "Yes", "No" or "Unknown" category, as appropriate.

Indicate whether the patient was referred for this visit by a different physician, provider, or office. This item provides an idea of the "flow" of ambulatory patients from one physician/provider/office to another. Notice that this item concerns referrals to the sample physician/CHC provider by a different physician, provider, or office. The interest is in referrals for this visit and not in referrals for any prior visit.

Referrals are any visits that are made because of the advice or direction of a physician/provider other than the physician/provider being visited.

Has the patient been seen in your practice before? / How many past visits to this practice in the last 12 months?

"Seen" means "provided care for" at any time in the past.

Enter "Yes, established patient" if the patient was seen before by any provider or staff member in the office/CHC. Exclude this visit.

Enter "No, new patient" if the patient has not been seen in the office/CHC before.

If "Yes" is entered, also indicate approximately how many past visits the patient has made to this office/CHC within the last 12 months. Do not include the current visit in your total.

If you cannot determine how many past visits were made, then enter "Unknown".

Include all visits to other physicians/CHC providers or health care providers in this office/CHC.

MAJOR REASON FOR THIS VISIT

Problem	Definition
1-New problem (< 3 months onset)	A visit for a condition, illness, or injury having a relatively sudden or recent onset (within 3 months of this visit).
2-Chronic problem, routine	A visit primarily to receive care or examination for a preexisting chronic condition, illness, or injury (onset of condition was 3 months or more before this visit).
3-Chronic problem, flare up	A visit primarily due to a sudden exacerbation of a pre-existing chronic condition.
4/5-Pre/Post surgery	A visit scheduled primarily for care required prior to or following surgery (e.g., pre-surgery tests, removing sutures).
6-Preventive care	General medical examinations and routine periodic examinations. Includes prenatal care, annual physicals, well-child exams, screening, and insurance examinations.

DIAGNOSIS

(1) Primary diagnosis

(2) Other

(3) Other

(4) Other

(5) Other

(1) Primary diagnosis:

This is one of the most important items on the Patient Record form.

The primary diagnosis-refers to the provider's primary diagnosis for this visit.

If possible, enter a final or provisional diagnosis, otherwise, use "problem" terms.

Do not enter "rule out" diagnosis. If the patient was not seen by a physician, then the diagnosis by the main health care provider should be recorded (this includes diagnoses made by mid-level providers at CHCs).

If a patient appears for postoperative care (follow-up visit after surgery), record the postoperative diagnosis as well as any other. The postoperative diagnosis should be indicated with the letters "P.O." Do not enter the operative procedure.

(2), (3), (4), (5), Other:

Enter up to four diagnoses which existed at the time of the visit if they are of DIRECT CONCERN to the visit. Include chronic disease.

Regardless of the diagnoses previously entered, does the patient now have:

Condition	Description
1. Alcohol misuse, abuse or	Select box if 1) any of these terms are used; or 2) if terms such as

dependence	alcoholism, excessive alcohol use, heavy drinking, problem drinking, binge drinking or chronic drinking are stated. 'Alcohol' may be abbreviated as 'EtOH.'
2. Alzheimer's disease/Dementia	Dementia is a loss of brain function that occurs with certain diseases. It affects memory, thinking, language, judgment, and behavior.
4. Asthma	Asthma includes extrinsic, intrinsic, and chronic obstructive asthma.
5.Cancer	Cancer includes any type of cancer (ca), such as carcinoma, sarcoma, leukemia, and lymphoma.
6. Cerebrovascular disease/stroke (CVA) or transient ischemic attack (TIA)	Cerebrovascular disease/History of stroke or transient ischemic attack (TIA) is a group of brain dysfunctions related to disease of the blood vessels supplying the brain. Hypertension is the most important cause. The results of cerebrovascular disease can include a stroke, or occasionally a hemorrhagic stroke. A transient ischemic attack is a brief episode in which the brain gets an insufficient blood supply. Include a history of stroke or TIA.
8. Chronic obstructive pulmonary disease (COPD)	Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis and emphysema, but excludes asthma.
9. Congestive heart failure (CHF)	Congestive heart failure (CHF) is generally defined as the inability of the heart to supply sufficient blood flow to meet the needs of the body. Does not include aystole or cardiac arrest.
10. Coronary artery disease (CAD), ischemic heart disease (IHD) or history of myocardial infarction (MI)	Only include if the patient had a heart attack or myocardial infarction (MI) prior to the sampled visit. A heart attack or MI occurs when the blood vessels that supply blood to the heart are blocked, preventing enough oxygen from getting to the heart. The heart muscle dies or becomes permanently damaged. Also known as acute myocardial infarction (AMI).
11. Depression	Depression includes affective disorders and major depressive disorders, such as episodes of depressive reaction, psychogenic depression, and reactive depression.
12. Diabetes mellitus (DM), Type 1	Type 1 diabetes mellitus is also known as insulin-dependent or IDDM. Excludes diabetes insipidus and gestational diabetes.
13. Diabetes mellitus (DM), Type 2	Type 2 diabetes mellitus is also known as non-insulin dependent or NIDDM. Excludes diabetes insipidus and gestational diabetes.
14. Diabetes mellitus (DM), Type unspecified	Excludes diabetes insipidus and gestational diabetes.
 15. End-stage renal disease (ESRD) 16. History of pulmonary embolism (PE) or deep vein thrombosis (DVT) 	Includes end-stage renal disease (ESRD) and chronic kidney failure due to diabetes or hypertension. May be abbreviated as "ESRD." Only include if the patient had a pulmonary embolism or a diagnosis of deep vein thrombosis (DVT) prior to the sampled visit. Pulmonary embolism (PE) is a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body through the bloodstream (embolism). Usually this is due to embolism of a thrombus (blood clot) from the deep veins in the legs, a process termed venous thromboembolism. Deep vein thrombosis (also known as deep venous thrombosis) is the formation of a blood clot ("thrombus") in a deep vein. It is a form of thrombophlebitis (inflammation of a vein with clot formation). DVT commonly affects the leg veins (such as the femoral vein or the popliteal vein) or the deep veins of the pelvis.
17. HIV Infection/AIDS	HIV infection is a condition caused by the human immunodeficiency virus which gradually destroys the immune

18. Hyperlipidemia	system and makes it harder for the body to fight infections. Asymptomatic (without symptoms) HIV infection is a phase of chronic infection with human immunodeficiency virus (HIV) during which there are no symptoms of HIV infection. AIDS (acquired immune deficiency syndrome) is the final stage of HIV disease, which causes severe damage to the immune system. Hyperlipidemia is the condition of abnormally elevated levels of any or all
	lipids and/or lipoproteins in the blood. Also known as hypercholesterolemia.
19. Hypertension	Hypertension or high blood pressure is a cardiac chronic medical condition in which the systemic arterial blood pressure is elevated. It is the opposite of hypotension. Hypertension is classified as either primary (essential) hypertension or secondary hypertension. "Primary hypertension" means high blood pressure with no obvious medical cause. "Secondary hypertension" is caused by other conditions that affect he kidneys, arteries, heart or endocrine system. Include both primary and secondary hypertension.
20. Obesity	Obesity is a term used to describe body weight that is much greater than what is healthy. Adults with a body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) greater than or equal to 30 kg/m2 are considered obese. Any patient who is more than 100 pounds overweight or who has a BMI greater than or equal to 40 kg/m2 is considered morbidly obese.
21. Obstructive sleep apnea (OSA)	Select box if obstructive sleep apnea (OSA), sleep apnea, or complex/mixed sleep apnea is stated. Do not select if central sleep apnea (CSA) is stated.
22. Osteoporosis	Osteoporosis refers to the thinning of bone tissue and loss of bone density over time. This reduction in the amount of bone mass leads to fractures after minimal trauma.
23. Substance abuse or dependence	Select box if 1) any of these terms are used; 2) if terms such as addiction, addict, illicit drug use, or injection/intravenous drug use (IDU/IVDU/IVDA) are stated; or 3) if specific drug use is stated (e.g., cocaine use, opioid dependence), not including tobacco/nicotine or alcohol.
24. None of the above	Enter "None of the above" if none of the conditions listed above exist.

SERVICES

Enter all services that were ordered or provided during this visit for the purpose of screening (i.e., early detection of health problems in asymptomatic individuals) or diagnosis (i.e., identification of health problems causing individuals to be symptomatic).

EACH SERVICE ORDERED OR PROVIDED SHOULD BE ENTERED.

At visits for a complete physical exam, several tests may be ordered prior to the visit, so that the results can be reviewed during the visit. Since these services are related to the visit, the appropriate items should be entered.

Enter "NONE" if no examinations, blood tests, imaging services, non-medication treatment, health education, or other tests/services were ordered or provided.

Services meriting special attention are as follows:

Service	Definition/Special Instructions
Examinations/Screenings:	
2- Alcohol misuse screening (includes AUDIT, MAST, CAGE, T-ACE)	AUDIT, MAST, CAGE, and T-ACE are names of screening questionnaires. Select box if 1) any of these terms are used; or 2) if AUDIT-C or CAGE-AID is stated. CAGE-AID screens for alcohol and substance use. 'Alcohol' may be abbreviated as 'EtOH.'
4-Depression screening	Includes affective disorders and major depressive disorders, such as episodes of depressive reaction, psychogenic depression, and reactive depression.
5-Domestic Violence Screening	Check box if intimate partner violence listed.
6-Foot exam	A foot exam includes visual inspection, sensory exam, and pulse exam.
8-Pelvic exam	A pelvic exam is an internal examination of the female reproductive organs.
10-Retinal/Eye exam	A retinal exam includes any of the following: ophthalmoscopy, funduscopy, and dilated retinal exam (DRE). An eye exam includes any of the following: ophthalmoscopy, funduscopy, slit lamp exam, visual field (VF) exam, and visual acuity exam (vision test).
	Ophthalmoscopy (funduscopy or fundoscopy) is a test that allows a health professional to see inside the fundus of the eye (interior surface of the eye, opposite the lens, and includes the retina, optic disc, and macula) and other structures using an ophthalmoscope (or funduscope). It is done as part of an eye exam and may be done as part of a routine physical exam.
	A slit lamp exam uses an instrument that provides a magnified, three-dimensional (3-D) view of different parts of the eye.
12- Substance abuse screening (includes NIDA/NM ASSIST, CAGE-AID, DAST- 10)	NIDA/NM ASSIST, CAGE-AID and DAST-10 are names of screening questionnaires. NM ASSIST and CAGE-AID screen for alcohol and substance use. Select box if screening ordered or performed 1) around substance use/abuse; illicit drug use, or injection/intravenous drug use (IDU/IVDU/IVDA); or 2) around use of a specific substance (e.g., cocaine use, opioid dependence), not including tobacco/nicotine or alcohol.
Laboratory tests:	
13-Basic metabolic panel	Examples of documentation of a basic metabolic panel (BMP) include SMA-7, Chem-1, CPBASIC. A basic metabolic panel includes kidney tests (BUN/creatinine), electrolytes (sodium, potassium, bicarbonate, and chloride) and glucose.

15 Chlomydia toot	Might be abbroviated CT
15-Chlamydia test	Might be abbreviated CT
16-Comprehensive metabolic panel	Examples of documentation of a CMP include SMA-18 or 20, Chem-20, CPCOMP. A CMP includes the 7 basic metabolic panel (BMP) tests as well as albumin, alkaline phosphatase, ALT, AST, GGT, bilirubin, calcium, cholesterol and triglycerides, lactate dehydrogenase, phosphate, total serum protein, and uric acid.
17-Creatinine /Renal function panel	Select box if 1) any of these terms are used; or 2) if terms such as BUN-to-Creatinine ratio; BUN/Creatinine; or BUN/Cr are stated. Creatinine may be abbreviated as 'Cr.' Select box for blood (serum or plasma) Creatinine test. Do not select box for urine Creatinine; urine Albumin-to-Creatinine ratio; Creatinine Clearance; or Creatine Kinase.
18-Culture, blood	Might be abbreviated Cx or C&S-culture and sensititivity
19-Culture, throat	Might be abbreviated Cx or C&S-culture and sensititivity; do not check box for rapid strep test
20-Culture, urine	Might be abbreviated Cx or C&S-culture and sensititivity
21-Culture, other	Might be abbreviated Cx or C&S-culture and sensititivity
22-Glucose, serum	Select box for blood Glucose test. Do not select box for urine Glucose test.
23- Gonorrhea test	Might be abbreviated GC
24-HbA1C (Glycohemoglobin) 25- Hepatitis testing/ Hepatitis	The HbA1C or glycohemoglobin test measures the amount of glucose that is bound to hemoglobin and is usually reported as a percent. It is different from the hemoglobin (Hgb) test that may be a part of the complete blood count (CBC) or performed as a single test which is generally reported in g/dL (grams per deciliter). HbA1C is directly tied to the concentration of glucose in the blood. Since red blood cells have a life span of approximately 90 days, measuring the amount of glucose bound to hemoglobin can provide an assessment of average blood sugar control in patients with diabetes during the 60-90 days prior to the test. This is the purpose of the glycosolated hemoglobin (glycohemoglobin) tests, most commonly known as the hemoglobin A1C measurement. The laboratory abbreviation is HbA1C and it is also known as A1C.
panel	listed
26-HIV test	Also known as AIDS test, AIDS screen, and HIV serology. Antibodies to the HIV virus are often detected by an HIV screening test called an ELISA. The ELISA test is repeated if positive. The ELISA method is very sensitive but requires another test, a Western Blot, to confirm the results.

27-HPV DNA test	The HPV DNA test detects the presence of human papillomavirus in women and is performed by collecting cells from the cervix.
28-Lipid profile	A lipid profile includes any of the following tests: cholesterol, LDL, HDL, cholesterol/HDL ratio, triglycerides, coronary risk profile, and lipid profile.
29- Liver enzymes/Hepatic function panel	Check box if liver function tests, LFTs, AST, ALT, aspartate aminotransferase or alanine aminotransferase are listed
30-PAP test	A Pap test (also called a Pap smear, cervical smear) is a screening test used in gynecology to detect pre-cancerous and cancerous cells of the cervix. A sample of cells is collected from the outer opening of the cervix by scraping it with a spatula. The cells are spread on a glass slide and fixed or a specimen is suspended in a liquid solution.
31-Pregnancy/HCG test	A pregnancy test may be done on either urine or blood. HCG or human chorionic gonadotropin is a hormone that is produced during pregnancy. Include: HCG, beta HCG, total HCG, and total beta HCG.
32-PSA (prostate specific antigen)	A PSA test is used primarily to screen for prostate cancer and measures the amount of prostate-specific antigen in the blood.
34- TSH/Thyroid panel	Check box if T3, T4, thyroxine, Free T4, FT4 or thyroid function panel listed
36-Vitamin D Test	Check box if 25-Hydroxyvitamin D, 25OHD, 25- hydroxycholecalciferol, or 25-hydroxyergocalciferol are listed
Imaging:	
37-Bone mineral density	A bone mineral density test measures the amount of calcium in a specific region of the bone and is used to detect osteoporosis.
39-Echocardiogram	During an echocardiogram, sound waves are used to create a moving picture of the heart. The picture is much more detailed than an x-ray image and involves no radiation exposure.
40-Ultrasound	Might be abbreviated US or U/S
Procedures:	

44-Audiometry	
	Audiometry is the testing of hearing ability, involving thresholds and differing frequencies.
45-Biopsy	Only enter if provided at the sampled visit. During a biopsy, a small piece of tissue is removed for microscopic examination and/or culture to help the provider make a diagnosis. There are 3 types of biopsies: needle, open, and closed. "Excisional biopsy" should be included under biopsy rather than excision.
46-Cardiac stress test	Cardiac stress tests are used in medicine and cardiology to measure the heart's ability to respond to external stress in a controlled clinical environment. The stress response is induced by exercise or drug stimulation. Cardiac stress tests compare the coronary circulation while the patient is at rest with the same patient's circulation observed during maximum physical exertion, showing any abnormal blood flow to the heart's muscle tissue (the myocardium).
47-Colonoscopy	Only enter if provided at the sampled visit. Colonoscopy is the endoscopic examination of the colon and the part of the small bowel with a camera on a flexible tube passed through the anus in order to detect polyps, malignant tumors, and sources of bleeding. It may provide a visual diagnosis (e.g. ulceration, polyps) and grants the opportunity for biopsy or removal of suspected lesions. Colonoscopy is similar to, but not the same as, sigmoidoscopy—the difference being related to which parts of the colon each can examine.
48- Cryosurgery (cryotherapy)/ Destruction of tissue	Check box if LN2, liquid nitrogen, TCA or trichloroacetic acid listed
50-Electroencephalogram EEG)	Electroencephalogram (EEG) is the recording of electrical activity along the scalp. EEG measures voltage fluctuations resulting from ionic current flows within the neurons of the brain. In clinical contexts, EEG refers to the recording of the brain's spontaneous electrical activity over a short period of time, usually 20–40 minutes, as recorded from multiple electrodes placed on the scalp. In neurology, the main diagnostic application of EEG is in the case of epilepsy, as epileptic activity can create clear abnormalities on a standard EEG study. A secondary clinical use of EEG is in the diagnosis of coma, encephalopathies, and brain death.
51-Electromyelogram (EMG)	Electromyography (EMG) is a technique for evaluating and recording the electrical activity produced by skeletal muscles. EMG is performed using an instrument called an electromyograph, to produce a record called an electromyogram. An electromyograph detects the electrical potential generated by muscle cells when these cells are electrically or neurologically activated. The signals can be analyzed to detect medical abnormalities, activation level, recruitment order or to analyze the biomechanics of human or animal movement.
52-Excision of tissue	Only enter if provided at the sampled visit. Excision of tissue is the removal of tissue (e.g., polyps, cysts, and moles) by cutting. In surgery, an excision (or resection) is the complete removal of an organ or a tumor, as opposed to a

	biopsy.
53-Fetal monitoring	Fetal monitoring lets the health care provider monitor the baby's heartbeat in the uterus, including during labor. The procedure can be done with monitors outside the body (external monitoring) or in the uterus (internal monitoring).
54-Peak flow	The peak expiratory flow (PEF), also called peak expiratory flow rate (PEFR) is a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. It measures the airflow through the bronchi and thus the degree of obstruction in the airways. It is usually used for asthma patients.
55-Sigmoidoscopy	Only enter if provided at the sampled visit. Sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon. There are two types of sigmoidoscopy, flexible sigmoidoscopy, which uses a flexible endoscope, and rigid sigmoidoscopy, which uses a rigid device. The flexible endoscope transmits an image of the inside of the rectum and colon, so the provider can carefully examine the lining of these organs. A sigmoidoscopy is similar to, but not the same as, a colonoscopy. A sigmoidoscopy only examines up to the sigmoid, the most distal part of the colon, while colonoscopy examines the whole large bowel.
56-Spirometry	Spirometry measures how much air a patient can inhale and exhale. It also measures how fast a patient can exhale and is a common test used to diagnose asthma, chronic obstructive pulmonary disease (COPD) and certain other conditions that affect breathing. It may also be used periodically to check how well a patient's lungs are working once the patient is being treated for a chronic lung condition.
57-Tonometry	In ophthalmology, tonometry is the procedure eye care professionals perform to determine the intraocular pressure (IOP), the fluid pressure inside the eye. It is an important test in the evaluation of patients with glaucoma. Most tonometers are calibrated to measure pressure in millimeters of mercury (mmHg).
58- Tuberculosis skin testing/PPD	Check box if TB skin testing listed or PPD was placed; DO NOT check box if TB skin test/PPD was read
59- Upper gastrointestinal endoscopy/EGD	EGD abbreviation for esophagogastroduodenoscopy
Treatments:	

61-Complementary alternative medicine (CAM)	Complementary alternative medicine (CAM) includes medical interventions neither widely taught in medical schools nor generally available in physician offices or hospitals (e.g., acupuncture, chiropractic, homeopathy, massage or herbal therapies).
62-Durable medical equipment	Durable medical equipment is that which can withstand repeated use (i.e., could normally be rented and used by successive patients); is primarily used to serve a medical purpose; generally is not useful to a person in the absence of illness or injury; and is appropriate for use in the patient's home (e.g., cane, crutch, walker, wheelchair).
63-Home health care	Home health care includes services provided to individuals and families in their places of residence for the purpose of promoting, maintaining, or restoring health or for maximizing the level of independence while minimizing the effects of disability and illness (including terminal illness). Services may include skilled nursing care; help with bathing, using toilet or dressing provided by home health aides; and physical therapy, speech language pathology services, and occupational therapy.
64-Mental health counseling, excluding psychotherapy	Mental health counseling includes general advice and counseling about mental health issues and education about mental disorders. It includes referrals to other mental health professionals for mental health counseling, but excludes psychotherapy.
65- Occupational therapy	Might be abbreviated OT
66-Physical therapy	Physical therapy includes treatments using heat, light, sound, or physical pressure or movement (e.g., ultrasonic, ultraviolet, infrared, whirlpool, diathermy, cold or manipulative therapy).
67-Psychotherapy	Psychotherapy includes all treatment involving the intentional use of verbal techniques to explore or alter the patient's emotional life in order to effect symptom reduction or behavior change.
68-Radiation therapy	Radiation therapy uses high-energy radiation to shrink tumors and kill cancer cells. X-rays, gamma rays, and charged particles are types of radiation used for cancer treatment. The radiation may be delivered by a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy, also called brachytherapy). Systemic radiation therapy uses radioactive substances, such as radioactive iodine, that travel in the blood to kill cancer cells.
69-Wound care	Wound care includes the cleaning, debridement, and dressing of burns and the repair of lacerations with skin tape or sutures. It only Includes the removal of foreign bodies only if a wound exists. If an object is removed from an orifice (e.g., ear, nose), then enter "foreign body removal" in "Other service."
Health education/Counseling:	

70- Alcohol abuse counseling	This category includes education or counseling performed at the visit as well as orders or referrals for education/counseling for the condition or topic. Alcohol might be abbreviated EtOH
71/72-Asthma education	Asthma education includes providing Information regarding the elimination of allergens that may exacerbate asthma or other activities that could lead to an asthma attack or instruction on the use of medication, such as an inhaler.
73- Diabetes education	Might be abbreviated DM education/counseling
74-Diet/Nutrition	Diet or nutrition education includes any topic related to the foods and/or beverages consumed by the patient. Examples include general dietary guidelines for health promotion and disease prevention, dietary restrictions to treat or control a specific medical problem or condition and dietary instructions related to medications. Includes referrals to other health professionals, for example, dietitians and nutritionists.
75-Exercise	Exercise education includes any topics related to the patient's physical conditioning or fitness. Examples include information aimed at general health promotion and disease prevention and information given to the patient to treat or control a specific medical condition. It includes referrals to other health and fitness professionals, but excludes referrals for physical therapy.
76-Family planning/Contraception	Family planning allows individuals and couples to anticipate and attain their desired number of children and the spacing and timing of their births. It is achieved through use of contraceptive methods and the treatment of involuntary infertility. Contraception is the deliberate use of artificial methods or other techniques to prevent pregnancy as a consequence of sexual intercourse. The major forms of artificial contraception are: barrier methods, of which the commonest is the condom; the contraceptive pill, which contains synthetic sex hormones that prevent ovulation in the female; intrauterine devices, such as the coil, which prevent the fertilized ovum from implanting in the uterus; and male or female sterilization. It includes information given to the patient to assist in conception or intended to help the patient understand how to prevent conception.
77- Genetic counseling	Might be in chart as refer to genetic counselor or refer for genetic counseling
78-Growth/Development	Growth and development counseling refers to any topics related to the growth and development of a child.
79-Injury prevention	Education on injury prevention refers to any topic aimed at minimizing the chances of injury in one's daily life. It may include issues as diverse as drinking and driving, seat belt use, child safety, avoidance of injury during various physical activities, and the use of smoke detectors.

80-STD prevention	STD prevention includes educating patients about STD transmission, safe sex, and condom use; screening patients for syphilis, gonorrhea, Chlamydia, and HIV; and partner notification.
81-Stress management	Stress management counseling refers to information intended to help patients reduce stress through exercise, biofeedback, yoga, etc. It includes referrals to other health professionals for the purpose of coping with stress.
82- Substance abuse counseling	Select box if education counseling ordered or performed 1) around substance use/abuse; illicit drug use, or injection/intravenous drug use (IDU/IVDU/IVDA); or 2) around use of a specific substance (e.g., cocaine use, opioid dependence), not including tobacco/nicotine or alcohol.)
84-Weight reduction	Education on weight reduction refers to Information given to the patient to assist in the goal of weight reduction. It includes referrals to other health professionals for the purpose of weight reduction.
Other services not listed: 85-Other	Enter any other examinations, tests, imaging services, non- medication treatment, and health education that was ordered or provided at this visit that were not listed above. This may include the following scope procedures which should only be entered if they were provided at this visit: Arthroscopy – Arthroscopy is a surgical procedure used to look inside a joint. When performing arthroscopic surgery, the surgeon can see inside the joint with a small camera. Cystoscopy – A cystoscopy involves the insertion of a thin tube or cystoscope into the urethra and then into the urinary bladder to visualize the bladder. Endoscopy – An endoscopy involves the insertion of a thin, tube- like instrument (endoscope) into an organ or cavity. Examples include: bronchoscopy, esophagoscopy, gastroscopy, and laparoscopy.

MEDICATIONS & IMMUNIZATIONS

If medications or immunizations were ordered, supplied, administered, or continued at this visit, list up to 30 using either the brand or generic names.

Record the exact drug name (brand or generic) written on any prescription or on the medical record.

Do not enter broad drug classes, such as "laxative," "cough preparation," "analgesic," "antacid," "birth control pill," or "antibiotic." The one exception is "allergy shot."

If no medication was prescribed, provided, or continued, then enter "0" and continue.

Medication, broadly defined, includes the specific name of any:

- Prescription and over-the-counter medications, anesthetics, hormones, vitamins, immunizations, allergy shots, and dietary supplements
- · Medications and immunizations which the physician/provider ordered or provided prior to this visit

and instructs or expects the patient to continue taking regardless of whether a "refill" is provided at the time of visit

For each medication, record if it was new or continued.

If more than 30 drugs are listed, then record according to the following level of priority:

- 1. All medications (including OTC drugs)/immunizations associated with the listed diagnoses.
- 2. All new medications (including OTC drugs)/immunizations, excluding vitamins and dietary Supplements.
- 3. All continued medications (including OTC drugs)/immunizations, excluding vitamins and dietary supplements
- 4. Vitamins and dietary supplements.

PROVIDERS

Enter all providers seen during this visit.

If care was provided, at least in part, by a person not represented in the 5 categories, enter "Other".

For mental health provider, include pyschologist, counselors, social workers, and therapist who provide mental health counseling. Exclude psychiatrists.

TIME SPENT WITH PROVIDER

Include here the length of time the physician/CHC provider spent with the patient. DO NOT include the time the patient spent waiting to see the physician/CHC provider or receiving care from someone other than the physician/CHC provider.

For example, DO NOT include the time someone other than the sampled provider spent giving the patient an inoculation or the time a technician spent administering an electrocardiogram.

It is entirely possible that for visits such as these, the patient would not see the physician/CHC provider at all. In that case, "0" minutes should be recorded. DO NOT include physician's/CHC provider's time spent preparing for a patient such as reviewing the patient's medical records or test results before seeing the patient.

If more than one patient is seen by the physician/CHC provider at the same time, apply the following rule:

If the physician/CHC provider can easily separate the time spent with each (e.g., 3 minutes with one and 27 minutes with the other), he/she should record that on the Patient Record forms. If the physician/CHC provider cannot easily estimate how much time was spent with each, he/she should divide the total time equally among the patients seen together.

VISIT DISPOSTION

Visit Disposition	Description
1-Return to referring	The patient was referred for this visit from another physician/provider

physician	whom they will return to for follow-up care.
2-Refer to other physician	The patient was instructed to consult or seek care from another provider.
	The patient may or may not return to this office at a later date.
3- Return in less than 1 week	The patient was told to schedule an appointment or was given an
	appointment to return to the office/CHC in less than 1 week.
4- Return in 1 week to less	The patient was told to schedule an appointment or was given an
than 2 months	appointment to return in 1 week to less than 2 months.
5- Return in 2 months or	The patient was told to schedule an appointment or was given an
greater	appointment to return in 2 months or greater.
6- Return at unspecified time	The patient was told to schedule an appointment or was given an
	appointment to return but the time was not specified in the chart.
7- Return as needed (p.r.n.)	The patient was not scheduled to return at a specific time but was
	instructed to return for care as needed.
8- Refer to ER/Admit to	The patient was instructed to go to the emergency room/department for
hospital	further evaluation and care immediately or the patient was admitted as an
	inpatient in the hospital.
9-Other	Any other disposition no included in the above list.

TESTS

Look back in the medical record to see if blood was drawn (for any the 7 tests listed) on the day of the sampled visit or during the 12 months prior to the sampled visit. Include tests in the medical record, regardless of who ordered them.

Enter "Yes" if you find documentation that blood for the test was drawn during this time period, otherwise enter "None found."

Enter the most recent result of each test, where applicable. If any of the test results for the most recent visit are not available in the medical record at the time of abstraction, do not follow-up and obtain the information at a later date.

The HbA1C or A1C or glycohemoglobin test measures the amount of glucose that is bound to hemoglobin and is usually reported as a percent. It is usually ordered for patients who have diabetes and is different from the hemoglobin (Hgb) test that may be a part of the complete blood count (CBC) or performed as a single test which is generally reported in g/dL (grams per deciliter).

C. DEFINITIONS OF CERTAIN TERMS USED IN NAMCS

Ambulatory patient -- A non-institutionalized person who comes to the doctor's office (definition of office below) for personal health reasons.

Continuity of care -- Continuity of care is a goal of health care achieved through an interdisciplinary process involving patients, families, health care professionals, and providers in the management of a coordinated plan of care. Based on changing needs and available resources, the process optimizes quality outcomes in the health status of patients. It may involve professionals from many different disciplines within multiple systems.

Drug mention(s) --The physician's entry of a pharmaceutical agent ordered or provided--by any route of administration--for prevention, diagnosis, or treatment. Generic as well as brand-name drugs are included. Along with all new drugs, the physician also records continued medications if the patient was specifically instructed or expected to continue the medication.

Drug visit -- A drug visit is a visit at which medication was prescribed or provided by the physician.

Office – Place which the sampled provider identifies as a location for ambulatory practice, customarily including consulting, examination, and/or treatment spaces which patients associate with the particular provider. The office may be part of a free-standing clinic, or one of several offices operated by a group or partnership, neighborhood/community health center, or family planning clinic.

Visit --A direct, personal exchange between ambulatory patient and the physician (or members of his/her staff) for the purpose of seeking care and rendering health services.

PATIENTS

In-scope -- All ambulatory patients seen by the physician or members of his/her staff in the physician's office(s) or seen by the sampled provider (physician or mid-level provider) in the community health center at any time during the one-week reporting period. [Note: Visits to community health centers are NOT included on the 2014 NAMCS Public Use Data File. They are expected to be released separately at a later date.] If a patient is seen by a sampled provider's staff, the staff member must be associated with or supervised by the sampled provider in order to be included in NAMCS.

Out-of-scope:

- -- Patients seen by the sampled provider in a hospital, nursing home, or other extended-care institution, or the patient's home. [**Note:** If a doctor has a **private** office (which fits the definition of "office") located in a hospital, the ambulatory patients seen there would be considered "in-scope."]
- Patients who call on the telephone and receive advice from the sampled provider.
- Patients who come to the office only to leave a specimen, pick up insurance forms, or pay their bills.
- Patients who come to the office only to pick up medications previously prescribed by the sampled provider.

PHYSICIANS

In-Scope -- All sampled providers currently in practice who spend any time caring for ambulatory patients at an office location (see definition of office above). In offices, sampled providers include physicians (MDs and DOs). In community health centers, sampled providers include physicians (MDs and DOs) along with physician assistants, nurse practitioners, and nurse mid-wives.

Out-of-Scope -- Those sampled providers who treat patients only indirectly. For office-based physicians, out-of-scope will include physician specialists in anesthesiology, pathology and forensic pathology, radiology, therapeutic radiology, and diagnostic radiology. [Note: A more detailed list is available by contacting the Ambulatory and Hospital Care Statistics Branch.] In community health centers, out-of-scope includes non-medical providers (such as dentists, optometrists, or social workers).The following kinds of physicians are also out-of-scope:

- Physicians employed full-time by the Federal Government and having no private practice (e.g., physicians who work for the V.A.).
- Physicians employed full-time by an institution to serve its own population. The physician does not see ambulatory patients from outside the institutional community. For example, the physician works for Ford Motor Company, and provides care only to ambulatory patients and their families employed by Ford.
- Physicians who spend no time during a normal week seeing ambulatory patients (e.g., physicians who exclusively teach or are engaged in research).

- Physicians employed full-time by a hospital working with inpatients, in an ED or OPD, with no
 private practice.
- Physicians in military service, with no private practice.
- Physicians who treat only institutionalized patients (e.g., patients in nursing homes, hospitals, and prisons).

Physician specialty -- Principal specialty (including general practice) as designated by the physician at the time of the survey. Those physicians for whom a specialty was not obtained were assigned the principal specialty recorded in the Master Physician files maintained by the AMA or AOA.

Metropolitan status — Physicians are classified by their location in metropolitan statistical area as follows:

Metropolitan statistical area (MSA)—As defined by the U.S. Office of Management and Budget, the definition of an individual MSA involves two considerations: first, a city or cities of specified population, that constitute the central city and identify the county in which it is located as the central county; second, economic and social relationships with "contiguous" counties that are metropolitan in character so that the periphery of the specific metropolitan area may be determined. MSAs may cross state lines. In New England, MSAs consist of cities and towns rather than counties.

Non-MSA—Non-MSA areas are those not defined as MSAs, including rural and micropolitan areas.

Region of practice location -- The four geographic regions which correspond to those used by the U.S. Bureau of the Census, are as follows:

Region	States Included
Northeast	Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
Midwest	Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
South	Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia
West	Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming, Alaska, Hawaii

Division	States Included
1 – New England	Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont
2 – Middle Atlantic	New Jersey, New York, Pennsylvania,
3 – East North Central	Illinois, Indiana, Michigan, Ohio, Wisconsin
4 – West North Central	Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota
5 – South Atlantic	Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South
	Carolina, Virginia, West Virginia
6 - East South Central	Alabama, Kentucky, Mississippi, Tennessee
7 - West South Central	Arkansas, Louisiana, Oklahoma, Texas
8 – Mountain	Arizona, Colorado, Idaho, New Mexico, Montana, Utah, Nevada, Wyoming
9 – Pacific	Alaska, California, Hawaii, Oregon, Washington

APPENDIX II REASON FOR VISIT CLASSIFICATION

A. SUMMARY OF CODES

MODULE

CODE NUMBER

SYMPTOM MODULE

General Symptoms	1001-1099
Symptoms Referable to Psychological and Mental Disorders	1100-1199
Symptoms Referable to the Nervous System (Excluding Sense Organs)	1200-1259
Symptoms Referable to the Cardiovascular and Lymphatic Systems	1260-1299
Symptoms Referable to the Eyes and Ears	1300-1399
Symptoms Referable to the Respiratory System	1400-1499
Symptoms Referable to the Digestive System	1500-1639
Symptoms Referable to the Genitourinary System	1640-1829
Symptoms Referable to the Skin, Nails, and Hair	1830-1899
Symptoms Referable to the Musculoskeletal System	1900-1999

DISEASE MODULE

Infective and Parasitic Diseases	2001-2099
Neoplasms	2100-2199
Endocrine, Nutritional, Metabolic, and Immunity Diseases	2200-2249
Diseases of the Blood and Blood-forming Organs	2250-2299
Mental Disorders	2300-2349
Diseases of the Nervous System	2350-2399
Diseases of the Eye	2400-2449
Diseases of the Ear	2450-2499
Diseases of the Circulatory System	2500-2599
Diseases of the Respiratory System	2600-2649
Diseases of the Digestive System	2650-2699
Diseases of the Genitourinary System	2700-2799
Diseases of the Skin and Subcutaneous Tissue	2800-2899
Diseases of the Musculoskeletal System and Connective Tissue	2900-2949
Congenital Anomalies	2950-2979
Perinatal Morbidity and Mortality Conditions	2980-2999

DIAGNOSTIC, SCREENING AND PREVENTIVE MODULE

General Examinations	3100-3199
Special Examinations	3200-3299
Diagnostic Tests	3300-3399
Other Screening and Preventive Procedures	3400-3499
Family Planning	3500-3599

TREATMENT MODULE

Medications	4100-4199
Preoperative and Postoperative Care	4200-4299
Specific Types of Therapy	4400-4499
Specific Therapeutic Procedures	4500-4599
Medical Counseling	4600-4699
Social Problem Counseling	4700-4799
Progress Visit, NEC	4800-4899

MODULE	CODE NUMBER
INJURIES AND ADVERSE EFFECTS MODULE	
Injury by Type and/or Location Injury, NOS Poisoning and Adverse Effects	5001-5799 5800-5899 5900-5999
TEST RESULTS MODULE	6100-6700
ADMINISTRATIVE MODULE	7100-7140
UNCODABLE ENTRIES	8990-8999
BLANK	-9

NOTE: NOS = Not otherwise specified; NEC = not elsewhere classified

B. REASON FOR VISIT CLASSIFICATION TABULAR LISTING

SYMPTOM MODULE GENERAL SYMPTOMS (1001-1099) 1005.0 Chills 1010.0 Fever Includes: High temperature Other symptoms of body temperature 1012.0 Excludes: Chills (1005.0) Fever (1010.0) 1012.1 Feeling cold 1012.2 Feeling hot 1012.3 Feeling hot and cold 1015.0 Tiredness, exhaustion Includes: Exercise intolerance Fatigue Lack of energy No energy Run down Worn out 1020.0 General weakness 1025.0 General ill feeling Includes: Diffuse Cx Feeling bad all over Illness, NOS Malaise Not feeling well Multiple complaints Sick, NOS

Excludes: General symptoms of infants (10800)

1030.0 Fainting (syncope)

> Includes: Blacking out Fainting spells Passing out

Excludes: Unconsciousness (5840.0) 1035.0 Symptoms of fluid abnormalities Includes: Fluid imbalance Fluid retention Holding water

1035.1 Edema

Includes: Ankles swelling (both) Bloated Dropsy Legs (both) Peripheral Swollen with water

Excludes: Swelling of one ankle (1930.5) Swelling of one leg (1920.5)

1035.2 Excessive sweating, perspiration Includes: Cold sweats Diaphoresis

1035.3 Excessive thirst

1040.0 Weight gain

> Includes: Fat pads (localized) Fatty deposits Obesity Overweight Too fat

Excludes: Counseling for weight problem (4600.0)

Multiple medical problems

1045.0 Weight loss

1045.1 Recent weight loss

1045.2 Underweight

1046.0 Symptoms of face, NEC

> Includes: Mass

Excludes: Facial pain 1055.4 Facial paralysis 1230.0

1050.0	1	ed symptoms (not referable to a	1065.0	Tumor or mass, site	unspecified
		oody system)		1065.1	Internal mass, NOS
	1050.1 0	Chest pain, soreness			
		Excludes: Heart pain (1265.0)	1066.0	Lesion, Internal NOS	6 (excludes brain and skin)
	1050.2	- · · · ·	1070.0	Bleeding, multiple or	unspecified sites
	1050.2 C	Chest discomfort, pressure, tightness, heaviness	1075.0	Symptoms of growth	and developmental disorders
		Includes:		Includes:	
		C - pressure		Develo	pmental regression
	1050.3 H	Burning sensation in the chest		1075.1	Lack of growth
1055.0	system	ot referable to a specific body			Includes: Failure to thrive Immaturity, physical
	Includes				Poor weight gain
	Buttoc Glutea				Slowness, physical Too short
	Perine				100 short
	Exclude	•		1075.2	Excessive growth
		ninal pain (see 1545.1-1545.3)			Includes:
		pain (1050.1)			Development, early (physical)
	Phanto	m leg/limb (2307.0)			Too big for age Too tall
	1055.1	Rib pain			
	1055.2	Side pain, flank pain	1080.0	NEC	f infants (under 1 year of age),
	1055.2			Excludes	
	1055.3	Groin pain		Genera	l ill feeling (1025.0)
		Includes:		1080.1	Cranky, crying too much, fussy,
		Pubic pain			fidgety, irritable
	1055.4	Facial pain		1080.2	Regurgitation, spitting up
		Includes:			Excludes:
		Jaw pain			Vomiting (1530.0)
		Pain over eye			
10.00 0				1080.3	Feeding problem, eating difficulty
1060.0	Pain and related sym	ptoms, NEC	1095.0	C	d a succional info stimu
	1060.1	Pain, unspecified	1085.0	General or unspecific Code also symptoms etc.)	of specified joint (hip, shoulder,
		Includes:		Includes	
		Ache all over (generalized) Incisions (postopcode 4205.0			on, NOS
		also)		Intection	01, 1103
		usoj	1090.0	Allergy, NOS	
	1060.2	Cramps, spasms, site unspecified			
				Includes	
		Excludes:		Angioe	
		Menstrual cramps (1745.2)		U	c reaction, NOS
	1060.3	Stiffness, site unspecified			llergy, NOS llergy, NOS
				F 1 1	
				Exclude	
				U	c skin reaction (2825.0) y to medications (5905.0)
					allergy (2635.0)
				1.4041	0, ()

PAGE 171

1095.0 Disorders of motor functions

Includes: Ataxia Clumsiness Difficulty in walking Dyskinesia Fall, NOS Limping Staggering Stumbling Uncoordinated Unsteady gait

1096.0 Dyslexia, NOS

SYMPTOMS REFERABLE TO PSYCHOLOGICAL AND MENTAL DISORDERS (1100-1199)

- 1100.0 Anxiety and nervousness
 - Includes: Apprehension Anxiety disorder Bad nerves Jittery Panicky feeling Stress Tension Upset Worried
- 1105.0 Fears and phobias

Includes: General fearfulness Agoraphobia

1110.0 Depression

Includes: Crying excessively Dejected Distress (NOS) Feeling down Feeling low Grief Hopelessness Sadness Tension Tension headache (also code 1210.0) Unhappy

1115.0 Anger

Includes: Bitterness Hostile feelings

Excludes: Temper problems (1130.4)

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

1120.0 Problems with identity and self-esteem

Includes: Co-dependency Dependency Don't like myself Guilt Helpless Identity crisis Insecurity, emotional Lack of motivation Loss of identity No confidence No goals Poor boundaries Self derogation Too much is expected of me

1125.0 Restlessness

Includes: Can't rest Hyperactivity Overactivity

1130.0 Behavioral disturbances

Includes: Agitated Behavior problem Gambling problem Lack of self control Out of control

1130.1 Antisocial behavior

Includes: Avoiding people Excessive shyness Lying Social isolation Withdrawal

1130.2 Hostile behavior

Includes: Aggressiveness Child abuser Child neglecter Combative Criminality Cruelty Destructiveness Elder abuser Homicidal Negativism Parent abuser Quarrelsome Spouse abuser Spouse batterer Wufe batterer

1130.0	Behavioral disturband 1130.3 1130.4	ces (cont.) Hysterical behavior Temper problems Includes: Blowing up Fussy Irritability Losing temper Temper tantrums Excludes: Fussy infants (1080.1)	1150.0	halluc Exclude Drug a Drug d Intoxic Overde	:: buse eeking nt or excessive use of stimulants, inogens, depressants, etc.
	1130.5	Obsessions and compulsions	1150.1 1155.0	Substance Abuse, No Delusions or hallucir Includes	nations
1135.0	Disturbances of sleep Includes Night te 1135.1	: rrors Insomnia		Flashb Grandi Hearin Ideas c	ack osity g voices ff reference ine is poisoned
		Includes: Can't sleep Sleeplessness Trouble falling asleep	1160.0	Psychosexual disorde	ers Frigidity, loss of sex drive, lack of
	1135.2	Sleepiness (hypersomnia)		1160.2	response, lack of libido Homosexuality, concerns with
		Includes: Can't stay awake Drowsiness		1160.3	Impotence, Erectile dysfunction
		Groggy		1160.4	Premature ejaculation
	1135.3 1135.4	Nightmares Sleepwalking		1160.5	Masturbation excessive, concerns about
	1135.5	Apnea Includes:		1160.6	Orgasm, problem with
		Sleep apnea (use additional code 1420.0 if breathing		1160.7	Preoccupation with sex
1140.0	Smoking problems	problem)	1165.0	• • •	oroblems relating to psychological al disorders, NEC s:
	Includes	:		Bad att Blunte	titude d affect
	Can't q	uit smoking ng too much		Can't c Change	
	partic	s: al symptoms of smoking (see cular symptom) r's cough (1440.0)		Danger Deja v Disorie	icted affect r to self u feelings ented ilty concentrating
1145.0	Alcohol-related probl			Feeling Frantic	g heavy
	Includes Alcoho Drinkir			Frustra Going Guarde Hate e	crazy
		s: e effects of alcohol (5915.0) lism (2320.0)		Losing	ed ng disability my mind fluctuation

PAGE 173

PAGE 174

1165.0 Other symptoms or problems relating to psychological 1215.0 Memory, disturbances of and mental disorders, NEC (cont.) Includes: Mood swings Amnesia Non-communicative Forgetfulness Overwhelmed Lack or loss of memory Peculiar thinking Temporary loss of memory Psychological problems, NOS Racing thoughts 1220.0 Disturbances of sensation Reserved Rumination 1220.1 Loss of feeling (anesthesia) Sundown syndrome Trouble concentrating Includes: Wandering around Lack of sensation No response to pain Numbness Excludes: Character disorder (2315.0) Stunned Personality disorder (2315.0) Excludes: Post-op complications of 1165.1 Nailbiting anesthesia 1165.2 Thumbsucking Note: Use additional code to identify body SYMPTOMS REFERABLE TO THE NERVOUS SYSTEM part. (EXCLUDING SENSE ORGANS) (1200 - 1259) 1220.2 Increased sensation (hyperesthesia) 1200.0 Abnormal involuntary movements 1220.3 Abnormal sensation (paresthesia) Includes: Jerking Includes: Shaking Burning legs Tics Burning, tingling sensation Tremors Needles and pins Twitch Prickly feeling Stinging Excludes: Eye movements (see 1325.0-1325.4) 1220.4 Other disturbances of sense, Eyelid twitch (1340.4) including smell and taste 1205.0 Convulsions 1225.0 Vertigo - dizziness Includes: Includes: Febrile convulsions (Code fever also) Falling sensation Fits Giddiness (dizziness) Seizure disorders Lightheadedness Seizures Loss of sense of equilibrium or balance Spells Room spinning 1230.0 Weakness (neurologic) Excludes: Fainting (1030.0) Includes: Drooping, facial or NOS 1207.0 Symptoms of head, NEC Right- or left-sided weakness Excludes: Headache, pain in head (1210.0) Excludes: General weakness (1020.0) 1210.0 Headache, pain in head Includes: Post-traumatic (also code 5575.0) Excludes: Migraine (2365.0)

Sinus headache (1410.1) Symptoms of head, NEC (1207.0)

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

1235.0	Disorders of speech,	speech disturbance	1270.0	Other symptoms of the	he heart
	Includes				
		ng for words		Includes	
		h/verbal apraxia		Bad he	art condition
	Unable	e to speak		Poor he	
	1235.1	Stuttering, stammering		Weak I	
	1235.2	Slurring	1275.0	Symptoms of lymph	glands (or nodes)
1240.0	Other symptoms refe Includes	erable to the nervous system		1275.1	Swollen or enlarged glands
		lesion		1275.2	Sore glands
	Confu				
	-	tive decline	1280.0	Other symptoms refe	
		ged nerves		cardiovascular/lymp	
	Neura	wegative		(blocked blood vesse	ei, spider vein)
		ed nerve			Includes:
	Postic				Telangiectasia
	1 00110				
	Exclude			1280.1	Poor circulation
	Nerv	e block 4560.0			Includes:
					Cold feet, hands
	1240.1 A	praxia			
				1280.2	Pallor, paleness
		Excludes:		1000.2	Theshed blocking
		Speech/verbal apraxia 1235.0		1280.3	Flushed, blushing
	OMS REFERABLE MPHATIC SYSTEM	TO THE CARDIOVASCULAR IS (1260-1299)	SYMPT (1300-13		TO THE EYES AND EARS
1260.0	Abnormal pulsations	and palpitations			
			1305.0	Vision dysfunctions	
	1260.1	Increased heartbeat			
		T 1 1		Exclude	
		Includes:		Refract	tive errors (2405.0)
		Pulse too fast Rapid heartbeat		1305.1	Blindness and half vision
	1260.2	Decreased heartbeat		1505.1	Includes: Visual field deficit
	1200.2	Decreased heartbeat			visual field deficit
		Includes:		1305.2	Diminished vision
		Pulse too slow			
		Slow heart			Includes:
					Blurred vision
	1260.3	Irregular heartbeat			Can't see distances
		T 1 1			Difficulty reading
		Includes:			Focus, Eyes won't (other than
		Fluttering			Infant 1335.0)
		Jumping Racing			Obstruction, Vision Poor vision
		Skipped beat			Scotoma
		Skipped beat			Trouble seeing
1265.0	Heart pain				Weak eyes
	······				
	Includes	3:		1305.3	Extraneous vision
	Angina	al pain			
	Heart	distress			Includes:
	Pain of	ver heart			Cloudy vision Fuzzy vision

Excludes: Angina pectoris (2515.0) Chest pain (1050.1)

1305.4 Double vision (diplopia)

Spots in front of eyes (floaters)

1310.0	Discharge from eye		1335.0	Other and unspecified	l symptoms referable to eye, NEC
	1310.1	Bleeding		(cont.)	
	1310.2	Tearing, watering (lacrimation)		1335.1	Contact lens problems
	1310.2	Pus, matter, white discharge, matted		1335.2	Allergy
	1510.5	T us, matter, white discharge, matter		1335.3	Swelling
1315.0	Eye infection and inf	flammation			Excludes: Foreign body (5600.0)
	1315.1	Pinkeye			Injury (5510.0) Abrasion (5410.0)
1320.0	Abnormal sensations	s of the eye	1340.0	Symptoms of eyelids	
	Includes Foreig Tired e	n body sensation	13-0.0	Symptoms of Cyclids	Includes: Can't close eye Lesion Rash
	1320.1	Pain		1240 1	Infection, inflammation, swelling
		Includes:		1340.1	
		Irritation		1340.2	Itching
	1320.2	Itching		1340.3	Mass or growth
	1320.3	Burning, stinging		1340.4	Abnormal movement
	1320.4	Strain			Includes: Blinking
1325.0	Abnormal eye move	ments			Drooping Squinting
	1325.1	Abnormal retraction			Twitching
	1325.2	Cross-eyed	1345.0	Hearing dysfunctions	
	1325.3 1325.4	Pupils unequal Deviation Includes: Drifting Lazy eye Turns in		1345.1	Diminished hearing Includes: Deafness Hearing loss Trouble hearing Heightened or acute hearing
1330.0	Abnormal appearance	e of eyes		1345.3	Extraneous hearing
	1330.1	Abnormal color Includes: Bloodshot Red		1949.5	Includes: Ringing (tinnitus) Excludes: Hearing things (1155.0)
		Excludes: Yellow (1610.2)	1350.0	Discharge from ear	
	1330.2	Protrusion (exophthalmos)		Includes: Fluid in	
	1330.3	Cloudy, dull, hazy appearance, cloudy capsule		1350.1	Bleeding
1335.0	Other and unenecific	ed symptoms referable to eye, NEC		1350.2	Pus (purulent drainage), otorrhea
1555.0	-			1350.3	Swimmer's ear
	Includes Defect				

Eyes not focusing (infant)

1355.0	Earache, or ear infe	ction	1405.0	Other symptoms of	nose (cont.)
	1355.1	Earache, pain		1405.4	Problem with appearance of nose
1260.0	1355.2	Ear infection			Includes: Bump(s)
1360.0	Plugged feeling in e	ar			Too large Undesirable appearance
	Include	25:			
	Block		1410.0	Sinus problems	
	-	estion in ear		T 1 1.	
	Crack Ear fe	eels full		Include Sinus	
		need cleaning			drainage
	Ear w	•			
	Poppi	ng		1410.1	Pain and pressure
1365.0	NEC	ed symptoms referable to the ears,			Includes: Sinus headache
	Inclue			1 4 1 0 0	
		problem tachian tube dysfunction		1410.2	Sinus inflammation, infection
		ssure		1410.3	Sinus congestion
		l, redness			2
			1415.0	Shortness of breath	
	1365.1	Itching			
	1365.2	Growths or mass		Include	es: hlessness
	1505.2	Growins of mass			f breath
	1365.3	Pulling at ears, picking at ears			tion of suffocation
	1365.4	Abnormal size or shape, "ears stick out"	1420.0	Labored or difficult	breathing (dyspnea)
				Include	
		Excludes:		Anox	
		Foreign body in ear (5620.0)			hing stopped
		TO THE RESPIRATORY SYSTEM		Can't	catch breath
(1400-14	99)			Heavy Hypo:	y breathing
1400.0	Nasal congestion				ratory distress
	8			Smoth	
	Include	es:		Troub	le breathing
		by nose	1 425 0	TT ^T	
		ss mucus obstruction	1425.0	Wheezing Include	
		nasal drip			ng respiration
		y nose			6 1
	Sniff		1430.0	Breathing problems	, NEC
	Stuffy	y nose			
1405.0	Other symptoms of	nose		Include Hurts	to breathe
1105.0	Exclud			Turts	to breattle
	Nasal	allergy (2635.0)		1430.1	Disorders of respiratory sound, NEC
	1405.1	Nosebleed (epistaxis)			
	1405.2	Sore in nose			Includes: Abnormal breathing sounds Snoring
	1405.3	Inflammation and swelling			Rales
		Includes:			Rattles
		Infection			Stridor
		Red nose		1430.2	Rapid breathing (hyperventilation)
		Sore nose			

PAGE 178

1435.0 1470.0 Abnormalities of sputum or phlegm Sneezing 1440.0 1470.1 Cough Coughing up blood Includes: Includes: Hemoptysis Congested Croupy cough Smoker's cough 1470.2 Pus in sputum 1445.0 Head cold, upper respiratory infection (coryza) 1470.3 Excessive sputum Includes: Includes: Cold, NOS Productive Excludes: 1475.0 Congestion in chest Chest cold (1475.0) Includes: 1450.0 General viral infection Lung congestion Chest cold 1450.1 Flu 1480.0 Disorders of voice Includes: 1480.1 Hoarseness, loss of voice Grip Influenza Includes: Excludes: Croaky Croup (2600.0) 1480.2 Hypernasality 1455.0 Symptoms referable to throat, raw throat 1485.0 Other symptoms referable to the respiratory system, 1455.1 Soreness NEC Includes: Includes: Throat hurts Drainage in throat 1455.2 Pain (burning, throat on fire) 1485.1 Lung pain 1455.3 1485.2 Lung infection Infection Includes: Throat virus SYMPTOMS REFERABLE TO THE DIGESTIVE SYSTEM (1500-1639) Excludes: 1500.0 Symptoms of teeth and gums Strep throat (2010.0) 1455.4 Irritation, scratch, tickle, itch Includes: Loose tooth (no injury) 1455.5 Swelling Teething, one year old and over Tooth infection 1455.6 Lump or mass 1500.1 Toothache Includes:

Sensation of something in throat

Excludes: Foreign body in throat (5615.0)

1460.0 Symptoms referable to tonsils

Includes: Hypertrophy Infection Inflammation

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

1500.2

1500.3

Includes:

1501.1

1501.2

Symptoms of the jaw, NOS

1501.0

Gum pain

Jaw problem, unspecified

Swelling

Lump or mass

Bleeding gums

1505.0	Symptoms referable	to lips	1535.0	Heartburn and indige	estion (dyspepsia)
	Includes: Sore or			Includes: Acid in stomach Excessive belching	
	1505.1	Cracked, bleeding, dry, chapped	1540.0	Gastrointestinal infec	5
	1505.2	Abnormal color		Includes	:: nal virus
	1505.3	Cold sore		Stomac	
1510.0	Symptoms referable	to mouth			astroenteritis
	Include: Blister	s: · in mouth	1545.0	Stomach and abdomi	inal pain, cramps and spasms
		ng at the mouth		Includes	
		on of mouth		Gastric	e pain
		too thick		Exclude	e.
	White 1510.1	Pain, burning, soreness			pain (1055.3)
	1510.2 1510.3	Bleeding Dryness		1545.1	Abdominal pain, cramps, spasms, NOS
	1510.4	Ulcer, sore			
1515.0	Symptoms referable	-			Includes: Abdominal discomfort, NO Gas pains Intestinal colic
	Include			1515.0	
		on tongue n tongue		1545.2	Lower abdominal pain, cramps, spasms,
	1515.1	Pain			Includes: Right lower quadrant (RLQ) pain
	1515.2	Bleeding			Left lower quadrant (LLQ) pain Inguinal pain
	1515.3 1515.4	Inflammation, infection, swelling		1545.3	Upper abdominal pain, cramps, spasms
	1515.4	Abnormal color, ridges, coated			spasiiis
1520.0	Difficulty in swallow	ving (dysphagia)			Includes: Epigastric pain
	Includes				Left upper quadrant (LUQ) pain Pain in umbilical region
	Choki Inabili	ty to swallow			Right upper quadrant (RUQ) pain
1525.0	Nausea Include:	ç.	1565.0	Change in abdominal	l size
	Feel li	ke throwing up us stomach		1565.1	Distention, fullness, NOS
	Upset	o stomach stomach			Includes: Abdominal bloating Stomach fullness
1530.0	Vomiting			1565.2	Mass or tumor
	Include: Can't l Dry he Retchi	keep food down eaves			Includes: Mass in groin Mass, inguinal
	Throw	ing up		1565.3	Abdominal swelling, NOS
		es: gitation, infants (1080.2) ing blood (1580.2)			

PAGE 179

PAGE 180

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

1570.0	Appetite, abnormal		1600.0	Other symptoms or char	nges in bowel function (cont.)
	1570.1	Excessive appetite Eats too much Always hungry			ncontinence of stool Includes: Dirty pants (encopresis)
	1570.2	Decreased appetite Decreased fluid intake	1605.0	Symptoms referable to a	Leaking stools
		Loss of appetite Not eating	1605.0	Symptoms referable to a	anus-rectum
		Not hungry		1605.1 P	Pain
1575.0	Difficulty eating				Includes:
		g problem, difficulty eating (less than ear [1080.3])			Burning Irritation
	one y	[1000.5])		1605.2 B	Bleeding
1580.0	Gastrointestinal blee Includes:			1605.3 S	Swelling or mass
	Bowel			1605.4 It	tching
	1580.1 1580.2	Blood in stool (melena) Vomiting blood (hematemesis)	1610.0	Symptoms of liver, gall	bladder, and biliary tract
1585.0	Flatulence	volinting blood (hematemesis)		1610.1 P	Pain
1385.0				1610.2 J	aundice
	Includes Bloate				Includes:
		tion due to gas			Yellow eyes
		ive gas			Yellow skin
	Gas				
	Exclude		1615.0	Other and unspecified system	ymptoms referable to digestive
	Gas pa	ins (1545.1)		Includes:	
1590.0	Constipation			Abdomina	al pressure
1595.0	Diarrhea			Bad breat Epigastric	
				Gastrointe	estinal distress
	Includes			Halitosis	
	Loose			Hiccoughs	s tion (adult)
	The ru	lis		Sour taste	
1600.0	Other symptoms or c	hanges in bowel function		Stomach p	problem
	1600.1	Discharge in stools		Stomach t	trouble
	100011		SYMPT	OMS REFERABLE T	O THE GENITOURINARY
		Includes:	SYSTEM	M (1640-1829)	
		Guaiac positive Hemocult positive Mucus	1640.0	Abnormalities of urine	
		Pus		Excludes:	findings of urine tests (6200.0)
	1600.2	Worms		Abilotilia	Thinkings of urfile tests (0200.0)
	1600.3	Changes in size, color, shape, or		1640.1 B	Blood in urine (hematuria)
	1000.5	odor		1640.2 P	Pus in urine
		Includes: Bulky stools		1640.3 U	Jnusual color or odor
		Too narrow Unusual odor or color	1645.0	Frequency and urgency	of urination
					Excessive urination, night (nocturia)

1650.0	Painful urination		1680.0	Other symptoms refe	erable to urinary tract
	Include: Burnir	s: g, discomfort		Urethr	s: l stones al bleeding ry irritation
1655.0	Incontinence of urine	e (enuresis)		Exclude	•
	1655.1 In	nvoluntary urination, can't hold urine, dribbling, wetting pants	1700.0	Symptoms of penis	
	1655.2 H	Bedwetting		1700.1	Pain, aching, soreness, tenderness, painful erection
1660.0	Other urinary dysfur			1700.2	Infection, inflammation, swelling
		s: le going y pressure		1700.3	Lumps, bumps, growths, warts
		Stream	1705.0	Penile discharge	
	1660.1	Retention of urine	1710.0	Symptoms of prostat	te
		Includes: Can't urinate		Include: Prosta	s: te trouble
	1660.2	Hesitancy		1710.1	Swelling
		Includes: Difficulty in starting stream		1710.2	Infection
	1660.3	Large volume	1715.0	Symptoms of the scr	rotum and testes
	1000.5	-		1715.1	Pain, aching, tenderness
		Includes: Polyuria		1715.2	Swelling, inflammation
	1660.4	Small volume		1715.3	Growths, warts, lumps, bumps
1665.0	Symptoms of bladde	r		1715.4	Itching, jock itch
	Include: Bladde	s: er trouble	1720.0	Include	male reproductive system s: l in semen
	1665.1	Pain		Early	sexual development, males al ejaculation
	1665.2	Infection			
	1665.3	Mass		Exclude Psycho	es: osexual problems (1160.0-1160.6)
1670.0	Symptoms of the kid	Ineys	1730.0	Absence of menstru	ation (amenorrhea)
	Includes Kidney 1670.1	s: y trouble Pain		Missee	ss: ted pregnancy (3200.0) d a period (3200.0) late (3200.0)
	1670.2	Infection			
	1670.3	Mass	1735.0	Irregularity of menst	
1675.0	Urinary tract infection	on, NOS		1735.1	Frequent
	Includes Genito	s: purinary infection		1735.2	Infrequent
		infection		1735.3	Unpredictable

PAGE 181

1740.0	Irregularity of mens	trual flow	1765.0	Other vaginal sympton	oms
	1740.1	Excessively heavy (menorrhagia)		1765.1	Pain
	1740.2	Scanty flow (oligomenorrhea)		1765.2	Infection
	1740.3	Abnormal material, including clots		1765.3	Itching, burning
1745.0	Menstrual symptom	s, other and unspecified		1765.4	Vaginal dryness
	Include Long	s: periods	1770.0	Vulvar disorders	
	1745.1	Premenstrual symptoms, PMS		1770.1 1770.2 1770.3	Itching and irritation, swelling Mass, lump Growth, wart, cyst, ulcer, sore
		Includes: Bloating before periods Premenstrual tension	1775.0	Pelvic symptoms	
		or irritability		1775.1	Pain
	1745.2 Painful r	nenstruation (dysmenorrhea)		1775.2	Pressure or dropping sensation
		Includes: Menstrual cramps Pain in legs and back			Includes: Feeling of uterus falling out
		during menstruation		1775.3	Infection, inflammation
1750.0	Menopausal sympto	ms	1790.0	Problems of pregnan Includes:	cy
	1750.1	Early or late onset of menopause		Fetal movemen	t
	1750.2	Vasomotor symptoms-hot flashes		Exclude Routin	s: e prenatal visits (3205.0)
	1750.3	Emotional symptoms, change of life problems		1790.1	Pain during pregnancy
1755.0	Uterine and vaginal	-		1790.2	Spotting, bleeding during pregnancy
	Exclude Bleed	es: ing during pregnancy (1790.2)		1790.3	Symptoms of onset of labor
	1755.1	Intermenstrual bleeding (metrorrhagia)			Includes: Water broke Ruptured membranes
		Includes: Bleeding between periods Breakthrough bleeding	1701.0	D	Labor pain, contractions Labor, NOS
	1755.2	Postmenopausal bleeding	1791.0	Postpartum problem	
	1755.3	Postcoital bleeding, female		Includes Bleedi Pain	
1760.0	Vaginal discharge			Exclude	s:
	Includes: Bloody, brown, white (leukorrhea),				rtum examination, routine (3215.0)
		ssive	1795.0	system	erable to the female reproductive
					exual development, female nt miscarriage

Whiteheads

1800.0	Pain or soreness of b		1835.0	Discoloration or abn	ormal pigmentation
	Includes Tender			Includes	
	Tender	lless		Birthm	
1805.0	Lump or mass of bre	ast		Blotch	
1005.0	Earlip of mass of ore				s under eyes
	Includes	:		Freckle	•
	Bump			Redne	
	Knot			Spots	
	Nodule	2		1	
	Cyst			Exclude	s:
					ng (1280.3)
1810.0	Other symptoms refe	brable to breast			(see 5405.0-5430.0)
	1010.1				ng (1280.3)
	1810.1	Bleeding or discharge from nipple		Jaundi	ce (1610.2)
		or breast	1010.0		
	1910.2	Destrortum mehleme	1840.0	Infections of skin, N	US
	1810.2	Postpartum problems		Includes	
		Includes:			s. ng wound
		Engorgement			ed blister
		Postpartum infection			ed wound
		Nursing difficulties		lineete	a would
		Turshig unreduces		Exclude	·S'
	1810.3	Problems with shape or size			e's foot (2025.0)
	101010				d drainage (as treatment)
		Includes:			
		Too large		1840.1	Infection of skin of head or neck
		Too small			area
		Sagging			
		Uneven development		1840.2	Infection of skin of arm, hand, or
		L.			finger
1815.0	Symptoms of infertil	ity			-
				1840.3	Infection of skin of leg, foot, or
	Includes				toe
		et pregnant			
		y to conceive	1845.0	Symptoms of skin m	oles
	Sterilit	У		T 1 1	
1820.0	Hormona deficiency	or problem		Includes	s: nole, NOS
1820.0	Hormone deficiency	or problem		SKIII II	iole, NOS
1825.0	Symptoms of sexual	dysfunction		1845.1	Change in size or color
	~)	-,			
	Includes	:		1845.2	Bleeding mole
	Dyspar	eunia			-
	Painful	l intercourse	1850.0	Warts, NOS	
	Exclude			Includes	
	•	logical disorders (see 1160.0-		Condy	
	1160.0	5)		Condy	loma acuminatum
SVMDT	OMS DEFEDADIE T	OTHE SPIN NATES AND HAD		Exclude	
(1830-18		O THE SKIN, NAILS, AND HAIR			r's warts (2015.0)
(1050-10	<i>)</i>)			1 lantai	rs waits (2015.0)
1830.0	Acne or pimples		1855.0	Other growths of ski	n
	Includes			In also de -	
		: mplexion		Includes Callus	
	Blackh			Callus	
	Blemis			Coms Cysts,	NOS
	Breaki			Cysts, Cyst, s	
		exion, NOS			rowth, NOS
	Whiteh			Skin g	

Skin tag

1860.0 Skin rash 1890.0 Symptoms referable to hair and scalp Includes: Includes: Scalp lesion Rash Skin eruption Too little hair 1890.1 Excludes: Poison ivy (2825.0) Includes: Poison oak (2825.0) Alopecia Baldness 1860.1 Falling out Diaper rash Losing hair 1865.0 Skin lesion, NOS 1890.2 Unwanted hair Includes: Blister Includes: Abnormal hairiness Face Papule Hirsutism Pustule Superfluous hair Raw area Sore 1890.3 Dryness, flaky scalp, dry scalp Ulcer 1890.4 Itching 1870.0 Skin irritations, NEC 1895.0 Navel problems 1870.1 Pain Includes: 1870.2 Itching Umbilicus not healing 1875.0 Swelling of skin Protrusion SYMPTOMS REFERABLE TO THE MUSCULOSKELETAL Includes: Bumps, lumps SYSTEM (1900-1999) Nodules These codes exclude all injuries (See Injuries and Adverse Effects Welts, except hives (2825.0) Tumor, skin Module.) 1880.0 Other symptoms referable to skin The following fifth digits should be used with categories 1900-1970 in place of the zero when there is adequate information Excludes: given: Navel problems (1895.0) pain, ache, soreness, discomfort .1 1880.1 Oiliness .2 cramps, contractures, spasms .3 limitation of movement, stiffness, tightness 1880.2 Dryness, peeling, scaliness, .4 weakness swelling (for example, one leg/one ankle; if both roughness .5 legs/ankles code to 1035.1) 1880.3 Wrinkles .6 lump, mass, tumor 1885.0 Symptoms referable to nails 1900.0 Neck symptoms 1885.1 Infected 1905.0 Back symptoms 1885.2 Ingrown 1910.0 Low back symptoms 1885.3 Brittle, breaking, splitting, cracked, 1915.0 Hip symptoms ridged 1920.0 Leg symptoms 1925.0 Knee symptoms 1930.0 Ankle symptoms 1935.0 Foot and toe symptoms

- 1940.0 Shoulder symptoms
- 1945.0 Arm symptoms

1950.0	Elbow symptoms	2015.0	Viral diseases
170010		201010	
1955.0	Wrist symptoms		Includes:
			Chickenpox
1960.0	Hand and finger symptoms		Genital warts
	Includes:		German measles (rubella)
	Ring stuck on finger		Hepatitis (infectious and NOS)
			Herpes simplex
1965.0	Symptoms of unspecified muscles		Human Papillomavirus (HPV)
			Infectious mononucleosis
1970.0	Symptoms of unspecified joints		Measles
			Meningitis, Viral
1975.0	Musculoskeletal deformities		Mumps
	Includes:		Plantar's warts
	Crooked back		Poliomyelitis
	Hammer toe		PPS
			Rabies
	Excludes:		Respiratory syncytival virus (RSV)
	Clubfoot (2960.0)		Shingles (Herpes zoster)
	Curvature of spine (2910.0)		Smallpox, NOS
			Venereal warts
	1975.1 Bowlegged, knock-kneed		Verruca
	1975.2 Posture problems		2015.1 Human immunodeficiency virus (HIV) with or without associated conditions
	1975.3 Pigeon-toed, feet turn in		(),
	6		Includes:
1980.0	Other musculoskeletal symptoms		Acquired immunodeficiency
	j I		syndrome
	Includes:		AIDS
	Bone pain		AIDS-like syndrome
	Stump pain		AIDS-related complex
			ARC
			HIV positive
	DISEASE MODULE		in (positive
			Excludes:
			Results, follow-up of test for
INFECT	TIVE AND PARASITIC DISEASES (2001-2099)		HIV (6106.0)
2005.0	Intestinal infectious diseases		2015.2 Hemorrhagic fevers
	Includes:		Includes:
	Cholera		Botulism
	Dysentery		Ebola
	Enteritis		Fever, Hemorrhagic
	Gastroenteritis		Marburg
	Giardia		Marburg
	Salmonella	2020.0	Sexually transmitted diseases
	Sumonena	2020.0	Sexually transmitted diseases
2010.0	Streptococcal infection		Includes:
			Chlamydia
	Includes:		Gonorrhea
	Streptococcal tonsillitis		Syphilis
	Scarlet fever		
		2025.0	Fungus infections (mycoses)

Includes: Athlete's foot Candidiasis monilia Dermatophytoses Moniliasis Ringworm Thrush Tinea Yeast infection

PAGE 185

2030.0	Parasitic diseases	2120.0	Cancer, female genital tract
	Includes:		
	Ascaris		Includes:
	Leeches		Cervix
	Lice		Endometrium
	Maggots		Fallopian tube(s)
	Pinworms		Ovary(ies)
	Scabies		Uterus
	Seables		Vagina
2031.0	Songia contigomia		Vagna Vulva
2031.0	Sepsis, septicemia		vuiva
2035.0	Other and unspecified infectious and parasitic diseases	2125.0	Cancer, male genital tract
	Includes:		Includes:
	Bacterial infection		Epididymitis
	Behcet's syndrome		Penis
	Cattleman's disease		Prepuce (foreskin)
	E. Coli		Prostate
	Food poisoning, NOS		Scrotum
	Lyme disease		Spermatic Cord
	PCP (pneumocystis carinii)		Testes
			Testes
	Plague	2126.0	Company of an in any tract
	Staphylococcal infections	2126.0	Cancer of urinary tract
	Trichomonas vaginitis		
	Tuberculosis		Includes:
	Tularemia		Bladder
			Kidney
NEOPL	ASMS (2100-2199)		Renal pelvis
			Ureter
<u>Malignar</u>	nt neoplasms:		Urethra
2100.0	Cancer, gastrointestinal tract	2130.0	Other malignant neoplasms
	Includes:		Includes
	Colon		Includes:
			Bone cancer
	Esophagus		Metastatic carcinoma
	Liver		Brain tumor
	Small intestine		Carcinoma-in-situ, NOS
	Stomach		
2105.0	Cancer, respiratory tract	2135.0	Hodgkin's disease, lymphomas, leukemias
2105.0	Cancer, respiratory tract		Includes:
	Includes:		
			Cancer of blood
	Bronchus		Lymphosarcoma
	Larynx		Multiple myeloma
	Lung		Polycythemia vera
	Throat		
	Trachea	<u>Benign a</u>	nd uncertain nature neoplasms:
2110.0	Cancer, skin and subcutaneous tissues	2140.0	Fibroids and other benign uterine neoplasms
		2110.0	Includes:
	Includes:		Cervical polyp
	Basal cell carcinoma		Leiomyomata
	Melanoma		
			Myoma Nahathian ayat
	Squamous cell carcinoma		Nabothian cyst
2115.0	Cancer, breast		
2110.0	Current, Dicust		

2145.0	Other benign neoplasms Includes:	2215.0	Other endocrine, nutritional, metabolic and immu diseases (cont.)
	Bartholin's cyst Dermoid cyst (ovary)		Overian dysfunction
	Hemangioma		Ovarian dysfunction Poor nutrition
	Lipoma		Sugar reaction (if due to drug, code
	Nasal polyp		59050)
	Nevus		Wilson's syndrome
	Ovarian cyst		wilson's syncholic
	Rectal polyp	DISFAS	SES OF THE BLOOD AND BLOOD-FO
	Vaginal inclusion		NS (2250-2299)
	Vocal cord	OKOIII	
		2250.0	Anemia
	Excludes:	2250.0	/ monna
	Cyst, NOS (1855.0)		Includes:
	Epidermoid cyst (2825.0)		Anemia, NOS
	Pilonidal cyst (2825.0)		Iron deficiency anemia
	Sebaceous cyst (2825.0)		Pernicious anemia
	Sebaccous cyst (2825.0)		Sickle cell anemia
2150.0	Neoplasm of uncertain nature		Siekle een allenna
2150.0	Includes:	2255.0	Other diseases of blood and blood-forming organ
		2233.0	Includes:
	Myelodysplasia		
	Plasmacytoma		Hemophilia HS Durpure
	Englisher		HS Purpura
	Excludes:		Pancytopenia
	Brain tumor (2130.0)		Thrombocytopenia
ENDOCI	DINE NUTDITIONAL METADOLICAND		von Willebrand's disease
	RINE, NUTRITIONAL, METABOLIC AND	MENTA	L DISODDEDS (2200 2240)
INIMUN	ITY DISEASES (2200-2249)	NIEN I A	AL DISORDERS (2300-2349)
2200.0	Disassas of the thread aland	2300.0	Organia navahasas
2200.0	Diseases of the thyroid gland	2500.0	Organic psychoses
	T 1 1		Includes:
	Includes:		Alcoholic psychoses
	Goiter		Drug withdrawal
	Hyperthyroidism		Organic brain syndromes
	Hypothyroidism		Senile dementia
	Myxedema		
	Thyroid nodule	2205.0	
	Thyrotoxicosis	2305.0	Functional psychoses
2201.0			I l. d
2201.0	Diabetic skin ulcer (wound check)		Includes:
2205.0			Autism Director disease
2205.0	Diabetes mellitus		Bipolar disease
2210.0	Gout, hyperuricemia		Depression, Major
2215.0	Other endocrine, nutritional, metabolic and immunity		Manic-depressive psychoses
	diseases		Paranoid states
	Includes:		Psychosis, NOS
	Amyloidosis		Schizophrenia, all types
	Barter's Syndrome		
	Calcium deficiency	2310.0	Neuroses
	Cystinosis		
	Disorders of intestinal absorption		Includes:
	Electrolyte imbalance		Anxiety reaction
	Female hormone deficiency		Depressive neurosis
	Hematochromatosis		Depressive reaction
	HL, elevated		Neurosis, NOS
	Hormone imbalance		Obsessive compulsive neurosis
	Hypercholesterolemia		
	Hyperlipidemia		Excludes:
	Hypoglycemia		Anxiety (1100.0)
	Impaired immune system		Depression (1110.0)
	Iron deficiency		
	Low blood sugar		
	Malnutrition		

PAGE 187

inity

also

RMING

2315.0	Personality and character disorders	2370.0	Other and unsp (cont.)	pecified diseases of the nervous system
2320.0	Alcoholism			Phantom leg/limb pain
	Includes:			Reflex sympathetic dystrophy
	Alcohol dependence			Thoracic outlet syndrome
	Excludes:		J	Fourette's syndrome
	Adverse effect of alcohol (5915.0)	DISEAS	ES OF THE EY	Е (2400-2449)
	Alcohol abuse (1145.0)			· · · ·
	Alcohol-related problems (1145.0)	2400.0	Inflammatory of	diseases of the eye
2321.0	Davis demondence		In	cludes:
2321.0	Drug dependence			Blepharitis
	Includes:			Conjunctivitis
	Drug addiction			Ophthalmia
	Nicorette dependency			ritis
				Keratitis (includes sicca)
	Excludes: Abnormal drug usage (1150.0)			Sty Ulcer
	Adverse effect of drug abuse (5910.0)		(licer
	Overdose, intentional (5820.1)		Ex	xcludes:
			Ι	infection, NOS (1315.0)
2325.0	Mental retardation			
2220.0		2405.0	Refractive erro	or
2330.0	Other and unspecified mental disorders		In	aludas
	Includes:			cludes: Anisometropia
	Adolescent adjustment reaction			Astigmatism
	Attention deficit disorder (ADD)			Hyperopia, farsightedness
	Attention deficit hyperactivity disorder		Ν	Myopia, nearsightedness
	(ADHD)		1	Presbyopia
	Note: Use additional code (1125.0) for		Б	
	hyperactivity. Bruxism			xcludes: Fest for refractive errors (3230.0)
	Dyslexia, Mental		1	Test for remactive errors (3230.0)
	Eating disorder	2410.0	Cataract	
	Grief reaction			
	Sexual deviations	2415.0	Glaucoma	
	Transient situational disturbances			Includes:
	2330.1 Attention deficit disorder			Glaucoma suspect Hypertensive ocular disease
				Increased ocular pressure
DISEASI	ES OF THE NERVOUS SYSTEM (2350-2399)			
		2420.0	Other diseases	of the eye
2350.0	Multiple sclerosis		In	aludaa
2355.0 2360.0	Parkinson's disease (paralysis agitans) Epilepsy			cludes: Amaurosis fugax
2365.0	Migraine headache			Amblyopia
2370.0	Other and unspecified diseases of the nervous system			Aphakia
				Color blindness
	Includes:			Dacrocystitis
	Acute lateral sclerosis			Esotropia
	Alzheimer's disease Bell's palsy			Exotropia Krukenberg's spindle
	Carpal tunnel syndrome			Macular degeneration
	Cerebral palsy			Macular hole
	Demyelinating disease		I	Pterygium
	Guillain-Barre			Retinal detachment
	Meningitis		5	Strabismus
	Morton's neuroma Muscular dystrophy	DICEAC	ES OF THE EA	P (2450-2499)
	Myasthenia gravis	DISEAS	LO OF THE LA	AR (2730-2477)
	Narcolepsy	2450.0	Otitis media	
	Neurofibromatosis			
	Neuropathy			
	Paralysis, NEC			

Ventricular tachycardia

2455.0	Other diseases of the ear	2525.0	Cerebrovascular disease Includes:		
	Includes:		Carotid stenosis		
	Abscess		Cerebral arteriosclerosis		
	Labyrinthitis		Cerebral hemorrhage		
	Meniere's disease		Cerebral stenosis		
	Ruptured tympanic membrane		Cerebrovascular accident (CVA)		
			Stroke		
	Excludes:		TIA		
	Deafness (1345.1)				
	Infection, NOS (1355.2)	2530.0	Atherosclerosis		
		200010	Includes:		
DISEAS	ES OF THE CIRCULATORY SYSTEM (2500-2599)		Arteriosclerosis Hardening of the arteries		
2500.0	Rheumatic fever and chronic rheumatic heart disease		6		
	Includes:		Excludes:		
	Chorea		Cerebral arteriosclerosis (2525.0)		
2505.0	Hypertension with involvement of target organs	2535.0	Phlebitis, thrombophlebitis		
200010	Includes:	200010	Includes:		
	HCD		Phlebothrombosis		
	HCVD		T medounomoosis		
	Hypertensive cardiovascular disease	2540.0	Varicose veins		
	Hypertensive eardiovasedial disease	2540.0	variose venis		
	Pulmonary hypertension	2545.0	Hemorrhoids		
	Renal hypertension	2545.0	Includes:		
	Renai hypertension		Perineal tags		
2510.0	Hypertension, hypertensive		I etilleat tags		
2510.0	Includes:	2550.0	Other disease of circulatory system		
		2550.0	Includes:		
	High blood pressure				
2515.0	Ischemic heart disease		Aneurysm		
2515.0	Includes:		Artery diseas Blood clots		
	Angina pectoris Arteriosclerotic cardiovascular disease		Pulmonary embolism		
			Heart disease, NOS		
	(ACVD) Artorica claratic heart disease (ASHD)		Infarct(s), NOS		
	Arteriosclerotic heart disease (ASHD)		Lymphadenonathy		
	Coronary		Lymphadenopathy		
	Coronary artery disease		Lymphedema		
	Heart attack		Postphlebitic syndrome		
	Ischemic cardiomyopathy		Raynaud's disease		
	Myocardial infarction		Stasis dermatitis		
2520.0	Other hand discourse		Temporal arteritis		
2520.0	Other heart disease		Vasculitis		
	Includes:		Venous insufficiency		
	Aortic valve stenosis	DICEAC			
	Arrhythmia, NOS	DISEAS	ES OF THE RESPIRATORY SYSTEM (2600-2649)		
	Atrial fibrillation	2600.0			
	Cardiac arrhythmia	2600.0	Upper respiratory infections except tonsillitis		
	Cardiac dysrhythmias				
	Cardiomyopathy		Includes:		
	Cardiomyopathy (congestive)		Croup		
	Congestive heart failure		Laryngitis		
	Cor pulmonale		Pharyngitis		
	Heart failure		Rhinitis		
	Heart murmur		Sinusitis		
	Mitral valve prolapse				
	Mitral valve regurgitation		Excludes:		
	Paroxysmal tachycardia		Allergic rhinitis (2635.0)		
	Premature ventricular contractions		Cold (1445.0)		
	(PVCs)		Nose infection, NOS (1405.3)		

Cold (1445.0) Nose infection, NOS (1405.3) Sinus infection, NOS (1410.2) Throat infection, NOS (1455.3)

2605.0

2610.0

2620.0

2625.0

2630.0

2635.0

2640.0

Tonsillitis 2660.0 Hernia of abdominal cavity Includes: Bronchitis Abdominal Includes: Femoral Acute bronchitis Hiatus Bronchitis, NOS Inguinal Chronic bronchitis Umbilical Ventral Emphysema Asthma 2665.0 Diseases of the intestine and peritoneum Pneumonia Includes: Includes: Abscess, rectal Adhesions (abdominal or NOS; if states Bacterial pneumonia Bronchopneumonia post-op, code 42050 also) Crohn's disease Pneumonitis Viral pneumonia Diverticulitis Diverticulosis Hay fever Fissure - rectal, anal Fistula - rectal, anal Includes: Ileitis Allergic rhinitis Irritable bowel syndrome Allergy to: Proctitis Small bowel obstruction Dust Pollen Spastic colitis Ulcerative colitis Animals Ragweed Nasal allergy Excludes:

Intestinal virus (1540.0)

2670.0 Diseases of the liver, gallbladder, and pancreas

> Includes: Biliary colic Cholecystitis Cholelithiasis (gallstones) Cirrhosis Liver diseases Pancreatitis

2675.0 Other diseases of digestive system, NEC Includes: Mandibular cyst

> 2675.1 Dental abscess 2675.2 Dental cavities 2675.3 Canker sore 2675.4 Stomatitis 2675.5 Temperomandibular joint (TMJ) pain, Temperomandibular joint (TMJ) syndrome

DISEASES OF THE GENITOURINARY SYSTEM (2700-2799)

2700.0Cystitis

> Excludes: Bladder infection (1665.2)

Includes:

Other respiratory diseases

Bronchiolitis Bronchospasm Chronic obstructive pulmonary disease Deviated nasal septum Hemothorax Other respiratory problems Pleurisy Pneumothorax Pulmonary edema Respiratory failure SARS

DISEASES OF THE DIGESTIVE SYSTEM (2650-2699)

Pollenosis

2650.0 Diseases of the esophagus, stomach, and duodenum

> Includes: Barrett's esophagus Duodenal ulcer Esophageal ulcer Esophagitis Gastritis GERD Peptic ulcer Reflux Stomach ulcer

Excludes: Gastroenteritis (2005.0) Stomach flu (1540.0)

2655.0 Appendicitis, all types

2705.0 Urinary tract disease except cystitis

Includes: Bladder stones Glomerulonephritis Glomerulonephrosis Kidney cyst Kidney stones Neurogenic bladder Pyelonephritis Renal failure Ureteral calculus Urethritis Urolithiasis

Excludes: Bladder infection (1665.2) Kidney infection, NOS (1670.2) Passed stones (1680.0) Urinary tract infection (1675.0)

2710.0 Diseases of the male genital organs

> Includes: Benign prostatic hypertrophy (BPH) Epididymitis Hvdrocele Peyronie's disease Phimosis Prostatitis

Excludes: Prostate infection (1710.2)

2715.0 Fibrocystic and other diseases of breast

> Includes: Abscess Mastitis

Excludes: Cancer (2115.0) Infection (1810.0)

2720.0 Pelvic inflammatory disease (PID)

> Includes: Oophoritis Pelvic peritonitis Salpingitis

Excludes: Pelvic infection, NOS (1775.3)

2725.0 Cervicitis, vaginitis

> Includes: Cervical erosion Vulvovaginitis

2730.0

2735.0

2736.0

2800.0

2805.0

Includes: Cervical dysplasia Cystocele Dysfunctional uterine bleeding Endometriosis Polycystic ovaries Procidentia uteri Prolapse of uterus Rectal-vaginal fistula Rectocele Vulvitis Diagnosed complications of pregnancy and puerperium (Double code when possible, for example Htn 2510.0 and pregnant 2735.0) Do not code with 3205.0 Includes: Advanced maternal age (if age<35, use 3205.0) Diabetes during pregnancy Ectopic pregnancy Edema of pregnancy Fetal death in utero Gallstones High blood pressure during pregnancy High risk pregnancy Hyperemesis Intrauterine growth retardation (IUGR) Miscarriage (if patient is pregnant) Multiple pregnancy Placenta previa Post dates Previous C-Section RH sensitization Spontaneous abortion Threatened abortion Toxemia, Adolescent Twins Young maternal age Excludes: Abortion induced (3520.0) Other diseases of the genitourinary system, NEC DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE (2800-2899)Carbuncle, furuncle, boil, cellulitis, abscess, NEC Impetigo

- 2810.0 Seborrheic dermatitis Includes: Dandruff
- 2815.0 Eczema and dermatitis, NOS Includes: Allergic dermatitis
- 2820.0 Psoriasis Includes: Psoriatic Arthritis

2825.0 Other diseases of the skin

Includes: Allergic skin reactions Epidermal inclusion cyst Folliculitis Hidradenitis Hives Keloid Keratosis Lupus erythematosus, NOS Paronychia Pilonidal cyst Poison ivy Poison oak Pressure ulcer Rosacea Sebaceous cyst Urticaria

Excludes: Acne (1830.0) Cyst, NOS (1855.0)

DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE (2900-2949)

2900.0 Arthritis

Includes: Osteoarthritis Rheumatism, NOS Rheumatoid arthritis Septic

2905.0 Nonarticular rheumatism

Includes: Bursitis Ganglion cyst Lumbago Myositis Polymyalgia theumatica Radiculitis/Radiculopathy Synovitis Tendinitis Tenosynovitis

Excludes: Rheumatism, NOS (2900.0)

2910.0 Other musculoskeletal or connective tissue disease Includes: Baker's cyst Bone cysts Bone spur Bunions Cervical myelopathy Curvatures of spine Degenerative disc diseases Dupuytren's contracture Exostosis Kyphoscoliosis Kyphosis

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

2910.0 Other musculoskeletal or connective tissue disease (cont.)

Osteomyelitis Osteoporosis Paget's Plantar fistula Scleroderma Scoliosis Sjogen's Slipped disc Spondylosis Spur, NOS Systemic lupus erythematosus

CONGENITAL ANOMALIES (2950-2979)

- 2950.0 Congenital anomalies of heart and circulatory system
- 2955.0 Undescended testicles

Includes: Hypospadias

2960.0 Other and unspecified congenital anomalies

Includes: Absence of organs Blocked tear duct Cleft palate Cleft lip Clubfoot Congenital dislocation of hip Deformed earlobe Down syndrome Duplication of organs Dysmorphic Harelip Mitochondrial disorders Turner's Syndrome

PERINATAL MORBIDITY AND MORTALITY CONDITIONS (2980-2999)

2980.0 Prematurity

Includes: Late effects of prematurity Premature infant

2990.0 All other perinatal conditions

DIAGNOSTIC, SCREENING, AND PREVENTIVE MODULE

GENERAL EXAMINATIONS (3100-3199)

3100.0 General medical examination

Includes: Annual exam Checkup, NOS Checkup, routine

3100.0	General medical examination (cont.)	3225.0	Gynecological examination
	Englished NOS		Includes:
	Evaluation, NOS General exam		Pelvic exam
	Healthy adult		Excludes:
	Healthy child (includes 1 year and older)		Examination for birth control
	History and physical (H&P)		medication (3505.0)
	Multiphasic screening exam		Examination for birth control, NOS
	Nursing home visit		(3500.0)
	Physical exam		Examination involving IUD (3510.0)
	Preventive		Repeat or abnormal Pap smear
	Regular exam		(6300.0)
	Routine exam		()
	Welcome to Medicare	3230.0	Eye examination
	Excludes:		Includes:
	Administrative exam (7100.0-7140.0)		Check contacts
	Followup visit (4800.0)		Check glasses
	Gynecological exam (3225.0)		For contacts
	Health care maintenance (under 1 year)		For glasses
	Pre-op exam (4200.0)		Glasses, NOS
	Prenatal exam (3205.0)		Grid
	Progress visit (4800.0)		Need new glasses
2105.0			No change in vision
3105.0	Well baby examination (any child under 1 year of		Routine ophthalmologic exam
	age)		Test for nearsightedness, farsightedness
3130.0	General psychiatric or psychological examination		To test my eyes Vision about the same
5150.0	(mental health)		Vision stable
	(mental heatin)		Vision test
	Includes:		Vision test Visual field test
	Psychological testing		visual field test
	i sjenological testing		Excludes:
	Excludes:		Fitting glasses or contacts (4515.0)
	Court- or school-ordered examination		
	(7140.0)	3235.0	Heart examination
OPECIA	E EX A MANI A DECINICI (2000-2000)		In the design
SPECIA	L EXAMINATIONS (3200-3299)		Includes: Cardiac care
3200.0	Pregnancy, unconfirmed		Cardiac checkup
5200.0	r regnancy, uncommed		Heart checkup
	Includes:		Teur checkup
	HCG	3240.0	Other special examination
	Late menses Icode 4800.0 if followup		F
	indicated)		Includes:
	Late menstruation		AICD check
	Might be pregnant		Check tubes
	Missed period		Examination of functioning internal
	Period late		prosthetic devices: implants,
	Possible pregnancy		stents, shunts, etc.
	Pregnancy test		Hearing aid
			ICD check
3205.0	Prenatal examination, routine		Neurological exam
			Pacemaker check
	Includes:		Thyroid
	Normal antepartum visit		
	Pregnancy, NOS	DIAGNO	OSTIC TESTS (3300-3399)
	Routine obstetrical care	2200.0	Sonsitization test
2215.0	Doctroritum examination routing	3300.0	Sensitization test
3215.0 3220.0	Postpartum examination, routine Breast examination		Includes:
5220.0	Excludes:		Allergy test
	Breast thermography (3340.0)		Excludes:
	Mammography (3340.0)		To check results of skin tests (6600.0)
	Xerography (3340.0)		To encer results of skin tests (0000.0)

3305.0	Skin immunity test Includes:	3330.0	Diagnostic endoscop	ies
	PPD test		Includes	:
	Tuberculin test		Arthros	
			Cystos	
	Excludes:		Laparo	
			Proctos	
	To check results of skin tests (6600.0)			
2210.0			Siginoi	idoscopy
3310.0	Glucose level determination (Hgb A1C-			
	glycosolated hemoglobin)	3335.0	Biopsies	
		3340.0	Mammography, xero	graphy, breast thermography
	Includes:			
	Blood sugar test		Exclude	s:
	Check sugar		Breast	examination (3220.0)
	Glucose tolerance test			
	Test for diabetes	3345.0	Diagnostic radiology	
3314.0	Human immunodeficiency virus (HIV) test		Includes	:
	• • •		Angiog	gram/angiography
	Includes:		Bone d	
	AIDS test		Bone s	•
			CT sca	
	Excludes:			osalpingogram
	To check results of human		IVP	osaipingogram
	immunodeficiency		MRI	
	•			
	virus test (6106.0)		Myelog	
2215.0				sotope scanning
3315.0	Other blood test		Venog	ram
	Includes:		X-ray	
	Blood alcohol			
	Blood count	3350.0		ardiogram, treadmill, stress testing,
	Blood culture		holter monitor	
	Blood test, NOS			
	Blood thinning test	3355.0	EEG, electroencepha	logram
	CBC			
	Check cholesterol	3360.0	Hearing test	
	Prothrombin time			
	PSA		Includes	:
	Sickle cell anemia test		Hearin	g exam
	Excludes:	3365.0	Pap smear	
	Premarital blood test (7135.1)		Includes:	
			Anal pa	ıp
	3315.1 Blood test for sexually			
	transmitted disease	3366.0	Nasal swab	
3320.0	Blood pressure test	3370.0	Other and unspecifie	d diagnostic tests
	Includes:		Includes	
	Blood pressure check			centesis
	Check blood pressure		Centes	
			Cervici	
3325.0	Urine test		Drug s	creening
			Echoca	urdiogram
	Includes:		Electro	nic fetal monitoring
	Estriol for fetal evaluation		Exposu	are to PID
	Test urine for sugar		Lab tes	st, NOS
	Urinalysis		Pulmor	nary function test
	Urine culture		Spinal	tap
			Ultrasc	1
			3370.1	Glaucoma test
				Includes:
				ATN check
				Check intraocular pressure
				-

3370.0	Other and unspecified diagnostic tests (cont.) 3370.2 Throat culture	FAMIL	Y PLANNING (3500-3599)
		3500.0	Family Planning, NOS
	3370.3 Heart catheterization		To also do co
	2270 4 Other outputs		Includes: Birth control. NOS
	3370.4 Other cultures		
	Includes:		Counseling, examinations,
	Skin		and general advice
			regarding:
OTHER	SCREENING AND PREVENTIVE PROCEDURES		Genetics
(3400-34)			Preop/counseling for vasectomy Sterilization
2400.0			Fertility, NOS
3400.0	Prophylactic inoculations		Unwanted pregnancy, contraceptive, NOS Excludes:
	Includes:		Procedures performed [See Counseling
	Flu shot		and examinations for pregnancy
	F/U vaccine		interruption (3515.0) through Artificial
	Immunization		insemination (3530.0)]
	Influenza shot		Specified types of birth control:
	HPV (Human Papillomavirus) vaccine		Birth control medication
	Rhogam		(3505.0)
	Tetanus shot		IUD (3510.0)
	Vaccination	3505.0	Contragentive medication
3405.0	Exposure to sexually transmitted disease (STD)	3505.0	Contraceptive medication
5105.0	Exposure to sexually transmitted disease (51D)		Includes:
	Includes:		Depo Provera
	Check for STD		Examinations, instructions, and advice
	May have STD		regarding:
	Concerns about or exposure to HPV		Birth control pills
	(Human Papillomavirus)		Contraceptive implants
			Foams, jellies
3408.0	Possible HIV		Oral contraceptives
			Renewing pill prescription
3409.0	Exposure to human immunodeficiency virus (HIV)		Norplant checkup
			Norplant insertion/removal (also code
	Includes:		4520.0)
	Exposed to AIDS	2510.0	
3410.0	Exposure to other infectious diseases	3510.0	Contraceptive device
5410.0	Exposure to other infectious diseases		Includes:
	Includes:		Diaphragm insertion, removal, checkup
	Chickenpox		IUD insertion, removal, checkup
	Infectious hepatitis		10D insertion, removal, encekup
	Measles	3515.0	Counseling and examinations for pregnancy
	Mumps	5515.0	interruption
	Pathogens		interruption
	Tuberculosis		Includes:
			Evaluation for an arrangement for
3415.0	Exposure to bodily fluids of another person, NOS		abortion
			Wants abortion
	Includes:		
	Blood exposure	3520.0	Abortion to be performed (at this visit)
	Exposure to another's secretions		
		3525.0	Sterilization and sterilization reversal to be performed (at this visit)
			Includes:
			Male - vasectomy
			Family tabal listics

Female - tubal ligation

3530.0 Artificial insemination (at this visit) Includes: Assisted reproductive technologies Fetal reduction Infertility treatment Intrauterine insemination In vitro fertilization 3535.0 Preconception counseling and education Includes: Counseling, examinations, and general advice regarding: Artificial insemination Desires pregnancy Egg donor Infertility Monitoring cycles Semen analysis Sperm donor Sperm washing Tubal reversal TREATMENT MODULE MEDICATIONS (4100-4199) 4100.0 Allergy medication Includes: Allergy shots Allergy treatments

Excludes: Allergy testing (3300.0)

4110.0 Injections

Antibiotics Fat Hormones Injections, NOS Includes : Iron Lupron Depot Therapeutic use Shots, NOS Steroid Vitamins

Excludes: Allergy shots (4100.0) Botox injection related to cosmetic purpose (4556.1) Cosmetic injections, NOS (4556.0) Immunizations (3400.0) Inoculations (3400.0) Vaccinations (3400.0)

4111.0 Noncompliance with medication therapy

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

4115.0 Medication, other and unspecified kinds

Includes: Antibiotics, NOS Check medication Drug studies For medication Hormone refill Medication for pain Oral Placebo effect Prescribe medication Renew prescription Request prescription Request scripts Scripts

Excludes: Antibiotic medication injections (4110.0) Birth control medication (3505.0) Eyeglass prescription (see Eye examination (3230.0) and Fitting glasses and contact lenses (4515.0))

PREOPERATIVE AND POSTOPERATIVE CARE (4200-4299)

4200.0 Preoperative visit for specified and unspecified types of surgery

> Includes: Discuss any surgery Discussion of cosmetic surgery Pre-op examination Surgical consultation

4205.0 Postoperative visit

Includes: Check graft Check implant Check shunt Check stoma Check surgical wound Clotted graft/shunt Endoscopy follow-up F/U Endoscopy (immediate post-op care) Postop care Postop pain (code 1060.1 first) Postop suture removal (code suture removal first) Suture removal follow-up

Excludes:

Complications of surgical or medical procedures and treatments (5930.0)

SPECIFIC TYPES OF THERAPY (4400-4499)

4400.0	D11		
4400.0	Physical	medicine and	rehabilitation

Includes: Back adjustment Cardiac rehabilitation Heat therapy Hydrotherapy Occupational therapy Physical therapy Pulmonary rehabilitation Recreational therapy Speech therapy Therapeutic exercises Vocational rehabilitation

4401.0 Cardiopulmonary resuscitation (CPR)4405.0 Respiratory therapy

Includes: Asthma treatment Inhalation therapy Inhaler/breathing treatment

4410.0 Psychotherapy

Includes: Psychoanalysis

4410.1 Group counseling

- Includes: 12 Step programs (e.g., AA, Overeaters Anonymous) Family therapy Group therapy
- 4415.0 Radiation therapy Includes treatment of s/p
- 4420.0 Acupuncture
- 4425.0 Chemotherapy

SPECIFIC THERAPEUTIC PROCEDURES (4500-4599)

- 4500.0 Tube insertion
 - Includes: Chest tube Flushed catheter G-tube PEG, Replacement PICC Port-a-cath placement Trach replacement

Excludes: Flushed urinary catheter 4510.0

4505.0 Cauterization, all sites

4507.0 IV therapy, infusion

4510.0 Urinary tract instrumentation and catheterization

Includes: Flushed urinary catheter Urethral dilation Urinary catheterization

Excludes: Cystoscopy [see Diagnostic endoscopies (3330.0)]

4515.0 Fitting glasses and contact lenses

Includes: Broken or lost glasses or contacts Clean glasses or contacts Pick up glasses or contacts Prescription renewal

Excludes: Eye examination (3230.0)

4518.0 Detoxification

4518.1 Alcohol

4518.2 Drug

4520.0 Minor surgery

Includes: Ear tube removal Ears pierced Joint manipulation Norplant insertion/removal (also code 3505.0) Ring removal Tattoo removal Tube removal

4520.1 Wart removed

4521.0 Major surgery

Includes: Aspiration bone marrow Balloon angiogram Cervical conization Cholecystectomy Laser surgery, eye Lens extraction Liver biopsy Percutaneous transluminal angiogram Polypectomy PTCA (balloon) Pubovaginal sling

4525.0 Kidney dialysis

4529.0 Internal prosthetic devices (fit, adjust, remove) 4560.0 Other specific therapeutic procedures, NEC (cont.) Sclerotherapy Includes: Breast implants Skin rejuvenation TENS unit, NOS Cardiac pacemaker Joint prostheses Ultraviolet treatment VNS Wrinkle reduction Wound care, NOS Excludes: Complications of surgical or medical Excludes: procedures and treatments Pinched nerve (1240.0) (5930.0) 4565.0 Transplants, NOS 4530.0 External prosthetic devices, artificial body parts (fit, adjust, remove) Includes: Stem cell Excludes: Prosthetic complications (5930.0) 4565.1 Complication 4535.0 Corrective appliances Includes: Includes: Fitting and adjusting: Bone marrow Back brace Dental cap, crown 4565.2 Rejection Earplugs Eye patch MEDICAL COUNSELING (4600-4699) Hearing aid Diet and nutritional counseling Jobst or ted stockings 4600.0 59 Leg brace Neck brace Includes: Orthopedic shoes Check weight Walking cane 4604.0 Cast, splint - application, removal Dressing, bandage - application, change, packing Includes: AIDS counseling Irrigation, lavage ARC counseling Suture - insertion, removal transmitting AIDS 4556.0 Cosmetic injection, NOS 4556.1 Botox injection 4605.0 Medical Counseling, NOS Excludes: Therapeutic use (4110.0) Includes: 4556.2 Collagen injection Alcohol 4560.0 Other specific therapeutic procedures, NEC Coordination of care Includes: Disease counseling Adjust device Drug Apheresis Drug rehabilitation Cardioversion Locate advocate Cosmetic Micro-neddling Medical consultation Cryotherapy New patient Cut toe nails Open house Debridement Patient education Earwick Personal problem ECT Enema Referral Epidural Relapse prevention Schedule test or study Eve exercises Second opinion Insulin pump Joint injection Nerve block To meet doctor

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

Failure (includes bone marrow)

Counseling for weight reduction

Human immunodeficiency virus (HIV) counseling

AIDS information, education Worried, concerned about getting,

Questions about condition To learn about a condition Trouble toilet training Wants to talk to doctor

- 4540.0
- 4545.0
- 4550.0
- 4555.0
- Pessary, Change/Clean

Phototherapy

4605.0	Medical Counseling, NOS (cont.)	4725.0	Occupational problems
	4605.1 Family history of cardiovascular disease		Includes: Job dissatisfaction Out of work
	4605.2 Family history of cancer		Problem with boss or coworkers Unable to work
	4605.3 Family history of diabetes	1720.0	Unemployment
	4605.4 Family history of other disease or condition	4730.0	Social adjustment problems Includes:
SOCIAL	PROBLEM COUNSELING (4700-4799)		Discrimination problems
4700.0	Economic problem		Don't have any friends Loneliness Neighborhood and community relations
	Includes:		problems Social indiction
	Can't pay bills Too little income		Social isolation
4702.0	Problem with access to medical care	4735.0	Legal problems
			Includes:
	Includes: Blocked access to medical care		Imprisonment, prosecution Lawsuits, litigation
	Care not covered by insurance		Lawould, highlon
	Insurance problem		4735.1 Police involvement in
	Limited access to medical care		outpatient visit circumstances
4705.0	Marital problems		Includes: Brought in by police
	Includes:		Police called
	Alcoholic spouse Custody battle	4740.0	Other social problems
	Divorce, desertion, separation	4740.0	other social problems
	Marriage counseling, NOS		Includes:
	Premarital counseling Problem with husband, wife		Disabled Disappointment in others Disasters
4710.0	Parent-child problems		[Other person] is drunk Homeless
	Includes:		Housing and clothing problems
	Adopted or foster child		Pregnancy out-of-wedlock
	Concern about childhood behavior Discipline		Problem with boyfriend or girlfriend Problems of aging
	Maturation problems		Relationship problems
	Oppostional defiance	PROGR	
	Working mother Working parent	PROGR	ESS VISIT, NEC (4800-4899)
4715.0	Other problems of family relationship	4800.0	Progress visit, NOS (Use only when the only information given is progress or followup)
	Includes:		Includes: Chronic, NOS
	Aged parents or in-laws		Followup, NOS
	Brother sister difficulty		Getting better
	Divorced parents		I'm better
	Family fights and disruptions Problems with relatives		I'm the same I'm worse
	riotenis will featives		Monthly visit
4720.0	Educational problems		Ongoing treatment, NOS
	Includes: Absenteeism, truancy		Recheck Revisit
	Hates school		Routine followup
	Problems with teachers		Same problems, NOS
	School behavior problems		Touching base

4800.0	Progress visit, NOS (Use only when the only information given is progress or followup) (cont.)	5045.0 5050.0	Hand and fingers Fracture, other and unspecified nd strains:
	Excludes:	•	
	Followup, disease (Code to disease) Followup, injury (Code to injury)	5105.0	Cervical spine, neck Includes:
	Followup, symptom (Code to symptom) Followup, test results (Code to 6100.0-	5110.0	Whiplash Back
	6700.0) General checkup (3100.0) Dector proving following (2005.0)	5115.0	Knee
	Postoperative followup (4205.0) Preventive medicine (3100.0)	5120.0	Ankle
IN	JURIES AND ADVERSE EFFECTS MODULE	5125.0	Wrist
	BY TYPE AND/OR LOCATION (5001-5799)	5130.0	Sprain or strain, other and unspecified
	and dislocations:	Laceratio	ns and cuts:
5005.0	Head and face Includes:	5205.0	Head and neck area Excludes: Face (5210.0)
	Facial bones Jaw Nose Skull	5210.0	Facial area Includes: Eye Ear
5010.0	Spinal column		Forehead Lip Nose
	Back Neck	5215.0	Trunk area
	Vertebrae	5215.0	Includes: Perineum
5015.0	Trunk area, except spinal column Includes:	5220.0	Lower extremity
	Clavicle Collarbone Pelvic scapula Rib		Includes: Ankle Foot
5020.0		5225.0	Upper extremity
3020.0	Leg Includes: Femur Fibula Hip Knee Tibia		Includes: Arm Fingers Hand Wrist
5025.0	Ankle	5230.0	Laceration and cuts, site unspecified
5030.0	Foot and toes	Puncture	wounds:
5035.0	Arm	5305.0	Head, neck and facial area
	Includes: Elbow Humerus	5310.0 5315.0	Trunk area Lower extremity
	Radius Shoulder Ulna	5320.0	Upper extremity

5325.0	Puncture wound, site unspecified	5555.0 Arm 5560.0 Elbow
	Includes:	
Contusio	Needlestick, NOS ns, abrasions, and bruises:	5565.0 Wrist
5405.0	Head, neck, and face	5570.0 Hand and finger(s)
5105.0	Excludes:	5575.0 Injury, multiple or unspecified Includes post-traumatic (NOS) headach
	Eye (5410.0)	(and 1210.0) Foreign body:
5410.0	Eye	5600.0 Eye
	Includes:	
	Black eye Contusion	5605.0 Nose
	Corneal abrasion	5610.0 Skin
5415.0	Trunk area	5615.0 Digestive tract (if choking present, code 15200 first)
	Includes:	Includes: Mouth
	Injury to scrotum	Rectum
5420.0	Lower extremity	Throat
5425.0	Upper extremity	5616.0 Respiratory tract
5430.0	Contusion, abrasion, bruise, site unspecified	5620.0 Other and unspecified sites
Injury, ot	her and unspecified type:	
5505.0	Head, neck, and face	Burns, all degrees:
	Includes:	5705.0 Head, neck, and face Includes eyes
	Post concussive syndrome	
	Tooth fracture Tooth knocked out	5710.0 Trunk area
	Traumatic brain injury (TBI)	5715.0 Extremities
	Excludes:	Includes:
	Loose tooth (no injury) 1500.0	Lower
5510.0	Eye	Upper
5515.0	Back	5720.0 Burn, site unspecified 5750.0 Sunburn, windburn
001010		·····
	Includes: Tail bone	Excludes: Sun poisoning 5920.0
5520.0	Chest and abdomen	Bites:
	Includes: Internal injuries	5755.0 Insect
5525.0	•	Includes:
	Hip	Sting Tick
5530.0	Leg	5760.0 Animal ,snake, human
5535.0	Knee	
5540.0	Ankle	
5545.0 5550.0	Foot and toe(s) Shoulder	

INJURY, NOS (5800-5899)		5830.0	Rape
5800.0	Late effects of an old injury		Includes: Sexual assault
	Includes:		
	Deformities		5830.1 Sexual abuse
5805.0	Scars Motor vehicle accident, type of injury unspecified		Includes:
			Molestation
	Includes: Auto accident	5835.0	Dead on arrival (DOA)
	Car accident	5855.0	Dead on arrival (DOA)
	Motorcycle accident		Includes:
	·		Death
5810.0	Accident, NOS		
			Excludes:
	Includes: Fall, type or location of injury		Cardiac arrest (5837.0)
	unspecified		Cardiopulmonary arrest (5839.0) Respiratory arrest (5836.0)
5815.0	Violence, NOS		
5015.0	violence, ivos	5836.0	Respiratory arrest
	Includes:		
	Abuse		Excludes:
	Beat up		Cardiac arrest (5837.0)
	In a fight		Cardiopulmonary arrest (5839.0)
	Stabbing		Dead on arrival (5835.0) Drowning (5838.0)
	Excludes:		Near drowning (5838.0)
	Violence against oneself (5818.0,		Total drowning (5656.6)
	5820.0)	5837.0	Cardiac arrest
			Includes:
	5815.1 Child abuse or neglect		Code blue
	Excludes:		Excludes:
	Child sexual abuse (5830.1)		Cardiopulmonary arrest (5839.0)
	enna sexual abase (5656.1)		CPR (4401.0)
	5815.2 Battered spouse		Dead on arrival (5835.0)
			Respiratory arrest (5836.0)
	5815.3 Elder abuse	5000 0	
	5815.4 Gunshot wound	5838.0	Drowning
	5815.4 Gunshot wound		Includes: Near drowning
5818.0	Intentional self-mutilation		
		5839.0	Cardiopulmonary arrest
	Includes:		Excludes:
	Self-abuse		Cardiac arrest (5837.0)
	Tried to hurt self		Respiratory arrest (5836.0)
	Excludes:	5840.0	Unconscious on arrival
	Suicide attempt (5820.0)		
5820.0	Suicide attempt		Includes:
	Includes:		Coma
	Found in car with motor running		Found unconscious
	Hanging oneself Slashed wrists		Knocked out Shock
	Code also: Laceration of wrists		Shock
	(5225.0)		Unresponsive
	Stabbed oneself		• · · · · ·
	5820.1 Overdose, intentional		
	Excludes:		
	Unintentional overdose		
	(5910.0)		

5841.0 State of consciousness not specified Includes: Brought in by ambulance Found on floor Verbally unresponsive

5842.0 Altered level of consciousness, NOS

Excludes: Adverse effect of alcohol 5915.0 Adverse effect of drug abuse 5910.0

POISONING AND ADVERSE EFFECTS (5900-5999)

5900.0 Unintentional poisoning

5900.1 Food poisoning NOTE: 5900.1 has been deleted. Food poisoning has been moved to 2035.0, Other and unspecified infectious and parasitic diseases.

> 5900.2 Ingestion, inhalation, or exposure to potentially poisonous products

> > Includes: Heavy metal toxicity Household products Chemicals Drugs Gas Smoke Lead Mace in eyes

5905.0 Adverse effect of medication

Includes:

Allergy to medication Anaphylactic shock Bad reaction to prescribed medication Penicillin allergy Sugar too low (insulin reaction) (Code 2215.0 also)

5910.0 Adverse effect of drug abuse

Includes: Bad trip Combination of drugs and alcohol (nonsuicidal) Drug-induced hallucinations Freaked out on drugs Ingestion of drugs for nonmedicinal purposes Unintentional overdose

Excludes: Intentional overdose (5820.1) 5915.0 Adverse effect of alcohol

5916.0

Includes: Acute intoxication Drunk Intoxication Alcohol poisoning

> Includes: Acute alcohol toxicity Alcoholic stupor Respiratory depression/impairment due to high alcohol level in blood Respiratory distress due to alcohol poisoning/toxicity Nondrug toxic substance poisoning Nonresponsive due to alcohol poisoning/toxicity Unconsciousness due to alcohol poisoning/toxicity

Excludes: Alcohol intoxication (5915.0) Drunkenness (5915.0)

5920.0 Adverse effects of environment

- Includes: Air pollution Frostbite Hypothermia Noise pollution Sun damage Sun poisoning Too hot Water pollution
- 5921.0 Adverse effects of second-hand smoke (Code also symptomatic conditions related to second-hand smoke exposure, for example, bronchitis, emphysema) Includes:

Persons living with heavy smoker Exposure in public buildings Work environment exposure

5922.0 Adverse effects of terrorism and bioterrorism Includes: Anthrax, skin Anthrax, respiratory (inhalation) Bombing Food/water contamination Smallpox

Note: Use an additional code to identify the complaint, symptom, or disease, if any.

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

5925.0	Adverse	effects, other and unspecified Includes:		ESULTS MODULE
		Seasickness	(Inclu	ides all abnormal test results and followups for test results)
5930.0	Complica treatm	ations of surgical or medical procedures and ents	6100.0	For results of blood glucose tests
		Includes: Artificial openings (ostomies, stoma) Catheter Foreign body (accidentally left during surgery e.g. sponge, instrument) Medical complication, NOS Non-healing surgical wound Post-op fever	6105.0	Includes: Abnormal glucose tolerance test Elevated blood sugar Glucose control High blood sugar Hyperglycemia Sugar in blood For results of cholesterol and triglyceride tests
		Post-op hemorrhage (bleeding) Post-op infection or inflammation Post-op sepsis (septicemia) Shunt Tubes		Includes: High cholesterol
		Wound dehiscence Use additional code to identify condition	6106.0	For results of test for human immunodeficiency virus (HIV)
		Such as: UTI (1675.0) Fever (1010.0)		Includes: Results of AIDS test
		Excludes: Postpartum conditions (1791.0 and 1810.2) Complication of transplant organs (4565.1-4565.2)	6110.0	Excludes: History of positive HIV test findings (2015.1) For other findings of blood tests
5935.0	Systemic unspecif SIRS, NO			Includes: Calcium Elevated sed rate Low potassium
	5935.1	Sepsis SIRS due to infectious process without acute organ dysfunction	6200.0	Positive blood culture Positive serology, VDRL PSA results For results of urine tests
	5935.2	Severe sepsis SIRS due to infectious process with acute organ dysfunction Sepsis with acute organ dysfunction Sepsis with multiple organ dysfunction (MOD)	5200.0	Includes: Abnormal urinalysis Positive urine culture Sugar in urine
	5935.3	Systemic inflammatory response syndrome due to noninfectious process without acute organ dysfunction	6300.0	For cytology findings Includes: Abnormal Pap smear
	5935.4	Systemic inflammatory response syndrome due to noninfectious process with acute organ dysfunction		Atypical Pap smear For results of Pap smear of cervix or other area Positive Pap smear Repeat Pap smear
			6400.0	For radiological findings

Includes: Abnormal X-ray X-ray results Xeromammography results

6500.0 For results of EKG, Holter monitor review, abnormal thallium stress test

6600.0	For results of skin te	sts	7130.0	Disability examination
	Includes: PPD re Result	esults s of allergy testing		Includes: Evaluation of disability Social Security examination
6700.0	For other and unspec	ified test results	7131.0 7135.0	Worker's comp exam Premarital examination
	Abnor Abnor Abnor Colond CT sca Failed MRI Result Result To dise	mal EEG mal lab test results, NOS mal scans mal pulmonary function test oscopy results	7137.0	7135.1 Premarital blood test Direct admission to hospital Includes: Admit to hospital Direct admit For admission Here for admission Involuntary commitment Pre admission evaluation Pre admission exam Voluntary commitment
	ADMINISTR	ATIVE MODULE	7140.0	Other reason for visit required by party other than the patient or the health care provider
7100.0	Physical examination employment	n required for school or		Includes:
	7100.1	Physical examination required for employment Includes: Preemployment examination Required company physical Return to work checkup Teacher's certificate physical		Medical certificate Physical certificate Physical examination for adoption Psychiatric examination required by court Travel WIC medical clearance Social worker visit
	7100.2	Executive physical examination		UNCODABLE ENTRIES
	7100.3	Physical examination required for school	8990.0	Problems, complaints, NEC
		Includes: College	8991.0 8993.0	Patient unable to speak English Patient (or patient's spokesperson) refused care
		Day care center Grade school High school Nursery school		Includes: Left AMA Walked out
	7100.4	Physical examination for extracurricular activities Includes: Athletics Boy Scouts or Girl Scouts Camp Little League	8997.0 8998.0	Entry of "none" or "no complaint" Includes: Asymptomatic, NOS Doing well Feeling good Insufficient information
7120.0	Driver's license exan	nination, DOT	8999.0	Illegible entry
7125.0	Insurance examination	on		SPECIAL CODE
			-9	Blank

APPENDIX III

A. GENERIC CODES AND NAMES IN NUMERIC ORDER

This list reflects the new classification being used to code drugs reported in NAMCS. Starting with 2006 data, the Multum Lexicon Plus system was used to classify drugs in NAMCS. Drugs starting with a "d" prefix are those for which a match was found in the Multum Lexicon Plus[®], a proprietary database of Cerner Multum, Inc., and the code reflects the Multum code for the drug. Drugs starting with a "a" prefix are those which were added to the NCHS database in 2006 and 2007 for which a match could not be found in Multum but for which ingredients could be identified. Drugs starting with a "c" prefix are those drugs added to the NCHS database in 2006 and 2007 for which ingredients could not be determined. Drugs starting with "a" or "c" were assigned codes by NCHS. As of 2008 data, new "a" and "c" codes are no longer being used to code drugs in the NCHS database. Starting in 2008, drugs which were added to the NCHS database for which no match could be found in Multum use an "n" prefix. Ingredients are separated by dashes (for two ingredients only) or semi-colons (for three or more ingredients).

a07001 FOLIC ACID;NIACIN;VITAMIN E;PYRIDOXINE;CYANOCOBALAMIN a07002 CHOLECALCIFEROL-CALCIUM CITRATE a07008 ZINC;VITAMINS;FOLIC ACID;POTASSIUM IODIDE;MAGNESIUM AMINO ACIDS CHELATE a07027 CALCIUM;MAGNESIUM;CHOLECALCIFEROL a07033 HIV VACCINE a07035 ANALGESICS: DIETARY SUPPLEMENT: ANTIOXIDANTS a07044 DIETARY SUPPLEMENT-PROTEIN a07047 MUSHROOM EXTRACT a07048 POLIDOCHANOL a07055 4-AMINOPYRIDINE a07065 CURCUMIN a07069 CYANOACRYLATE a07071 TYROSINE a10000 ACACIA GUM; ALOE VERA TOPICAL; GUM GHATTI a10049 BENZYL ALCOHOL; DIMETHICONE; PETROLATUM TOPICAL a10051 BENZYL ALCOHOL; SOYBEAN OIL; STARCH TOPICAL a10067 ASCORBIC ACID;BIOTIN;FOLIC ACID;VITAMIN B COMPLEX;ZINC ACETATE a10068 ASCORBIC ACID; BIOTIN; VITAMIN B COMPLEX a10069 ACETYLCYSTEINE;ALPHA LIPOIC ACID;BIOTIN;CHROMIUM CHLORIDE;THIAMINE a10096 ASPIRIN-BUFFERS a10111 CALCIUM REPLACEMENT-SODIUM FLUORIDE a10114 CALCIUM REPLACEMENT; ERGOCALCIFEROL; PHOSPHORUS a10124 CALCIUM REPLACEMENT-SODIUM PROPIONATE a10125 CALCIUM REPLACEMENT-ERGOCALCIFEROL a10127 CALCIUM REPLACEMENT-CHOLECALCIFEROL a10133 CALCIUM ION;CHLORIDE ION;MAGNESIUM ANTACIDS;POTASSIUM ION;SODIUM ION a10138 CALCIUM ION; IRON PREPARATIONS; MULTIVITAMIN a10140 CALCIUM ION; MAGNESIUM CHLORIDE; POTASSIUM ION; SODIUM CHLORIDE a10143 CALCIUM PANTOTHENATE; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIMEROSAL a10147 CALCIUM PANTOTHENATE;NIACIN;PYRIDOXINE;RIBOFLAVIN;THIAMINE a10150 CANTHARIDIN; PODOPHYLLUM RESIN TOPICAL; SALICYLIC ACID TOPICAL a10155 CARMELLOSE;GELATIN;MINERAL OIL;PECTIN a10156 ALGINIC ACID;BORIC ACID TOPICAL;CARMELLOSE;GLYCERIN TOPICAL;PROPYLENE GLYCOL a10159 CASEIN;COCONUT OIL;CORN OIL;MULTIVITAMIN;SUCROSE a10160 CASEIN;COCONUT OIL;MAGNESIUM AMINO ACIDS CHELATE;SUCROSE;TAPIOCA a10162 CASEIN; CORN OIL; LECITHIN; MULTIVITAMIN; SODIUM ION a10163 CASEIN;MULTIVITAMIN;SAFFLOWER OIL;SOYBEAN OIL;SUCROSE a10172 CETEARETH; PETROLATUM TOPICAL; PROPYLENE GLYCOL; SORBITOL a10176 AMMONIUM LACTATE TOPICAL;CETYL ALCOHOL;GLYCERYL;MINERAL OIL;PARABENS a10227 CAJEPUT;COTTONSEED OIL;EUCALYPTUS OIL;PEPPERMINT;PINE OIL

a10242 DEXTROSE;FRUCTOSE;PHOSPHORIC ACID

a10245 DEXTROSE-POTASSIUM REPLACEMENT SOLUTIONS a10246 DEXTROSE; POTASSIUM REPLACEMENT SOLUTIONS; SODIUM CHLORIDE; SODIUM CITRATE a10249 DEXTROSE-RINGERS LACTATED a10252 DEXTROSE-NORMAL SALINE a10255 DEXTROSE-NUTRITIONAL PRODUCTS a10266 DEXTROSE; POTASSIUM CHLORIDE; STERILE WATER a10267 DEXTROSE-SODIUM CHLORIDE a10279 DEXTROSE-STERILE WATER a10300 ASCORBIC ACID; ELECTROLYTES; MINERALS; VITAMIN B COMPLEX a10304 ELECTROLYTES-POLYETHYLENE GLYCOL 3350 a10312 ETHANOL; EUCALYPTUS OIL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL; THYMOL a10338 GLYCINE-IMMUNE GLOBULIN INTRAMUSCULAR a10340 FENNEL; GLYCYRRHIZA; SENNA; SUCROSE; SULFUR TOPICAL a10362 HYDROCORTISONE TOPICAL; IODOCHLORHYDROXYQUIN; PRAMOXINE TOPICAL a10366 IRON PREPARATIONS; MINERALS; MULTIVITAMIN a10385 ETHINYL ESTRADIOL; IRON PREPARATIONS; NORETHINDRONE a10391 CYANOCOBALAMIN; FOLIC ACID; IRON PREPARATIONS a10392 ASCORBIC ACID;CYANOCOBALAMIN;FOLIC ACID;IRON PREPARATIONS a10435 ASCORBIC ACID-IRON PREPARATIONS a10438 FLUORIDE; IRON PREPARATIONS; MULTIVITAMIN a10439 DOCUSATE-IRON PREPARATIONS a10442 IRON PREPARATIONS-MULTIVITAMIN a10452 LACTOSE-NORETHINDRONE a10453 LACTOSE-MOMETASONE NASAL a10454 EPLERENONE-LACTOSE a10455 LACTOSE-TROSPIUM a10462 ACETAMINOPHEN: ALUMINUM HYDROXIDE: ASPIRIN: CAFFEINE: MAGNESIUM ANTACIDS a10463 ALUMINUM HYDROXIDE; DIPHENHYDRAMINE TOPICAL; LIDOCAINE; MAGNESIUM ANTACIDS a10464 ASPIRIN; CALCIUM CARBONATE; MAGNESIUM ANTACIDS a10465 ALUMINUM HYDROXIDE; ASPIRIN; MAGNESIUM ANTACIDS a10472 ALUMINUM HYDROXIDE;CALCIUM CARBONATE;MAGNESIUM ANTACIDS a10474 ALUMINUM HYDROXIDE-MAGNESIUM ANTACIDS a10475 ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS; SIMETHICONE a10482 GUAIFENESIN; MENTHOL; PARABENS; PHENYLALANINE a10500 ALLANTOIN TOPICAL; ALLIUM CEPA; METHYLPARABEN; POLYETHYLENE GLYCOL 3350; SORBIC ACID a10502 GLYCERIN TOPICAL; METHYLPARABEN; MINERAL OIL; STERILE WATER a10511 MINERALS-VITAMINS a10520 LECITHIN;MALTODEXTRIN;MINERALS;MULTIVITAMIN;WATER a10522 MINERALS; MULTIVITAMIN; SOY FIBER; SOY PROTEIN a10526 ASCORBIC ACID;FOLIC ACID;MINERALS;VITAMIN A;VITAMIN E a10530 MINERALS-MULTIVITAMIN a10537 BENZOCAINE TOPICAL:NUTMEG OIL:PETROLATUM TOPICAL:ZINC TOPICAL AGENTS, EXTERNAL USE a10563 BENZOCAINE TOPICAL;MENTHOL TOPICAL;OXYQUINOLONE;ZINC TOPICAL AGENTS, EXTERNAL USE a10585 METHYCLOTHIAZIDE-PARGYLINE a10588 MINERAL OIL-PEANUT OIL a10623 ASPARTAME; MANNITOL; NICOTINE; PHENYLALANINE a10625 LIVE YEAST CELL: PHENYLMERCURIC NITRATE; SHARK LIVER OIL a10640 POTASSIUM REPLACEMENT SOLUTIONS-SODIUM CHLORIDE a10655 POTASSIUM ACIDIFYING-SODIUM ACID PHOSPHATE a10664 HP GUAR; POLYETHYLENE GLYCOL 3350; PROPYLENE GLYCOL; SODIUM BORATE TOPICAL a10675 GLYCERIN TOPICAL-PROPYLENE GLYCOL a10678 CARBOHYDRATES;MULTIVITAMIN;PROTEIN SUPPLEMENT a10685 PEG-150; QUATERNIUM; SODIUM LAURETH-13 CARBOX; SODIUM TRIDECETH SULFATE a10697 GINSENG;MEADOWFOAM OIL;PETROLATUM TOPICAL;SAFFLOWER OIL;SESAME OIL a10703 GLYCERIN TOPICAL; PETROLATUM TOPICAL; PHENYLEPHRINE TOPICAL; SHARK LIVER OIL a10704 BALSAM PERU TOPICAL; MINERAL OIL; SILICONE; ZINC TOPICAL AGENTS, EXTERNAL USE a10707 SOAP-WATER

a10715 MULTIVITAMIN-SODIUM FLUORIDE a10716 ERTAPENEM;SODIUM BICARBONATE;SODIUM HYDROXIDE a10717 CITRIC ACID;SODIUM CITRATE;SODIUM ION a10726 POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE;SODIUM SULFATE a10729 ALLANTOIN TOPICAL;COAL TAR TOPICAL;SALICYLIC ACID TOPICAL;SQUALENE a10730 HORSETAIL; MANGANESE SULFATE; STEARIC ACID a10737 ETHANOL-SUCROSE a10738 AMPICILLIN-SULBACTIN SODIUM a10747 POLYETHYLENE GLYCOL 3350;SALICYLIC ACID TOPICAL;SURFACTANT a10785 CALCIUM CARBONATE; CHOLECALCIFEROL; VITAMIN K a10816 BALSAM PERU TOPICAL;BENZYL BENZOATE TOPICAL;BISMUTH RESORCIN TOPICAL;BISMUTH SUBGALLATE: ZINC TOPICAL AGENTS, EXTERNAL USE a10818 ETHANOL;SULFUR TOPICAL;ZINC SULFATE;ZINC TOPICAL AGENTS, EXTERNAL USE a10822 CALAMINE TOPICAL:CAMPHOR TOPICAL:MENTHOL TOPICAL:PHENOL TOPICAL:ZINC TOPICAL AGENTS, EXTERNAL USE a10834 CYANOCOBALAMIN;FOLIC ACID;VITAMIN B a10840 ASCORBIC ACID;FOLIC ACID;VITAMIN B COMPLEX;VITAMIN E;ZINC a10849 ASCORBIC ACID;FOLIC ACID;VITAMIN B COMPLEX a10851 ASCORBIC ACID;CHOLECALCIFEROL;VITAMIN A;VITAMIN B COMPLEX;VITAMIN E a10864 CARBOHYDRATES;FAT SUPPLEMENT, ORAL;MAGNESIUM AMINO ACIDS CHELATE; MULTIVITAMIN; PROTEIN a10870 ARGININE: ASCORBIC ACID: CARBOHYDRATES: POTASSIUM CITRATE: VITAMIN E a10873 FOLLICLE STIMULATING HORMONE-LEUTENIZING HORMONE a10874 CHONDROITIN; GLUCOSAMINE; HYALURONIC ACID; METHYLSULFONYLMETHANE a10876 MINERAL OIL-PETROLEUM a10879 PENICILLIN (OBSOLETE)-PENICILLIN G BENZATHINE a10882 DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; VITAMIN E a10893 ARGININE;GLUTAMINE;HMB a10897 HOMATROPINE METHYL BROMIDE-HYDROCODONE a10900 ESTRADIOL-ESTRIOL a10903 ASCORBIC ACID; COPPER GLUCONATE; LUTEIN; VITAMIN E; ZINC a10904 BETA-CAROTENE; BILBERRY; LUTEIN; LYCOPENE; VITAMIN E a10909 ADRENALINE; TETRACAINE TOPICAL; XYLOCAINE a10911 TRIAMCINOLONE-XYLOCAINE a10915 CALCIUM ACETATE;CHOLECALCIFEROL;COPPER GLUCONATE;MAGNESIUM;ZINC a10919 PYRIDOXINE-ZINC a10921 MULTIVITAMIN-ZINC a10922 BLACK COHOSH; BORIC ACID TOPICAL; ISOFLAVONES; KAVA; MULTIVITAMIN a10928 BENZONATATE-PARABENS a10936 BURDOCK ROOT: INDIAN RHUBARB ROOT: SHEEP SORREL: SLIPPERY ELM a10946 BIFIDOBACTERIUM INFANTIS: GLOBULIN PROTEIN: LACTOBACILLUS ACIDOPHILUS a10947 BIFIDOBACTERIUM BIFIDUM;LACTOBACILLUS ACIDOPHILUS;LACTOBACILLUS BULGARICUS;LACTOBACILLUS CASEI;LACTOBACILLUS RHAMNOSUS a10950 CHORIOGONADOTROPIN ALFA; MANNITOL; ORTHOPHOSPHORIC ACID a10956 CHLORPHENIRAMINE-HYDROCODONE POLISTIREX a10961 BUROW'S SOLUTION; CAMPHOR TOPICAL; MENTHOL TOPICAL; PHENOL TOPICAL a10962 BENZOCAINE TOPICAL; BUTYL AMINOBENZOATE; TETRACAINE TOPICAL a10963 ALOE VERA TOPICAL; MENTHOL TOPICAL; SALICYLIC ACID TOPICAL; TEA TREE OIL; VITAMIN E TOPICAL a10968 MINERAL OIL; MINERAL WAX; PETROLATUM TOPICAL; WOOLWAX ALCOHOL a10972 ACETIC ACID TOPICAL; HYDROCORTISONE OTIC; PROPYLENE GLYCOL DIACETATE; SODIUM ACETATE a10973 ALUMINUM HYDROXIDE;DONNATAL;LIDOCAINE;MAGNESIUM HYDROXIDE;SIMETHICONE a10975 DIBASIC SODIUM PHOSPHATE-SODIUM PHOSPHATE a10978 DIPHTHERIA TOXOID; FILAMENTOUS HEMAGGLUTININ; PERTACTIN; PERTUSSIS, ACELLULAR; TETANUS TOXOID a10980 BEESWAX;LANOLIN TOPICAL;PETROLATUM TOPICAL a10982 ZINC CITRATE-ZINC GLUCONATE a10986 MULTIVITAMIN-WHEY a10988 L-METHYLFOLATE; METHYLCOBALAMIN; PYRIDOXINE

a1099	0 ASCORBIC ACID;CALCIUM CHLORIDE;CALCIUM PHOSPHATE, TRIBASIC;MG
- 4 0 0 0	
	91 CHICORY ROOT EXTRACT-LACTOBACILLUS GG
	00 LANOLIN ALCOHOL;MINERAL OIL;PETROLATUM TOPICAL;SODIUM CHLORIDE
	03 ALLANTOIN TOPICAL;CALCIUM LACTATE;CHOLINE BITARTRATE;PORCINE STOMACH
	04 ALOE VERA TOPICAL;BLACK WALNUT;CASCARA SAGRADA;RHUBARB;SENNA
	27 ACETAMINOPHEN-MISCELLANEOUS ANALGESICS
	30 CONTRACEPTIVES-NORETHINDRONE
	31 MISCELLANEOUS UNCATEGORIZED AGENTS-PHENTOLAMINE
	33 ANTISEPTIC AND GERMICIDES-ETHANOL
	42 CIPROFLOXACIN-HYDROCORTISONE
	04 ACETAMINOPHEN;CHLORPHENIRAMINE;PHENYLPROPANOLAMINE;SALICYLAMIDE
	26 BUPIVACAINE-LIDOCAINE
	27 BUPIVACAINE;LIDOCAINE;TRIAMCINOLONE
	29 DIPHENHYDRAMINE-LIDOCAINE
	34 LIDOCAINE-TRIAMCINOLONE
	35 LIDOCAINE-METHYLPREDNISOLONE TOPICAL
	37 ALUMINUM HYDROXIDE;LIDOCAINE;MAGNESIUM HYDROXIDE;SIMETHICONE
	38 EPINEPHRINE TOPICAL;LIDOCAINE;TETRACAINE TOPICAL
	46 GENTAMICIN OPHTHALMIC-PREDNISOLONE
	51 ATROPINE;HYOSCYAMINE;METHENAMINE;METHYLENE BLUE;PHENYL SALICYLATE
	57 METHENAMINE-SODIUM SALICYLATE
	59 HYOSCYAMINE;METHENAMINE;METHYLENE BLUE;PHENYL SALICYLATE;SODIUM BIPHOSPHATE
	53 POLYMYXIN B SULFATE-TRIMETHOPRIM
	66 DORZOLAMIDE OPHTHALMIC-TIMOLOL
	73 EPHEDRINE;PYRILAMINE;THEOPHYLLINE
	00 ASPIRIN;CAFFEINE;CINNAMEDRINE
	98 ATROPINE;CHLORPHENIRAMINE;HYOSCYAMINE;PHENYLEPHRINE;PHENYLPROPANOLAMINE
a1120	06 ALUMINUM HYDROXIDE;ATROPINE;HYOSCYAMINE;PHENOBARBITAL;SCOPOLAMINE
a112 ⁻	16 BUPIVACAINE-TRIAMCINOLONE
a112	59 AMMONIUM CHLORIDE-DEXTROMETHORPHAN
	74 DEXTROMETHORPHAN;DOXYLAMINE;ETHANOL;SODIUM CITRATE
a112	78 ALUMINUM HYDROXIDE; DIPHENHYDRAMINE; MAGNESIUM HYDROXIDE; SIMETHICONE
a1128	34 ETHINYL ESTRADIOL;FERROUS FUMARATE;NORETHINDRONE
a1128	35 FLUOROURACIL;IRINOTECAN;LEUCOVORIN
	36 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN
	21 CYANOCOBALAMIN:FOLIC ACID:PYRIDOXINE

a11291 CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE

a11293 BETAINE;CYANOCOBALAMIN;FOLIC ACID;PYRIDOXINE

a11296 ASCORBIC ACID;CARBONYL IRON;CYANOCOBALAMIN;FOLIC ACID

a11298 FOLIC ACID;MULTIVITAMIN;SODIUM CHLORIDE;THIAMINE

a11303 FOLIC ACID-IRON POLYSACCHARIDE

a11315 INSULIN-INSULIN ISOPHANE

a11319 MANNITOL-PEMETREXED

a11320 AZACITIDINE-MANNITOL

a11325 NEOMYCIN-POLYMYXIN B SULFATE

a11328 BACITRACIN TOPICAL; NEOMYCIN; POLYMYXIN B SULFATE

a11329 BACITRACIN OPHTHALMIC;NEOMYCIN;POLYMYXIN B SULFATE

a11330 BACITRACIN OPHTHALMIC: HYDROCORTISONE OPHTHALMIC: NEOMYCIN: POLYMYXIN B SULFATE

a11331 DEXAMETHASONE OPHTHALMIC; NEOMYCIN; POLYMYXIN B SULFATE

a11332 HYDROCORTISONE OTIC:NEOMYCIN:POLYMYXIN B SULFATE

a11344 HYDROCORTISONE OTIC;NEOMYCIN;POLYMYXIN B OPHTHALMIC

a11345 NEOMYCIN-POLYMYXIN B OPHTHALMIC

a11350 ERGOCALCIFEROL;NIACIN;RIBOFLAVIN;THIAMINE;VITAMIN A

a11354 ASCORBIC ACID;NIACIN;RIBOFLAVIN;THIAMINE;VITAMIN E a11357 CYANOCOBALAMIN;NIACIN;PYRIDOXINE;RIBOFLAVIN;THIAMINE a11360 DEXPANTHENOL;NIACIN;PYRIDOXINE;RIBOFLAVIN;THIAMINE a11383 BELLADONNA-PHENOBARBITAL a11394 BACITRACIN TOPICAL-POLYMYXIN B SULFATE a11396 DEXAMETHASONE OPHTHALMIC; NEOMYCIN OPHTHALMIC; POLYMYXIN B SULFATE a11400 DEXTRAN 1;HYDROXYPROPYL METHYLCELLULOSE OPHTHALMIC;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE a11415 ERGOCALCIFEROL; RIBOFLAVIN; THIAMINE; VITAMIN A; VITAMIN E a11419 ASCORBIC ACID;COPPER GLUCONATE;VITAMIN A;VITAMIN E;ZINC OXIDE TOPICAL a11420 CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; VITAMIN A a11421 CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A a11423 ERGOCALCIFEROL; PYRIDOXINE; RIBOFLAVIN; VITAMIN A a11424 ERGOCALCIFEROL; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A a11429 ASCORBIC ACID; ERGOCALCIFEROL; RIBOFLAVIN; THIAMINE; VITAMIN A a11431 ASCORBIC ACID; CHOLECALCIFEROL; FLUORIDE; VITAMIN A a11434 DEXPANTHENOL TOPICAL; ERGOCALCIFEROL; VITAMIN A; VITAMIN E TOPICAL a11436 CHOLECALCIFEROL-VITAMIN A a11440 ASCORBIC ACID-VITAMIN E a11445 ASCORBIC ACID;CYANOCOBALAMIN;PYRIDOXINE;RIBOFLAVIN a11446 ASCORBIC ACID;CYANOCOBALAMIN;PYRIDOXINE;RIBOFLAVIN;THIAMINE a11447 CYANOCOBALAMIN;L-METHYLFOLATE;PYRIDOXINE;RIBOFLAVIN a11450 CHOLINE; INOSITOL; RIBOFLAVIN; THIAMINE a11458 PANCREATIN-PYRIDOXINE a11461 MAGNESIUM OXIDE-PYRIDOXINE a11465 CYANOCOBALAMIN-THIAMINE a11471 CALCIUM CARBONATE:CALCIUM CITRATE;MAGNESIUM CITRATE;MAGNESIUM OXIDE a11472 CALCIUM CARBONATE-CHOLECALCIFEROL a11473 CALCIUM CARBONATE; MAGNESIUM GLUCONATE; MAGNESIUM OXIDE a11477 FLUORIDE-MULTIVITAMIN a11479 CHONDROITIN;GLUCOSAMINE;MANGANESE SULFATE a11484 BENZALKONIUM CHLORIDE TOPICAL; EDETATE DISODIUM; OCULAR LUBRICANT; SODIUM CHLORIDE;SODIUM PHOSPHATE a11490 POTASSIUM CITRATE-SODIUM CHLORIDE a11493 SODIUM CHLORIDE-STERILE WATER a11499 CITRIC ACID; POTASSIUM BICARBONATE; SODIUM BICARBONATE a11500 GLYCERIN TOPICAL: PHENOL TOPICAL: SODIUM BICARBONATE: SODIUM BORATE TOPICAL a11501 SODIUM BICARBONATE-SODIUM CHLORIDE NASAL a11518 CONJUGATED ESTROGENS-PROGESTERONE a11520 NYSTATIN-TRIAMCINOLONE a11523 NYSTATIN TOPICAL-TRIAMCINOLONE a11524 EDETATE DISODIUM-UREA TOPICAL a11549 EDETATE DISODIUM-RIFAXIMIN a11550 SODIUM POLYSTYRENE SULFONATE-SORBITOL a11558 NAPHAZOLINE OPHTHALMIC-PHENIRAMINE a11576 ANTIPYRINE OTIC-BENZOCAINE TOPICAL a11579 ANTIPYRINE OTIC; BENZOCAINE TOPICAL; GLYCERIN OTIC a11580 BENZOCAINE TOPICAL;CALAMINE TOPICAL;CAMPHOR TOPICAL;MENTHOL TOPICAL a11585 BENZOCAINE TOPICAL-RESORCINOL TOPICAL a11608 BALSAM PERU TOPICAL:BORIC ACID TOPICAL:CASTOR OIL:PETROLATUM TOPICAL:ZINC OXIDE TOPICAL a11610 BARIUM SULFATE-BISACODYL a11614 MINERAL OIL-PETROLATUM TOPICAL a11615 LANOLIN TOPICAL; MINERAL OIL; PETROLATUM TOPICAL a11621 AMMONIUM LACTATE TOPICAL-MINERAL OIL a11631 DIPHTHERIA TOXOID;HAEMOPHILUS B CONJUGATE VACCINE (OBSOLETE);PERTUSSIS, ACELLULAR; TETANUS TOXOID a11632 HEPATITIS A VACCINE (OBSOLETE)-HEPATITIS B VACCINE a11640 COAL TAR-SALICYLIC ACID TOPICAL-SODIUM HYALURONATE OPHTHALMIC a11645 DEXTRAN 1-HYDROXYPROPYL METHYLCELLULOSE OPHTHALMIC a11646 DEXTRAN, LOW MOLECULAR WEIGHT-HYDROXYPROPYL METHYLCELLULOSE OPHTHALMIC

a11648 CHLORHEXIDINE TOPICAL-ISOPROPYL ALCOHOL TOPICAL a11654 FLUOCINOLONE TOPICAL; HYDROQUINONE TOPICAL; TRETINOIN a11664 ALUMINUM SULFATE TOPICAL;CAMPHOR TOPICAL;LACTOBACILLUS ACIDOPHILUS;MENTHOL TOPICAL;SALICYLIC ACID TOPICAL a11685 BENZALKONIUM CHLORIDE TOPICAL-CYANOCOBALAMIN NASAL a11686 ALBUMIN HUMAN-PACLITAXEL a11687 IODINE-IOPAMIDOL a11689 DEXTRAN 1-METHYLCELLULOSE a11692 AMYLASE;LIPASE;PROTEASE a11693 AMYLASE-PAPAIN TOPICAL a11697 NAPHAZOLINE NASAL-PHENIRAMINE a11703 CALCIUM ACETATE-CHOLECALCIFEROL a11705 CALCIUM ACETATE-MULTIVITAMIN a11706 CETYLPYRIDINIUM TOPICAL-ETHANOL a11715 MENTHOL TOPICAL-ZINC OXIDE TOPICAL a11717 BETAMETHASONE TOPICAL-CLOTRIMAZOLE TOPICAL a11724 BACITRACIN TOPICAL; NEOMYCIN TOPICAL; POLYMYXIN B OPHTHALMIC a11727 ACETIC ACID TOPICAL-HYDROCORTISONE OTIC a11730 BUDESONIDE NASAL-FORMOTEROL a11732 LANOLIN TOPICAL-PETROLATUM TOPICAL a11733 LACTOBACILLUS ACIDOPHILUS-PECTIN a11738 CAMPHOR TOPICAL; MENTHOL TOPICAL; PHENOL TOPICAL a11741 CAMPHOR TOPICAL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL a11748 BACITRACIN TOPICAL-POLYMYXIN B OPHTHALMIC

a11750 CHLOROXYLENOL TOPICAL;HYDROCORTISONE OTIC;PRAMOXINE OTIC

a11757 ASCORBIC ACID-CRANBERRY

a11759 CETEARETH; DIMETHICONE; GLYCERIN TOPICAL; HYALURONIC ACID

- a11764 DIPHTHERIA TOXOID;PERTACTIN;TETANUS TOXOID
- a11765 HYDROCORTISONE TOPICAL-LIDOCAINE
- a11768 ACETAMINOPHEN; ETHANOL; GLYCERIN; HYDROCODONE; PARABENS

a50000 UNDETERMINED a50035 ACETONE a50235 AMMONIA SPIRIT AROMATIC a50613 BILE SALTS a50635 BISMUTH ANTI-DIARRHEA a50675 BROMELAINS a50770 CALCIUM REPLACEMENT a50860 CANTHARIDIN a51209 CHROMIUM a51325 COCOA BUTTER a51330 COCONUT OIL a51390 CONTACT LENS SOLUTION a51675 DEXTROSE a51740 DIETARY SUPPLEMENT a51817 DIMETHICONE a52023 ELECTROLYTES a52125 ETHOPROPAZINE a52190 EUCALYPTUS OIL a52395 GELATIN a52535 HAMAMELIS WATER a52640 HYDROCHLORIC ACID a52775 INFANT FORMULA a52885 IRON PREPARATIONS a52968 KELP a52990 LACTOSE a53010 LAVENDER OIL a53025 LEMON OIL a53105 LINSEED OIL a53155 LYPRESSIN a53175 MAGNESIUM ANTACIDS a53298 MEGLUMINE a53315 MENINGOCOCCAL VACCINE a53615 METHYL ALCOHOL a53753 MOLYBDENUM a53940 NITROGEN a54015 OINTMENT HYDROPHILIC a54020 OLEANDOMYCIN a55115 RINGERS LACTATED a55140 SACCHARIN a55145 SAFFLOWER OIL a55210 SESAME OIL a55218 SILICONE a55310 SODIUM CARBONATE a55330 SODIUM FLUORIDE a55335 SODIUM GLUTAMATE a55510 SUCCINLYCHOLINE a55520 SUCROSE a55623 SURFACTANT a55815 THYMOL a56198 VITAMIN K

a56214 WHEAT GERM a56265 ZINC TOPICAL AGENTS, EXTERNAL USE a56340 VITAMIN B a56345 VITAMIN B COMPLEX a56580 POLOXAMER 188 a56740 INTERFERON BETA a57001 BLOOD SUGAR DIAGNOSTIC a57014 ERYTHROPOIETIN a57024 MAGNESIUM ION a57034 PHOSPHORUS a57050 HYDROACTIVE DRESSING a57092 RECOMBINANT HUMAN DEOXYRIBONUCLEASE a57158 TECHNETIUM a57166 PROTEIN a57194 HYPERTONIC SALINE a57204 HEPATITIS C VACCINE a57210 QUERCETIN a59603 HEPATITIS VACCINE a59611 THYROID STIMULATING HORMONE a59615 SOMATOSTATIN a59632 DEHYDROEPIANDROSTERENE a59717 ANDROGENS a59729 MELARSOPROL a59812 DOMPERIDONE a59814 FOLLITROPIN ALPHA a59841 GRAPESEED a70009 HYALURONIC ACID a70010 SEROTONIN a70048 OIL OF EVENING PRIMROSE a70048 OIE OF EVENING FRIMROS a70071 DOCOSAHEXAENOIC ACID a70105 HAWTHORN a70113 PERINDOPRIL ERBUMINE a70116 SOY a70123 BISMUTH a70159 SILVER a70223 FERRIMIN a54020OLEANDOMYCINa70223FERRIMINa54030OLIVE OILa70271SPIRULINAa54175PANTOTHENIC ACIDa70295PUMPKIN SEED OILa54325PERTUSSIS IMMUNE GLOBULINa70327ISOFLAVONESa54555PNEUMOCOCCAL VACCINEa70385SILYBUMa54555POLIO VACCINEa70479BORAGE OILa54655POTASSIUM REPLACEMENT SOLUTIONSa70480ALPHA LIPOICACIDa54740POTASSIUM SODIUM TARTRATEa70484CARBOXYMETHYLCELLULOSE SODIUMa54760PRAZEPAMa70491HYOSCYNAMINE SULFATEa54895PROPYLENE GLYCOLa70521GRIFFONIA SIMPLICIFOLIAa54922PROTEIN SUPPLEMENTa70607OXYQUINOLONE SULFATEa55061RACEMETHIONINEa70607OXYQUINOLONE SULFATEa55115RINGERS LACTATEDa70699LYCOPENE a70699 LYCOPENE a70700 GAMMA LINOLENIC ACID a70725 ASPARTAME a70732 EPIDURAL a70759 ALFALFA a70795 L-GLUTAMINE a70799 MAGNESIUM a70836 GAMMA-AMINOBUTRYIC ACID a70891 HYDROGEL a70892 SILICONE (LIQUID) a70996 PREGNENOLONE a70998 ACETYLSALICYLIC ACID a71002 FLOXACILLIN

a71008	TECHNETIUM TC 99M MERTIATIDE
	INJECTION
a71021	HISTERLIN
a71037	POLY-LACTIC ACID
a71048	FLUZINAMIDE
a71048 a71058	D-RIBOSE
c00009	CEPHALOSPORINS
c00012	MISCELLANEOUS ANTIBIOTICS
c00025	MISCELLANEOUS ANTINEOPLASTICS
c00027	RADIOPHARMACEUTICALS
c00030	ANTITOXINS AND ANTIVENINS
c00033	IMMUNE GLOBULINS
c00039	MISCELLANEOUS BIOLOGICALS
c00040	CARDIOVASCULAR AGENTS
c00042	ANGIOTENSIN CONVERTING ENZYME
	INHIBITORS
c00049	DIURETICS
c00051	MISCELLANEOUS CARDIOVASCULAR
000001	AGENTS
c00053	VASODILATORS
c00055	ANTIHYPERTENSIVE COMBINATIONS
c00057	CENTRAL NERVOUS SYSTEM AGENTS
c00058	ANALGESICS
c00059	MISCELLANEOUS ANALGESICS
c00061	NONSTEROIDAL ANTI-INFLAMMATORY
	AGENTS
c00065	ANTIEMETIC;ANTIVERTIGO AGENTS
c00067	ANXIOLYTICS, SEDATIVES, AND
	HYPNOTICS
c00070	MISCELLANEOUS ANXIOLYTICS,
	SEDATIVES AND HYPNOTICS
c00072	GENERAL ANESTHETICS
c00076	MISCELLANEOUS ANTIDEPRESSANTS
c00070	MISCELLANEOUS CENTRAL NERVOUS
00000	SYSTEM AGENTS
-00092	ANTICOAGULANTS
c00082	
c00087	GASTROINTESTINAL AGENTS
c00088	ANTACIDS
c00090	ANTIDIARRHEALS
c00091	DIGESTIVE ENZYMES
c00095	LAXATIVES
c00096	MISCELLANEOUS GI AGENTS
c00098	ADRENAL CORTICAL STEROIDS
c00099	ANTIDIABETIC AGENTS
c00100	MISCELLANEOUS HORMONES
c00102	CONTRACEPTIVES
c00105	MISCELLANEOUS AGENTS
c00107	CHELATING AGENTS
c00109	LOCAL INJECTABLE ANESTHETICS
c00103	MISCELLANEOUS UNCATEGORIZED
00110	AGENTS
00110	RADIOCONTRAST AGENTS
c00112	
c00115	NUTRITIONAL PRODUCTS
c00117	MINERALS AND ELECTROLYTES
c00118	ORAL NUTRITIONAL SUPPLEMENTS
c00119	VITAMINS
c00123	ANTIHISTAMINES
c00124	
c00127	DECONGESTANTS

c00129	MISCELLANEOUS RESPIRATORY AGENTS
c00131	ANTIASTHMATIC COMBINATIONS
c00132	UPPER RESPIRATORY COMBINATIONS
c00133	TOPICAL AGENTS
c00135	ANTISEPTIC AND GERMICIDES
c00136	DERMATOLOGICAL AGENTS
c00138	TOPICAL STEROIDS
c00139	TOPICAL ANESTHETICS
c00140	MISCELLANEOUS TOPICAL AGENTS
c00143	TOPICAL ACNE AGENTS
c00164	OPHTHALMIC GLAUCOMA AGENTS
c00168	OPHTHALMIC LUBRICANTS AND
	IRRIGATIONS
c00169	MISCELLANEOUS OPHTHALMIC AGENTS
c00172	MISCELLANEOUS OTIC AGENTS
c00174	MISCELLANEOUS ANTIHYPERLIPIDEMIC
	AGENTS
c00178	SKELETAL MUSCLE RELAXANTS
c00187	MISCELLANEOUS SEX HORMONES
c00193	ANTIMIGRAINE AGENTS
c00194	ANTIGOUT AGENTS
c00198	MISCELLANEOUS ANTIEMETICS
c00206	MISCELLANEOUS ANTIPARKINSON AGENTS
c00219	NUTRACEUTICAL PRODUCTS
c00213	HERBAL PRODUCTS
c00220	PSYCHOTHERAPEUTIC AGENTS
c00243	LEUKOTRIENE MODIFIERS
c00248	TOPICAL EMOLLIENTS
c00251	ANTIPSYCHOTICS
c00254	IMMUNOLOGIC AGENTS
c00266	MISCELLANEOUS GENITOURINARY TRACT
	AGENTS
c00290	TOPICAL ANTIBIOTICS
c00296	INHALED CORTICOSTEROIDS
c00301	GLUCOCORTICOIDS
c00309	MISCELLANEOUS ANTIDIABETIC AGENTS
c00331	RADIOLOGIC AGENTS
c00355	FUNCTIONAL BOWEL DISORDER AGENTS
c00363	PROBIOTICS
c00899	PHARMACEUTICAL AID
d00001	ACYCLOVIR
d00002	AMIODARONE
d00003	AMPICILLIN
d00004	ATENOLOL
d00006 d00007	CAPTOPRIL
d00007	CEFAZOLIN CEFOTAXIME
d00008 d00009	CEFTAZIDIME
d00009	CEFTIZOXIME
d00010	CIPROFLOXACIN
d00011 d00012	CODEINE
d00012	ENALAPRIL
d00013	GENTAMICIN
d00015	IBUPROFEN
d00016	LABETALOL
d00017	MEPERIDINE
d00018	NADOLOL
d00019	NAPROXEN

d00020 QUINIDINE d00021 RANITIDINE d00022 WARFARIN d00023 ALLOPURINOL d00024 AZATHIOPRINE d00027 HALOPERIDOL d00028 KETOPROFEN d00029 NAFCILLIN d00030 PENTAMIDINE d00031 PROBENECID d00032 PROPRANOLOL d00033 SULINDAC d00034 ZIDOVUDINE d00035 CHLOROQUINE d00036 CYCLOPHOSPHAMIDE d00037 DOXYCYCLINE d00038 FLUCYTOSINE d00039 INDOMETHACIN d00040 OXAZEPAM d00041 TETRACYCLINE d00043 CLINDAMYCIN d00044 CLONIDINE d00045 DILTIAZEM d00046 ERYTHROMYCIN d00047 RIFAMPIN d00048 VERAPAMIL d00049 ACETAMINOPHEN d00050 METHADONE d00051 NIFEDIPINE d00052 CEFTRIAXONE d00054 TOLMETIN d00055 CEFOTETAN d00056 CEFUROXIME d00057 PIPERACILLIN d00058 CARBAMAZEPINE d00059 LIDOCAINE d00060 METHOTREXATE d00061 LITHIUM d00064 CHLORPROMAZINE d00066 GANCICLOVIR d00067 AZTREONAM d00068 ETHAMBUTOL d00069 TOBRAMYCIN d00070 FUROSEMIDE d00071 FLUCONAZOLE d00072 CEFIXIME d00073 CEFPROZIL d00074 CEFOPERAZONE d00077 AMPHOTERICIN B d00078 DIDANOSINE d00079 CYCLOSPORINE d00080 CEFADROXIL d00081 CEFACLOR d00082 IMIPENEM-CILASTATIN d00083 VALPROIC ACID d00084 PREDNISOLONE d00085 RIBAVIRIN d00086 AMANTADINE d00088 AMOXICILLIN d00089 AMOXICILLIN-CLAVULANATE d00091 AZITHROMYCIN

d00094 CEFOXITIN d00095 CEFPODOXIME d00096 CEPHALEXIN d00097 CLARITHROMYCIN d00098 DAPSONE d00100 GRISEOFULVIN d00101 ISONIAZID d00102 ITRACONAZOLE d00103 KETOCONAZOLE d00106 METHENAMINE d00108 METRONIDAZOLE d00110 MINOCYCLINE d00112 NITROFURANTOIN d00113 NORFLOXACIN d00114 OFLOXACIN d00115 OXACILLIN d00116 PENICILLIN d00119 SULFAMETHOXAZOLE d00121 TICARCILLIN d00123 TRIMETHOPRIM d00124 SULFAMETHOXAZOLE-TRIMETHOPRIM d00125 VANCOMYCIN d00128 ACEBUTOLOL d00132 HYDRALAZINE d00133 METHYLDOPA d00134 METOPROLOL d00135 MINOXIDIL d00136 NITROPRUSSIDE d00137 PINDOLOL d00138 PRAZOSIN d00139 TIMOLOL d00140 CIMETIDINE d00141 FAMOTIDINE d00142 THEOPHYLLINE d00143 PHENYTOIN d00144 NORTRIPTYLINE d00145 DESIPRAMINE d00146 AMITRIPTYLINE d00148 DIAZEPAM d00149 LORAZEPAM d00150 COLCHICINE d00153 DICLOXACILLIN d00153 DICLOXACILLIN d00154 MEBENDAZOLE d00155 MICONAZOLE d00161 ACETAZOLAMIDE d00164 ADENOSINE d00168 ALPRAZOLAM d00169 AMILORIDE d00170 ASPIRIN d00174 ATROPINE d00175 BENZTROPINE d00178 BROMOCRIPTINE d00179 BUMETANIDE d00180 BUPIVACAINE d00181 BUPROPION d00182 BUSPIRONE d00184 CARBIDOPA d00185 CARBOPLATIN d00189 CHLORDIAZEPOXIDE d00190 CHLOROTHIAZIDE d00191 CHLORPHENIRAMINE

d00192 CHLORTHALIDONE d00193 CHOLESTYRAMINE d00195 CISPLATIN d00197 CLONAZEPAM d00198 CLORAZEPATE d00199 CLOZAPINE d00200 CROMOLYN d00204 DANAZOL d00206 DEXAMETHASONE d00207 DEXTROMETHORPHAN d00208 DIFLUNISAL d00210 DIGOXIN d00211 DIHYDROERGOTAMINE d00212 DIPHENHYDRAMINE d00213 DIPYRIDAMOLE d00214 DISOPYRAMIDE d00215 DOBUTAMINE d00216 DOPAMINE d00217 DOXEPIN d00218 DOXORUBICIN d00219 DROPERIDOL d00220 EDROPHONIUM d00223 EPOETIN ALFA d00224 ESMOLOL d00227 ETHOSUXIMIDE d00230 ETOPOSIDE d00231 FELODIPINE d00233 FENTANYL d00234 FLECAINIDE d00235 FLUOROURACIL d00236 FLUOXETINE d00237 FLUPHENAZINE d00238 FLURAZEPAM d00239 FLURBIPROFEN d00241 FOLIC ACID d00242 FOSINOPRIL d00245 GEMFIBROZIL d00246 GLIPIZIDE d00248 GLYBURIDE d00252 HEPARIN d00253 HYDROCHLOROTHIAZIDE d00254 HYDROCORTISONE d00255 HYDROMORPHONE d00259 IMIPRAMINE d00260 INDAPAMIDE d00262 INSULIN d00265 IPRATROPIUM d00268 ISOSORBIDE DINITRATE d00269 ISOSORBIDE MONONITRATE d00270 ISRADIPINE d00272 KETAMINE d00273 KETOROLAC d00275 LEUCOVORIN d00277 LEVODOPA d00278 LEVOTHYROXINE d00279 LINCOMYCIN d00280 LOVASTATIN d00282 MANNITOL d00284 MEDROXYPROGESTERONE

d00285 MEFENAMIC ACID d00286 MEFLOQUINE d00287 MELPHALAN d00289 MERCAPTOPURINE d00290 METHIMAZOLE d00292 METHSUXIMIDE d00293 METHYLPREDNISOLONE d00295 METHYLTESTOSTERONE d00297 METIPRANOLOL OPHTHALMIC d00298 METOCLOPRAMIDE d00299 METOLAZONE d00300 MEXILETINE d00301 MIDAZOLAM d00303 MISOPROSTOL d00305 MITOMYCIN d00308 MORPHINE d00310 NABUMETONE d00311 NALOXONE d00312 NEOMYCIN d00313 NEOSTIGMINE d00314 NIACIN d00315 NICARDIPINE d00316 NICOTINE d00318 NIMODIPINE d00321 NITROGLYCERIN d00322 NIZATIDINE d00322 NIZATIDINE d00323 NOREPINEPHRINE d00325 OMEPRAZOLE d00328 OXYBUTYNIN d00329 OXYCODONE d00333 PENICILLAMINE d00336 PENTOXIFYLLINE d00337 PHENAZOPYRIDINE d00340 PHENOBARBITAL d00343 PIROXICAM d00344 POLYMYXIN B SULFATE d00345 POTASSIUM CHLORIDE d00346 POVIDONE IODINE TOPICAL d00348 PRAVASTATIN d00350 PREDNISONE d00352 PRIMIDONE d00353 PROBUCOL d00355 PROCHLORPERAZINE d00358 PROPAFENONE d00360 PROPOXYPHENE d00361 PROPYLTHIOURACIL d00362 PROTAMINE d00363 PYRIDOSTIGMINE d00364 PYRIMETHAMINE d00365 QUINAPRIL d00366 QUININE d00370 OCTREOTIDE d00371 SOTALOL d00373 SPIRONOLACTONE d00377 SUCRALFATE d00379 SULFASALAZINE d00381 TAMOXIFEN d00384 TEMAZEPAM d00386 TERAZOSIN

d00387 TERFENADINE d00389 THIORIDAZINE d00391 THIOTHIXENE d00393 TOLAZAMIDE d00394 TOLBUTAMIDE d00395 TRAZODONE d00396 TRIAMTERENE d00397 TRIAZOLAM d00399 VECURONIUM d00401 VINCRISTINE d00402 VITAMIN A d00405 VITAMIN E d00409 RIBOFLAVIN d00412 PYRIDOXINE d00413 CYANOCOBALAMIN d00417 BIOFLAVONOIDS d00425 CALCIUM CARBONATE d00426 ASCORBIC ACID d00427 POTASSIUM PHOSPHATE-SODIUM PHOSPHATE d00428 FLUORIDE d00434 MANGANESE SULFATE d00434MANGANESE SULFATEd00700EPHEDRINEd00438SODIUM CHLORIDEd00704PHENYLEPHRINEd00439CITRIC ACID-POTASSIUM CITRATEd00708CARTEOLOLd00440SODIUM BICARBONATEd00709BISOPROLOLd00468MAGNESIUM SULFATEd00717GUANFACINEd00472TROMETHAMINEd00726DOXAZOSINd00475SODIUM PHOSPHATEd00728RAMIPRILd00485IODINE TOPICALd00730BENAZEPRILd004732LISINOPRUd00732LISINOPRU d00488 LYSINE d00491 LEVOCARNITINE d00496 INOSITOL d00497 OMEGA-3 POLYUNSATURATED FATTY ACIDS d00512 FILGRASTIM d00514TICLOPIDINEd00749ALBUTEROLd00521ALTEPLASEd00750METAPROTERENOLd00527FACTOR IX COMPLEX (OBSOLETE)d00752TERBUTALINEd00528AMINOCAPROIC ACIDd00755PIRBUTEROLd00529TRANEXAMIC ACIDd00758AMINOPHYLLINEd00541CONJUGATED ESTROGENSd00760BECLOMETHASONEd00550PROGESTERONEd00762ACETYLCYSTEINEd00554HYDROXYPROGESTERONEd00770PSEUDOEPHEDRINEd00555NORETHINDRONEd00771NAPHAZOLINE OPHTHALMICd00563TESTOSTERONEd00773TETRAHYDROZOLINE OPHTHALMICd00563FINASTERIDEd00774XYLOMETAZOLINE NASALd00563FINASTERIDEd00775ALPHA 1-PROTEINASE INHIBITORd00569CLOMIPHENEd00780CLEMASTINE d00514 TICLOPIDINE d00569 CLOMIPHENE d00572 CHORIONIC GONADOTROPIN (HCG) d00575 HISTRELIN d00577 SOMATROPIN d00578 ARGININE d00583 DESMOPRESSIN d00584 OXYTOCIN d00587 METHYLERGONOVINE d00593 GLUCAGON d00595 GLUCOSE d00596 ALGLUCERASE

d00598 CALCITONIN d00601 PAMIDRONATE d00604 CORTICOTROPIN d00608 FLUDROCORTISONE d00609 CORTISONE d00620 TRIAMCINOLONE d00626 DEXAMETHASONE TOPICAL d00628 BETAMETHASONE d00640 METHAZOLAMIDE d00649 ETHACRYNIC ACID d00651 UREA TOPICAL d00652 GLYCERIN d00653 ISOSORBIDE d00655 THYROID DESICCATED d00658 LIOTHYRONINE d00666 AMYL NITRITE d00686 AMTEINITRITE d00683 LIDOCAINE TOPICAL d00689 AMLODIPINE d00695 PAPAVERINE d00697 ISOPROTERENOL d00699 EPINEPHRINE d00700 EPHEDRINE d00732 LISINOPRIL d00732 LISINOFKIL d00733 PHENTOLAMINE d00735 METYROSINE d00743 SODIUM POLYSTYRENE SULFONATE d00744 COLESTIPOL d00746 SIMVASTATIN d00749 ALBUTEROL d00780 CLEMASTINE d00780 CLEMASTINE d00785 BROMPHENIRAMINE d00787 PROMETHAZINE d00790 CYPROHEPTADINE d00791 AZATADINE d00796 BENZONATATE d00797 GUAIFENESIN d00799 IODINATED GLYCEROL d00800 POTASSIUM IODIDE d00801 CAFFEINE d00803 AMPHETAMINE

d00804 DEXTROAMPHETAMINE d00806 PHENTERMINE d00807 BENZPHETAMINE d00809 PHENDIMETRAZINE d00810 DIETHYLPROPION d00813 BENZOCAINE TOPICAL d00817 HYDROXYCHLOROQUINE d00824 OPIUM d00833 OXYMORPHONE d00838 BUTORPHANOL d00839 NALBUPHINE d00840 BUPRENORPHINE d00842 SALSALATE d00843 SODIUM SALICYLATE d00848 DICLOFENAC d00851 ETODOLAC d00853 OXAPROZIN d00855 PERPHENAZINE d00859 MECLIZINE d00861 DIMENHYDRINATE d00862 TRIMETHOBENZAMIDE d00866 DRONABINOL d00867 ONDANSETRON d00874 AMOXAPINE d00875 PROTRIPTYLINE d00876 CLOMIPRAMINE d00880 SERTRALINE d00882 ISOCARBOXAZID d00883 PHENELZINE d00884 TRANYLCYPROMINE d00890 TRIFLUOPERAZINE d00897 LOXAPINE d00898 PIMOZIDE d00900 METHYLPHENIDATE d00902 ERGOLOID MESYLATES d00907 HYDROXYZINE d00910 ZOLPIDEM d00915 ESTAZOLAM d00923 BUTABARBITAL d00929 METHOHEXITAL d00931 ETOMIDATE d00933 PROPOFOL d00934 NITROUS OXIDE d00960 CARISOPRODOL d00962 CHLORZOXAZONE d00963 CYCLOBENZAPRINE d00964 METAXALONE d00965 METHOCARBAMOL d00966 ORPHENADRINE d00967 BACLOFEN d00968 DANTROLENE d00970 TRIHEXYPHENIDYL d00976 SELEGILINE d00978 ALUMINUM HYDROXIDE d00982 MAGNESIUM HYDROXIDE d00985 HYOSCYAMINE

d00986 SCOPOLAMINE

d00988 BELLADONNA

d00989 METHSCOPOLAMINE

d00991 CLIDINIUM d00992 GLYCOPYRROLATE d00999 DICYCLOMINE d01002 PANCRELIPASE d01003 PANCREATIN d01005 URSODIOL d01008 MAGNESIUM CITRATE d01012 PHENOLPHTHALEIN d01013 SENNA d01014 CASTOR OIL d01015 BISACODYL d01017 POLYCARBOPHIL d01018 PSYLLIUM d01019 MINERAL OIL d01021 DOCUSATE d01023 POLYETHYLENE GLYCOL 3350 WITH ELECTROLYTES d01024 LACTULOSE d01025 LOPERAMIDE d01026 BISMUTH SUBSALICYLATE d01027 SIMETHICONE d01028 CHARCOAL d01031 MESALAMINE d01068 DEMECLOCYCLINE d01070 OXYTETRACYCLINE d01097 RIFABUTIN d01104 PAROMOMYCIN d01105 IODOQUINOL d01113 COLISTIMETHATE d01115 BACITRACIN d01120 ATOVAQUONE d01123 PYRANTEL d01133 IMMUNE GLOBULIN INTRAVENOUS d01135 IMMUNE GLOBULIN INTRAMUSCULAR d01137 TETANUS IMMUNE GLOBULIN d01139 RHO (D) IMMUNE GLOBULIN d01147 RABIES VACCINE (OBSOLETE) d01148 RABIES IMMUNE GLOBULIN, HUMAN d01150 BCG d01156 TYPHOID VACCINE, INACTIVATED d01158 HAEMOPHILUS B CONJUGATE VACCINE (OBSOLETE) d01160 RUBELLA VIRUS VACCINE d01161 MUMPS VIRUS VACCINE d01163 POLIOVIRUS VACCINE, INACTIVATED d01164 INFLUENZA VIRUS VACCINE, INACTIVATED d01165 YELLOW FEVER VACCINE d01166 HEPATITIS B VACCINE (OBSOLETE) d01168 TETANUS TOXOID d01171 TUBERCULIN PURIFIED PROTEIN DERIVATIVE d01185 APRACLONIDINE OPHTHALMIC d01187 LEVOBUNOLOL OPHTHALMIC d01189 CARBACHOL OPHTHALMIC d01191 PILOCARPINE OPHTHALMIC d01199 HOMATROPINE OPHTHALMIC d01200 TROPICAMIDE OPHTHALMIC d01201 CYCLOPENTOLATE OPHTHALMIC

PAGE 218

d01226HYDROXYPROPYL METHYLCELLULOSE
OPHTHALMICd01334GOSERELIN
GOSERELINd01227BOTULINUM TOXIN TYPE A (OBSOLETE)d01337HYDROXYUREAd01232CARBAMIDE PEROXIDE TOPICALd01376PACLITAXELd01233CARBAMIDE PEROXIDE TOPICALd01385SDIUM TETRADECYL SULFATEd01234BUTOCONAZOLE TOPICALd01385BETA-CAROTENEd01235CLOTRIMAZOLEd01386YOHIMBINEd01236CLOTRIMAZOLEd01387ALPROSTADILd01237TERCONAZOLE TOPICALd01387ALPROSTADILd01238BUTOCONAZOLE TOPICALd01387ALPROSTADILd01240SULFANILAMIDE TOPICALd01389DISULFIRAMd01241CLINDAMYCIN TOPICALd01398MEPIVACAINEd01242NONOXYNOL 9 TOPICALd01398MEPIVACAINEd01244ISOTRETINOINd01407FLUMAZENILd01245ISOTRETINOINd01407FLUMAZENILd01246BENZOYL PEROXIDE TOPICALd01427BETHANECHOLd01256NULFRAULANI TOPICALd01427BETHANECHOLd01256SULFACETAMIDE SODIUM TOPICALd01427BETHANECHOLd01267NITROFURAZONE TOPICALd01445BARIUM SULFATEd01263SULFR SULFADIAZINE TOPICALd01451GADOPENTETATE DIMEGLUMINEd01267SULFACETAMIDE SODIUM TOPICALd01451GADOPENTETATEd01267MUPIROCIN TOPICALd01451IOATRIZOATEd01274TOLNAFTATE TOPICALd01473DIATRIZOATEd01274TOL d01322 ALUMINUM CHLORIDE HEXAHYDRATE TOPICAL d01325 ALUMINUM CHLORIDE HEXAHYDRATE TOPICAL d01205 ALUMINUM CHLORIDE HEXAHYDRATE d01325ARNICA TOPICALd03135PHYTONADIONEd01332HEXACHLOROPHENE TOPICALd03137CALCIUM-VITAMIN Dd01333BENZALKONIUM CHLORIDE TOPICALd03140MULTIVITAMINd01335SODIUM HYPOCHLORITE TOPICALd03141MULTIVITAMIN WITH IRON

d01213NATAMYCIN OPHTHALMICd01338PHYSIOLOGICAL IRRIGATING SOLUTIONd01215TRIFLURIDINE OPHTHALMICd01341LOMUSTINEd01217TETRACAINEd01346FLUDARABINEd01218PROPARACAINE OPHTHALMICd01348MEGESTROLd01219FLUORESCEIN OPHTHALMICd01351ESTRAMUSTINEd01225BORIC ACID TOPICALd01353LEUPROLIDEd01226HYDROXYPROPYL METHYLCELLULOSEd01369INTERFERON ALFA-2Bd01327POTHHALMICd01323HYDROXYUN TYPE A (OPSOL FTE) d01288CLOBETASOL TOPICALd03007MEASLES;MUMPS;RUBELLA VIRUS
VACCINEd01289CLOCORTOLONE TOPICALd03041ENOXAPARINd01290DESONIDE TOPICALd03050LORATADINEd01291DESOXIMETASONE TOPICALd03051INTERFERON BETA-1Bd01292DIFLORASONE TOPICALd03052HYDROCHLOROTHIAZIDE-TRIAMTERENEd01293FLUOCINOLONE TOPICALd03054AMYLASEd01294FLUOCINONIDE TOPICALd03066CITRIC ACIDd01295FLURANDRENOLIDE TOPICALd03071DIPHENOXYLATEd01297HALCINONIDE TOPICALd03073ETHYNODIOLd01298HALOBETASOL TOPICALd03073ETHYNODIOLd01301DIBUCAINE TOPICALd03077ISOMETHEPTENE MUCATEd01303PRAMOXINE TOPICALd03077ISOMETHEPTENE MUCATEd01304COCAINE TOPICALd03078SODIUM CITRATEd01305SALICYLIC ACID TOPICALd03110DIPHTH;PERTUSSIS, ACEL;TETANUS
(OBSOLETE)d01319HYDROQUINONE TOPICALd03116BISMUTH SUBGALLATEd01320FORMALDEHYDE TOPICALd03126CALCITRIOLd01321CAPSAICIN TOPICALd03128ERGOCALCIFEROLd01322ALUMINUM CHI ORIDE HEXAHYDPATE100102CURRENTIANE

PAGE 219

d03145	MULTIVITAMIN WITH MINERALS
d03148	MULTIVITAMIN, PRENATAL
d03149	ASCORBIC ACID-FERROUS SULFATE
d03154	DOXYLAMINE
d03157	PAROXETINE
d03158	RIMANTADINE
d03160	SUMATRIPTAN
d03162	ETHANOL
	-
d03165	PIPERACILLIN-TAZOBACTAM
d03170	FELBAMATE
d03171	GRANISETRON
d03180	RISPERIDONE
d03181	VENLAFAXINE
d03182	GABAPENTIN
	-
d03183	FLUVASTATIN
d03189	TORSEMIDE
d03190	OXICONAZOLE TOPICAL
d03191	TERBINAFINE TOPICAL
d03192	ZINC OXIDE TOPICAL
d03193	AMILORIDE-HYDROCHLOROTHIAZIDE
d03195	MICONAZOLE TOPICAL
d03197	BETAMETHASONE TOPICAL
d03200	ERYTHROMYCIN TOPICAL
d03202	KETOCONAZOLE TOPICAL
d03203	MINOXIDIL TOPICAL
d03203	
	FLUOROURACIL TOPICAL
d03205	HYDROCORTISONE TOPICAL
d03206	TRIAMCINOLONE TOPICAL
d03208	METRONIDAZOLE TOPICAL
d03210	SELENIUM SULFIDE TOPICAL
d03211	CIPROFLOXACIN OPHTHALMIC
	KETOROLAC OPHTHALMIC
d03214	
d03220	FLURBIPROFEN OPHTHALMIC
d03221	PREDNISOLONE OPHTHALMIC
d03222	TOBRAMYCIN OPHTHALMIC
d03225	PREDNICARBATE TOPICAL
d03226	SALIVA SUBSTITUTES
d03227	FLUOROMETHOLONE OPHTHALMIC
d03228	
d03238	ETHINYL ESTRADIOL-NORETHINDRONE
d03241	ETHINYL ESTRADIOL-NORGESTREL
d03242	ETHINYL ESTRADIOL-LEVONORGESTREL
d03244	CONJUGATED ESTROGENS-
	METHYLTESTOSTERONE
d03245	ESTERIFIED ESTROGENS-
003245	
	METHYLTESTOSTERONE
d03247	HYDROCHLOROTHIAZIDE-
	SPIRONOLACTONE
d03258	ATENOLOL-CHLORTHALIDONE
d03264	HYDROCHLOROTHIAZIDE-METOPROLOL
d03265	BENAZEPRIL-HYDROCHLOROTHIAZIDE
d03266	HYDROCHLOROTHIAZIDE-LISINOPRIL
d03276	DYPHYLLINE-GUAIFENESIN
d03280	EPHEDRINE;
	PHENOBARBITAL; THEOPHYLLINE
d03289	ACETAMINOPHEN-PSEUDOEPHEDRINE
d03292	IBUPROFEN-PSEUDOEPHEDRINE
d03292	ACETAMINOPHEN-CHLORPHENIRAMINE
d03298	CHLORPHENIRAMINE-PSEUDOEPHEDRINE

d03299	CHLORPHENIRAMINE- PHENYLPROPANOLAMINE
d03300	CHLORPHENIRAMINE-PHENYLEPHRINE
d03301	BROMPHENIRAMINE-PSEUDOEPHEDRINE
d03302	BROMPHENIRAMINE-
000002	PHENYLPROPANOLAMINE
400040	
d03313	CHLORPHENIRAMINE;PHENYLEPHRINE;
	PYRILAMINE
d03314	CHLORPHENIRAMINE;
	PHENYLEPHRINE;PPA
d03316	PSEUDOEPHEDRINE-TRIPROLIDINE
d03317	PHENYLEPHRINE-PROMETHAZINE
d03318	PHENIRAMINE;PPA;PYRILAMINE
d03319	APAP;CHLORPHENIRAMINE;
	PHENYLPROPANOLAMINE
d03322	ASA;CHLORPHENIRAMINE;
000022	PHENYLPROPANOLAMINE
400004	ACETAMINOPHEN;CHLORPHENIRAMINE;
d03331	
100000	PHENYLEPHRINE
d03338	CHLORPHENIRAMINE;
	METHSCOPOLAMINE;PE
d03340	HOMATROPINE-HYDROCODONE
d03342	ACETAMINOPHEN;
	DEXTROMETHORPHAN;PSE
d03347	ACETAMINOPHEN;
	CHLORPHENIRAMINE;DM;PSE
d03352	HYDROCODONE-PSEUDOEPHEDRINE
d03354	DEXTROMETHORPHAN-
000004	PSEUDOEPHEDRINE
402256	CHLORPHENIRAMINE-HYDROCODONE
d03356	
d03357	CODEINE-PROMETHAZINE
d03359	CHLORPHENIRAMINE-
	DEXTROMETHORPHAN
d03360	DEXTROMETHORPHAN-PROMETHAZINE
d03364	CODEINE;PHENYLEPHRINE;
	PROMETHAZINE
d03368	BROMPHENIRAMINE;
	DEXTROMETHORPHAN;PSE
d03369	CHLORPHENIRAMINE;
	DEXTROMETHORP;PHENYLEPHRINE
d03370	CHLORPHENIRAMINE;
000070	DEXTROMETHORPHAN;PSE
d03372	BROMPHENIRAMINE;
003372	
-100070	
d03379	GUAIFENESIN-PSEUDOEPHEDRINE
d03381	GUAIFENESIN-PHENYLEPHRINE
d03382	GUAIFENESIN-PHENYLPROPANOLAMINE
d03388	ETHINYL ESTRADIOL-ETHYNODIOL
d03389	ESTRADIOL-TESTOSTERONE
d03393	CODEINE-GUAIFENESIN
d03394	CODEINE-IODINATED GLYCEROL
d03396	GUAIFENESIN-HYDROCODONE
d03398	CODEINE;GUAIFENESIN;
	PSEUDOEPHEDRINE
d03400	DEXTROMETHORPHAN-GUAIFENESIN
d03409	DEXTROMETHORPHAN:
003409	GUAIFENESIN;PSEUDOEPHEDRINE
402444	
d03411	DEXTROMETHORPHAN;GUAIFENESIN;PPA

PAGE 220

d03416	CHLORPHENIRAMINE;
	HYDROCODONE;PSE
d03419	CHLORPHENIRAMINE;DM;
u03419	
	GUAIFENESIN;PHENYLEPHRINE
d03423	ACETAMINOPHEN-CODEINE
d03425	ACETAMINOPHEN;
	BUTALBITAL;CAFFEINE;CODEINE
402426	ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE
d03426	
d03428	ACETAMINOPHEN-HYDROCODONE
d03431	ACETAMINOPHEN-OXYCODONE
d03432	ASPIRIN-OXYCODONE
d03433	MEPERIDINE-PROMETHAZINE
d03434	
	ACETAMINOPHEN-PROPOXYPHENE
d03435	ASA;CAFFEINE;PROPOXYPHENE
d03436	BELLADONNA-OPIUM
d03437	ACETAMINOPHEN;
	ASPIRIN;CAFFEINE;SALICYLAMIDE
d03439	ACETAMINOPHEN; ASPIRIN; CAFFEINE
d03445	ACETAMINOPHEN-DIPHENHYDRAMINE
d03449	ASPIRIN-CAFFEINE
d03455	ACETAMINOPHEN;BUTALBITAL;CAFFEINE
d03456	ACETAMINOPHEN-BUTALBITAL
d03457	ASPIRIN;BUTALBITAL;CAFFEINE
d03459	APAP;DICHLORALPHENAZONE;
	ISOMETHEPTENE
d03462	AMITRIPTYLINE-CHLORDIAZEPOXIDE
d03463	AMITRIPTYLINE-PERPHENAZINE
d03473	CARBIDOPA-LEVODOPA
d03474	ALUMINUM HYDROXIDE-MAGNESIUM
	HYDROXIDE
d03478	AL HYDROXIDE;MG
	HYDROXIDE SIMETHICONE
403485	
d03485	ATROPINE;HYOSCYAMINE;
	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE
d03485 d03492	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM
	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE
d03492	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM
d03492 d03496 d03498	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE
d03492 d03496 d03498 d03506	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE
d03492 d03496 d03498	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN;
d03492 d03496 d03498 d03506 d03524	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL
d03492 d03496 d03498 d03506	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN;
d03492 d03496 d03498 d03506 d03524	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL
d03492 d03496 d03498 d03506 d03524 d03536	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC
d03492 d03496 d03498 d03506 d03524	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE
d03492 d03496 d03498 d03506 d03524 d03536 d03541	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CAPTOPRIL-HYDROCHLOROTHIAZIDE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CAPTOPRIL-HYDROCHLOROTHIAZIDE CARBINOXAMINE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CAPTOPRIL-HYDROCHLOROTHIAZIDE CARBINOXAMINE-PSEUDOEPHEDRINE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576 d03593	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM CARBONATE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576 d03593 d03600	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM CARBONATE POTASSIUM BICARBONATE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576 d03576 d03593 d03600 d03613	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM CARBONATE POTASSIUM BICARBONATE PSYLLIUM-SENNA
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576 d03593 d03600	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM CARBONATE POTASSIUM BICARBONATE
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576 d03576 d03593 d03600 d03613	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM CARBONATE POTASSIUM BICARBONATE PSYLLIUM-SENNA
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576 d03576 d03576 d03593 d03600 d03613 d03618	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM CARBONATE POTASSIUM BICARBONATE PSYLLIUM-SENNA HYOSCYAMINE;METHENAM;M- BLUE;PHENYL SALICYL
d03492 d03496 d03498 d03506 d03524 d03536 d03541 d03546 d03555 d03561 d03562 d03566 d03569 d03570 d03576 d03576 d03593 d03600 d03613	ATROPINE;HYOSCYAMINE; PB;SCOPOLAMINE CHLORDIAZEPOXIDE-CLIDINIUM DOCUSATE-SENNA CASANTHRANOL-DOCUSATE ATROPINE-DIPHENOXYLATE BACITRACIN;NEOMYCIN; POLYMYXIN B TOPICAL DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC PREDNISOLONE-SULFACETAMIDE SODIUM OPHTHALMIC HYDROCORTISONE-PRAMOXINE TOPICAL HYDROCORTISONE-NEOMYCIN TOPICAL BETAMETHASONE-CLOTRIMAZOLE TOPICAL NYSTATIN-TRIAMCINOLONE TOPICAL CARBINOXAMINE CARBINOXAMINE-PSEUDOEPHEDRINE BROMODIPHENHYDRAMINE-CODEINE CALCIUM CARBONATE-MAGNESIUM CARBONATE POTASSIUM BICARBONATE PSYLLIUM-SENNA HYOSCYAMINE;METHENAM;M-

d03625	ACETIC ACID-HYDROCORTISONE OTIC
d03627	ANTIPYRINE-BENZOCAINE OTIC
d03632	CETYLPYRIDINIUM TOPICAL
d03640	BUDESONIDE NASAL
d03641	PETROLATUM TOPICAL
d03644	LACTOBACILLUS ACIDOPHILUS
d03646	LACTOBACILLUS ACIDOPHILUS AND
	BULGARICUS
d03647	ISOPROPYL ALCOHOL TOPICAL
d03649	BENZOIN TOPICAL
d03652	COLCHICINE-PROBENECID
d03653	CALAMINE TOPICAL
d03655	LIDOCAINE-PRILOCAINE TOPICAL
d03656	ETHYL CHLORIDE TOPICAL
d03663	LECITHIN
	-
d03664	PHENOL TOPICAL
d03665	MENTHOL TOPICAL
d03666	MENTHOL-PHENOL TOPICAL
d03669	METHYL SALICYLATE-MENTHOL TOPICAL
d03676	NALOXONE-PENTAZOCINE
d03680	ASPIRIN;CITRIC ACID;SODIUM
000000	
	BICARBONATE
d03684	THROMBIN TOPICAL
d03686	UNDECYLENIC ACID TOPICAL
d03687	ALUMINUM ACETATE TOPICAL
d03689	CALCIUM ACETATE
d03690	ALUMINUM SULFATE-CALCIUM ACETATE
000000	
	TOPICAL
d03692	BENZYLPENICILLOYL-POLYLYSINE
d03701	CORN STARCH TOPICAL
d03702	SULFUR TOPICAL
d03703	COAL TAR TOPICAL
d03707	ALOE VERA TOPICAL
d03708	LANOLIN-MINERAL OIL TOPICAL
d03712	CAMPHOR TOPICAL
d03718	TRACE ELEMENTS
d03740	ENALAPRIL-HYDROCHLOROTHIAZIDE
d03744	BISOPROLOL-HYDROCHLOROTHIAZIDE
d03751	DEXBROMPHENIRAMINE-
000701	
	PSEUDOEPHEDRINE
d03752	TACROLIMUS
d03756	BACITRACIN TOPICAL
d03759	SALMETEROL
d03766	ROCURONIUM
d03768	OCULAR LUBRICANT
d03770	EMOLLIENTS, TOPICAL
d03773	STAVUDINE
d03774	DOXEPIN TOPICAL
d03775	FAMCICLOVIR
d03780	DESOGESTREL
d03781	ETHINYL ESTRADIOL-NORGESTIMATE
d03782	DESOGESTREL-ETHINYL ESTRADIOL
d03783	BUPIVACAINE-EPINEPHRINE
d03784	EPINEPHRINE-LIDOCAINE
d03788	CALCIPOTRIENE TOPICAL
d03790	POTASSIUM PHOSPHATE
d03796	MAGNESIUM CHLORIDE
d03797	MAGNESIUM OXIDE
d03798	MAGNESIUM GLUCONATE
d03804	FLUVOXAMINE
d03805	DORZOLAMIDE OPHTHALMIC
200000	

d03806 ALBENDAZOLE d03807 METFORMIN d03808 NEFAZODONE d03809 LAMOTRIGINE d03810 VINORELBINE d03811 ABCIXIMAB d03811ADDIAINADd03973GETCERINGOTTTTALMICd03812DALTEPARINd03977OFLOXACIN OPHTHALMICd03818LORATADINE-PSEUDOEPHEDRINEd03977OFLOXACIN OPHTHALMICd03819CONJUGATED ESTROGENS-
MEDROXYPROGESTERONEd03982TETRACAINE TOPICALd03820HEPATITIS A VACCINE (OBSOLETE)d03986GANCICLOVIR OPHTHALMICd03821LOSARTANd03990CARBAMIDE PEROXIDE OTICd03822FERROUS GLUCONATEd03994COLLOIDAL OATMEAL TOPICALd03823IRON POLYSACCHARIDEd03998STERILE WATERd03824FERROUS SULFATEd04002PIPERONYL BUTOXIDE-PYRETHRINSd03825NISOLDIPINETOPICALd03826TRAMADOLd04003HYDROGEN PEROXIDE TOPICALd03827CETIRIZINEd04008TRANDOLAPRILd03828LANSOPRAZOLEd04009DOCETAXEL d03812 DALTEPARIN d03828 LANSOPRAZOLE d03829AMLODIPINE-BENAZEPRILd04009DOCE TAXELd03829AMLODIPINE-BENAZEPRILd04010GEMCITABINEd03830HYDROCHLOROTHIAZIDE-LOSARTANd04011INTERFERON BETA-1Ad03832VARICELLA VIRUS VACCINEd04012TERBINAFINE d03833 DIVALPROEX SODIUM d03835 MOEXIPRIL d03836 ACITRETIN d03838 VALACYCLOVIR d03839 MYCOPHENOLATE MOFETIL d03840 IOPROMIDE d03846 ACARBOSE d03847 CARVEDILOL d03848 AZELAIC ACID TOPICAL d03849 ALENDRONATE d03850 BICALUTAMIDE d03850BICALUTAMIDEd03857BENZOYL PEROXIDE-ERYTHROMYCIN
TOPICALd04035AMPHETAMINE-DEXTROAMPHETAMINE
d04037d04037TIMOLOL OPHTHALMIC d03858 LAMIVUDINE d03862 MAGNESIUM AMINO ACIDS CHELATE d04040 FEXOFENADINE d03864 GLIMEPIRIDE d03866 CALCIUM CITRATE d03869 RILUZOLE d03873 ANASTROZOLE au3882CEFEPIMEAIVINUONIUM LACTATE TOPICALd03884TROLAMINE SALICYLATE TOPICALd04050OLANZAPINEd03888BENZOCAINE;BUTAMBEN;TETRACAINE
TOPICALd04052PENTOSAN POLYSULFATE SODIUM
d04053d03804KAOLINI PERTITIONd04053ZAFIPI LIKAST d03874 CEFTIBUTEN

d03964 BACITRACIN;NEOMYCIN;POLYMYXIN B **OPHTHALMIC** d03965 BACITRACIN-POLYMYXIN B OPHTHALMIC d03973 ERYTHROMYCIN OPHTHALMIC d03974 GENTAMICIN OPHTHALMIC d03975 GLYCERIN OPHTHALMIC d03977 OFLOXACIN OPHTHALMIC d04009 DOCETAXEL d04014 TOPOTECAN d04015 ADAPALENE TOPICAL d04016 IODIXANOL d04017 LATANOPROST OPHTHALMIC d04025 MIRTAZAPINE d04026 IRINOTECAN d04027 MEROPENEM d04028 CIDOFOVIR d04029 NEVIRAPINE d04022 SULFACETAMIDE SODIUM-SULFUR TOPICAL d04038 BETAXOLOL OPHTHALMIC d04041 FOSPHENYTOIN d04043 FOLLICLE STIMULATING HORMONE d04047 MIDODRINE d04048 BRIMONIDINE OPHTHALMIC d04049 AMMONIUM LACTATE TOPICAL d03897LACTASEd04054PENCICLOVIR TOPICALd03898SODIUM CHLORIDE, HYPERTONIC,
OPHTHALMICd04056ZINC GLUCONATEd03904BALSAM PERU;CASTOR OIL;TRYPSIN
TOPICALd04063BUTENAFINE TOPICALd03915HYDROCODONE-POTASSIUM
GUAIACOLSULFONATEd04066ALBUTEROL-IPRATROPIUM
d04068d03922ACETAMINOPHEN-CAFFEINE
d03952d04083GADODIAMIDEd03952CITRIC ACID-SODIUM CITRATE
d03962d04090LACTIC ACID TOPICAL
d04093d03962POTASSIUM BICARBONATE-POTASSIUM
CITRATEd04001IVERMECTIN d04053 ZAFIRLUKAST d04054 PENCICLOVIR TOPICAL

d04102 TIZANIDINE d04103 ZILEUTON d04105 ATORVASTATIN d04106 FOSFOMYCIN d04107 AMLEXANOX TOPICAL d04109 LEVOFLOXACIN d04110 MIGLITOL d04111 GLATIRAMER d04112 CABERGOLINE d04113 VALSARTAN d04115 TOPIRAMATE d04117 OLOPATADINE OPHTHALMIC d04118 NELFINAVIR d04120 CAFFEINE-ERGOTAMINE d04121 TAMSULOSIN d04125 IMIQUIMOD TOPICAL d04126 ANAGRELIDE d04128 LVP SOLUTION d04129 LVP SOLUTION WITH POTASSIUM d04131 PARENTERAL NUTRITION SOLUTION d04134 POLYMYXIN B OPHTHALMIC d04138 TAZAROTENE TOPICAL d04141 HYDROCHLOROTHIAZIDE-MOEXIPRIL d04142 CHROMIUM PICOLINATE d04145 PRAMIPEXOLE d04156 LETROZOLE d04159 SORBITOL d04160 SODIUM BIPHOSPHATE-SODIUM PHOSPHATE d04166 ACETAMINOPHEN:DM; GUAIFENESIN; PSEUDOEPHEDRINE d04172 CALAMINE-PRAMOXINE TOPICAL d04186 PHENYLEPHRINE NASAL d04195 CHLOROPHYLLIN d04196 BACITRACIN;HC;NEOMYCIN; POLYMYXIN B TOPICAL d04197 HYDROCORTISONE; NEOMYCIN; POLYMYXIN B TOPICAL d04208 SILVER NITRATE TOPICAL d04212 GLYCERIN TOPICAL d04215 ROPINIROLE d04219 LAMIVUDINE-ZIDOVUDINE d04220 QUETIAPINE d04221 TIAGABINE d04222 IRBESARTAN d04223 MOMETASONE NASAL d04225 HYDROCODONE-IBUPROFEN d04228 ACETIC ACID OTIC d04233 TRIAMCINOLONE NASAL d04237 DEXAMETHASONE-LIDOCAINE d04240 HYLAN G-F 20 d04241 POTASSIUM CHLORIDE-SODIUM CHLORIDE d04242 SODIUM CHLORIDE NASAL d04245 HYDROCHLOROTHIAZIDE-IRBESARTAN d04248 METHYLCELLULOSE d04249 CELLULOSE d04253 ZOLMITRIPTAN d04255 RITUXIMAB d04256 CEFDINIR d04258 CLOPIDOGREL

d04260	SIBUTRAMINE
d04261	RALOXIFENE
d04262	DACLIZUMAB
d04266	EPROSARTAN
d04267	REPAGLINIDE
d04269	ACETAMINOPHEN;CAFFEINE;
001200	DIHYDROCODEINE
d04270	FEXOFENADINE-PSEUDOEPHEDRINE
d04271	DICLOFENAC-MISOPROSTOL
d04272	AMOXICILLIN;CLARITHROMYCIN;
007272	LANSOPRAZOLE
d04275	BECLOMETHASONE NASAL
d04276	BUDESONIDE
d04279	FLUNISOLIDE NASAL
d04283	FLUTICASONE NASAL
d04284	
d04285	NARATRIPTAN
d04286	FENOFIBRATE
d04289	MONTELUKAST
d04203	LOTEPREDNOL OPHTHALMIC
d04293	HYDROCHLOROTHIAZIDE-VALSARTAN
d04293	TOLTERODINE
d04295	OXYMETHOLONE
d04298	PHENYLEPHRINE TOPICAL
d04299	SILDENAFIL
d04300	RISEDRONATE
d04301	BRINZOLAMIDE OPHTHALMIC
d04309	FLUOROMETHANE TOPICAL
d04300	CAPECITABINE
d04312	PARICALCITOL
d04317	DIPHTHERIA TOXOID
d04322	CANDESARTAN
d04323	PALIVIZUMAB
d04328	RIZATRIPTAN
d04329	SODIUM HYALURONATE
d04331	THALIDOMIDE
d04332	CITALOPRAM
d04342	INFLIXIMAB
d04344	ROTAVIRUS VACCINE
d04349	LEFLUNOMIDE
d04352	COAL TAR-SALICYLIC ACID TOPICAL
	EFAVIRENZ
	TRASTUZUMAB
d04362	COPPER GLUCONATE
d04363	SEVELAMER
d04364	TELMISARTAN
d04365	ETANERCEPT
d04368	TANNIC ACID TOPICAL
d04369	INSULIN REGULAR
d04370	INSULIN ISOPHANE
d04374	INSULIN ISOPHANE-INSULIN REGULAR
d04375	ESTRADIOL-NORETHINDRONE
d04376	ABACAVIR
d04377	THYROTROPIN ALFA
d04378	MODAFINIL
d04380	CELECOXIB
d04382	CILOSTAZOL
d04387	SODIUM FERRIC GLUCONATE COMPLEX
d04395	CLOTRIMAZOLE TOPICAL
d04397	FLUORIDE TOPICAL
d04399	

d04530 STRONTIUM-89 CHLORIDE d04532 MELOXICAM d04534 LINEZOLID d04537 RIVASTIGMINE

004401	
d04404	TAZOBACTAM
d04405	CLAVULANATE
d04406	TYPHOID VACCINE, LIVE
d04411	GARLIC
d04412	GINSENG
d04413	GINKGO
d04416	VALERIAN
d04417	CREATINE
d04418	GLUCOSAMINE
d04419	CHONDROITIN
	CHONDROITIN-GLUCOSAMINE
d04420	
d04422	KAVA
d04425	DEHYDROEPIANDROSTERONE
d04427	
d04429	
d04433	ROFECOXIB
d04434	ROSIGLITAZONE
d04435	DOXERCALCIFEROL
d04436	MALATHION TOPICAL
d04441	KETOTIFEN OPHTHALMIC
d04442	PIOGLITAZONE
d04447	GANIRELIX
d04448	RABEPRAZOLE
d04451	
	ZALEPLON
	SIROLIMUS
d04459	
	ENTACAPONE
d04460 d04461	EXEMESTANE
d04462	OSELTAMIVIR
d04466	MILK THISTLE
d04468	CLOVE
d04469	BEE POLLEN
d04470	-
d04472	BLACK COHOSH
d04476	BILBERRY
d04481	ROYAL JELLY
d04487	PEPPERMINT
d04490	GREEN TEA
d04497	ASPIRIN-DIPYRIDAMOLE
d04499	LEVETIRACETAM
d04500	MOXIFLOXACIN
	AMINOLEVULINIC ACID TOPICAL
d04503	AMINOLEVULINIC ACID TOPICAL
	NEDOCROMIL OPHTHALMIC
d04504	NEDOCROMIL OPHTHALMIC GATIFLOXACIN
d04504 d04505	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE
d04504 d04505 d04507	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE
d04504 d04505 d04507 d04509	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL
d04504 d04505 d04507	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO
d04504 d04505 d04507 d04509 d04510	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE
d04504 d04505 d04507 d04509 d04510 d04512	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE CEVIMELINE
d04504 d04505 d04507 d04509 d04510 d04512 d04513	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE CEVIMELINE OXCARBAZEPINE
d04504 d04505 d04507 d04509 d04510 d04512 d04513 d04514	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE
d04504 d04505 d04507 d04509 d04510 d04512 d04513 d04514 d04516	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON
d04504 d04505 d04507 d04509 d04510 d04512 d04513 d04514 d04516 d04521	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON NETTLES
d04504 d04505 d04507 d04509 d04510 d04512 d04513 d04514 d04516 d04521 d04523	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON NETTLES UBIQUINONE
d04504 d04505 d04507 d04509 d04510 d04512 d04513 d04514 d04516 d04521	NEDOCROMIL OPHTHALMIC GATIFLOXACIN DEXMEDETOMIDINE BEXAROTENE HYDROCHLOROTHIAZIDE-QUINAPRIL INSULIN LISPRO-INSULIN LISPRO PROTAMINE CEVIMELINE OXCARBAZEPINE PANTOPRAZOLE ALOSETRON NETTLES UBIQUINONE

d04400 DIMETHYL SULFOXIDE TOPICAL

d04401 IMIPENEM

d04534	LINEZOLID
d04537	RIVASTIGMINE
d04538	INSULIN GLARGINE
d04541	AZELASTINE OPHTHALMIC
d04547	ATOVAQUONE-PROGUANIL
d04557	CLOBAZAM
d04572	FORMOTEROL
d04611	FLUTICASONE-SALMETEROL
d04654	DOXYLAMINE-PYRIDOXINE
d04674	DIPHTH;HAEMOPHILUS;
	PERTUSSIS;TETANUS;POLIO
d04675	DIPHTHERIA:PERTUSSIS,
	ACEL;TETANUS;POLIO
d04685	HEPATITIS A-HEPATITIS B VACCINE
d04694	TENECTEPLASE
d04695	COLESEVELAM
d04697	INSULIN ASPART
d04698	ARGATROBAN
d04090 d04700	BALSALAZIDE
d04700	DOCOSANOL TOPICAL
d04702	GLYBURIDE-METFORMIN
d04703 d04704	EFLORNITHINE TOPICAL
	ZOLEDRONIC ACID
d04708	
d04711	
d04717	
d04718	
d04719	COAGULATION FACTOR VIIA
d04721	ESTRADIOL-MEDROXYPROGESTERONE
d04722	DICLOFENAC TOPICAL
d04723	CALCIUM CARBONATE;FAMOTIDINE;MG
10 4705	HYDROXIDE
d04725	IRON SUCROSE
d04726	5-HYDROXYTRYPTOPHAN
d04727	ABACAVIR;LAMIVUDINE;ZIDOVUDINE
d04732	TRYPTOPHAN
d04737	HYDROCHLOROTHIAZIDE-TELMISARTAN
d04739	RIMABOTULINUMTOXINB
d04740	TACROLIMUS TOPICAL
d04742	BENZOYL PEROXIDE-CLINDAMYCIN
	TOPICAL
d04743	NATEGLINIDE
d04746	PEGINTERFERON ALFA-2B
d04747	ZIPRASIDONE
d04749	ESOMEPRAZOLE
d04750	GALANTAMINE
d04753	TRAVOPROST OPHTHALMIC
d04754	BIMATOPROST OPHTHALMIC
d04755	VALGANCICLOVIR
d04756	ALEMTUZUMAB
d04757	ALMOTRIPTAN
d04758	IMATINIB
d04760	DROSPIRENONE-ETHINYL ESTRADIOL
d04764	CETIRIZINE-PSEUDOEPHEDRINE
d04766	ACETAMINOPHEN-TRAMADOL
d04771	DARBEPOETIN ALFA
d04772	ETONOGESTREL
d04773	ETHINYL ESTRADIOL-ETONOGESTREL

d04774 TENOFOVIR d04776 FROVATRIPTAN d04777 DEXMETHYLPHENIDATE d04779 ETHINYL ESTRADIOL-NORELGESTROMIN d04782 BOSENTAN d04783 ERTAPENEM d04784 PIMECROLIMUS TOPICAL d04785 DESLORATADINE d04786 FONDAPARINUX d04787 LOVASTATIN-NIACIN d04788 DUTASTERIDE d04790 PEGFILGRASTIM d04791 FLUOCINOLONE;HYDROQUINONE; TRETINOIN TOPICAL d04796 PERFLUTREN d04797 ALFUZOSIN d04799 FULVESTRANT d04801 OLMESARTAN d04803 VORICONAZOLE d04804 CHARCOAL-SORBITOL d04805 RASBURICASE d04806 SODIUM OXYBATE d04811 OXALIPLATIN d04812 ESCITALOPRAM d04813 HORSE CHESTNUT d04815 EPLERENONE d04819 BUPRENORPHINE-NALOXONE d04820 METFORMIN-ROSIGLITAZONE d04823 GLIPIZIDE-METFORMIN d04824 EZETIMIBE d04825 ARIPIPRAZOLE d04826 NITAZOXANIDE d04827 ATOMOXETINE d04828 TERIPARATIDE d04829 TIOTROPIUM d04832 DIPHTHERIA;HEPB; PERTUSSIS, ACEL; POLIO; TETANUS d04835 ADALIMUMAB d04836 CYCLOSPORINE OPHTHALMIC d04839 INSULIN ASPART-INSULIN ASPART PROTAMINE d04844 CAMPHOR-MENTHOL TOPICAL d04845 IBRITUMOMAB d04848 INULIN d04849 ELETRIPTAN d04851 ROSUVASTATIN d04855 APREPITANT d04857 GATIFLOXACIN OPHTHALMIC d04859 GEMIFLOXACIN d04860 MOXIFLOXACIN OPHTHALMIC d04863 CHLORPHENIRAMINE; IBUPROFEN; PSEUDOEPHEDRINE d04871 BORTEZOMIB d04877 CARBIDOPA;ENTACAPONE;LEVODOPA d04878 HYDROCHLOROTHIAZIDE-OLMESARTAN d04881 OMALIZUMAB d04882 ATAZANAVIR d04888 PALONOSETRON d04890 CIPROFLOXACIN-DEXAMETHASONE OTIC d04893 VARDENAFIL d04894 DAPTOMYCIN

d04896	TADALAFIL
d04898	EPINASTINE OPHTHALMIC
d04899	MEMANTINE
d04900	SALICYLIC ACID-UREA TOPICAL
	FOSAMPRENAVIR
d04905	
u0 - 303	DEXTROMETHORPH;PHENYLEPHRINE
404044	
d04911	
10 40 45	TETRAFLUOROETHANE TOPICAL
d04915	
	FLUOXETINE-OLANZAPINE
d04920	
	VACCINE
d04921	()
	ADULT;ADOL
d04929	TROSPIUM
d04935	TINIDAZOLE
d04986	ACAMPROSATE
d05044	BETAMETHASONE-CALCIPOTRIENE
	TOPICAL
d05047	PEMETREXED
d05048	
d05049	
d05101	CETUXIMAB
d05145	ARTEMETHER-LUMEFANTRINE
d05214	
	MYCOPHENOLIC ACID
	CINACALCET
	HYALURONAN
	INSULIN GLULISINE
	BRIMONIDINE-TIMOLOL OPHTHALMIC
d05337	
10 - 000	
d05338	
d05343	HAEMOPHILUS B CONJUGATE (PRP-T)
	VACCINE
d05346	GADOBUTROL
d05348	EZETIMIBE-SIMVASTATIN
d05350	POLYETHYLENE GLYCOL 3350
d05351	ACETAMINOPHEN;
	PHENYLTOLOXAMINE;SALICYLAMIDE
d05352	EMTRICITABINE-TENOFOVIR
d05354	ABACAVIR-LAMIVUDINE
d05355	DULOXETINE
d05357	IBANDRONATE
d05366	ACETAMINOPHEN;
400000	DEXTROMETHORPHAN;DOXYLAMINE
d05395	LANTHANUM CARBONATE
d05399	AMOXICILLIN;
000000	CLARITHROMYCIN;OMEPRAZOLE
d05411	CHLORPHENIRAMINE-
u03411	METHSCOPOLAMINE
d05440	
d05412	ERLOTINIB
d05413	SOLIFENACIN
d05414	NATALIZUMAB
d05420	
10 - 10 -	LIDOCAINE;MGOH;SIMETH TOPICAL
d05421	
d05422	DARIFENACIN

d05425 LOTEPREDNOL-TOBRAMYCIN OPHTHALMIC d05428 GADOBENATE DIMEGLUMINE d05432 MENINGOCOCCAL CONJUGATE VACCINE d05433 DIGESTIVE ENZYMES;HYOSCYAMINE; PHENYLTOLOXAMIN d05435 CITRIC ACID;MG OXIDE;NA PICOSULFATE d05436 INSULIN DETEMIR d05465 CICLESONIDE d05471 ALPHA-D-GALACTOSIDASE d05473 DESLORATADINE-PSEUDOEPHEDRINE d05487 MICAFUNGIN d05488 PRAMLINTIDE d05508 PREGABALIN d05518 BROMFENAC OPHTHALMIC d05524 HYDROXYETHYL STARCH d05525 ENTECAVIR d05526 ALENDRONATE-CHOLECALCIFEROL d05529 EXENATIDE d05530 DROSPIRENONE-ESTRADIOL d05535 HEME IRON POLYPEPTIDE d05537 TIGECYCLINE d05540HYDRALAZINE-ISOSORBIDE DINITRATEd06032FLUOCINOLONE OTICd05541LIDOCAINE-TETRACAINE TOPICALd06214COLLAGEN d05543 DAPSONE TOPICAL d05578 RAMELTEON d05612 RASAGILINE d05626EVEROLIMUSd06618SODIUM SULFATEd05633NEPAFENAC OPHTHALMICd06418SODIUM SULFATEd05635METFORMIN-PIOGLITAZONEd06635MILNACIPRANd05645MEASLES;MUMPS;RUBELLA;VARICELLAd06662AMLODIPINE-VALSARTANvirus vaccinevirus vaccined06663LISDEXAMEETAMINE d05646 SACCHAROMYCES BOULARDII LYO d05647 FERRIC SUBSULFATE TOPICAL d05649 CEFTRIAXONE-LIDOCAINE d05651 SODIUM HYALURONATE TOPICAL d05659 DEFERASIROX d05691 SORAFENIB d05694 ABATACEPT d05696 LENALIDOMIDE d05702 METHYLSULFONYLMETHANE d05703 CHONDROITIN;GLUCOSAMINE; METHYLSULFONYLMETHANE d05704 IMMUNE GLOBULIN SUBCUTANEOUS d05719 RANOLAZINE d05736 LUBIPROSTONE d05753 MICONAZOLE-ZINC OXIDE TOPICAL d05770 OMEPRAZOLE-SODIUM BICARBONATE d05773 L-METHYLFOLATE d05776 IODINE d05781 TETANUS;DIPHTH;PERTUSS (TDAP) ADULT;ADOL d05782 DIPHTHERIA;TETANUS;PERTUSSIS (DTAP) d07069 RUFINAMIDE PFD d05787 ALGLUCOSIDASE ALFA d05788 DECITABINE d05807 VARENICLINE

d05813 ZOSTER VACCINE LIVE

d05815 FLUORESCEIN

d05817 HUMAN PAPILLOMAVIRUS VACCINE d05819 DIPHENHYDRAMINE-IBUPROFEN d05825 DARUNAVIR d05831 DASATINIB d05835 RANIBIZUMAB OPHTHALMIC d05842 LEVOLEUCOVORIN d05847 EFAVIRENZ;EMTRICITABINE;TENOFOVIR d05848 ROTIGOTINE d05851 LEVOCETIRIZINE d05853 POSACONAZOLE d05856 GLIMEPIRIDE-PIOGLITAZONE d05866 GUAR GUM d05874 ANTIHEMOPHILIC FACTOR-VON WILLEBRAND FACTOR d05879 PANITUMUMAB d05893 ARFORMOTEROL d05896 SITAGLIPTIN d05899 CICLESONIDE NASAL d05973 CLINDAMYCIN-TRETINOIN TOPICAL d05974 ANTIHEMOPHILIC FACTOR d05982 SINECATECHINS TOPICAL d06008 BENZYL ALCOHOL TOPICAL d06243 DIOSMIPLEX d06297 PALIPERIDONE d06370 TURMERIC LA 006662 AMEODIPINE-VALSARTAN d06663 LISDEXAMFETAMINE d06665 ALISKIREN d06672 LAPATINIB d06673 ECULIZUMAB d06720 METFORMIN-SITAGLIPTIN d06834 BISMUTH SUBCITRATE POTASSIUM;METRONIDAZO;TCN d06841 AMBRISENTAN d06842 ARMODAFINIL d06848 LUTEIN d06851 AZITHROMYCIN OPHTHALMIC d06857 ACETIC;ANTIPYRINE; BENZOCAINE; POLYCOS OTIC d06860 OXYGEN d06867 BIOTIN d06900 COLLAGEN TOPICAL d06905 AMLODIPINE-OLMESARTAN d07048 RALTEGRAVIR d07057 NILOTINIB d07064 BROMPHENIRAMINE; DIPHENHYDRAMINE;PHENYLEPHRINE d07076 ETRAVIRINE d07077 ALISKIREN-HYDROCHLOROTHIAZIDE d07080 FOSAPREPITANT d07110 NIACIN-SIMVASTATIN d07113 DESVENLAFAXINE d07121 BENDAMUSTINE

d07130	NAPROXEN-SUMATRIPTAN	d07669	INCOBOTULINUMTOXINA
	REGADENOSON		ALCAFTADINE OPHTHALM
	OLOPATADINE NASAL		ROFLUMILAST
d07132	CERTOLIZUMAB		CARBOXYMETHYLCELLUL
d07134	METHYLNALTREXONE		
		007691	MAGNESIUM;POTASSIUM; SULFATES
	DABIGATRAN	107000	
d0/162	FESOTERODINE		FINGOLIMOD
	DIFLUPREDNATE OPHTHALMIC	d07697	DROSPIRENONE;ETHINYL
d07302	CHLOPHEDIANOL;		ESTRADIOL;LEVOMEFOL
	GUAIFENESIN;PSEUDOEPHEDRINE	d07705	LURASIDONE
d07315	GLUTAMINE	d07706	CEFTAROLINE
d07320	ROMIPLOSTIM	d07707	DEXTROMETHORPHAN-QL
	BIFIDOBACTERIUM INFANTIS	d07709	METFORMIN-SAXAGLIPTIN
d07349	LACOSAMIDE	d07716	ERIBULIN
d07354	SILODOSIN	d07721	TICAGRELOR
d07356	RIVAROXABAN	d07725	ALISKIREN;AMLODIPINE;
d07371	GLUTAMINE ROMIPLOSTIM BIFIDOBACTERIUM INFANTIS LACOSAMIDE SILODOSIN RIVAROXABAN FENOFIBRIC ACID ADAPALENE-BENZOYL PEROXIDE TOPICAL ICATIBANT DEXLANSOPRAZOLE USTEKINUMAB FEBUXOSTAT		HYDROCHLOROTHIAZIDE
d07382	ADAPALENE-BENZOYL	d07727	PENICILLIN G BENZATHINE
	PEROXIDE TOPICAL	d07739	SPINOSAD TOPICAL
	ICATIBANT	d07740	VILAZODONE
	DEXLANSOPRAZOLE	d07754	AZILSARTAN
d07396	USTEKINUMAB	d07764	FAMOTIDINE-IBUPROFEN
	FEBUXOSTAT	d07766	ABIRATERONE
d07400	BIFIDOBACTERIUM-LACTOBACILLUS	d07767	LINAGLIPTIN
d07400	PRASUGREL		EZOGABINE
	DEGARELIX		RILPIVIRINE
	GOLIMUMAB		EMTRICITABINE;RILPIVIRI
d07435	AMLODIPINE;		CRIZOTINIB
	HYDROCHLOROTHIAZIDE;VALSARTAN		APIXABAN
	ILOPERIDONE	d07804	RUXOLITINIB
	BESIFLOXACIN OPHTHALMIC	d07012	AFLIBERCEPT OPHTHALM
d07440	ILOPERIDONE BESIFLOXACIN OPHTHALMIC TAPENTADOL DRONEDARONE FERUMOXYTOL LIRAGLUTIDE SAXAGLIPTIN ASENAPINE TAFLUPROST OPHTHALMIC BEPOTASTINE OPHTHALMIC ULIPRISTAL TOCILIZUMAB PAZOPANIB COPPER LACTOBACILLUS REUTERI	d07010	
	DRONEDARONE	d07010	AZILSARTAN-CHLORTHALI LACTOBACILLUS CASEI-OI
	FERUMOXYTOL	007019	ACIDS
d07459	LIRAGLUTIDE	407000	INGENOL TOPICAL
		d07022	
407407	SAXAGLIPTIN	007823	
d07473	ASENAPINE	007825	LINAGLIPTIN-METFORMIN
	TAFLUPROST OPHTHALMIC	d07854	ASCORBIC ACID-CARBON
	BEPOTASTINE OPHTHALMIC	d07863	AVANAFIL
d07495	ULIPRISTAL	d07868	AZELASTINE-FLUTICASON
	TOCILIZUMAB	d07874	PERTUZUMAB
	PAZOPANIB	d07875	LORCASERIN
	COPPER	d07876	MIRABEGRON
	LACTOBACILLUS REUTERI	d07881	PHENTERMINE-TOPIRAMA
	ESLICARBAZEPINE	d07882	CARFILZOMIB
	OFATUMUMAB		ACLIDINIUM
	ROMIDEPSIN		ICOSAPENT
d07519	HEME IRON POLYPEPTIDE-IRON	d07896	CAPSAICIN;MENTHOL;MET
	POLYSACCHARIDE		SALICYLATE TOPICAL
d07546	DALFAMPRIDINE	d07898	ELVITEGRAVIR
d07548	COLLAGENASE CLOSTRIDIUM	d07899	COBICISTAT; ELVITEGRAVI
	HISTOLYTICUM		EMTRICITABINE; TENOFO
d07631	ESOMEPRAZOLE-NAPROXEN	d07900	ENZALUTAMIDE
d07634	DUTASTERIDE-TAMSULOSIN		LINACLOTIDE
	PITAVASTATIN		TERIFLUNOMIDE
	DENOSUMAB		REGORAFENIB
	ONABOTULINUMTOXINA		TOFACITINIB
	ABOBOTULINUMTOXINA		DAPAGLIFLOZIN
	FORMOTEROL-MOMETASONE		CABOZANTINIB
	AMLODIPINE;		TEDUGLUTIDE
307000	HYDROCHLOROTHIAZIDE;OLMESARTAN		ALOGLIPTIN-METFORMIN
		007304	

d07669	INCOBOTULINUMTOXINA
d07670	ALCAFTADINE OPHTHALMIC
d07684	ROFLUMILAST
d07685	CARBOXYMETHYLCELLULOSE
d07691	MAGNESIUM;POTASSIUM;SODIUM
007031	SULFATES
d07692	FINGOLIMOD
d07692	DROSPIRENONE;ETHINYL
u07097	ESTRADIOL;LEVOMEFOLATE
407705	LURASIDONE
d07705	
d07706	
d07707	DEXTROMETHORPHAN-QUINIDINE METFORMIN-SAXAGLIPTIN
d07709	
d07716	ERIBULIN
d07721	TICAGRELOR
d07725	
	HYDROCHLOROTHIAZIDE
d07727	PENICILLIN G BENZATHINE
d07739	SPINOSAD TOPICAL
d07740	VILAZODONE
d07754	AZILSARTAN
d07764	FAMOTIDINE-IBUPROFEN
d07766	ABIRATERONE
d07767	LINAGLIPTIN
d07769	EZOGABINE
	RILPIVIRINE
d07796	- , ,
d07800	CRIZOTINIB
d07804	APIXABAN
d07812	RUXOLITINIB
d07815	AFLIBERCEPT OPHTHALMIC
d07818	AZILSARTAN-CHLORTHALIDONE
d07819	LACTOBACILLUS CASEI-OMEGA-3 FATTY
	ACIDS
d07822	INGENOL TOPICAL
d07823	AXITINIB
d07825	LINAGLIPTIN-METFORMIN
d07854	ASCORBIC ACID-CARBONYL IRON
d07863	AVANAFIL
d07868	AZELASTINE-FLUTICASONE NASAL
d07874	PERTUZUMAB
d07875	LORCASERIN
d07876	MIRABEGRON
d07881	PHENTERMINE-TOPIRAMATE
d07882	CARFILZOMIB
d07885	ACLIDINIUM
d07891	ICOSAPENT
d07896	CAPSAICIN;MENTHOL;METHYL
	SALICYLATE TOPICAL
d07898	ELVITEGRAVIR
d07899	COBICISTAT;ELVITEGRAVIR;
	EMTRICITABINE; TENOFOV
d07900	ENZALUTAMIDE
d07902	LINACLOTIDE
d07905	TERIFLUNOMIDE
d07913	REGORAFENIB
d07925	
	DAPAGLIFLOZIN
d07920	
	TEDUGLUTIDE
001330	

d07965 ALOGLIPTIN-PIOGLITAZONE d08041 POMALIDOMIDE d08070 OSPEMIFENE d08079 DIMETHYL FUMARATE d08080 CANAGLIFLOZIN d08086 BRIMONIDINE-BRINZOLAMIDE **OPHTHALMIC** d08089 ATORVASTATIN-EZETIMIBE d08100 FLUTICASONE-VILANTEROL d08104 TRAMETINIB d08113 AFATINIB d08114 LEVOMILNACIPRAN d08117 DOLUTEGRAVIR d08119 BRIMONIDINE TOPICAL d08125 VORTIOXETINE d08128 DEXTRANOMER-SODIUM HYALURONATE d08170 IBRUTINIB d08182 SIMEPREVIR d08184 SOFOSBUVIR d08188 UMECLIDINIUM-VILANTEROL n00002 RED YEAST RICE-UBIQUINONE n00011 LIDOCAINE; BELLADONNA; ALUMINUM HYDROXIDE-MAGNESIUM HYDROXIDE n08004 BIRTH CONTROL PILLS n08012 PACKED RED BLOOD CELLS n08013 CALCIUM HYDROXYLAPATITE n08027 BOSWELLIC ACID n08028 CHLORINE BLEACH n08029 CODEINE; ACETAMINOPHEN; CAFFEINE; BUTALBITAL n08041 5-AMINOSALICYLATES n08045 MALIC ACID n08053 ECZEMA CREAM n08058 POMEGRANATE JUICE n08061 PYRIDINE n08063 TROPONIN n08069 IODOFORM n08073 HELICOBACTER PYLORI VACCINE n08078 EMPIRIC ANTIBIOTICS n08079 PROSTATE MEDICATION n08081 DABIGATRAN n08105 RESVERATROL n08113 ZINC-CALCIUM n08138 LIDOCAINE-CEFTRIAXONE n08140 OMEGA 6 FATTY ACID n08191 PRUNE JUICE n08201 POLYETHYLENE GLYCOL 400 n08223 FLUOROQUINOLONES n08237 N-ACETYL-CYSTEINE n08242 GYMNEMA SYLVESTRE n08258 TETROFOSMIN n08259 HONEY, TOPICAL n09000 PETROLATUM TOPICAL:SORBITAN SESQUIOLEATE; METHYL PARABEN n09001 RADIOCONTRAST AGENTS n09002 CALCIUM CITRATE-MAGNESIUM n09006 HYDROXYDIONE n09010 LIDOCAINE-TRIAMCINOLONE n09012 BUPIVACAINE-METHYLPREDNISOLONE

n09027	MAGNESIUM HYDROXIDE-
	BELLADONNA;ERGOTAMINE;
	PHENOBARBITAL
n09033	OLIVE LEAF EXTRACT
n09035	LIDOCAINE;ATROPINE;
	HYOSCYAMINE;PB;SCOPOLAMINE;
	CALCIUM CARBONATE
n09046	ACAI
n09049	POLYSORBATE 80 GLYCEROL
n09063	ARGENTYN
n09069	LIDOCAINE OPHTHALMIC;
	DIPHENHYDRAMINE;
	NYSTATIN
n09070	GLUCOSE-INSULIN
n09081	DIMETHYL SULFOXIDE;HEPARIN;
	CORTISONE; POTASSIUM BICARBONATE
n09083	ARNICA MONTANA
n09100	CAPRYLIDENE
n09114	CHERRY EXTRACT
n09135	LIDOCAINE;EPINEPHRINE;TETRACAINE
n09140	SILVER NITRATE TOPICAL-POTASSIUM
	NITRATE
n09147	WHEY PROTEIN ISOLATE
n09148	OMEGA-3 POLYUNSATURATED FATTY
	ACIDS;OMEGA-6 POLYUNSATURATED
	FATTY ACIDS;OMEGA-9
	POLYUNSATURATED FATTY ACIDS
n09150	SODIUM CHLORIDE-SODIUM
	BICARBONATE
n09155	ALUMINUM HYDROXIDE-MAGNESIUM
	HYDROXIDE-LIDOCAINE
n09181	ORAL NUTRITIONAL SUPPLEMENTS
n09185	MISCELLANEOUS ANTIBIOTICS
n09186	ABIRATERONE
n09189	RIVAROXABAN
n09204	MUPIROCIN TOPICAL;BETAMETHASONE
	TOPICAL;MICONAZOLE
	TOPICAL;IBUPROFEN
n10015	GLUTATHIONE
n11002	DIPHENHYDRAMINE-ALUMINUM
	HYDROXIDE-MAGNESIUM HYDROXIDE
n11003	PRILOCAINE TOPICAL;LIDOCAINE
	TOPICAL;TETRACAINE TOPICAL
n11008	CANNABIS (MEDICAL MARIJUANA)
n11009	TNF ALPHA INHIBITOR
n12001	ASCORBIC ACID-BIOFLAVONOIDS
n12004	FOLIC ACID;ASCORBIC
	ACID;NIACIN;THIAMINE;
	RIBOFLAVIN;PYRIDOXINE;
	CYANOCOBALAMIN;PANTOTHENATE;
	BIOTIN
n12009	KETAMINE;BACLOFEN;
	CYCLOBENZAPRINE;
10015	GABAPENTIN;LIDOCAINE
n12017	FLUOROURACIL;OXALIPLATIN;
- 40000	
n12022	BETA-SITOSTEROL
n13006	
n14000	CISPLATIN-IRINOTECAN

n14002 BISMUTH SUBNITRATE; METRONIDAZOLE;TETRACYCLINE n14003 CYTOXAN;ETOPOSIDE; VINCRISTINE;PREDNISONE n14005 BUPROPION-NALTREXONE n14006 CURCUMIN-BOSWELLIN n14007 BACLOFEN;CYCLOBENZAPRINE; DICLOFENAC;TETRACAINE n14008 EMPAGLIFLOZIN n14009 EFINACONAZOLE n14011 RETIGABINE

B. DRUG ENTRY CODES AND NAMES IN NUMERIC ORDER

 B. DRUG ENTRY CODES AND NAMES IN NUMERIC ORDER

 00000
 SENOSOL
 00142
 ANTIANXIETY
 00227
 PLEXION

 00000
 SENOSOL
 00150
 MEDICATION
 00322
 WIRHO SDF

 00000
 SENOSOL
 00151
 MEDICATION
 00332
 CAM

 00000
 SENOSOL
 00151
 MCDOERM CQ PATCH
 00333
 CICAM

 00000
 SENOSOL
 00151
 FUEL
 00331
 FUEL
 00331
 FUEL
 00332
 FUEL
 00331
 FUEL
 00331

<page-header>2014 NAMES MERCED CARE2014 B2014 BADAM2015 ACARE2144 BADAM2016 ACARE2144 BADAM2017 ACARE2144 BADAM2018 ACARE2144 BADAM2018 ACARE2144 BADAM2019 ACARE2145 BATTEND2019 ACARE2145 BATTEND2019 ACARE2156 BATTEND (CARE2019 ACARE2157 ALTEND (CARE2019 A

<page-header>
 MARCAN DECOMPONDENCINC CONTROL DECOMPONDENCINC DEPENDENT IN DEPARTMENT I

<page-header>2014 NAME ALCONSTANT04079GLUCALX0407GLUCALXGLUCALXGLUCALX</td

04440 BISMUTH SUBSALICYLATE 04637 PROSHIELD

<page-header>9642 302014 NAMES MICRO-DATA FILE DOCUMENTATION - VPENDIX II, DRUG ENTRY LIST04440BISMUTH SUBSALICYLATE
044420487 CROSHIELD
0442 O'NST-CAL
0442 O'NST-CAL
0442 O'NST-CAL
0442 O'NST-CAL
0442 O'NST-CAL
0444 D'NORMUNI LACTATE
0444 D'NORMUNI LATTATE
0444 D'NORMUNI LACTATE
0444 D'NORMUNI LACTATE
04 05099 CLOTRIMAZOLE-

<page-header>2014 NAMES MICRO-DATA FLED COLUMENTATION, APPENDIX IN OUCCOUNTS OF A DATA PARA00000 COLUMENTATION00000 COL

<page-header>

 PAGE 2014
 2014 NAMES CALCAL CALCULATION CONCENTION C

<page-header>2014 NAMES CARCARACTER DECOMMENTATION, APPCHAIR DECOMMENTATION733773377337733773387339733973397330</td

<page-header>

<page-header><page-header>

<page-header>

<page-header>2014 NAMES AND CONTRACT ALL CONCUMENTATION APPENDIX INCLUSION0024CONTRACT0937 SULPONATE
0938 DIFFORME
0938 DIFFOR

 1945240
 2014 NAMES ALL CALCAL ALL PLACE UNDER CALCAL ALL CALCAL CALCAL CALCAL ALL CALCAL ALL CALCAL CALCAL ALL CALCAL CALCAL ALL CALCAL CALL CALCAL CALCAL ALL CALCAL CALCAL ALL CALCAL CALL CAL

<page-header>2014 NAMES MORE DECIDENT CONCENTRATION APPENDENT INCOMPACTATION2014 AUX1011MILORIDE12122171 CHARLER1012MILORIDE12122171 CHARLER1013MILORIDE12122171 CHARLER1014MILORIDE12122171 CHARLER1015MILORIDE12122171 CHARLER1016MILORIDE12142171 CHARLER1017MILORIDE12142171 CHARLER1018MILORIDE12142171 CHARLER1019MILORIDE12142171 CHARLER1019MILORIDE12162171 CHARLER1019MILORIDE12162171 CHARLER1019MILORIDE12142171 CHARLER1019MILORIDE12142171 CHARLER1019MILORIDE12142171 CHARLER1019MILORIDE12142171 CHARLER1019MILORIDE12142171 CHARLER1019MILORIDE12142171 CHARLER1019MILORIDE121

PAGE 244 2014 NAMCS MICRO-DATA FILE DOCUMENTATION – APPENDIX III, DRUG ENTRY LIST

<page-header>2014 NAMES MERCEDADA FLEE DOCUMENTATION, APPENDIX II - DRUG PATTERNAM1400COLUMNA1400COLUMNA14024FENGADAN1410LUDENT1410LUDENT14025FENGADAN1410LUDENT1410LUDENT14026FENGADAN1410LUDENT1410LUDENT14036FENGADAN1411SATELLAR SR1411SATELLAR SR14036FENGADAN1411SATELLAR SR1411SATELLAR SR14036FENGADAN1411SATELLAR SR1411SATELLAR SR14036FENGADAN1411SATELLAR SR1411SATELLAR SR14036FENGADAN1411SATELLAR SR1411SATELLAR SR14036FENGADAN1412SATELLAR SR1411SATELLAR SR14036FENGADAN1412SATELLAR SR1412SATELLAR SR14036FENGADAN1412SATELLAR SR1412SATELLAR SR14036FENGADAN1412SATELLAR SR1412SATELLAR SR14036FENGADAN1412SATELLAR SR1412SATELLAR SR14036FENGADAN1412SATELLAR SR1412SATELLAR SR14036FENGADAN1412SATELLAR SR1414SATELLAR SR14036FENGADAN1416FENGADAN1416SATELLAR SR14036FENGADAN1417FENGADAN1416SATELLAR SR14036FENGADAN1417FENGADAN1416SATELLAR SR14036F

<page-header>2014 NAME ALCONSTANT2012 NUMERIAN
VERNEN2110 NUMERIAN
VE

<page-header>PAGE 402014 NORCET REALSTATE STATE ST

<page-header>2014 NUMEX NUCLEAR NUMBER31335THERAPE UT30002015 NULFARILATION31335THERAPE UT31352016 NULFARILATION31335THERAPE UT31352017 NUMEX31355THERAPE UT31352018 NULFARIE31355THERAPE UT31352018 NULFARIE31555THERAPE UT31352019 NULFARIE31555THERAPE UT31352019 NUMER31555THERAPE UT31352019 NUMER31555THERAPE UT31352010 NUMER31555THERAPE UT31352011 NUMER31555THERAPE UT31352012 NUMER31555THERAPE UT31352013 NUMERE31555THERAPE UT31352014 NUMERE31555THERAPE UT31352015 NUMERE31650THERAPE UT31352015 NUMERE31650THERAPE UT31652015 NUMERE31650THERAPE UT31752015 NUMERE31650THERAPE UT31752015 NUMERE31755THERAPE UT<t

<page-header>2014 NAMES MICROADER PELCICICATION OF POPULATION OF POP

<page-header>PAGE 202014 MACRE CONCUMENTATION - APPENDIX I, DRUG CONCUMENTATION - APPENDIX I, D

<page-header>2014 NAMES MUCCIDENT FLE DOCUMENTATION, APPENDIX I - DATA SECOND3338 MINALER3338 MINALER3338 MINALER3338 MINALER3338 MINALER3338 MINALER3338 MINALER3338 MINALER3349 MINALER3440 MINALER3441 CERPACIN3441 MINALER3441 MINALER3442 MINALER3442 MINALER3444 MINALER

<page-header>20232014 NAME CONCRETE CONCRETE CONCRETE CONCRETE CONCRETE CONCRETE CONCRETE2025PRAVAS</

<page-header>2014 NUMBER97181NUT III9812981

99059 MICARDIS 99066 SINEMET CR 99067 VIOXX 99068 ZOVIA 1/35E 99073 CIPRO HC 99073 CIPROTIC 99074 CITALOPRAM 99075 ENBREL 99075 ENBREL 99076 GLUCOSAMINE SULFATE 99211 CITRACAL + D 99213 DIASTAT 99080 MIRALAX 99088 ZIAGEN 99089 ACIPHEX 99089ACIPHEX99216FEXOFENADINE99090ACTOS99218FORMULA SUPPLEMENT99095HERCEPTIN99219GINKGO BILOBA99098NITROQUICK99222IV SEDATION99099PLETAL99223LEVORA99101QUETIAPINE FUMARATE99224OMEGA-399102THERATEARS99225RALOXIFENE99105ULTRA MEGA ONE99227UNIRETIC99106XOPENEX99999ILLEGIBLE 99106 XOPENEX 99107 ZADITOR 99108 BETA AGONIST 99109 BUFFERED LIDOCAINE 99112 D-5-W 99114 ENDOCET 99117 LIDOCAINE BICARBONATE 99118 NECON 99119 NITROPASTE 99123 MORPHINE SULFATE 99124 NASAL DROPS 99125 NITRODRIP 99127 LIDOCAINE/EPINEPHRINE/ TETRACAINE 99128 LIPASE 99129 Q-PAP 99132 EVISTA 99133 ALBUTEROL 99138 KELP 99139 MAGIC MOUTHWASH 99142 PRENATAL VITAMINS W/ IRON 99144 RACEMIC EPINEPHRINE 99145 UROGESIC BLUE 99152 EVENING PRIMROSE OIL 99155 L-CARNITINE 99156 LIPID LOWERING AGENT 99157 LOPIDINE 99161 ROPINIROLE HCL 99167 COQ-10 99168 CREATINE 99169 DEPO-MEDROXY-PROGESTERONE 99171 NETTLE 99172 NOVOLIN 70/30 99174 PHOSPHORUS 99176 PLEDGETS 99183 THERAVITE 99184 TRIVORA 99187 ACTICIN 99188 BOOST PLUS 99189 CALCIUM W/ VITAMIN D

99190 CORTIC 99194 ABACAVIR SULFATE 99201 ORTHO-CYCLEN 99203 RITUXIMAB 99204 REOPRO 99207 BRIMONIDINE 99210 CARTIA 99214 DIOVAN HCT 99216 FEXOFENADINE 99999 ILLEGIBLE

Appendix III Multum Lexicon End-User License Agreement

1. Introduction

A. This License Agreement (the "License") applies to the Multum Lexicon database (the "Database"). This License does not apply to any other products or services of Cerner Multum, Inc. ("Multum"). A "work based on the Database" means either the Database or any derivative work under copyright law; i.e., a work containing the Database or a substantial portion of it, either verbatim or with modifications. A translation of the Database is included without limitation in the term "modification". Each end-user/licensee is addressed herein as "you".

B. Your use of the Database acknowledges acceptance of these restrictions, disclaimers, and limitations. You expressly acknowledge and agree that Multum is not responsible for the results of your decisions resulting from the use of the Database, including, but not limited to, your choosing to seek or not to seek professional medical care, or from choosing or not choosing specific treatment based on the Database.

C. Every effort has been made to ensure that the information provided in the Database is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive.

D. Multum does not assume any responsibility for any aspect of healthcare administered or not administered with the aid of information the Database provides.

2. Terms and Conditions for Copying, Distribution and Modification

A. You may copy and distribute verbatim copies of the Database as you receive it, in any medium, provided that you conspicuously and appropriately publish on each copy an appropriate copyright notice and disclaimer of warranty; keep intact all the notices that refer to this License and to the absence of any warranty; and give any other recipients of the Database a copy of this License (the readme.txt file) along with the Database and anything else that is part of the package, which should be identified.

B. You may modify your copy or copies of the Database or any portion of it to form a derivative work, and copy and distribute such modifications or work under the terms of Section 2.A. above, provided that you also meet all of these conditions:

i) You must cause the modified files to carry prominent notices stating that they are derived from the Multum Lexicon database from Cerner Multum, Inc. and that you changed the files and the date of any change(s).

ii) If you incorporate modified files into a computer program, you must cause it, when started running for interactive use in the most ordinary way, to print or display an announcement including an appropriate copyright notice, a notice that you have modified the Multum Lexicon database from Cerner Multum, Inc., and a notice that there is no warranty (or that you provide the warranty) and telling the user how to view a copy of this License.

C. It is not the intent of this section to claim rights or contest your rights to work written entirely by you; rather, the intent is to exercise the right to control the distribution of derivative or collective works based on the Database.

D. You may copy and distribute the Database (or a work based on it, under Section 2.B.) in an encoded form under the terms of Sections 2.A. and 2.B. above provided that you also do one of the following:

i) Accompany it with the complete corresponding machine-readable plain text, which must be distributed under the terms of Sections 2.A and 2.B. above on a medium customarily used for software interchange; or,

ii) Accompany it with a written offer to give any third party, for no charge, a complete machine-readable copy of the Database (and the entirety of your derivative work based on it, under Section 2.B.), to be distributed under the terms of Sections 2.A. and 2.B. above on a medium customarily used for software interchange.

E. You may not copy, modify, sublicense, or distribute the Database except as expressly provided under this License. Any attempt otherwise to copy, modify, sublicense or distribute the Database will automatically terminate your rights under this License. However, parties who have received copies, or rights, from you under this License will not have their licenses terminated so long as such parties remain in full compliance.

F. You are not required to accept this License. However, nothing else grants you permission to copy, modify or distribute the Database or its derivative works. These actions are prohibited by law if you do not accept this License. Therefore, by copying, modifying or distributing the Database (or any work based on the Database), you indicate your acceptance of this License to do so, and all its terms and conditions for copying, distributing or modifying the Database or works based on it.

G. Each time you redistribute the Database (or any work based on the Database), the recipient automatically receives a license from Multum to copy, distribute or modify the Database subject to these terms and conditions. You may not impose any further restrictions on the recipients' exercise of the rights granted herein. You are not responsible for enforcing compliance by third parties to this License.

3. Disclaimer of Warranties; Limitation of Damages

A. BECAUSE THE DATABASE IS LICENSED FREE OF CHARGE, THERE IS NO WARRANTY FOR THE PROGRAM OR DATA, TO THE EXTENT PERMITTED BY APPLICABLE LAW. EXCEPT WHEN OTHERWISE STATED IN WRITING. MULTUM AND/OR OTHER PARTIES PROVIDE THE DATABASE "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED, STATUTORY OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE ENTIRE RISK AS TO THE QUALITY AND PERFORMANCE OF THE DATABASE IS WITH YOU. SHOULD THE DATABASE PROVE DEFECTIVE, INCOMPLETE, OR INACCURATE, YOU ASSUME THE RESPONSIBILITY AND COST OF ALL NECESSARY SERVICING, REPAIR OR CORRECTION.

B. IN NO EVENT (UNLESS REQUIRED BY APPLICABLE LAW OR AGREED TO IN WRITING) WILL MULTUM, OR ANY OTHER PARTY WHO MAY MODIFY AND/OR REDISTRIBUTE THE DATABASE AS PERMITTED ABOVE, BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR INDIRECT DAMAGES, INCLUDING DAMAGES FOR LOSS OF PROFITS, LOSS OF BUSINESS, OR DOWN TIME, EVEN IF MULTUM OR ANY OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

C. IN ADDITION, WITHOUT LIMITING THE FOREGOING, THE DATABASE HAS BEEN DESIGNED FOR USE IN THE UNITED STATES ONLY AND COVERS THE DRUG PRODUCTS USED IN PRACTICE IN THE UNITED STATES. MULTUM PROVIDES NO CLINICAL INFORMATION OR CHECKS FOR DRUGS NOT AVAILABLE FOR SALE IN THE UNITED STATES AND CLINICAL PRACTICE PATTERNS OUTSIDE THE UNITED STATES MAY DIFFER SUBSTANTIALLY FROM INFORMATION SUPPLIED BY THE DATABASE. MULTUM DOES NOT WARRANT THAT USES OUTSIDE THE UNITED STATES ARE APPROPRIATE.

D. You acknowledge that updates to the Database are at the sole discretion of Multum. Multum makes no representations or warranties whatsoever, express or implied, with respect to the compatibility of the Database, or future releases thereof, with any computer hardware or software, nor does Multum represent or warrant the continuity of the features or the facilities provided by or through the Database as between various releases thereof.

E. Any warranties expressly provided herein do not apply if: (i) the end-user alters, mishandles or improperly uses, stores or installs all, or any part, of the Database, (ii) the end-user uses, stores or installs the Database on a computer system which fails to meet the specifications provided by Multum, or (iii) the breach of warranty arises out of or in connection with acts or omissions of persons other than Multum.

4. Assumption of Risk, Disclaimer of Liability, Indemnity

A. THE END-USER ASSUMES ALL RISK FOR SELECTION AND USE OF THE DATABASE AND CONTENT PROVIDED THEREON. MULTUM SHALL NOT BE RESPONSIBLE FOR ANY ERRORS, MISSTATEMENTS, INACCURACIES OR OMISSIONS REGARDING CONTENT DELIVERED THROUGH THE DATABASE OR ANY DELAYS IN OR INTERRUPTIONS OF SUCH DELIVERY.

B. THE END-USER ACKNOWLEDGES THAT MULTUM: (A) HAS NO CONTROL OF OR RESPONSIBILITY FOR THE END-USER'S USE OF THE DATABASE OR CONTENT PROVIDED THEREON, (B) HAS NO KNOWLEDGE OF THE SPECIFIC OR UNIQUE CIRCUMSTANCES UNDER WHICH THE DATABASE OR CONTENT PROVIDED THEREON MAY BE USED BY THE END-USER, (C) UNDERTAKES NO OBLIGATION TO SUPPLEMENT OR UPDATE CONTENT OF THE DATABASE, AND (D) HAS NO LIABILITY TO ANY PERSON FOR ANY DATA OR INFORMATION INPUT ON THE DATABASE BY PERSONS OTHER THAN MULTUM.

C. MULTUM SHALL NOT BE LIABLE TO ANY PERSON (INCLUDING BUT NOT LIMITED TO THE END-USER AND PERSONS TREATED BY OR ON BEHALF OF THE END-USER) FOR, AND THE END-USER AGREES TO INDEMNIFY AND HOLD MULTUM HARMLESS FROM ANY CLAIMS, LAWSUITS, PROCEEDINGS, COSTS, ATTORNEYS' FEES, DAMAGES OR OTHER LOSSES (COLLECTIVELY, "LOSSES") ARISING OUT OF OR RELATING TO (A) THE END-USER'S USE OF THE DATABASE OR CONTENT PROVIDED THEREON OR ANY EQUIPMENT FURNISHED IN CONNECTION THEREWITH AND (B) ANY DATA OR INFORMATION INPUT ON THE DATABASE BY END-USER, IN ALL CASES INCLUDING BUT NOT LIMITED TO LOSSES FOR TORT, PERSONAL INJURY, MEDICAL MALPRACTICE OR PRODUCT LIABILITY.

5. Miscellaneous

A. You warrant that you have authority within the organization you identified during registration for the Database to enter into license agreements with other organizations including Multum.

B. You agree that Multum may identify you and/or your organization by name as a "licensee", "licensed user", or "licensing organization" of the Database or a "client" of Multum in Multum's external market communications. You also agree that Multum may issue, if it desires, a press release stating that you and/or your organization have licensed the Database.

C. If conditions are imposed on you (whether by court order, agreement or otherwise) that contradict the conditions of this License, they do not excuse you from the conditions of this License. If you cannot distribute so as to satisfy simultaneously your obligations under this License and any other obligations, then as a consequence you may not distribute the Database at all.

D. If any portion of this License is held invalid or unenforceable under any particular circumstance, the balance of this License is intended to apply and the License as a whole is intended to apply in other circumstances.

E. If the distribution and/or use of the Database is or becomes restricted in certain countries either by patents or by copyrighted interfaces, Multum may add an explicit geographical distribution limitation excluding those countries, so that distribution is permitted only in or among countries not thus excluded. In such case, this License incorporates the limitation as if written in the body of this License.

Multum Lexicon Copyright (c) 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2008 Cerner Multum, Inc. 2000 South Colorado Blvd, Suite 11000 Denver, Colorado 80222

APPENDIX III. MULTUM CLASSIFICATION OF THERAPEUTIC CLASSES (DRUG CATEGORIES)

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
001	anti-infectives	002	Amebicides		
001	anti-infectives	003	Anthelmintics		
001	anti-infectives	004	Antifungals	235	polyenes
001	anti-infectives	004	Antifungals	236	azole antifungals
001	anti-infectives	004	Antifungals	237	miscellaneous antifungals
001	anti-infectives	004	Antifungals	310	echinocandins
001	anti-infectives	005	antimalarial agents	238	antimalarial quinolones
001	anti-infectives	005	antimalarial agents	239	miscellaneous antimalarials
001	anti-infectives	005	antimalarial agents	328	antimalarial combinations
001	anti-infectives	006	antituberculosis agents	230	aminosalicylates
001	anti-infectives	006	antituberculosis agents	231	thiocarbamide derivatives
001	anti-infectives	006	antituberculosis agents	232	rifamycin derivatives
001	anti-infectives	006	antituberculosis agents	233	streptomyces derivatives
001	anti-infectives	006	antituberculosis agents	234	miscellaneous antituberculosis agents
001	anti-infectives	006	antituberculosis agents	329	antituberculosis combinations
001	anti-infectives	006	antituberculosis agents	457	hydrazide derivatives
001	anti-infectives	007	antiviral agents	175	protease inhibitors
001	anti-infectives	007	antiviral agents	176	NRTIS
001	anti-infectives	007	antiviral agents	177	miscellaneous antivirals
001	anti-infectives	007	antiviral agents	227	NNRTIS
001	anti-infectives	007	antiviral agents	228	adamantane antivirals
001	anti-infectives	007	antiviral agents	229	purine nucleosides
001	anti-infectives	007	antiviral agents	281	neuraminidase inhibitors
001	anti-infectives	007	antiviral agents	327	antiviral combinations
001	anti-infectives	007	antiviral agents	330	antiviral interferons
001	anti-infectives	007	antiviral agents	364	antiviral chemokine receptor antagonist

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
001	anti-infectives	007	antiviral agents	366	integrase strand transfer inhibitor
001	anti-infectives	008	carbapenems		
001	anti-infectives	009	cephalosporins	159	first generation cephalosporins
001	anti-infectives	009	cephalosporins	160	second generation cephalosporins
001	anti-infectives	009	cephalosporins	161	third generation cephalosporins
001	anti-infectives	009	cephalosporins	162	fourth generation cephalosporins
001	anti-infectives	009	cephalosporins	379	fifth generation cephalosporins
001	anti-infectives	010	leprostatics		
001	anti-infectives	011	macrolide derivatives	304	macrolides
001	anti-infectives	011	macrolide derivatives	305	ketolides
001	anti-infectives	012	miscellaneous antibiotics		
001	anti-infectives	013	penicillins	222	penicillinase resistant penicillins
001	anti-infectives	013	penicillins	223	antipseudomonal penicillins
001	anti-infectives	013	penicillins	224	aminopenicillins
001	anti-infectives	013	penicillins	225	beta-lactamase inhibitors
001	anti-infectives	013	penicillins	226	natural penicillins
001	anti-infectives	014	quinolones		
001	anti-infectives	015	sulfonamides		
001	anti-infectives	016	tetracyclines		
001	anti-infectives	017	urinary anti-infectives		
001	anti-infectives	018	aminoglycosides		
001	anti-infectives	240	lincomycin derivatives		
001	anti-infectives	315	glycylcyclines		
001	anti-infectives	406	glycopeptide antibiotics		
020	antineoplastics	021	alkylating agents		
020	antineoplastics	022	antineoplastic antibiotics		
020	antineoplastics	023	antimetabolites		
020	antineoplastics	024	antineoplastic hormones		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
020	antineoplastics	025	miscellaneous antineoplastics		
020	antineoplastics	026	mitotic inhibitors		
020	antineoplastics	323	antineoplastic monoclonal antibodies		
020	antineoplastics	324	antineoplastic interferons		
020	antineoplastics	343	tyrosine kinase inhibitors		
020	antineoplastics	383	antineoplastic detoxifying agents		
020	antineoplastics	391	MTOR kinase inhibitors		
020	antineoplastics	397	multikinase inhibitors		
020	antineoplastics	398	BCR-ABL tyrosine kinase inhibitors		
020	antineoplastics	399	CD52 monoclonal antibodies		
020	antineoplastics	400	CD33 monoclonal antibodies		
020	antineoplastics	401	CD20 monoclonal antibodies		
020	antineoplastics	402	VEFG/VEGFR inhibitors		
020	antineoplastics	403	MTOR inhibitors		
020	antineoplastics	404	EGFR inhibitors		
020	antineoplastics	405	HER2 inhibitors		
020	antineoplastics	408	histone deacetylase inhibitors		
020	antineoplastics	429	trifunctional monoclonal antibodies		
020	antineoplastics	431	anti-CTLA-4 monoclonal antibodies		
020	antineoplastics	447	CD-30 monoclonal antibodies		
020	antineoplastics	449	hedgehog pathway inhibitors		
020	antineoplastics	454	proteasome inhibitors		
028	biological	030	antitoxins and antivenins		
028	biological	034	in vivo diagnostic biologicals		
028	biological	036	erythropoiesis-stimulating agents		
028	biological	390	hematopoietic stem cell mobilizer		
040	cardiovascular agents	041	agents for hypertensive emergencies		
040	cardiovascular agents	042	angiotensin converting enzyme inhibitors		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
040	cardiovascular agents	043	antiadrenergic agents, peripherally acting		
040	cardiovascular agents	044	antiadrenergic agents, centrally acting		
040	cardiovascular agents	045	antianginal agents		
040	cardiovascular agents	046	antiarrhythmic agents	385	group I antiarrhythmics
040	cardiovascular agents	046	antiarrhythmic agents	386	group II antiarrhythmics
040	cardiovascular agents	046	antiarrhythmic agents	387	group III antiarrhythmics
040	cardiovascular agents	046	antiarrhythmic agents	388	group IV antiarrhythmics
040	cardiovascular agents	046	antiarrhythmic agents	389	group V antiarrhythmics
040	cardiovascular agents	047	beta-adrenergic blocking agents	274	cardioselective beta blockers
040	cardiovascular agents	047	beta-adrenergic blocking agents	275	non-cardioselective beta blockers
040	cardiovascular agents	048	calcium channel blocking agents		
040	cardiovascular agents	049	diuretics	154	loop diuretics
040	cardiovascular agents	049	diuretics	155	potassium-sparing diuretics
040	cardiovascular agents	049	diuretics	156	thiazide and thiazide-like diuretics
040	cardiovascular agents	049	diuretics	157	carbonic anhydrase inhibitors
040	cardiovascular agents	049	diuretics	158	miscellaneous diuretics
040	cardiovascular agents	050	inotropic agents		
040	cardiovascular agents	051	miscellaneous cardiovascular agents		
040	cardiovascular agents	052	peripheral vasodilators		
040	cardiovascular agents	053	vasodilators		
040	cardiovascular agents	054	vasopressors		
040	cardiovascular agents	055	antihypertensive combinations		
040	cardiovascular agents	056	angiotensin II inhibitors		
040	cardiovascular agents	303	agents for pulmonary hypertension		
040	cardiovascular agents	319	vasopressin antagonists		
040	cardiovascular agents	325	sclerosing agents		
040	cardiovascular agents	340	aldosterone receptor agonists		
040	cardiovascular agents	342	renin inhibitors		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
			CATEGORT NAME		
040	cardiovascular agents	396	prostaglandin D2 antagonists		
040	cardiovascular agents	430	anticholinergic chronotropic agents		
040	cardiovascular agents	433	catecholamines		
057	central nervous system agents	058	analgesics	059	miscellaneous analgesics
057	central nervous system agents	058	analgesics	060	narcotic analgesics
057	central nervous system agents	058	analgesics	061	nonsteroidal anti-inflammatory agents
057	central nervous system agents	058	analgesics	062	salicylates
057	central nervous system agents	058	analgesics	063	analgesic combinations
057	central nervous system agents	058	analgesics	191	narcotic analgesic combinations
057	central nervous system agents	058	analgesics	193	antimigraine agents
057	central nervous system agents	058	analgesics	278	cox-2 inhibitors
057	central nervous system agents	064	anticonvulsants	199	hydantoin anticonvulsants
057	central nervous system agents	064	anticonvulsants	200	succinimide anticonvulsants
057	central nervous system agents	064	anticonvulsants	201	barbiturate anticonvulsants
057	central nervous system agents	064	anticonvulsants	202	oxazolidinedione anticonvulsants
057	central nervous system agents	064	anticonvulsants	203	benzodiazepine anticonvulsants
057	central nervous system agents	064	anticonvulsants	204	miscellaneous anticonvulsants
057	central nervous system agents	064	anticonvulsants	311	dibenzazepine anticonvulsants
057	central nervous system agents	064	anticonvulsants	345	fatty acid derivative anticonvulsants
					gamma-aminobutyric acid reuptake
057	central nervous system agents	064	anticonvulsants	346	inhibitors
057	central nervous system agents	064	anticonvulsants	347	gamma-aminobutyric acid analogs
057	central nervous system agents	064	anticonvulsants	348	triazine anticonvulsants
057	central nervous system agents	064	anticonvulsants	349	carbamate anticonvulsants
057	central nervous system agents	064	anticonvulsants	350	pyrrolidine anticonvulsants
					carbonic anhydrase inhibitor
057	central nervous system agents	064	anticonvulsants	351	anticonvulsants
057	central nervous system agents	064	anticonvulsants	352	urea anticonvulsants
057	central nervous system agents	064	anticonvulsants	446	neuronal potassium channel openers
057	central nervous system agents	064	anticonvulsants	456	ANPA receptor antagonists
057	central nervous system agents	065	antiemetic/antivertigo agents	195	5HT3 receptor antagonists

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
057	central nervous system agents	065	antiemetic/antivertigo agents	196	phenothiazine antiemetics
057	central nervous system agents	065	antiemetic/antivertigo agents	197	anticholinergic antiemetics
057	central nervous system agents	065	antiemetic/antivertigo agents	198	miscellaneous antiemetics
057	central nervous system agents	066	antiparkinson agents	205	anticholinergic antiparkinson agents
057	central nervous system agents	066	antiparkinson agents	206	miscellaneous antiparkinson agents
057	central nervous system agents	066	antiparkinson agents	276	dopaminergic antiparkinson agents
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	068	barbiturates
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	069	benzodiazepines
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	070	miscellaneous anxiolytics, sedatives and hypnotics
057	central nervous system agents	071	CNS stimulants		
057	central nervous system agents	072	general anesthetics		
057	central nervous system agents	073	muscle relaxants	074	neuromuscular blocking agents
057	central nervous system agents	073	muscle relaxants	178	skeletal muscle relaxants
057	central nervous system agents	073	muscle relaxants	179	skeletal muscle relaxant combinations
057	central nervous system agents	080	miscellaneous central nervous system agts		
057	central nervous system agents	253	anorexiants		
057	central nervous system agents	312	cholinergic agonists		
057	central nervous system agents	313	cholinesterase inhibitors		
057	central nervous system agents	378	drugs used in alcohol dependence		
081	coagulation modifiers	082	anticoagulants	261	heparins
081	coagulation modifiers	082	anticoagulants	262	coumarins and indandiones
081	coagulation modifiers	082	anticoagulants	283	thrombin inhibitors
081	coagulation modifiers	082	anticoagulants	285	factor Xa inhibitors
081	coagulation modifiers	083	antiplatelet agents	211	platelet aggregation inhibitors
081	coagulation modifiers	083	antiplatelet agents	212	glycoprotein platelet inhibitors
081	coagulation modifiers	083	antiplatelet agents	463	protease-activated receptor-1 antagonists
081	coagulation modifiers	084	heparin antagonists		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
081	coagulation modifiers	085	miscellaneous coagulation modifiers		
081	coagulation modifiers	086	thrombolytics		
081	coagulation modifiers	384	platelet-stimulating agents		
087	gastrointestinal agents	088	antacids		
087	gastrointestinal agents	090	antidiarrheals		
087	gastrointestinal agents	091	digestive enzymes		
087	gastrointestinal agents	092	gallstone solubilizing agents		
087	gastrointestinal agents	093	GI stimulants		
087	gastrointestinal agents	094	H2 antagonists		
087	gastrointestinal agents	095	laxatives		
087	gastrointestinal agents	096	miscellaneous GI agents		
087	gastrointestinal agents	272	proton pump inhibitors		
087	gastrointestinal agents	277	5-aminosalicylates		
087	gastrointestinal agents	354	H. pylori eradication agents		
087	gastrointestinal agents	355	functional bowel disorder agents	089	anticholinergics/antispasmodics
087	gastrointestinal agents	355	functional bowel disorder agents	356	serotoninergic neuroenteric modulators
087	gastrointestinal agents	355	functional bowel disorder agents	362	chloride channel activators
087	gastrointestinal agents	355	functional bowel disorder agents	375	peripheral opioid receptor antagonists
097	hormones	098	adrenal cortical steroids	300	corticotrophin
097	hormones	098	adrenal cortical steroids	301	glucocorticoids
097	hormones	098	adrenal cortical steroids	302	mineralocorticoids
097	hormones	100	miscellaneous hormones		
097	hormones	101	sex hormones	102	contraceptives
097	hormones	101	sex hormones	182	androgens and anabolic steroids
097	hormones	101	sex hormones	183	estrogens
097	hormones	101	sex hormones	184	gonadotropins
097	hormones	101	sex hormones	185	progestins
097	hormones	101	sex hormones	186	sex hormone combinations
097	hormones	101	sex hormones	187	miscellaneous sex hormones

	Level 1		Level 2		Level 3
CAT		CAT		CAT	
ID	CATEGORY NAME	ID	CATEGORY NAME	ID	CATEGORY NAME
					gonadotropin releasing hormones and
097	hormones	101	sex hormones	279	analogs
097	hormones	103	thyroid drugs		
097	hormones	288	5-alpha-reductase inhibitors		
097	hormones	295	growth hormones		
097	hormones	318	insulin-like growth factor		
097	hormones	357	growth hormone receptor blockers		
097	hormones	377	prolactin hormones		
097	hormones	410	adrenal corticosteroid inhibitors		
097	hormones	411	calcitonin		
097	hormones	413	antigonadotropic agents		
097	hormones	414	antidiuretic hormones		
097	hormones	416	somatostatin and somatostatin analogs		
097	hormones	417	selective estrogen receptor modulators		
097	hormones	418	parathyroid hormone and analogs		
			gonadotropin-releasing hormone		
097	hormones	419	antagonists		
097	hormones	420	antiandrogens		
097	hormones	422	antithyroid agents		
097	hormones	423	aromatase inhibitors		
097	hormones	424	estrogen receptor antagonists		
097	hormones	426	synthetic ovulation stimulants		
097	hormones	428	progesterone receptor modulators		
105	miscellaneous agents	106	antidotes		
105	miscellaneous agents	107	chelating agents		
105	miscellaneous agents	108	cholinergic muscle stimulants		
105	miscellaneous agents	109	local injectable anesthetics		
105	miscellaneous agents	110	miscellaneous uncategorized agents		
105	miscellaneous agents	111	psoralens		

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
105	miscellaneous agents	114	illicit (street) drugs		
105	miscellaneous agents	192	antirheumatics		
105	miscellaneous agents	270	antipsoriatics		
105	miscellaneous agents	284	viscosupplementation agents		
105	miscellaneous agents	320	smoking cessation agents		
105	miscellaneous agents	460	phosphate binders		
113	genitourinary tract agents	263	impotence agents		
113	genitourinary tract agents	264	urinary antispasmodics		
113	genitourinary tract agents	265	urinary pH modifiers		
113	genitourinary tract agents	266	miscellaneous genitourinary tract agents		
113	genitourinary tract agents	412	uterotonic agents		
113	genitourinary tract agents	427	tocolytic agents		
115	nutritional products	116	iron products		
115	nutritional products	117	minerals and electrolytes		
115	nutritional products	118	oral nutritional supplements		
115	nutritional products	119	vitamins		
115	nutritional products	120	vitamin and mineral combinations		
115	nutritional products	121	intravenous nutritional products		
122	respiratory agents	123	antihistamines		
122	respiratory agents	124	antitussives		
122	respiratory agents	125	bronchodilators	126	methylxanthines
122	respiratory agents	125	bronchodilators	180	adrenergic bronchodilators
122	respiratory agents	125	bronchodilators	181	bronchodilator combinations
122	respiratory agents	125	bronchodilators	299	anticholinergic bronchodilators
122	respiratory agents	127	decongestants		
122	respiratory agents	128	expectorants		
122	respiratory agents	129	miscellaneous respiratory agents		
122	respiratory agents	130	respiratory inhalant products	296	inhaled corticosteroids

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
122	respiratory agents	130	respiratory inhalant products	297	mucolytics
122	respiratory agents	130	respiratory inhalant products	298	mast cell stabilizers
122	respiratory agents	130	respiratory inhalant products	407	inhaled anti-infectives
122	respiratory agents	131	antiasthmatic combinations		
122	respiratory agents	132	upper respiratory combinations		
122	respiratory agents	243	leukotriene modifiers		
122	respiratory agents	273	lung surfactants		
122	respiratory agents	435	selective phosphodiesterase-4 inhibitors		
133	topical agents	134	anorectal preparations		
133	topical agents	135	antiseptic and germicides		
133	topical agents	136	dermatological agents	137	topical anti-infectives
133	topical agents	136	dermatological agents	138	topical steroids
133	topical agents	136	dermatological agents	139	topical anesthetics
133	topical agents	136	dermatological agents	140	miscellaneous topical agents
133	topical agents	136	dermatological agents	141	topical steroids with anti-infectives
133	topical agents	136	dermatological agents	143	topical acne agents
133	topical agents	136	dermatological agents	144	topical antipsoriatics
133	topical agents	136	dermatological agents	248	topical emollients
133	topical agents	136	dermatological agents	290	topical antibiotics
133	topical agents	136	dermatological agents	291	topical antivirals
133	topical agents	136	dermatological agents	292	topical antifungals
133	topical agents	136	dermatological agents	380	topic debriding agents
133	topical agents	136	dermatological agents	381	topical depigmenting agents
133	topical agents	136	dermatological agents	382	topical antihistamines
133	topical agents	136	dermatological agents	394	topical astringents
133	topical agents	136	dermatological agents	395	topical keratolytics
133	topical agents	136	dermatological agents	448	topical non-steroidal anti-inflammatories
133	topical agents	136	dermatological agents	450	topical antineoplastics

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
133	topical agents	136	dermatological agents	451	topical photochemotherapeutics
133	topical agents	136	dermatological agents	453	topical rubefacient
133	topical agents	136	dermatological agents	461	topical anti-rosacea agents
133	topical agents	146	mouth and throat products		
133	topical agents	147	ophthalmic preparations	163	ophthalmic anti-infectives
133	topical agents	147	ophthalmic preparations	164	ophthalmic glaucoma agents
133	topical agents	147	ophthalmic preparations	165	ophthalmic steroids
133	topical agents	147	ophthalmic preparations	166	ophthalmic steroids with anti-infectives
133	topical agents	147	ophthalmic preparations	167	ophthalmic anti-inflammatory agents
133	topical agents	147	ophthalmic preparations	168	ophthalmic lubricants and irrigations
133	topical agents	147	ophthalmic preparations	169	miscellaneous ophthalmic agents
133	topical agents	147	ophthalmic preparations	267	ophthalmic antihistamines and decongestants
133	topical agents	147	ophthalmic preparations	286	mydriatics
133	topical agents	147	ophthalmic preparations	287	ophthalmic anesthetics
133	topical agents	147	ophthalmic preparations	321	ophthalmic diagnostic agents
133	topical agents	147	ophthalmic preparations	322	ophthalmic surgical agents
133	topical agents	147	ophthalmic preparations	353	anti-angiogenic ophthalmic agents
133	topical agents	148	otic preparations	170	otic anti-infectives
133	topical agents	148	otic preparations	171	otic steroids with anti-infectives
133	topical agents	148	otic preparations	172	miscellaneous otic agents
133	topical agents	148	otic preparations	370	otic steroids
133	topical agents	148	otic preparations	392	otic anesthetics
133	topical agents	148	otic preparations	393	cerumenolytics
133	topical agents	150	sterile irrigating solutions		
133	topical agents	151	vaginal preparations	149	spermicides
133	topical agents	151	vaginal preparations	268	vaginal anti-infectives
133	topical agents	151	vaginal preparations	269	miscellaneous vaginal agents

PAGE 272

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

	Level 1		Level 2		Level 3
CAT		CAT		CAT	
ID	CATEGORY NAME	ID	CATEGORY NAME	ID	CATEGORY NAME
133	topical agents	247	nasal preparations	244	nasal lubricants and irrigations
133	topical agents	247	nasal preparations	245	nasal steroids
133	topical agents	247	nasal preparations	246	nasal antihistamines and decongestants
133	topical agents	247	nasal preparations	344	nasal anti-infectives
153	plasma expanders				
218	alternative medicines	219	nutraceutical products		
218	alternative medicines	220	herbal products		
218	alternative medicines	363	probiotics		
242	psychotherapeutic agents	249	antidepressants	076	miscellaneous antidepressants
242	psychotherapeutic agents	249	antidepressants	208	SSRI antidepressants
242	psychotherapeutic agents	249	antidepressants	209	tricyclic antidepressants
242	psychotherapeutic agents	249	antidepressants	250	monoamine oxidase inhibitors
242	psychotherapeutic agents	249	antidepressants	306	phenylpiperazine antidepressants
242	psychotherapeutic agents	249	antidepressants	307	tetracyclic antidepressants
242	psychotherapeutic agents	249	antidepressants	308	SSNRI antidepressants
242	psychotherapeutic agents	251	antipsychotics	077	miscellaneous antipsychotic agents
242	psychotherapeutic agents	251	antipsychotics	079	psychotherapeutic combinations
242	psychotherapeutic agents	251	antipsychotics	210	phenothiazine antipsychotics
242	psychotherapeutic agents	251	antipsychotics	280	thioxanthenes
242	psychotherapeutic agents	251	antipsychotics	341	atypical antipsychotics
254	immunologic agents	033	immune globulins		
254	immunologic agents	037	toxoids		
254	immunologic agents	039	miscellaneous biologicals		
254	immunologic agents	104	immunosuppressive agents	441	calcineurin inhibitors
254	immunologic agents	104	immunosuppressive agents	442	TNF alfa inhibitors
254	immunologic agents	104	immunosuppressive agents	443	interleukin inhibitors
254	immunologic agents	104	immunosuppressive agents	444	selective immunosuppressants
254	immunologic agents	104	immunosuppressive agents	445	other immunosuppressants
254	immunologic agents	104	immunosuppressive agents		

Level 1		Level 2		Level 3	
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
254	immunologic agents	257	immunosuppressive monoclonal antibodies		
254	immunologic agents	434	sphingosine 1-phosphate receptor modulators		
254	immunologic agents	436	BLyS-specific inhibitors		
254	immunologic agents	437	immunostimulants	031	bacterial vaccines
254	immunologic agents	437	immunostimulants	032	colony stimulating factors
254	immunologic agents	437	immunostimulants	038	viral vaccines
254	immunologic agents	437	immunostimulants	256	interferons
254	immunologic agents	437	immunostimulants	432	vaccine combinations
254	immunologic agents	437	immunostimulants	438	interleukins
254	immunologic agents	437	immunostimulants	439	other immunostimulants
254	immunologic agents	437	Immunostimulants	440	therapeutic vaccines
331	radiologic agents	027	radiopharmaceuticals	338	diagnostic radiopharmaceuticals
331	radiologic agents	027	radiopharmaceuticals	339	therapeutic radiopharmaceuticals
331	radiologic agents	112	radiocontrast agents	333	miscellaneous iodinated contrast media
331	radiologic agents	112	radiocontrast agents	334	lymphatic staining agents
331	radiologic agents	112	radiocontrast agents	335	magnetic resonance imaging contrast media
331	radiologic agents	112	radiocontrast agents	336	non-iodinated contrast media
331	radiologic agents	112	radiocontrast agents	337	ultrasound contrast media
331	radiologic agents	112	radiocontrast agents	368	non-ionic iodinated contrast media
331	radiologic agents	112	radiocontrast agents	369	ionic iodinated contrast media
331	radiologic agents	112	radiocontrast agents	331	radiologic agents
331	radiologic agents	112	radiocontrast agents	464	miscellaneous diagnostic dyes
331	radiologic agents	332	radiologic adjuncts	374	cardiac stressing agents
331	radiologic agents	332	radiologic adjuncts	376	radiologic conjugating agents
358	metabolic agents	019	antihyperlipidemic agents	173	HMG-CoA reductase inhibitors
358	metabolic agents	019	antihyperlipidemic agents	174	miscellaneous antihyperlipidemic agents
358	metabolic agents	019	antihyperlipidemic agents	241	fibric acid derivatives

PAGE 274

2014 NAMCS MICRO-DATA FILE DOCUMENTATION

Level 1		Level 2			Level 3	
CAT		CAT		CAT		
ID	CATEGORY NAME	ID	CATEGORY NAME	ID	CATEGORY NAME	
358	metabolic agents	019	antihyperlipidemic agents	252	bile acid sequestrants	
358	metabolic agents	019	antihyperlipidemic agents	316	cholesterol absorption inhibitors	
358	metabolic agents	019	antihyperlipidemic agents	317	antihyperlipidemic combinations	
358	metabolic agents	099	antidiabetic agents	213	sulfonylureas	
358	metabolic agents	099	antidiabetic agents	214	biquanides	
358	metabolic agents	099	antidiabetic agents	215	insulin	
358	metabolic agents	099	antidiabetic agents	216	alpha-glucosidase inhibitors	
358	metabolic agents	099	antidiabetic agents	271	thiazolidinediones	
358	metabolic agents	099	antidiabetic agents	282	meglitinides	
358	metabolic agents	099	antidiabetic agents	309	miscellaneous antidiabetic agents	
358	metabolic agents	099	antidiabetic agents	314	antidiabetic combinations	
358	metabolic agents	099	antidiabetic agents	371	dipeptidyl peptidase 4 inhibitors	
358	metabolic agents	099	antidiabetic agents	372	amylin analogs	
358	metabolic agents	099	antidiabetic agents	373	incretin mimetics	
358	metabolic agents	099	antidiabetic agents	458	SGLT-2 inhibitors	
358	metabolics agents	194	antigout agents			
358	metabolic agents	289	antihyperuricemic agents			
358	metabolic agents	293	glucose elevating agents			
358	metabolic agents	359	peripherally acting antiobesity agents			
358	metabolic agents	360	lysosomal enzymes			
358	metabolic agents	361	miscellaneous metabolic agents			
358	metabolic agents	409	bone resorption inhibitors	217	bisphosphonates	
358	metabolic agents	409	bone resorption inhibitors	415	miscellaneous bone resorption inhibitors	
358	metabolic agents	452	CFTR potentiators			
358	metabolic agents	459	urea cycle disorder agents			
365	medical gas					
462	allergenics					
899	pharmaceutical aids					